Page 1

	rage
1	IN THE UNITED STATES DISTRICT COURT
2	FOR THE WESTERN DISTRICT OF LOUISIANA
3	MONROE DIVISION
4	X
5	THE STATE OF MISSOURI, et al., :
6	Plaintiffs, :
7	V. : Case No. 3:22-cv-01213-TAD-KDM
8	JOSEPH R. BIDEN, JR., et al., :
9	Defendants. :
10	x
11	Bethesda, Maryland
12	Wednesday, November 23, 2022
13	Videotaped Deposition of DR. ANTHONY FAUCI, a
14	Defendant herein, called for examination by counsel
15	for Plaintiffs in the above-entitled matter, pursuant
16	to notice, the witness being duly sworn by Stephanie
17	Barnes, a Notary Public in and for the State of
18	Maryland, taken at the offices of National Institutes
19	of Health, 31 Center Drive, Building 31, Bethesda,
20	Maryland, at 8:08 a.m., Wednesday, November 23, 2022,
21	and the proceedings being taken down by Stenotype by
22	Stephanie Barnes, and transcribed under her
23	direction.
24	
25	
1	

Page 2

Fax: 314.644.1334

1	APPEARANCES:
2	
3	On behalf of the Plaintiff the State of
4	Missouri:
5	D. JOHN SAUER, ESQ.
6	ERIC S. SCHMITT, ESQ.
7	JUSTIN D. SMITH, ESQ.
8	Missouri Attorney General's Office
9	221 West High Street
10	Jefferson City, Missouri 65101
11	(573) 751-8870
12	John.Sauer@ago.mo.gov
13	
14	On behalf of the Plaintiff the State of
15	Louisiana:
16	JEFFREY M. LANDRY, ESQ.
17	TRACY SHORT, ESQ.
18	WILBUR STILES, ESQ.
19	Louisiana Department of Justice
20	1885 North 3rd Street
21	Baton Rouge, Louisiana 70804
22	(225) 326-6766
23	
24	On behalf of the Plaintiffs Dr. Jayanta
25	Bhattacharya, Dr. Martin Kulldorff, Dr. Aaron

Page 3

Fax: 314.644.1334

1	Kheriaty, and Jill Hines:
2	JENIN YOUNES, ESQ.
3	
	JOHN J. VECCHIONE, ESQ.
4	New Civil Liberties Alliance
5	1225 19th Street, Northwest
6	Suite 450
7	Washington, D.C. 20036
8	(202) 918-6905
9	Jenin.younes@ncla.legal
10	John.vecchione@ncla.legal
11	
12	On behalf of the Plaintiff:
13	JONATHAN C. BURNS, ESQ.
14	Burns Law Firm
15	Post Office Box 191250
16	St. Louis, Missouri 63119
17	(314) 329-5040
18	John@Burns-law-firm.com
19	
20	On behalf of the Defendant the Department of
21	Justice:
22	ADAM KIRSCHNER, ESQ.
23	JOSH GARDNER, ESQ.
24	KYLA SNOW, ESQ.
25	INDRANEEL SUR, ESQ.

# Case 3:22-cv-01213-TAD-KDM Document 206-1 Filed 03/04/23 Page 4 of 446 PageID #: 11419

# **DR. ANTHONY FAUCI 11/23/2022**

Page 4

Fax: 314.644.1334

	rage 4
1	U.S. Department of Justice
2	1100 L Street, Northwest
3	Washington, D.C. 20530
4	(202) 598-3846
5	Adam.kirschner@usdoj.gov
6	Adam. KIISCIIIIeI@dSdOJ.gov
7	On behalf of the Defendant the Department of
8	Health and Human Services:
9	ANANT KUMAR, ESQ.
10	Department of Health and Human Services
11	26 Federal Plaza
12	Room 3908
13	New York, New York 10278
14	(212) 264-6373
15	Anant.kumar@hhs.gov
16	On behalf of the Defendant the National
17	Institute of Health:
18	CHRISTOPHER HAMMOND, ESQ.
19	Office of the General Counsel
20	Public Health Division
21	NIH Branch
22	31 Center Drive
23	
	Building 31
24	Bethesda, Maryland 20892
25	Christopher.hammond2@nih.gov

# Case 3:22-cv-01213-TAD-KDM Document 206-1 Filed 03/04/23 Page 5 of 446 PageID #: 11420

## **DR. ANTHONY FAUCI 11/23/2022**

Page 5

Fax: 314.644.1334

1	ALSO PRESENT:	
2	CORY DENNIS, Press Secretary	
3	JILL HINES, Plaintiff	
4	JAMES HOFT, Plaintiff	
5		
6		
7		
8		
9		
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

LEXITAS LEGAL Phone: 1.800.280.3376

www.lexitaslegal.com

# Case 3:22-cv-01213-TAD-KDM Document 206-1 Filed 03/04/23 Page 6 of 446 PageID #: 11421

# **DR. ANTHONY FAUCI 11/23/2022**

Page 6

Fax: 314.644.1334

		r age 0
1	CONTENTS	
2	WITNESS EXAMINATION	BY COUNSEL
3	DR. ANTHONY FAUCI FOR	PLAINTIFFS
4	BY MR. SAUER	10
5		
6	EXHIBITS	
7	FAUCI EXHIBIT NO.	PAGE
8	Exhibit No. 1 - December 30, 2011 Article	12
9	Exhibit No. 2 - EcoHealth Alliance	17
10	Project Details	
11	Exhibit No. 3 - Gain of Function Research	25
12	Exhibit No. 4 - Nature Medicine Article	31
13	Exhibit No. 5 - E-mails	37
14	Exhibit No. 6 - E-mails	43
15	Exhibit No. 7 - E-mails	83
16	Exhibit No. 8 - E-mails	96
17	Exhibit No. 9 - E-mails	111
18	Exhibit No. 10 - References	114
19	Exhibit No. 11 - E-mails	119
20	Exhibit No. 12 - E-mails	122
21	Exhibit No. 13 - E-mails	130
22	Exhibit No. 14 - E-mails	138
23	Exhibit No. 15 - E-mails	141
24	Exhibit No. 16 - Podcast Transcript	142
25	Exhibit No. 17 - Calendar Printout	148

# Case 3:22-cv-01213-TAD-KDM Document 206-1 Filed 03/04/23 Page 7 of 446 PageID #: 11422

# **DR. ANTHONY FAUCI 11/23/2022**

				Page 7
1	Eubibit No	10 0110	±-0	152
	Exhibit No.	_		
2		_	back Machine Article	158
3	Exhibit No.	20 - NIH	Record Article	163
4	Exhibit No.	21 - E-m	ails	167
5	Exhibit No.	22 - E-m	ails	170
6	Exhibit No.	23 - CON	FIDENTIAL E-mails	172
7	Exhibit No.	24 - Nat	ure Medicine Article	178
8	Exhibit No.	25 - NIH	Blog	182
9	Exhibit No.	26 - ABC	News Article	185
10	Exhibit No.	27 - E-m	ails	187
11	Exhibit No.	28 - Whi	te House Archives	196
12	Exhibit No.	29 - E-m	ails	201
13	Exhibit No.	30 - E-m	ails	203
14	Exhibit No.	31 - The	Hill Article	209
15	Exhibit No.	32 - Met	a Printout	210
16	Exhibit No.	33 - UnH	erd Article	212
17	Exhibit No.	34 - Pol	itico Article	213
18	Exhibit No.	35 - The	Lancelet Article	221
19	Exhibit No.	36 - Goo	d Morning America Article	226
20	Exhibit No.	37 - Bre	itbart Article	228
21	Exhibit No.	38 - Bre	itbart Article	232
22	Exhibit No.	39 - The	Washington Standard Article	242
23	Exhibit No.	40 - Glo	bal HCQ/QC Studies	245
24	Exhibit No.	41 - Gre	at Barrington Declaration	249
25	Exhibit No.	42 - E-m	ails	253
				ļ

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

www.lexitaslegal.com

# Case 3:22-cv-01213-TAD-KDM Document 206-1 Filed 03/04/23 Page 8 of 446 PageID #: 11423

# **DR. ANTHONY FAUCI 11/23/2022**

·		Page 8
1	Exhibit No. 43 - E-mails	263
2	Exhibit No. 44 - E-mails	266
3	Exhibit No. 45 - Washington Post Article	270
4	Exhibit No. 46 - E-mails	275
5	Exhibit No. 47 - CNBC Article	277
6	Exhibit No. 48 - Spiked Article	280
7	Exhibit No. 49 - YouTube Printout	283
8	Exhibit No. 50 - Google Printout	284
9	Exhibit No. 51 - Meta Printout	286
10	Exhibit No. 52 - E-mails	294
11	Exhibit No. 53 - CONFIDENTIAL E-mails	298
12	Exhibit No. 54 - CONFIDENTIAL E-mails	304
13	Exhibit No. 55 - CONFIDENTIAL E-mails	307
14	Exhibit No. 56 - CONFIDENTIAL E-mails	323
15	Exhibit No. 57 - CONFIDENTIAL E-mails	327
16	Exhibit No. 58 - CONFIDENTIAL E-mails	330
17	Exhibit No. 59 - Substack Article	334
18	Exhibit No. 60 - The Hill Article	340
19	Exhibit No. 61 - New York Times Article	343
20	Exhibit No. 62 - Substack Article	346
21	Exhibit No. 63 - E-mails	352
22	* Exhibits attached to transcript.	
23		
24		
25		

LEXITAS LEGAL Phone: 1.800.280.3376

Page 9

1	PROCEEDINGS
2	THE VIDEOGRAPHER: We are now on the
3	record. Today is November 23rd, 2022, and the time
4	on the video screen is 8:08 a.m. Eastern Standard
5	Time. This is the video recorded deposition
6	of Dr. Anthony Fauci taken in the matter of the State
7	of Missouri, et al, v. Joseph R. Biden, Jr., et al,
8	Case Number 3:22-CV-01213.
9	This is pending before the United States
10	District Court for the Western District of Louisiana
11	Monroe Division. This deposition is being conducted
12	at the NIAID at 31 Center Drive in Bethesda,
13	Maryland. The reporter today is Stephanie Barnes,
14	and my name is Daniel Holmstock. I am the legal
15	videographer.
16	Counsel, would you please introduce
17	yourselves and state whom you represent.
18	MR. SAUER: John Sauer of the Missouri
19	Attorney General's Office on behalf of all the
20	plaintiffs.
21	MR. KIRSCHNER: Adam Kirschner from the
22	U.S. Department of Justice on behalf of all the
23	defendants.
24	THE VIDEOGRAPHER: Will the court reporter
25	please administer the oath.

Page 10

1	Whereupon,
2	DR. ANTHONY FAUCI,
3	was called as a witness by counsel for Plaintiffs,
4	and having been duly sworn by the Notary Public, was
5	examined and testified as follows:
6	EXAMINATION BY COUNSEL FOR PLAINTIFFS
7	BY MR. SAUER:
8	Q. Good morning. Can you please state your
9	name for the record?
10	A. My name is Anthony S. Fauci.
11	Q. And, Dr. Fauci, what's your current
12	position?
13	A. I'm the director of the National Institute
14	of Allergy and Infectious Diseases at the National
15	Institutes of Health and the Chief Medical Advisor to
16	President Biden.
17	Q. When did you become the Chief Medical
18	Advisor to the President?
19	A. Very shortly after his inauguration. He
20	asked me to be the advisor between the election and
21	the inauguration, and I officially became his advisor
22	following his inauguration.
23	Q. And then how long have you been the
24	director of NIAID, if I can call it that?
25	A. I've been the director of NIAID for 38

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

Page 11

1	years a co	uple of weeks ago.
2	Q.	Congratulations.
3		Have you ever given a deposition before?
4	Α.	I have.
5	Q.	How many times?
6	Α.	Once.
7	Q.	How long ago was that?
8	Α.	You know, I don't know exactly the time,
9	but it was	probably anywhere between 15 and 20-plus
10	years ago.	
11	Q.	Can I go over some ground rules with you?
12	Α.	Sure.
13	Q.	First of all, when I ask a question, can
14	you and I	oe careful not to interrupt each other when
15	we're talk	ing for the clarity of the record?
16	Α.	Certainly.
17	Q.	And if I ask a question, if you don't
18	understand	the question, could you ask me to clarify
19	to make su	re you're answering the question that I'm
20	asking as	opposed to some other question you think I
21	might be a	sking? Can you do that today?
22	Α.	Certainly.
23	Q.	Can you give verbal answers, like you're
24	doing now,	instead of merely nodding or saying
25	"uh-huh,"	"huh-uh," can you say "yes" or "no" as the
Ī		

Page 12

1	questions go forward?
2	A. Yes.
3	Q. And maybe both of us can make an effort to
4	speak slowly. You're probably going to be better at
5	that than I will, but to make an effort to speak
6	slowly so that everything's getting transcribed.
7	Is that okay?
8	A. I will certainly do that.
9	Q. I'd like to start off by handing you a
10	document that I've asked the court reporter to mark
11	as Exhibit 1, and I just want to take can you take
12	a glance at this and see if you recognize it?
13	(FAUCI Exhibit No. 1 was marked for
14	identification.)
15	MR. KIRSCHNER: Counsel, this is a
16	standing objection for all of the documents you show.
17	I would ask that you preference your questions, to
18	the extent Dr. Fauci recognizes it, outside of the
19	capacity of preparation for the deposition, otherwise
20	I would object on work product grounds, but if you're
21	asking if you recognize a document outside of
22	anything that was shown in the context of deposition
23	preparation, I will not prevent him from answering.
24	MR. SAUER: You raise a good point.
25	BY MR. SAUER:
20	DI III. SHOLI.

Page 13

- 1 Q. Dr. Fauci, did you review any documents in
- 2 preparation for your deposition today?
- 3 A. We did a couple of documents -- a few
- 4 documents, yeah.
- 5 Q. What documents were those?
- 6 MR. KIRSCHNER: I object on work product
- 7 grounds, and I instruct the witness not to answer.
- 8 BY MR. SAUER:
- 9 Q. Can you look at the document in front of
- 10 you, Exhibit 1?
- 11 A. Yeah. So let me take a -- be careful I
- 12 read it, recognize it.
- Q. Well, let me ask you this: In 2011, did
- 14 you coauthor an op-ed with Francis Collins in the
- 15 Washington Post called "A Flu Virus Risk Worth
- 16 Taking"?
- 17 A. Well, I have it in front of me here, and
- 18 it has my name on it. So, yes, it looks like I
- 19 did coauthor an editorial in the Washington Post on
- 20 December 30th of 2011.
- Q. Do you remember doing it or do you only
- remember because you see it in front of you?
- 23 A. No. I vaguely remember. This was 11
- 24 years ago. I've written 1300 articles over my last
- 25 several years.

Page 14

1	Q. You look at the final paragraph on the
2	first page in the first or sort of the first
3	sentence of the final paragraph of the first page,
4	your op-ed states: "Given these uncertainties,
5	important information and insights can come from
6	generating a potentially dangerous virus in the
7	laboratory." Do you remember writing that?
8	MR. KIRSCHNER: Counsel, I would ask for
9	Dr. Fauci to have an opportunity to familiarize
10	himself with the document
11	THE WITNESS: Yeah.
12	MR. KIRSCHNER: prior to answering
13	questions about it.
14	THE WITNESS: Yeah. Let me just read it
15	and see.
16	BY MR. SAUER:
17	Q. Let me ask you a question unrelated to
18	that document just in general. Do you believe as you
19	sit here today that important information, insights,
20	can come from generating a potentially dangerous
21	virus in a laboratory?
22	A. Well, yeah, if you take it into the
23	correct context because when you say "Generating a
24	potentially dangerous virus in the laboratory," that
25	is usually in the context of, for example, taking

Page 15

Fax: 314.644.1334

1	this	H5N1	and	studvina	it	in	different	wavs	that
_			00-	~ ~ ~ ~ ,				0. , ~	00-

- 2 could potentially make it more dangerous but only
- 3 under very strict conditions laid out for the
- 4 quardrails of conducting experiments that could
- 5 potentially create such a dangerous virus. And if
- 6 you look at the context of this particular paper, the
- 7 point that Dr. Collins, Dr. Nabel and I were making
- 8 that there is a risk as we were talking about with
- 9 pandemic influenza to understand as best as possible.
- 10 And, in fact, if you go to the next paragraph, we say
- "Understanding the biology of virus transmission has
- 12 implications for outbreak prediction, prevention and
- 13 treatment."
- 14 And the point we were making in this
- 15 article is that there is a risk benefit to research
- 16 like this, and the point we were making it says "A
- 17 risk worth taking if the benefit is the protection of
- 18 the American and global public."
- 19 Q. You refer to conditions under which such
- 20 research should be done --
- 21 A. Right.
- 22 Q. -- when you're generating potentially
- 23 dangerous viruses.
- 24 A. Right.
- 25 Q. First of all, is that kind of

Page 16

1	
1	research generally referred to as gain-of-function
2	research?
3	A. Gain of function is a very potentially
4	misleading terminology, and that was one of the
5	reasons why several years ago outside groups, not the
6	NIH, made the determination that they would much more
7	strictly define the guardrails of experiments that
8	would require additional oversight and did away with
9	the terminology "gain of function" because it can
10	often be very confusing and misleading.
11	Q. When was that terminology "gain of
12	function" done away with?
13	A. At the time, I believe and I'm not a
14	hundred percent sure but there was a period of
15	time between, I think, 2011 and 2014 or '12 and '14,
16	I'm not sure, when there was a pause that was put on
17	research that was related to the manipulation of the
18	influenza virus in order to get more concrete and
19	more definitive guidelines about what the guardrails
20	of this research should be.
21	Q. Do those guardrails include things like
22	the level of biosafety biosafety level at which
23	such research should be done?

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

sure if it was explicitly said, but it certainly

That, I believe, was part of it. I'm not

Α.

24

25

Page 17

Fax: 314.644.1334

- 1 could be. There were two elements to it. There was
- 2 the pause, which any research that could potentially
- 3 have any collaterally dangerous aspects to it were
- 4 put on pause, and then a number of organizations
- 5 outside of the NIH, including the Office of Science
- 6 and Technology Policy, OSTP, the academies of
- 7 science, engineering and medicine, and a number of
- 8 working groups on the outside developed more clarity
- 9 to the kinds of oversight that would be needed. That
- 10 is referred to as P3CO or pandemic potential
- 11 pathogens care and oversight, and the --
- 12 Q. Is that some type -- go ahead.
- 13 A. And the reason for that was the lack of
- 14 clarity in the terminology "gain of function," which
- is often confusing. So it was felt by these outside
- 16 groups to be very clear on the kinds of experiments
- 17 that needed additional oversight.
- 18 Q. Could I give you a second document, which
- 19 I guess will be Exhibit 2?
- 20 (FAUCI Exhibit No. 2 was marked for
- 21 identification.)
- MR. KIRSCHNER: Just letting Dr. Fauci
- 23 know that the court reporter will provide him the
- 24 document that he's to look at. This -- these
- 25 are copies for counsel.

Page 18

Fax: 314.644.1334

1 Do you want to mark this one also? Thank 2 you. 3 BY MR. SAUER: 4 This Exhibit 2 is a document printed off 0. 5 of the NIH website called "Understanding the Risk of 6 Bat Coronavirus Emergence." Are you familiar with 7 the project that's referred to in this document 8 titled "Understanding the Risk of Bat Coronavirus 9 Emergence"? 10 Α. I'm vaguely familiar with the fact that 11 EcoHealth Alliance has been doing research on trying 12 to understand the bat coronavirus emergence. 13 Q. And was this project initiated in 2014 on 14 vour understanding? 15 I do not know. That is not something that Α. 16 I would have followed very carefully. 17 Would you have approved this in your 0. 18 capacity as head of NIAID? 19 Α. I do --20 MR. KIRSCHNER: Objection. Assuming 21 evidence not in the record.

They go through multiple levels of peer review, so I

I do not individually approve grants.

You may answer.

BY MR. SAUER:

Q.

Α.

2.2

2.3

24

25

Page 19

- 1 would not have, by standard way things work, have
- 2 seen this, read it, or individually approved it.
- 3 That's not the way things work in the
- 4 Institute.
- 5 Q. Do you have any recollection of this at
- 6 the time?
- 7 A. I have no recollection -- I have no
- 8 recollection of the initiation of this grant.
- 9 Q. If you flip to the second page, under
- 10 "Details," it mentions EcoHealth Alliance. You
- 11 referred to that a second ago, as the recipient of
- 12 the project.
- 13 A. Right.
- 14 Q. Is that right?
- 15 A. Right.
- 16 Q. And that's your understanding, they did
- 17 receive funding under this project; is that right?
- 18 MR. KIRSCHNER: Objection. Assuming
- 19 evidence not in the record.
- 20 MR. SAUER:
- Q. You may answer.
- 22 A. I'm sorry. Would you repeat the question.
- 23 I'm not understanding what the question is.
- Q. Is it your understanding that EcoHealth
- 25 Alliance received funding from NIAID under this

Page 20

1		
1	project?	
_	Project.	

- 2 A. Well, looking at this, I can't make that
- 3 connection. I do know, with all of the activity
- 4 that's been going on with EcoHealth Alliance and the
- 5 NIAID funding, that indeed, NIAID has funded
- 6 EcoHealth Alliance. I don't know if I can
- 7 specifically link it to this particular grant because
- 8 this is the first time that I have seen this piece of
- 9 paper.
- 10 Q. Got you. Above that, it lists a man
- 11 called Peter Daszak. How do you say his name, if you
- 12 **know?**
- 13 A. I'm not sure. I think it's Daszak. I
- 14 think so.
- 15 Q. Do you know Mr. Daszak?
- 16 A. I have met him once or twice. I would not
- 17 exactly characterize him as an acquaintance.
- 18 Q. In what connection have you met -- sorry,
- 19 go ahead.
- 20 MR. KIRSCHNER: Can you please let the
- 21 witness answer the questions.
- 22 MR. SAUER:
- Q. Go ahead.
- 24 A. So what's the question again.
- 25 Q. In what connection have you met him?

Page 21

1	A. You know, I don't even remember meeting
2	him, but I do know that someone showed me a picture
3	at a meeting where somebody said, here, take a
4	picture with him. And so I clearly must have met him
5	because there's a photograph, I believe, of he and I.
6	But that is not unusual, when you go to a
7	scientific meeting, you run into hundreds of people.
8	And I believe that this Dr. Daszak is one of the
9	people that I almost well, I did run into him
10	because I believe I've seen a photograph of he and I
11	together at a meeting.
12	But he's not somebody that I would have
13	had a major amount I think someone in one of the
14	thousands of e-mails of mine that have been foyered,
15	someone showed me, I think, or pointed out, that
16	there was an e-mail from Peter Daszak to me.
17	And I don't remember the content, but I
18	think it was some casual type of response to
19	something, but it's not someone that I deal with on a
20	regular basis. That is rather clear.
21	Q. On that the same page, below Daszak and
22	EcoHealth Alliance, there's a reference to NIAID
23	funding this grant from 1st June of 2014 to 31st May
24	2019.
25	Do you see that?

It says "Budget Start, 1st of June.

Page 22

Fax: 314.644.1334

2	Budget End." Is that what you're talking about?
3	Q. Yeah. Over there on the right.
4	A. Yeah.
5	Q. Did you later become aware that not at
6	any time, that NIAID was funding this project?
7	MR. KIRSCHNER: Objection. Vague.
8	Assuming evidence not in the record.
9	THE WITNESS: So I'm sorry. What is the
10	question?

- 12 Q. Did you, at any time later, become aware
- 13 that NIAID was funding this project understanding the
- 14 risk of bat Coronavirus emergence?
- 15 A. I became aware of this after all of the
- 16 attention was put on it, following the early part of
- January, February, mid-March of 2020, but I certainly
- 18 was not aware -- well, I wouldn't say certainly
- 19 because who knows what came across my desk.
- 20 Thousands of pieces of paper come across my desk.
- But I do not recall at all being aware of
- 22 the existence of this grant at the time that it was
- 23 initially funded of the dates shown on page 2.
- Q. If you go to the first page, in the
- abstract text, see that big paragraph that covers

1

11

MR. SAUER:

Page 23

1	most of the first page?
2	A. Yeah.
3	Q. Very bottom, last couple sentences. Do
4	you see where it begins number 3, and it says, "Test
5	predictions of COV interspecies transmission"?
6	A. Hold on. What line up from the bottom are
7	you talking about?
8	Q. Fourth line up from the bottom.
9	A. Fourth line up from the bottom. "Test
10	predictions"
11	Q. "Test predictions of CoV"
12	A. "Test predictions of predictive models
13	of post strains will be tested experimentally using
14	reverse genetics" yeah.
15	Q. What does reverse genetics refer to in
16	that line? Do you know?
17	MR. KIRSCHNER: Objection.
18	THE WITNESS: I'm not really quite sure
19	what they're referring to. Reverse genetics can mean
20	many things. Manipulation of a virus, recombination,
21	things like that. I'm not exactly sure what they
22	were referring to here.

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

a minute ago that you talked about in your

Q. Can it refer to what we were talking about

Fax: 314.644.1334

MR. SAUER:

23

24

25

Page 24

- 2011 op-ed about generating a more dangerous virus in
- 2 a laboratory.
- 3 Can reverse genetics refer to that?
- 4 MR. KIRSCHNER: Objection. Calls for
- 5 speculation.
- THE WITNESS: Yeah. You know, reverse
- 7 genetics is a very, very broad term that could have
- 8 multiple applications. The influenza virus vaccine
- 9 that I hope you were vaccinated with this year was
- 10 likely produced by reverse genetics.
- 11 So reverse genetics is a very broad
- 12 categorization.
- 13 MR. SAUER:
- 14 Q. Can it refer to genetic manipulation of a
- virus in a way that renders it either more
- 16 transmissible or more virulent?
- 17 MR. KIRSCHNER: Objection. Calls for
- 18 speculation.
- 19 MR. SAUER:
- 20 Q. Can it refer to that, on your
- 21 understanding?
- 22 A. Like I said, reverse genetics is a very
- 23 broad terminology, and it mean manipulation of a
- 24 virus. We do that when we create an attenuated
- 25 influenza virus, and I believe it can be done also to

Page 25

Fax: 314.644.1334

- 1 amplify the function of the virus.
- 2 Q. I'm going to hand you a document that
- 3 we've marked Exhibit 3.
- 4 (FAUCI Exhibit No. 3 was marked for
- 5 identification.)
- 6 MR. SAUER:
- 7 Q. Do you recognize this document?
- 8 MR. KIRSCHNER: Objection. To the extent
- 9 the question is asking for what Dr. Fauci was shown
- 10 during preparation, I would instruct the witness not
- 11 to answer on work product grounds. It's a standing
- 12 objection for all documents. Not saying whether we
- did or did not show him such documents, but to the
- 14 extent you're asking if he recognizes this document
- outside of the preparation, you can ask.
- 16 THE WITNESS: I don't recognize it as a
- 17 document that I've seen before, but I'm put before
- 18 me, I would say, tens of thousands of documents in my
- 19 capacity. I am aware of the concept of the
- 20 gain-of-function pause involving influenza, MERS and
- 21 SARS viruses.
- 22 MR. SAUER:
- Q. Let me ask you this: Can you flip to the
- second page of the document? At the top, it says:
- 25 "U.S. government gain-of-function deliberative

Page 26

- 1 process and research funding pause."
- You referred earlier in your testimony, I
- 3 believe, to a period starting in 2014 where there was
- 4 a pause on gain-of-function research.
- 5 Do you recall that?
- 6 MR. KIRSCHNER: Objection.
- 7 Mischaracterizes testimony.
- 8 MR. SAUER:
- 9 Q. Do you recall?
- 10 A. I'm sorry. I'm getting confused on your
- 11 questions.
- 12 Q. Well, let me ask you.
- MR. KIRSCHNER: I would ask counsel to
- 14 allow Dr. Fauci to familiarize himself with the
- 15 document prior to asking more questions.
- 16 THE WITNESS: So if the footnote says 1, I
- 17 have to find out what 1 is referring to. So if you
- 18 just give me a second.
- 19 MR. SAUER:
- Q. If you see there, it's the bottom line of
- 21 the second paragraph.
- 22 A. Okay.
- 23 THE COURT REPORTER: And if I could just
- 24 ask counsel to slow down a little bit, please.
- THE WITNESS: Okay. What's the question?

Page 27

1	BY MR. SAUER:
2	Q. The question is: Are you familiar with
3	the U.S. Government policy adopted in 2014 pausing
4	gain-of-function research on certain viruses?
5	A. Yes, I am familiar with it.
6	Q. And was there an exception in that policy?
7	Yes or no?
8	A. To my to my it says right here an
9	exception; so obviously there was.
10	Q. Were you aware of that exception at the
11	time
12	A. Because
13	Q it was adopted?
14	A. Either at the time it was adopted or
15	sometime thereafter. And to my recollection and,
16	again, this was 2014; so we're talking eight years
17	ago, but my recollection is that the pause was for
18	all research such as this until a new U.S. Government
19	research policy could be developed.
20	Q. And was there an exception to that pause
21	that's set forth in the footnote on your
22	understanding?
23	A. Yeah. The deliberations at the time based
24	on the need to continue certain critical research
25	that an exception clause was put in saying that under

Page 28

- 1 special circumstances -- and I'll read it so that you
- 2 get an understanding -- an exception from the pause
- 3 may be obtained if the head of a U.S. Government
- 4 funding agency determines that the research is
- 5 urgently needed to protect the public health or
- 6 national security.
- 7 So at the time that the pause on all of
- 8 this research was implemented, it was felt strongly
- 9 by just about everybody in the research community and
- 10 the public health community that if you paused
- 11 everything, there might be a situation where you
- 12 would want to do an experiment that would be urgently
- 13 necessary to protect the public health and national
- 14 security and, therefore, that would allow an
- 15 exception to be considered.
- 16 Q. Did you ever invoke that exception when --
- or you're the head of a U.S. Government funding
- 18 agency --
- 19 A. Yeah.
- 20 **Q.** -- aren't you?
- 21 A. Yeah.
- 22 Q. Did you ever invoke that exception during
- 23 the years the pause was in place?
- A. As I recall, exceptions were given to a
- 25 couple of experiments. To my recollection, that does

Page 29

- 1 not usually rise up to the office of the director but
- 2 is handled at the level of staff and deputy. So I
- 3 don't recall. It is possible, though I doubt it, but
- 4 it is possible that a piece of paper that was an
- 5 ultimate signoff on an exception came to my desk, but
- 6 I doubt it because I do not recall specifically ever
- 7 being someone that put a piece of paper in front of
- 8 me and said "we're going to have an exception. Would
- 9 you sign off on it?" So it is likely, though, again,
- 10 I'm not certain. It was eight years ago. It was
- 11 likely that it was done at the staff level or at the
- 12 level of my deputy or someone like that.
- 13 Q. It -- is it your understanding that anyone
- 14 at NIAID authorized any research under this pause
- 15 during the years that the gain -- the -- the
- 16 moratorium was in effect?
- 17 A. Again --
- 18 MR. KIRSCHNER: Objection. Calls for
- 19 speculation.
- 20 BY MR. SAUER:
- 21 Q. If you know?
- 22 A. My memory is vague about this because it
- 23 was eight years ago, but I understand in subsequent
- 24 discussions that there may have been a couple of
- 25 exceptions to that in the context of research that

Page 30

- 1 was considered necessary for the protection of the
- 2 public health or national security.
- 3 Q. Did any of those projects relate to
- 4 research on viruses conducted by EcoHealth Alliance?
- 5 MR. KIRSCHNER: Objection. Assumes
- 6 evidence not in the record.
- 7 THE WITNESS: Yeah. I'm not certain. I
- 8 don't -- I don't really recall. I know -- I believe
- 9 that after the fact, I was brought -- it was brought
- 10 to my attention that there were exceptions. I am not
- 11 quite sure what the exceptions were for, but there
- 12 were a couple of exceptions.
- 13 BY MR. SAUER:
- 14 Q. Who in your agency would have authorized
- 15 those, if not you?
- 16 A. Well, it could have been any of a number
- of people. It could have been people at the program
- 18 level. It could have been my deputy. It could have
- 19 been program managers and division directors.
- Q. Who's your deputy?
- 21 A. Dr. Hugh Auchincloss.
- Q. How do you say his last name, Auchincloss?
- A. Auchincloss, A-U-C-H-I-N-C-L-O-S-S.
- Q. What's his title?
- 25 A. Principal deputy director.

Page 31

1	Q. I'm giving you a document we've marked as
2	Exhibit 4.
3	
	(FAUCI Exhibit No. 4 was marked for
4	identification.)
5	BY MR. SAUER:
6	Q. And do you see this Nature Medicine
7	article entitled "A SARS-like cluster of circulating
8	bat coronaviruses shows potential for human
9	emergence"?
10	A. Yes.
11	Q. Were you familiar with this this
12	article when it was published in 2015?
13	A. I was not familiar with it when it was
14	published in 2015.
15	Q. When did you first become aware of it?
16	A. I believe again, I read a lot of
17	articles I believe it was brought to my attention
18	in the context of questions that were raised by
19	members of Congress about experiments that were
20	funded by the NIAID.
21	Q. So would that have been in and around 2021
22	time frame, do you know, when you first became aware
23	of it?
24	A. It certainly was after the beginning of
25	the COVID-19 outbreak.

Page 32

1	Q. How long after the beginning would you
2	estimate?
3	A. I don't recall.
4	Q. Would it have been right at the beginning
5	of the outbreak or months into it or years into it?
6	A. You know, years is where we are right now.
7	So it wouldn't have been years. So it likely would
8	have been several months, though I'm not a hundred
9	percent certain.
10	Q. And so who are the last two authors listed
11	on the top there?
12	A. Well, one is Ralph Baric, who I believe is
13	a scientist at North Carolina, who is a long-term
14	grantee of NIAID.
15	Q. Do you know Ralph Baric?
16	A. Not really. I know who he is. I doubt if
17	I've ever met him. I may have met him at one of the
18	meetings where there are thousands of scientists
19	saying hi to each other, but I know who he is. He is
20	a scientist at University of North Carolina.
21	Q. And he's funded by NIAID?
22	A. He is.
23	Q. But you don't remember ever meeting him in
24	person?
25	A. Again, I don't recall. I could have met
	11. Again, I don a recarr. I could have met

Page 33

Fax: 314.644.1334

- 1 him. Again, I run into several thousands of
- 2 scientists that we refer to, but I don't recall
- 3 certainly having a relationship with him.
- 4 Q. How about the person that's listed
- 5 immediately before him listed here as Zhengli Shi?
- 6 Do you know who that is?
- 7 A. I believe, if I'm correct, that this is a
- 8 scientist who is at the Wuhan Institute of Virology,
- 9 I believe. I'm not a hundred percent certain. I get
- 10 sometimes confused with Asian names, but I believe
- 11 this is the person who is a scientist at the Wuhan
- 12 Institute.
- 13 Q. And are you aware generally that there's
- 14 someone called Shi Zhengli who's described in the
- 15 media as the bat woman who does research on bat
- 16 coronaviruses at the Wuhan lab --
- 17 A. Yeah, is that her? I don't know if that's
- 18 the same person. Like I said, when you're dealing
- 19 with Asian names, sometimes the first name is last
- 20 and the last name is first. So I -- I -- I believe
- 21 this is the person from Wuhan.
- 22 Q. Have you ever met that person before?
- 23 A. To my knowledge, I haven't. I don't --
- 24 I'm fairly certain I have not. I could possibly,
- 25 again, have run into her at one of the many

Page 34

1	scientific meetings that occur, but I don't
2	specifically recall ever personally running into her.
3	Q. Can I direct your attention to the
4	beginning of the pandemic or at least the beginning
5	of the outbreak? Do you remember when you first
6	became aware that there was an outbreak of a new
7	coronavirus in China?
8	A. It was either December 31st or the first
9	couple of days of the new year of 2020. So it was
10	either December the 31st of 19 2019 or the first
11	couple of days of 2020.
12	Q. Do you recall at some point somebody,
13	anybody, raising concerns to you in January of 2020
14	at the beginning of the outbreak or near
15	the beginning of the outbreak that the virus might
16	have been genetically engineered or originated in a
17	laboratory?
18	A. There was a phone call in late January of
19	2020, I believe, from Jeremy Farrar. There was one
20	other person on the phone. I believe it was
21	Christian Anderson, who piped me in on a three-way
22	call, saying that they looked at the virus and there
23	was some concern about the molecular configuration or
24	makeup of the virus that made them think there was a
25	possibility that there could have been a manipulation

Page 35

-				
- 1	$\sim$ $\pm$	+ 60	virus.	
- 1	()	1 11 —	V I I II 5 -	
	~	0110	·	

- 2 Q. Before that, had anyone raised a concern
- 3 like that to you?
- 4 A. To my recollection, no.
- 5 Q. How about Robert Redfield? Who's he?
- 6 A. Robert Redfield at the time was the
- 7 director of the Centers for Disease Control and
- 8 Prevention.
- 9 Q. Did he call you in mid January 2020 and
- 10 raise that kind of concern about whether or not the
- virus originated from nature or in a laboratory?
- 12 A. To my recollection, no. I know that Bob
- 13 today talks about that. I don't recall back in
- 14 January of 2020 whether Bob was involved or not in
- 15 any discussion about the manipulation of the virus.
- Q. Are you aware if there -- if there's any
- 17 relationship between Peter Daszak and Shi Zhengli,
- 18 the two coauthors of that study I showed you in
- 19 Exhibit 4? Do they work together or what's your
- 20 understanding of that?
- 21 MR. KIRSCHNER: Objection. Calls for
- 22 speculation. Vague. Ambiguous.
- THE WITNESS: Can you repeat the question?
- 24 BY MR. SAUER:
- Q. Are you -- do you know whether there's a

Page 36

Fax: 314.644.1334

1	working	relationship	hatwaan	Sh i	7honali	and
	WOLKING	Teracronsurb	DerMeeti	SIII	Thengri	and

- 2 Peter Daszak?
- 3 A. Well, I do know now. I didn't know it at
- 4 the time, but I do know now that EcoHealth has a
- 5 subaward from their original grant that goes to
- 6 Shi Zhengli at the Wuhan Institute of Virology.
- 7 Q. So they work together on research that's
- 8 funded directly by NIAID --
- 9 A. The -- yeah, the funding goes to EcoHealth
- 10 which awards a subaward. To my knowledge and
- 11 recollection, it is a five-year grant of somewhere
- 12 between 500,000 and \$600,000. I believe it averages
- about 120 to \$130,000 a year for a five-year period.
- 14 Q. Do you know whether Peter Daszak has
- 15 access to, for example, the genomes of viruses that
- 16 Shi Zhengli has generated at the Wuhan Institute of
- 17 Virology?
- 18 MR. KIRSCHNER: Objection.
- 19 Mischaracterizes the evidence.
- 20 MR. SAUER: I'm just asking him if he
- 21 knows.
- 22 MR. SAUER:
- Q. Do you know? I'm just asking if you know.
- A. Again, repeat the question. I want to
- 25 make sure I give you an accurate answer.

Page 37

1	Q. Do you know whether Peter Daszak had
2	access, or is in possession of data generated by Shi
3	Zhengli pursuant to their research together,
4	including the genomes of Coronaviruses?
5	A. I don't know absolutely for sure, but I
6	would imagine that if Peter Daszak is collaborating
7	scientifically with Shi Zhengli, that it is likely,
8	given the norms of scientific collaboration, that he
9	would have access to data if they were indeed
10	collaborating, which it looks like, from what I have
11	learned subsequently, that they are collaborators,
12	since he has a subaward to the Wuhan Institute that I
13	believe goes to Dr. Shi.
14	Q. Would it be ordinary practice for someone
15	in his position to have access to her data when he's
16	funding her, essentially through subawards?
17	A. That would be not be unusual and probably
18	likely.
19	Q. Can I give you Exhibit 5? We're
20	premarking them.
21	(FAUCI Exhibit No. 5 was marked for
22	identification.)
23	MR. SAUER:
24	Q. If you look at the top there, there's
25	someone sending an e-mail to you and Jen Routh called

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 38

1	Grea	Folkers.	Who's	Grea	Folkers?
_	$\sigma \pm \sigma \sigma$	TOTACTO.	11110	$\sigma \pm c \sigma$	TOTACTO.

- 2 A. Greg Folkers is a member of my inner
- 3 office. He's my immediate chief of staff in my
- 4 office group.
- 5 O. And then who's Jennifer Routh?
- 6 A. She's a member of our communications
- 7 staff.
- 8 Q. And then directly below her, who's
- 9 Courtney Billet?
- 10 A. She is the director of the Office of
- 11 Communication, Legislative Affairs, and Government
- 12 Outreach.
- 13 Q. And if you look at all these people on the
- 14 CC line, are they all within your kind of -- I think
- you described it as your inner office?
- 16 A. Yes. They are in the immediate office of
- 17 the director.
- 18 O. And it looks like the attachment was
- indicated with talking points for NIAID director,
- 20 Dr. Fauci?
- 21 A. Right.
- Q. Would that be a common thing for your
- 23 chief of staff to do, to prepare talking points for
- when you're going to a press appearance or something
- 25 like that?

Page 39

1	A. That would be a not unusual thing if I was
2	going to whatever, a meeting or a congressional
3	briefing or what-have-you, and a subject was brought
4	up that I was not particularly familiar with, that my
5	staff would put together talking points to at least
6	update or inform me about what the meeting was about
7	and things that I should know about it.
8	Q. If you look in the body of the e-mail,
9	that kind of second paragraph that begins: "Also,
10	hyphen, hyphen."
11	Do you see that?
12	A. Wait a second. Where are we now?
13	Q. Well, kind of very close to the top,
14	second kind of text cluster that begins, "Also, when
15	talking about CoV, not necessarily in this venue"
16	Do you see that?
17	A. No, I'm really sorry. As a placeholder,
18	looks good, that's the first paragraph. "Also,"
19	okay, we're talking I got it.
20	Q. And Greg Mr. Folkers says to you, "We
21	have on our team," and then in parentheses, Vincent
22	and folks we fund, Peter Daszak, Ralph Baric, Ian
23	Lipkin, et cetera, "probably the world's experts
24	on nonhuman coronaviruses."
25	Do you see that?

Page 40

1	A. Yes.
2	Q. Do know what he means when he said that
3	those people are on your team? Does he mean that you
4	fund them?
5	A. I think he means I'm speculating I
6	don't recall this e-mail of January 27th, 2020. But
7	my speculation is that what Mr. Folkers was referring
8	to were people that were in our group or that we know
9	and are colleagues of ours because I mean, Peter
10	Daszak, we've already mentioned, is a grantee. Ralph
11	Baric is a grantee. Ian Lipkin is a scientist at the
12	Columbia School of Public Health.
13	I believe Vincent, though I don't know,
14	could possibly be Vincent Munster, who is a scientist
15	who's employed by NIAID, and I believe that's what
16	Mr. Folkers was referring to when he was saying
17	when talking about COVID, these are people who are
18	well versed in that area.
19	Q. Who's do you know Ian Lipkin?
20	A. I do.
21	Q. Is he a grantee of
22	A. I believe he is. I mean, he is a
23	well-established scientist in New York City at the
24	Columbia School I believe it's the Mailman School
25	of Public Health.

Page 41

Fax: 314.644.1334

1 Two paragraphs down, it says, "NIAID has Q. 2 funded Peter's group, " referring to Mr. Daszak, "for 3 coronavirus in China for the past five years through 4 understanding the risk of bat coronavirus emergence"; 5 correct? And then the grant number. 6 Α. Yes, I see that. 7 0. And that, I take it, would be the grant that we referred to earlier in Exhibit 2, with the 9 same title, "Understanding the risk of bat 10 coronavirus emergence"? 11 MR. SAUER: Objection. Calls for 12 speculation. 13 THE WITNESS: I'm looking at 14 Exhibit Number 2 and the title is, "Understanding the 15 risk of bat coronavirus emergence," and that is the 16 quote that is here, and the grant number is 1R01 --17 BY MR. SAUER: 18 Q. Let me ask you this -- I don't need to the 19 hear the grant number? Can I just ask you --20 Α. Well, I'm trying to make sure that I'm 2.1 referring -- to give you a correct answer -- which is 2.2 the question you asked me: Is this referring to 2.3 this? And it looks like the grant numbers match and 24 the titles match, so my answer to your question is 25 yes -- they're referring to.

Page 42

1	MR. KIRSCHNER: Counsel, I just would ask
2	to let the witness fully respond before cutting him
3	off.
4	BY MR. SAUER:
5	Q. Do you recall that grant being placed on
6	your radar screen on January 27th of 2020?
7	A. Based on this e-mail, it looks like
8	Mr. Folkers has at least mentioned it, but I wouldn't
9	characterize that as being, quote, put on my radar
10	screen to the point of garnering my precise attention
11	to it.
12	Let me finish reading the e-mail. It
13	says, "That's now been renewed with a specific focus
14	to identify cohorts of people exposed to bats in
15	China and work out if they're getting sick from
16	COVID. Erik Stemmy is the program officer and the
17	collaborators include the Wuhan Institute and Ralph.
18	The results of the work."
19	Yeah, I mean, I think this was likely the
20	situation where, when the idea of an outbreak in
21	China was brought up, or the coronavirus, that my
22	staff thought it would be important for me to
23	understand just the kind of things we were doing.
24	And I think the important sentence in here, which is
25	relevant, is that the grant wanted to

Page 43

Fax: 314.644.1334

- 1 identify cohorts of people exposed to bats in China,
- 2 and the reason for that is wanting to see if there
- 3 was the possibility of spillover from bat viruses to
- 4 humans that might or might not be related to
- 5 SARS-CoV-2. I believe that was the intent of this
- 6 briefing talking points, if I'm not mistaken.
- 7 Q. You're being given an exhibit that's
- 8 labeled Exhibit 6.
- 9 (FAUCI Exhibit No. 6 was marked for
- 10 identification.)
- 11 MR. KIRSCHNER: Counsel, I would ask that
- 12 Dr. Fauci be given the opportunity to familiarize
- 13 himself with this document prior to being asked
- 14 questions related to it.
- 15 THE WITNESS: Okay. February 1st.
- 16 BY MR. SAUER:
- 17 Q. I think you testified earlier that you
- 18 recalled the first time the concern about the origin
- of the virus being posted on your radar screen was
- 20 from a call from Christian Anderson and Jeremy
- 21 Farrar; is that right?
- 22 A. Yeah. I believe that my recollection from
- 23 a few years ago, that that's the first I became aware
- 24 of this concept of the possibility of there being a
- 25 manipulation of the virus.

LEXITAS LEGAL Phone: 1.800.280.3376

Page 44

1	Q. Do you remember what was said in that
2	call?
3	A. To my recollection, on that call, Jeremy
4	and Christian said they had looked at or at least
5	Christian did, possibly Jeremy and maybe one other
6	scientist and said that it is possible that there
7	may have been a manipulation because it was an
8	unusual virus. And on that call, I and others said,
9	"Well, that being the case, we should bring together
10	a group of highly qualified international
11	evolutionary virologists to discuss the issue, and to
12	see what the way forward would be to try to clarify
13	that."
14	And that was the phone call that we
15	arranged, I believe for the following day, on
16	February 1st, if I'm not mistaken. I think those are
17	the dates. I'm fairly sure, but
18	Q. You say I and others on the call suggested
19	arranging a group of scientists to discuss this. Who
20	are the others?
21	A. Again, I believe I'm fairly certain,
22	although I'm not 100 percent that was a few years
23	ago that Jeremy Farrar was one and Christian
24	Anderson was another. Eddie Holmes could possibly
25	have been in on that. I know he got involved in this

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 45

Fax: 314.644.1334

2	Q. Who's Eddie Holmes?
3	A. Eddie Holmes is a very
4	well-recognized evolutionary virologist who works in
5	Australia.
6	Q. Does he receive funding from your agency?
7	A. I don't know. I'm not certain whether he
8	does or not.
9	Q. Do you know Eddie Holmes?
10	A. I don't know him personally, but I know of
11	him. He's a very highly what's the right word for

### 13 Q. Do you know Christian Anderson?

14 A. I know Christian. Not well. I've spoken

it? Highly respected evolutionary virologist.

- 15 to him a few times. I believe the first time -- and
- 16 again, when you say "Do you know," remember, we all
- 17 go to international meetings where there are
- 18 hundreds, if not thousands, of people that you
- 19 interact with over the years.
- To my recollection, I've heard of
- 21 Christian Anderson for a while. Christian is a
- 22 internationally renowned scientist. I believe maybe
- 23 the first time that I've actually spoken to Christian
- 24 was on that phone call, but it is possible that
- 25 without recalling, I ran into him and spoke to him on

1

12

later on.

Page 46

4	
1	other occasions.
2	Q. Do you know why he brought that concern to
3	you in particular?
4	MR. KIRSCHNER: Objection. Calls for
5	speculation.
6	THE WITNESS: I would imagine since I am,
7	with all due modesty, recognized as one of the top
8	infectious disease people in the country and the
9	director of the major research institution for
10	infectious diseases in the world that Christian and
11	Jeremy I know I've known Jeremy for a long time
12	that they thought it would be a good idea to give me
13	a call since I'm looked upon, rightly or not, as the
14	top government infectious diseases person, and they
15	felt, I believe you'll have to ask them but I
16	felt they believed, since I'm generally considered
17	the top government infectious disease person, that it
18	would be appropriate to let me know at the same time
19	as we brought in I don't have the list in front of
20	me of the scientists we brought together on the phone
21	call the following day, which was a Saturday let
22	me finish because I think it's important because
23	the people we brought in, we tried to get a large
24	international group of people together so we could
25	have well representation. As to my recollection,

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 47

- 1 there were people like Sir Patrick Vallance, who was
- 2 the chief scientist in England on the phone, among
- 3 other people.
- 4 BY MR. SAUER:
- 5 Q. Could I pause for a second?
- 6 A. Sure.
- 7 Q. This is a deposition. I'm going to ask
- 8 you questions, and I'm going to ask you to listen to
- 9 the question --
- 10 A. Right.
- 11 Q. -- and answer the question that I'm
- 12 asking --
- 13 A. Okay.
- 14 Q. -- and not go off on, like, a tangent.
- 15 A. Fine.
- 16 Q. Can you agree to do that, please?
- 17 A. I would be happy to do that.
- 18 MR. KIRSCHNER: And, counsel, I would also
- 19 ask you to let the witness provide proper context
- 20 where he feels is necessary in response to your
- 21 questions.
- MR. SAUER: Yeah.
- 23 BY MR. SAUER:
- Q. Let me direct your attention to the first
- 25 page of Exhibit 6 in front of you. At the bottom of

Page 48

- 1 that page, you see it indicates that on Friday,
- 2 January 31st, 2020, at 18:47, you wrote an e-mail to
- 3 Jeremy and Christian saying "this came out today.
- 4 You may have seen it. If not, it is of interest to
- 5 the current discussion"; correct?
- 6 MR. KIRSCHNER: Objection, Your Honor --
- 7 not Your Honor.
- 8 THE WITNESS: Well, you're very honorable
- 9 but go ahead.
- 10 MR. KIRSCHNER: I just would like the
- 11 witness to have an opportunity to familiarize himself
- 12 with the document.
- MR. SAUER: I'm just directing his
- 14 attention to that spot on the page.
- 15 BY MR. SAUER:
- 16 Q. Do you see the spot I referred to?
- 17 MR. KIRSCHNER: Well, I would like to make
- 18 sure that the witness is familiar with the
- 19 document --
- 20 BY MR. SAUER:
- 21 Q. Right here.
- 22 MR. KIRSCHNER: -- prior to answering
- 23 questions about the document.
- 24 BY MR. SAUER:
- 25 Q. So I just asked if you see that spot on

Page 49

1	the page?
2	A. Where it says "this just came out today"?
3	Q. Yeah.
4	A. Yes.
5	Q. And is that a reference to the article by
6	Jon Cohen in Science Magazine?
7	A. You know, I don't recall.
8	Q. You don't recall sending that message?
9	A. No, no. I
10	MR. KIRSCHNER: Object
11	THE WITNESS: No, no. Let me finish.
12	MR. KIRSCHNER: Go ahead.
13	THE WITNESS: You're asking me a question.
14	When you say "this just came out today," and on the
15	next page of Exhibit 6, there's an article by
16	Jon Cohen on mining coronavirus genomes for clues in
17	the outbreak, since they are juxtaposed together, I
18	imagine that that's what I sent, but I don't recall
19	specifically that article.
20	BY MR. SAUER:
21	Q. Do you know do you know why you would
22	have said that article is of interest to the current
23	discussion?
24	MR. KIRSCHNER: Objection. Assuming
25	evidence not in the record. Mischaracterizes the

Page 50

1	testimony.
2	THE WITNESS: Looking at the title of the
3	article, which is "Mining Genomes for Clues in the
4	Outbreak," you know, I'm not sure exactly why I would
5	have sent it. Imagine is that if they're referring
6	to the genomic makeup of the virus and we were
7	talking about the genomic makeup of SARS-CoV-2 that
8	raised some suspicion on the part of Christian and
9	Jeremy, that's an article in science by Jon Cohen
10	that talks about genomes of virus would be, as it
11	said, might be of interest to the current discussion.
12	I imagine that's what I was referring to.
13	BY MR. SAUER:
14	Q. If you look staying on Page 1, if you
15	look immediately above your e-mail, do you see the
16	kind of response e-mail from Dr. Anderson?
17	A. Let me read it.
18	Yeah.
19	Q. Okay. And you see in the second paragraph
20	that e-mail
21	A. Yeah.

24 Eddie, Bob, Mike and myself all find the genome

25 inconsistent with expectations from evolutionary

after discussions earlier today, says Dr. Anderson,

-- where he mentions I should mention that

Fax: 314.644.1334

22

23

Page 51

-	
1	theory?
2	A. Right.
3	Q. Do you know who Eddie is?
4	A. Eddie Holmes probably.
5	Q. Do you know who Bob is?
6	A. Could be Bob Garry. I'm not sure.
7	Q. And do you know Mike is?
8	A. I don't, but it could be Mike Laribee.
9	I'm not sure.
10	Q. Okay. And then immediately above that
11	at Dr. Anderson said, "the unusual features of the
12	virus make up a really small part of the genome so
13	one has to look really closely at all of the
14	sequences to see that some of the features
15	potentially look engineered
16	A. Right.
17	Q correct?
18	A. Yes.
19	Q. Does that is that the sort of concern
20	that he had raised in the call you had earlier that
21	day on Friday, January 31st?
22	A. The answer is, yes, he was referring to
23	some unusual features, but if I might just take an
24	extra five seconds, it says the unusual features of
25	the virus make up a really small part of the genome

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 52

Fax: 314.644.1334

- 1 and one has to look really closely, and that was the
- 2 tone of the discussion.
- 3 And just quickly referring to the last
- 4 sentence in the second paragraph when he was talking
- 5 about inconsistent with expectations from
- 6 evolutionary theory, the next sentence says, "but we
- 7 have to look at this much more closely and there are
- 8 still further analyses to be done, so those opinions
- 9 could still change."
- 10 Q. Did you think this was an alarming concern
- 11 that he was raising?
- 12 A. I think it was an interesting and
- important concern, and that was the reason why we all
- 14 agreed it would be a very good idea to get a larger
- 15 group of qualified evolutionary virologists to look
- 16 closely, more than just a quick look, but a look over
- 17 a period of a couple of days at the virus to see if,
- 18 in fact, this concern and suspicion was justified or
- 19 there could be another explanation for it.
- Q. Can you stay in that same document,
- 21 Exhibit 6, and flip ahead to the eighth page of the
- document that's got a Bates Number 2432 at the
- 23 bottom?
- MR. KIRSCHNER: Counsel, I, again, ask you
- 25 to allow Dr. Fauci sufficient time to -- actually,

LEXITAS LEGAL Phone: 1.800.280.3376

Page 53

- 1 counsel, this seems to be several documents together.
- 2 I'm a little confused what's going on with -- with --
- 3 with this exhibit.
- 4 BY MR. SAUER:
- 5 Q. Can you turn to the eighth page of the
- 6 exhibit, please?
- 7 MR. KIRSCHNER: Well, I would like for
- 8 Dr. Fauci to have an opportunity to familiarize
- 9 himself with this exhibit prior to answering
- 10 questions.
- 11 MR. SAUER: I just want him to look at the
- 12 eighth page.
- 13 BY MR. SAUER:
- 14 Q. Do you see the eighth page?
- 15 A. Is that 2421?
- 16 **o. 2432.**
- 17 A. Oh, excuse me, 2432. I'm sorry. This --
- 18 the numbers are kind of -- oh, it's going the
- 19 opposite direction. Sorry. The -- I got 2430 and
- 20 then it's followed by 2431, and then it's 2421.
- MR. KIRSCHNER: I have the same.
- THE WITNESS: I'm sorry. I'm confused.
- 23 BY MR. SAUER:
- Q. Can you go to -- starting at the first
- page, count eight pages. One, two, three, four,

Page 54

1	five, six, seven, look at the eighth page.
2	MR. KIRSCHNER: Well, counsel, this seems
3	to be out of order with the Bates stamping, and so I
4	would object to this as being misleading. 2432 is
5	inserted in this document between 2402 and 2426.
6	MR. SAUER: Off the record, please. Can
7	we go off the record?
8	THE VIDEOGRAPHER: Time is 9:04 a.m., and
9	we are going off the record.
10	(Discussion off the record.)
11	(Recess.)
12	THE VIDEOGRAPHER: The time is 9:05 a.m.,
13	and we're back on the record.
14	BY MR. SAUER:
15	Q. Dr. Fauci, do you see the eighth page of
16	this document?
17	A. Yeah. If it's the one that says, "Hugh,
18	it's essential that we speak," yeah.
19	Q. Correct, yeah. And at the top of this
20	page, you sent this e-mail to Hugh Auchincloss?
21	A. Correct.
22	Q. Is that how you say his name?
23	A. That's correct.
24	Q. You sent this e-mail to Hugh Auchincloss,
25	your principal deputy

Page 55

	raye 30
1	A. Yes.
2	Q. Did you send it at 12:29 a.m. on Saturday,
3	February 1st?
4	A. Yes.
5	Q. In the "To" e-mail, there's a cc there
6	that's redacted out. Do you know who you CC'd on
7	this e-mail?
8	A. No. I don't recall.
9	Q. Would you have CC'd one of your personal
10	e-mail addresses on this?
11	A. No, I very rarely do that.
12	Q. Have you ever done that? Have you
13	ever CC'd your personal e-mail on a
14	work-related matter?
15	A. You know, I don't recall. I doubt that.
16	I doubt that.
17	Q. Do you see there's an attachment listed on
18	this e-mail? Attachments? Do you see where it says,
19	Shi, et al., Nature Medicine
20	A. Yeah.
21	Q SARS Gain of Function?
22	A. Right.
23	Q. Do you know what that attachment was?
24	It's not included on the e-mail.
25	A. You know, it says, "SARS Baric, Shi, et

Page 56

1	al	Nature	Medicine."	T+	could	nossihla	, hatre
	$\alpha_{\perp}$	Nacarc	IICUTCTIIC.	_ L	COULU	POSSIBLY	i i a v C

- been -- it could possibly -- again, I don't know for
- 3 sure, but it's certainly consistent with it being
- 4 Exhibit No. 4.
- 5 O. And that is the 2015 article?
- 6 A. Right.
- 7 Q. Coauthored?
- 8 A. Right.
- 9 Q. In part by Ralph Baric and Shi Zhengli
- 10 that we talked about earlier?
- 11 A. Right.
- 12 Q. Do you recall attaching that particular
- exhibit to this e-mail to Hugh?
- 14 A. I can't say that I recall that particular,
- but it is certainly consistent with that because the
- 16 attachment title is Baric, Shi, Nature Medicine.
- 17 So it certainly is consistent with, and
- 18 maybe likely that that's what I was referring to.
- 19 All those things look consistent.
- 20 Q. In other words, that Exhibit 4 is a Nature
- 21 Medicine article; correct?
- 22 A. Exhibit 4 is a Nature Medicine article.
- 23 Q. And two of the coauthors are Baric and Shi
- 24 that we talked about earlier?
- 25 A. Correct. Yes.

Page 57

1	Q. And then did you describe it as a SARS
2	gain-of-function article?
3	MR. KIRSCHNER: Objection.
4	Mischaracterizes the evidence.
5	BY MR. SAUER:
6	Q. Did you describe it as that?
7	A. It looks like it was described as that.
8	Q. Do you know if you were the one who wrote
9	that title describing that article?
10	A. I don't recall. I'm not sure exactly why
11	those words got in there. It was maybe something
12	that was mentioned by Baric. I don't really recall.
13	That was some time ago.
14	Q. Do you think that that article, it refers
15	to the gain of function or do you not recall?
16	A. I don't recall.
17	Q. Do you know why you attached that article
18	to this e-mail to Hugh, your principal deputy?
19	A. I don't recall, but I believe and
20	again, I would say I don't precisely recall, but
21	there was some recollection or someone told you that,
22	you know, we do fund research in China,
23	particularly surveillance research I think you
24	referred to it when you gave me one of the exhibits
25	about the surveillance of what might be out in the

Page 58

Fax: 314.644.1334

- 1 community among bats. And at my recollection, I
- 2 brought to Hugh's attention, saying, "We have to
- 3 speak in the morning, because I want to find out what
- 4 the scope of what it is that we are funding so I'll
- 5 know what we're talking about."
- And that's what I was referring to when I
- 7 said you will have tasks today to give me some
- 8 information because this was the first that I had
- 9 heard about specifics of what EcoHealth and what
- 10 other people were doing, and I wanted my staff to say
- 11 get me up to date. So that's what I meant by you
- 12 have work to do.
- 13 Q. And you said that it was essential that we
- speak this morning, this a.m.; correct?
- 15 A. Right.
- 16 Q. And so you wanted him -- and you said keep
- your cell phone on; correct?
- 18 A. Right. Yeah. And the reason is that I
- 19 know that we were going to have a phone call with the
- 20 larger group of evolutionary virologists, and this is
- 21 the first that I had heard of what we may or may not
- 22 be funding through EcoHealth and others, and I wanted
- 23 to get a better scope of just what the terrain of
- 24 what we were doing in collaboration with different
- 25 scientists, and that's why I asked him that question.

LEXITAS LEGAL Phone: 1.800.280.3376

Page 59

1	Q. Did you call Hugh's cell phone that day?
2	A. I don't recall if I did.
3	Q. Do you remember talking to him at all that
4	day?
5	A. I might have, but I don't recall.
6	Q. Later in the e-mail, you say, "Read this
7	paper, as well as the e-mail that I will forward to
8	you now."
9	A. Right.
10	Q. What are the tasks that must be done
11	today?
12	A. I wanted to be briefed on the scope of
13	what our collaborations were and the kind of work
14	that we were funding in China. I wanted to know what
15	the nature of that work was.
16	Q. Were you concerned at that time that the
17	work that you had funded in China might have led to
18	the creation of the coronavirus?
19	A. I wasn't concerned that it might have, but
20	I didn't like the fact that I was completely in the
21	dark about the totality of the work that were
22	being done, and I was going into a phone call with a
23	larger group of established scientists and I wanted
24	to have at my fingertips just what we were and were
25	not doing.

Page 60

1	Q. In the call earlier that evening, had
2	Christian Anderson or Jeremy Farrar raised this 2015
3	Nature Medicine paper in any way?
4	A. I don't recall.
5	Q. How did you think of it? How did this
6	why were you, at midnight, a little after midnight,
7	thinking of this particular 2015 article?
8	A. I don't recall.
9	Q. Do you remember how this article kind of
10	got on your radar screen at all?
11	A. I don't recall.
12	Q. And I think I showed you earlier, the
13	e-mail, I think is Exhibit 5, where it refers to the
14	grant pursuant to that coronavirus from about three
15	days earlier? Do you remember that?
16	A. I'm sorry. You're going pretty quickly
17	Q. Sorry.
18	THE COURT REPORTER: Also, Counsel, I need
19	you to slow down.
20	BY MR. SAUER:
21	Q. Let's move on actually. Your testimony is
22	you do not remember how you became aware at this time
23	of the Shi, Baric Nature Medicine paper; correct?
24	A. Say that again? At this time, I'm sorry,

I'm not getting your question clearly.

25

Page 61

1	Q. Do you recall how you became aware of this
2	attachment that you've called Baric, Shi, et al.,
3	Nature Medicine SARS gain-of-function?
4	A. I don't recall I mean, I became aware
5	of it, but right now, I really don't recall what
6	specific day I became aware of it.
7	Q. In your e-mail, you tell Hugh, "Read this
8	paper as well as the paper I will forward to you
9	later on."
10	Can you turn to the next page?
11	A. Yeah.
12	Q. And here it's an e-mail just a couple
13	minutes later it's literally the same minute that
14	you sent to Hugh at 12:29 a.m. on Saturday, February
15	1st, 2020; correct?
16	A. Right.
17	Q. And here you're forwarding him that same
18	Jon Cohen article that you had sent to Christian
19	Anderson and Farrar?
20	A. Did I send it to Christian and Farrar?
21	Yeah.
22	Q. Remember sending it to him and saying to
23	him: This is of interest in the current discussion?
24	This same Jon Cohen e-mail or article?
25	A. I'm sorry. I'm getting confused with your

Page 62

Fax: 314.644.1334

- 1 question. So what is the question? 2 Q. Well, let me ask you this: Looking at 3 this second e-mail to Hugh Auchincloss? 4 Α. Right. 5 Why did you forward him this 0. 6 particular article? 7 MR. KIRSCHNER: Objection. Calls for 8 speculation. 9 THE WITNESS: Yeah, I actually don't 10 recall why I forwarded it to him. 11 BY MR. SAUER: 12 Did you -- you forwarded him two articles, 0. 13 right? The Baric, Shi Nature Medicine article at 14 12:29 a.m., and then the Jon Cohen Science article as 15 well? 16 Α. Yeah. 17 Do you know why you did that? 0. 18 I don't recall why I did that. I think I 19 wanted him to be aware because the question that I 20 was really getting at with him is that I want to find 21 out what the scope of what we were doing in China 2.2 because they obviously called me up and said they had 2.3 a concern about a virus. I wanted to make sure I
  - 25 Q. Do you remember --

knew everything that we were doing there.

24

Page 63

1	A. That was the purpose of my e-mail.
2	Q. Do you remember talking to him about that?
3	MR. KIRSCHNER: Objection. Asked and
4	answered.
5	BY MR. SAUER:
6	Q. If you know?
7	Do you remember talking to Hugh about that
8	concern?
9	A. I don't remember, but I think somewhere it
10	says I think I said I was going to call you
11	somewhere. I'm not I don't recall speaking to
12	him. I I recognize the e-mails because, as I said
13	and I'll repeat, I was going to be on a phone call
14	with a large group of people who are very versed in
15	the field, and I didn't want to go into the phone
16	call not knowing the scope of what our relationship
17	was regarding funding of grants in China. I was not
18	familiar with these grants.
19	Q. Did you ever raise those grants in China
20	in the phone call you had later that day with all the
21	scientists?
22	A. I don't believe I did. I might have, but
23	I don't believe I did. The discussion I was
24	relatively silent in the discussion with the group of
25	about a dozen people. They were all evolutionary

Page 64

Fax: 314.644.1334

- 1 virologists, and the nature of the discussion was
- 2 back and forth about the likelihood or not of there
- 3 being a manipulation.
- 4 No, I don't recall bringing this up. In
- 5 fact, what I did have -- heard in statements from
- 6 people who were on the call that I was, you know,
- 7 quite open and let people talk and decide what they
- 8 wanted to do, but that's not my field, evolutionary
- 9 virology.
- 10 Q. Do you remember saying anything at all on
- 11 that call?
- 12 A. I may have said a few things, but I was
- 13 relatively silent on that call.
- 14 Q. Do you know what they were?
- 15 A. What "what" were?
- 16 Q. The things that you may have said.
- 17 A. No, I don't recall, but I certainly was
- 18 not one of the people actively engaged in the
- 19 discussion. I was relatively quiet because I wanted
- 20 to hear what they had to say.
- 21 Q. Can you flip ahead in that document to --
- 22 five more pages from that ninth page that we were
- on -- or six more pages from that ninth page that we
- were on. There's a document that's Bates Number
- 25 **2421**.

LEXITAS LEGAL Phone: 1.800.280.3376

Page 65

1	A. 2421?
2	Q. Yeah. It's an e-mail from you to
3	A. Yes, got it.
4	Q Lawrence Tabak. Do you have that?
5	A. Yes.
6	Q. Who who who's Lawrence Tabak or
7	Tabak?
8	A. Lawrence Tabak is the at the time was
9	the deputy director of the National Institutes of
10	Health. He is currently the acting director of
11	the National Institutes of Health.
12	Q. Do you see did you forward him the same
13	article at 1:13 in the morning?
14	MR. KIRSCHNER: Objection.
15	Mischaracterizes the time.
16	BY MR. SAUER:
17	Q. Or was that done at a different time?
18	MR. KIRSCHNER: Just for the clarity of
19	the record, counsel, it says 13:19.
20	BY MR. SAUER:
21	Q. Sorry. At 1:19 in the morning?
22	MR. KIRSCHNER: In the morning or
23	afternoon?
24	BY MR. SAUER:
25	Q. Was it in the morning or the afternoon?

Page 66

1	Do you remember?
2	A. Thirteen is, I believe, the afternoon.
3	Q. Let me ask you this: Later that day,
4	then
5	A. Yeah.
6	Q on Friday, February 1st, did you
7	forward Lawrence Tabak the same
8	A. Yeah.
9	Q Nature Medicine article that you sent
10	to Hugh?
11	A. Yeah.
12	Q. Why?
13	A. I don't recall why, but likely I wanted to
14	make sure everyone was aware of what the discussions
15	were. Francis Collins, the director at the time of
16	the NIH, was on that phone call in the morning of
17	February 1st.
18	Q. But that phone call happened in the
19	morning to your recollection?
20	A. I believe it was in the morning.
21	Q. Are you sure it wasn't at 2:00 p.m.?
22	A. I don't recall.
23	Q. If your official calendar reflects a call
24	with Jeremy Farrar at 2:00 p.m. that day, that
25	Saturday, would you dispute that?

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 67

Fax: 314.644.1334

- 1 A. You know, I don't recall when it was. If
- 2 my calendar says it was at 2:00 p.m., then likely it
- 3 was at 2:00 p.m. I don't recall.
- 4 O. Was Mr. Tabak on that call?
- 5 A. I don't believe so. I know that
- 6 Francis Collins was. I don't believe that Larry was,
- 7 but he could have been.
- 8 Q. Were you sending it to him so that he
- 9 could give it to Francis Collins?
- 10 A. I don't recall. That is a possibility
- 11 that I would have done that.
- 12 Q. Had you discussed with Francis Collins
- 13 that day this concern about -- concern -- had you
- 14 discussed with Francis Collins that day the
- possibility that NIAID had funded research in China?
- 16 A. I don't believe so. I -- I mean, that we
- 17 funded research in China? Well, everybody knows we
- 18 fund research in China.
- 19 Q. More specifically, had you discussed with
- 20 Francis Collins that day an issue that you may
- 21 have -- that NIAID may have funded
- 22 coronavirus-related research in China?
- 23 A. You know, I'm not sure exactly the point
- 24 you're making.
- Q. I'm just asking if you discussed that

LEXITAS LEGAL Phone: 1.800.280.3376

Page 68

-	
1	issue with Francis Collins?
2	A. I don't recall
3	Q. Okay.
4	A to be honest with you.
5	Q. That's all I'm can you turn to the next
6	page? Do you see this e-mail exchange between you
7	and Hugh Auchincloss?
8	A. Yeah.
9	Q. Okay. What's the time of this e-mail?
10	17:51, is that 5:51 in the afternoon where you
11	sent
12	A. Yeah.
13	Q. And then you respond in the e-mail that he
14	sent you at 11:47 a.m. that morning; is that correct?
15	MR. KIRSCHNER: Counsel, I would ask if
16	you'd give Dr. Fauci a moment to familiarize himself
17	with this document prior to asking questions.
18	THE WITNESS: Okay. The paper you sent me
19	says the experiments were provided
20	^ (Witness reading to himself.)
21	THE WITNESS: I'm not sure what that means
22	since
23	(Witness reading to himself.)
24	THE REPORTER: And, Dr. Fauci, I need you
25	to speak up.

Page 69

- 1 THE WITNESS: Okay. I'm reading from an
- 2 e-mail from Hugh Auchincloss to me at 11:47 a.m. on
- 3 February 1st, 2020. And --
- 4 BY MR. SAUER:
- 5 Q. I'm not asking you to read the e-mail.
- 6 I'm just asking you to --
- 7 A. Okay. But she asked me to.
- 8 Q. I'm asking you to identify what time that
- 9 e-mail from Hugh was sent to you.
- 10 MR. KIRSCHNER: And, Counsel, I'm asking
- 11 you to give the witness an opportunity to familiarize
- 12 himself with this document.
- 13 THE WITNESS: And what's what I was
- 14 reading when you're telling me to read it out loud.
- 15 So let's get together here.
- 16 THE REPORTER: And if you read on the
- 17 record, I need you to speak up so that I can get it
- 18 on the record --
- 19 THE WITNESS: Okay. I'll keep my mouth
- 20 shut and read it silently so it's not on the record.
- Okay. What's the question, sir?
- 22 BY MR. SAUER:
- Q. Hugh e-mailed you saying, "The paper you
- sent me says the experience would perform before the
- 25 gain-of-function pause that have since been reviewed

Page 70

1	and approved by the NIH."
2	Do you know what he was referring to when
3	he said that?
4	A. I don't know exactly, but I'm assuming and
5	I think correctly, apropos of what I've been telling
6	you for the last several minutes, is that I wanted to
7	get a feel of the scope of what we were doing, and I
8	had mentioned to Hugh, I'm sure, "Hugh, I want to
9	know everything that's going on because I want to
10	make sure that I understand all of what our
11	involvement is in funding research in China."
12	And Hugh's response was he looked at it
13	and he said everything's been reviewed and approved
14	by NIH, and Emily, who is Emily Erbelding, is the
15	director of the Division of Microbiology and
16	Infectious Diseases, and she would have been the one
17	who was closest to the ground in understanding what
18	we were doing in funding China.
19	And it says, "Emily is sure that no
20	coronavirus work had gone through the P3 framework,
21	which means it did not rise to the level of concern
22	to get the extra approval of P3CO. She will try to
23	determine if we have any distant ties to this
24	work and above all of these sentences and
25	statements are compatible with what I mentioned to

Page 71

- 1 you a couple of times now is that this being the
- 2 first time I had heard of this, I wanted to be
- 3 briefed as to the extent of our involvement
- 4 with funding in China.
- 5 Q. Did you raise a specific concern with Hugh
- 6 about the possibility that the 2015 research paper
- 7 had been inconsistent with the gain-of-function
- 8 moratorium that was in place -- put in place in 2014?
- 9 MR. KIRSCHNER: Objection. Vague.
- 10 Ambiguous.
- 11 THE WITNESS: Again, I'm sorry. Did --
- 12 did I --
- 13 BY MR. SAUER:
- Q. Did you raise a specific concern with Hugh
- 15 that the research reflected in the Baric, Shi Nature
- 16 Medicine paper may have been inconsistent with the
- 17 pause on --
- 18 A. Right.
- 19 Q. -- gain-of-function funding research?
- 20 A. That is possible. As I've said, again,
- 21 very consistent with what I've been saying, I wanted
- 22 to make sure I had a good feel for the scope of what
- 23 we were doing regarding research that we fund in
- 24 China. Since that was not something that was on my
- 25 radar screen, and I will say so that you understand,

Page 72

- 1 this is a \$120,000 a year grant in a \$6.3 billion
- 2 portfolio. So --
- 3 Q. Above that on the e-mail you respond to
- 4 Hugh, "Okay, stay tuned." Do you see that?
- 5 A. Yes.
- 6 Q. Stay tuned. Did you have any follow-up
- 7 communications with him about this?
- 8 A. I don't recall.
- 9 Q. Do you remember talking to Emily Erbelding
- 10 about it at all?
- 11 A. I don't recall. I don't -- I might have.
- 12 I don't -- I believe certainly that Hugh did. He
- 13 said he did on the e-mail. He said, Emily is sure
- 14 that no coronavirus work has gone through the P3
- 15 framework. Whether I specifically spoke to Emily, I
- 16 don't recall but Hugh certainly did.
- 17 Q. And Emily works for NIAID?
- 18 A. Emily is the director of the Division of
- 19 Microbiology and Infectious Diseases at NIAID.
- Q. Can you turn the page one page in this
- 21 document?
- 22 A. Yeah.
- Q. Do you see in the bottom part of this
- 24 page, there's an e-mail from Jeremy Farrar dated
- 25 February 1st, 2020, at 1524?

Page 73

1	Α.	Yeah.
2		MR. KIRSCHNER: Again, Counsel, I would
3	ask you to	give Dr. Fauci an opportunity to
4	familiarize	e himself with this document.
5	MR. SAUER:	
6	Q.	You see immediately below that
7	A.	Yes.
8	Q.	where he says, "1st February, 2nd Feb
9	for Eddie"	?
10		Is Eddie Eddie Holmes?
11	A.	I believe it is. He is in Australia.
12	Q.	So he would be a different date than
13	everyone e	lse?
14	A.	Right.
15	Q.	And then he says, "Information and
16	discussion	is shared in total confidence and not to
17	be shared t	until agreement on next steps."
18		Do you see that?
19	A.	I do.
20	Q.	Do you remember any discussions with
21	Jeremy Far	rar about this call being kept in total
22	confidence	?
23	A.	I don't recall a discussion about
24	confidentia	ality or not, but I would imagine that
25	Jeremy a	and again, this is speculation I would
Ī		

Page 74

Fax: 314.644.1334

- 1 imagine that Jeremy wanted to make sure, when you
- 2 have something that obviously has a degree of
- 3 sensitivity to it, that he didn't want people just
- 4 blathering about it without proper discussion first,
- 5 and I think that's what he meant, but that's
- 6 speculation on my part.
- 7 Q. Do you remember Jeremy saying anything
- 8 about that, keeping it in confidence at any time?
- 9 A. I don't recall, but it is certainly
- 10 possible that he said that. It's understandable that
- 11 he would say that.
- 12 Q. Did you ever say anything about keeping in
- 13 confidence to your recollection?
- 14 A. I may have. I don't recall.
- 15 THE COURT REPORTER: And Counsel, I would
- 16 remind you to slow down, please.
- 17 BY MR. SAUER:
- 18 Q. Can you just turn one page further? Do
- 19 you see there, the last text on that page, he's got a
- 20 list of participants on a call?
- 21 A. Yes. I see that.
- 22 Q. Do you know how these participants were
- 23 selected?
- 24 A. It was predominantly -- to my
- 25 recollection, it was predominantly Christian and

LEXITAS LEGAL Phone: 1.800.280.3376

Page 75

Fax: 314.644.1334

- 1 Jeremy who made the selection of these people.
- 2 Q. Do you have any role in picking who would
- 3 participate in the call?
- 4 A. I don't believe I did. I felt that
- 5 Francis Collins should be on the call since he's the
- 6 director of NIH.
- 7 Q. And did you loop him in later?
- 8 A. I believe I did. I believe I sent him an
- 9 e-mail or somehow connected him with the pending
- 10 phone call.
- 11 Q. Who's Patrick Vallance at the bottom of
- 12 the list or valence?
- 13 A. Patrick Vallance is Sir Patrick Vallance,
- 14 who is the chief scientific -- or medical -- I
- 15 believe it's either one or the other -- I believe
- 16 it's the chief scientific officer who reports to the
- 17 prime minister of the United Kingdom.
- 18 Q. Is there anyone on this list who's
- 19 affiliated with government as opposed to being an
- 20 independent researcher?
- 21 A. You know, I don't know because many
- 22 scientists internationally have an affiliation with a
- 23 government. But looking at these names, I don't see
- 24 anybody there on this list that is known to me to be
- 25 affiliated with any government.

LEXITAS LEGAL Phone: 1.800.280.3376

Page 76

1	Q. What is Jeremy Farrar's role?
2	A. Jeremy, at the time and I believe he
3	still is is the director or CEO or head I'm not
4	sure what the title is but he is the chief person
5	at the Wellcome Trust in the United Kingdom.
6	Q. Does the Wellcome Trust award grants for
7	funding scientific research?
8	A. Yes, they do.
9	Q. About how much do they award per year, do
10	you know?
11	A. I do not know.
12	Q. Is it a significant amount?
13	A. I guess so. I don't know for sure. I
14	would imagine it is it's a predominant
15	organization in the UK.
16	MR. KIRSCHNER: Counsel, we've been going
17	for close to an hour and a half. How much longer on
18	this line of questioning?
19	MR. SAUER: Well, why don't we finish this
20	document. Are you okay?
21	MR. KIRSCHNER: Well, do you know how much
22	longer with this document?
23	MR. SAUER: Not long.
24	MR. KIRSCHNER: Okay.
25	BY MR. SAUER:

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 77

1	Q. You testified earlier that on this call
2	I take it that this call actually occurred, didn't
3	it?
4	A. The call on Saturday I believe it was
5	February 1st did occur.
6	Q. And you testified earlier there was
7	scientific back and forth
8	A. Right.
9	Q among some of the participants?
10	A. Right.
11	Q. And they were discussing and debating, you
12	know, whether the virus had originated from a
13	laboratory as opposed to in nature; correct? Do you
14	remember anything that anybody said on the call?
15	A. No. The only thing I do remember is that
16	there was what appeared to me to be good faith
17	discussion back and forth between people who knew
18	each other, people who had interacted with each
19	other, so they had mutual respect for each other's
20	opinion.
21	I got that impression in listening and I
22	was in a total listening mode because, as I
23	mentioned, these were evolutionary virologists who
24	were talking about the specifics of what detail made
25	them suspicious that it could have been a

Page 78

Fax: 314.644.1334

- 1 manipulation and the other side would counter and
- 2 show that this is compatible with a natural evolution
- 3 and they were going back and forth. The tenure of it
- 4 ended that we need more time and I believe that in
- 5 one of the e-mails that you asked me about a little
- 6 bit ago that they said we need some time to more
- 7 carefully look at this to see if we can come to a
- 8 sound conclusion based on further examination of the
- 9 sequences.
- 10 Q. Was there concern expressed in the call
- 11 that people might, you know, express in the media or
- social media conspiracy theories or anything like
- 13 **that?**
- MR. KIRSCHNER: Objection. Vaque.
- 15 Ambiguous.
- 16 BY MR. SAUER:
- 17 Q. If you recall?
- 18 A. You know, I don't -- I don't recall
- 19 whether that was discussed. I believe there was some
- 20 concern after that. Just the mention of something
- 21 being manipulated could create a lot of buzz-buzz and
- 22 discussion, but I don't really recall anything
- 23 specifically that was said during the call about
- 24 this.
- 25 Q. Do you remember any discussion of people

LEXITAS LEGAL Phone: 1.800.280.3376

Page 79

Fax: 314.644.1334

- 1 having concerns that expressions on social media that
- 2 the virus was originated in a lab might discredit
- 3 scientific funding projects?
- 4 A. I don't recall anything from that phone
- 5 call that said that.
- 6 Q. How about in this -- in this time period.
- 7 Is that something you ever discussed with Jeremy
- 8 Farrar?
- 9 MR. KIRSCHNER: Objection. Vaque.
- 10 Ambiguous.
- 11 THE WITNESS: I'm not sure if I discussed
- 12 it with Jeremy Farrar. I have a vague recollection
- 13 that there was concern about -- I don't think it had
- 14 anything to do with social media, but it was a
- 15 concern of diverting attention from the real task of
- 16 pursuing what needs to be pursued with this outbreak,
- 17 for the better good of the public health, a
- 18 distraction of some sort.
- 19 BY MR. SAUER:
- 20 Q. So are -- specifically, would the theory
- 21 that the virus escaped from a lab might be a
- distraction from the response to the virus's spread?
- 23 A. No. I think the general feeling among the
- 24 participants on the call is that they wanted to get
- 25 down to the truth and not wild speculation about

LEXITAS LEGAL Phone: 1.800.280.3376

Page 80

1	things. They are scientists, highly regarded
2	qualified evolutionary virologists, and they make as
3	their mantra always sticking with evidence and
4	sticking with data, and I believe there's always a
5	concern that when you throw speculations in that are
6	not based on data and evidence, that that's a
7	diversion from more proper things that should be
8	done.
9	I don't think there was any other concern
10	than sticking with the truth and sticking with data,
11	and part of the data would be to carefully look at
12	the virus in a careful measured way and to determine
13	whether or not the initial concern about the
14	molecular makeup upon further examination either
15	validated that concern or made it clear that that
16	concern was somewhat unwarranted, if not completely
17	unwarranted. That was the nature of the discussion.
18	Q. Was the consensus on the call, I think you
19	said earlier, that they needed more time
20	to investigate this possibility?
21	A. Right.
22	Q. And was the plan at the end of the call to
23	take more time to investigate that possibility?
24	A. The plan was to go and spend more time
25	carefully looking at it. That was the the sort of

Page 81

Fax: 314.644.1334

- 1 end conclusion that let's take a closer look at this,
- 2 and on taking a closer look, perhaps we can, you
- 3 know, come to a more evidence-and-fact-based
- 4 conclusion.
- 5 Q. Did they -- did they, in fact, do that?
- 6 Did they take more time and come to an
- 7 evidence-and-fact-based conclusion to your knowledge?
- 8 A. Oh, I believe that a few of -- Christian
- 9 and a few of the others carefully got together and
- 10 looked at it and examined the pros and the cons and
- 11 the ups and downs, and came to the conclusion that
- 12 their initial concern about the molecular basis of
- 13 the concern was unwarranted and that what they saw
- 14 was quite compatible and, in fact, suggestive of a
- 15 natural evolution.
- 16 Q. Did you have any further involvement after
- 17 the -- in this after the phone call? Like, were you
- 18 talking -- did you talk to people on this call later
- or were you included in e-mails about it after that?
- 20 A. Well, after that, I believe, at some time
- 21 later, a group of them -- I don't remember all of
- 22 them, but Christian was certainly one of them -- put
- 23 out a preprint, I believe, with that statement that
- 24 was subsequently followed by a manuscript in which
- 25 they laid out the molecular basis of why they felt

LEXITAS LEGAL Phone: 1.800.280.3376

Page 82

- 1 this was more likely to be compatible with a natural
- 2 evolution.
- 3 Q. During that time period, did you have any
- 4 other involvement in this issue? Did you have any
- 5 other communications related to it with any of these
- 6 people?
- 7 MR. KIRSCHNER: Objection. Vague.
- 8 Ambiguous.
- 9 THE WITNESS: When you say "involvement,"
- 10 could you be more specific?
- 11 BY MR. SAUER:
- 12 Q. Well, did you have any -- let me ask you
- 13 this: Did you have any communications after the
- 14 Saturday, February 1st, phone call that you just
- described, from that time period until a preprint was
- 16 published of their study, did you have any other
- discussions or communications with any of the people
- 18 on the call about this issue of the virus?
- 19 A. You know, I had not recalled that until, I
- 20 believe, in questions that were asked in letters that
- 21 came in from Congress and others that they may
- 22 have -- and I believe they did -- send
- 23 Francis Collins and I a preprint of the article that
- 24 came to the conclusion that the molecular
- 25 configuration of the virus was clearly compatible

Page 83

1	with a natural aggurrange
1	with a natural occurrence.
2	Q. Do you recall any communications with
3	Jeremy Farrar after that phone call?
4	A. You know, I don't. It is certainly
5	possible, but I don't specifically remember any
6	communications with Jeremy about that. But, you
7	know, Jeremy and I know each other reasonably well.
8	I would not be surprised if we did, but I don't
9	specifically recall a communication related to the
10	subject at question.
11	MR. SAUER: That's my last question on
12	this exhibit. Do you want to take a pause now?
13	MR. KIRSCHNER: Yeah. If if it's
14	9:37, if that works for Dr. Fauci?
15	THE WITNESS: Yeah, a short short
16	break. I'm good.
17	THE VIDEOGRAPHER: The time is 9:38 a.m.,
18	and we're going off the record.
19	(Recess.)
20	THE VIDEOGRAPHER: The time is 9:50 a.m.,
21	and we're back on the record.
22	BY MR. SAUER:
23	
	Q. Dr. Fauci, you're being handed
24	Exhibit 7
25	(FAUCI Exhibit No. 7 was marked for

Page 84

Fax: 314.644.1334

1 identification.) 2 BY MR. SAUER: 3 0. -- which is a collection of e-mails that were produced pursuant to FOIA. On the front page 4 5 here just at the very top, there's an e-mail from you 6 to Jeremy and Christian Anderson; correct? 7 Α. Correct. And it says, "Jeremy, Collins," and Q. 9 there's a huge redaction of everything you said. "Best regards, Tony." Do you see that? 10 11 Α. I do. 12 Do you have any recollection of what 0. 13 you're talking about in this e-mail? 14 No, I don't. I don't recall. Α. 15 0. Flip ahead four page -- to the 16 fourth page. There's an e-mail from Jeremy Farrar to 17 you on January 30th saying, "Tony, perfect timing. 18 Thank you. Great to catch up"; correct? 19 Yeah, the January 30th at 7:13 a.m.? Α. 20 Q. Right. 21 "Tony, perfect timing. Thank you. Α. Yeah. 22 Great to catch up." 2.3 And you responded, "Thanks, Jeremy. Great Q. 24 chatting with you and Patrick. Will stay in close 25 touch" --

Page 85

1	A. Right.
2	Q correct?
3	A. Correct.
4	Q. Do you recall and I guess this would be
5	two days before that Saturday conference call we
6	talked about?
7	A. Yeah.
8	Q. Did you have a phone call with
9	Patrick Vallance and a Jeremy Farrar on on that
10	day?
11	A. Well, I don't recall it, but it says here
12	in an e-mail from me to Jeremy on January 30th,
13	"Great chatting with you and Patrick." So I assume I
14	did, but I don't recall that that
15	Q. Do you know why you said, "We'll stay in
16	close touch"?
17	A. No, I don't recall.
18	Q. Do you remember what you-all you,
19	Jeremy, and Patrick may have said to each other on
20	that phone call?
21	A. No, I really don't recall that. I mean,
22	obviously it happened because I I refer to it in
23	the e-mail, but I don't recall that, no.
24	Q. Can you can you flip ahead? So we're
25	going to go one, two, three, four, five, six, seven,
1	

Page 86

1	eight, nine more pages to a page that has an e-mail
2	from Jeremy to you on February 1st saying "could you
3	join" at the top?
4	A. Yes.
5	Q. Correct?
6	A. I see that.
7	Q. And is this Jeremy inviting you to the
8	conference call that would happen later that day?
9	MR. KIRSCHNER: Objection. Speculative.
10	BY MR. SAUER:
11	Q. If you recall?
12	A. Yeah. It looks that way. I mean, I know
13	we had a conference call on February the 1st, and
14	Jeremy in this e-mail is saying "can you join," and
15	the names on the list are the names that were on the
16	call. So I would imagine it's quite reasonable to
17	assume that this is the invitation to join the call.
18	Q. Lower yeah. Lower down in Jeremy's
19	e-mail close to close to the bottom, about four
20	lines up from the bottom, he says, "My preference is
21	to keep this a really tight group."
22	Do you see that?
23	A. Yes.
24	Q. Do you know why that was his preference?
25	MR. KIRSCHNER: Objection. Speculative.

Page 87

Fax: 314.644.1334

1 THE WITNESS: You know, I don't really know why. I think -- I mean, I -- I could speculate 2 3 as to why that -- when you have too large a group --4 BY MR. SAUER: 5 To be clear, I'm not asking you to Q. 6 speculate. I'm just asking if you know. 7 example, did he tell you why he wanted it to be a 8 really tight group --9 No, he didn't tell me why, but I can -- I 10 can gather why if you're not interested in hearing 11 it --12 What do you gather? What do you gather? Q. 13 THE REPORTER: And please slow down, you 14 quys. 15 THE WITNESS: Okay. I'll slow down. Ι 16 said --17 BY MR. SAUER: 18 Q. What do you gather? 19 My knowledge of meetings of this sort is Α. 20 that when you want to get something done and you have 21 a task to do, that if you have a really large group 22 of people -- like, I've been on conference calls where there's 50 people on the call and nothing gets 2.3 done -- I believe, and I think it's a reasonable 24 25 assumption, that if you want to have a working group

Page 88

Fax: 314.644.1334

- 1 to have a serious discussion, you don't want to have
- 2 a hundred people on the call. You want to make it --
- 3 and I think that's -- I think that's what Jeremy was
- 4 referring to was he said, "I want to make it a tight
- 5 group."
- 6 Q. And then four lines lower he says,
- 7 "obviously" -- "obviously ask everyone to treat in
- 8 total confidence"; correct?
- 9 A. Yes.
- 10 Q. Do you know why it was obvious that it
- should be treated in total confidence?
- 12 MR. KIRSCHNER: Objection. Asked and
- 13 answered. Also speculative.
- 14 BY MR. SAUER:
- 15 Q. If you know. Why is that obvious?
- 16 A. Well, my speculation is that what
- 17 Jeremy meant is that when you're dealing with
- 18 something in which there is a suspicion of something
- 19 that would have great consequences but there's no
- 20 real evidence that it is, that you want to make sure
- 21 that you don't all of a sudden have a lot of people
- 22 talking about something based on no evidence.
- 23 So I think that's what he meant is until
- 24 we can get together and seriously discuss it, let's
- 25 not just make it widely disseminated.

LEXITAS LEGAL Phone: 1.800.280.3376

Page 89

1	Q. So he didn't like
2	A. I believe that's what he said, but I I
3	don't know.
4	Q. Do you know if he wanted Dr. Anderson to
5	not share his concerns about the origins of the virus
6	potentially being from a lab with anyone else?
7	MR. KIRSCHNER: Objection. Speculative.
8	Vague.
9	THE WITNESS: No. I believe based on what
10	the purpose of the call was to rather than be at the
11	level of speculation about something that may or may
12	not have been engineered, that we first get a group
13	of highly qualified international evolutionary
14	virologists to discuss it first before people on the
15	outside who have no knowledge of evolutionary
16	virology start wildly speculating about things.
17	BY MR. SAUER:
18	Q. Can you flip ahead a few pages so the page
19	you're on we're going to go ahead one, two,
20	three, four, five and then the sixth page, an e-mail
21	from you from Jeremy Farrar to you and Francis
22	Collins.
23	Do you see that?
24	A. Are you on the page, the top line says,
25	"From Jeremy Farrar, sent Saturday, 1st of February
Ī	

Page 90

1	at 13:27"?
2	MR. KIRSCHNER: I apologize. I'm not on
3	the right page then.
4	THE WITNESS: You got it.
5	MR. KIRSCHNER: Yep.
6	BY MR. SAUER:
7	Q. Farrar has responded "Excellent" to an
8	e-mail from you where you said "Jeremy, Francis will
9	be on the call. He is trying to phone you."
10	MR. KIRSCHNER: Counsel, I think we're on
11	two different pages. Dr. Fauci referred to a page
12	with a sub line re: Conference details. And you're
13	referring
14	BY MR. SAUER:
15	Q. Can you turn more pages?
16	A. Two more forward? Two more forward?
17	Q. Yeah.
18	A. Teleconference, re teleconference.
19	Q. Yeah. And Jeremy responded "Excellent" to
20	your e-mail saying, "Francis, Jeremy will be on the
21	call. He is trying to phone you"?
22	A. Right.
23	Q. Correct?
24	A. Correct.
25	Q. Do you recall discussing talking to

Page 91

1	Francis Collins about getting involved in the
2	conference call?
3	A. I don't specifically recall, but
4	certainly, it was my intention of making sure that
5	the director of the NIH was on the call. And given
6	what I said in the e-mail at 15:48 to Jeremy, I said,
7	"Francis will be on the call. He's trying to call
8	he's trying to phone you."
9	I mean, obviously that is totally
10	consistent with my having spoken to Francis and
11	saying, "Francis, you should be on a call. Why don't
12	you check with Jeremy to get some feel about what the
13	call is going to be about."
14	Q. Do you know if they talked to each other?
15	A. I don't know for sure whether they did.
16	Q. Can you start with that page you're on and
17	flip ahead a few pages? So one, two, three, four,
18	five, six, seven, eight, nine. And then you're on
19	the tenth page?
20	A. And what's the top line?
21	Q. At the top, it should say From Dr. Fauci,
22	Anthony, sent Saturday, February 1, 2020, at 20:30?
23	A. Yeah. And the subject is teleconference.
24	Q. Okay?
25	A. All right.

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 92

1	Q. And immediately below your e-mail saying,
2	"Yes," there's an e-mail from Jeremy Farrar sent to
3	you, Francis Collins, Patrick Vallance, and Mike
4	Ferguson; correct?
5	A. Yes.
6	Q. Who's Mike Ferguson?
7	A. You know, I should know. I don't know.
8	I've heard that name before, but I don't know who he
9	is. He was one of the I believe he was one of the
10	people on the call. Name is familiar, but, you know,
11	I probably should know who he is, but I don't.
12	Q. Okay. So Jeremy e-mailed to that smaller
13	group of people, "Can I suggest we shut down the call
14	and then redial just for five to ten minutes";
15	correct?
16	A. Yes.
17	Q. And you responded "yes"; correct?
18	A. Yeah.
19	Q. Did that happen did Jeremy shut down
20	the call?
21	A. You know, I don't recall.
22	Q. Do you know why Jeremy was wanting to have
23	the call paused for a minute and floated it only to
24	a small group of participants in the call?
25	MR. KIRSCHNER: Objection. Speculative.

Page 93

Fax: 314.644.1334

1 THE WITNESS: No, I -- I don't remember --2 I don't remember shutting down a call, actually. 3 BY MR. SAUER: 4 Do you remember Jeremy talking to you and 0. 5 Dr. Collins during the course of the call? 6 Α. No, I can't recall that. 7 0. Can you flip ahead one, two, three, four, 8 five pages? 9 The top is Jeremy Farrar, 2020, 19:09? Α. 10 And you see it's the same list of Q. Yes. 11 participants, Francis Collins, you, and Patrick 12 Vallance and Mike Ferguson; correct? 13 MR. KIRSCHNER: I apologize. I'm lost 14 myself on this. What's the top e-mail? 15 THE WITNESS: The top e-mail is Jeremy 16 Farrar, Saturday, 1st of February, 2020, 19:09. BY MR. SAUER: 17 18 0. I'm not on that one. Mine is 2013. 19 you turn two more pages? 20 Two more forward? Α. 21 Yeah. Q. 2.2 MR. KIRSCHNER: I'd just ask counsel to 2.3 identify the time when the --2.4 THE WITNESS: Okay. The one that says 25 Jeremy Farrar, teleconference 2013; right?

Page 94

Fax: 314.644.1334

- 2 Q. Do you remember if Francis Collins 3 responded to that e-mail about shutting down the 4 conference call? 5 No. I do not recall. I just don't recall Α. 6 anything about shutting down a conference call. 7 0. Okay. Can you turn three more pages to an 8 e-mail at 22-06-26? 9 Α. Yeah. 10 Q. And this is an e-mail chain between you, 11 Jeremy, and Francis Collins; correct?
- Q. Counsel, I would please ask if you can let
- 14 Dr. Fauci familiarize himself with the document as
- you're asking questions?

Α.

Yes.

- MR. SAUER: If he knows, he can answer the
- 17 questions. If he wants to familiarize, he can ask
- 18 for it.

1

12

BY MR. SAUER:

- 19 BY MR. SAUER:
- Q. If you go down halfway through the page,
- 21 there's an e-mail from Francis Collins to you and
- 22 Jeremy; correct?
- 23 A. Let me look at it.
- 24 Q. Labeled at 2050?
- 25 A. Right. Yes, I see that.

Page 95

1	Q. It says, "Hi, Jeremy. I can make myself
2	available at any time, 24/7, for the call with
3	Tedros"; correct?
4	A. Correct.
5	Q. Do you know who Tedros is?
6	A. Tedros is the director general of the
7	World Health Organization.
8	Q. So there was a plan to have a call with
9	the director general of the World Health Organization
10	at this time?
11	A. Correct.
12	Q. Do you remember that plan?
13	A. What I do recall from the discussion on
14	the call was that we needed to notify various
15	relevant people as to the fact that this was being
16	looked into. One of the obvious relevant people
17	would be the director of the World Health
18	Organization.
19	Q. Do you specifically remember a plan
20	between you, Francis, and Jeremy to contact
21	Dr. Tedros?
22	MR. KIRSCHNER: Objection.
23	Mischaracterizes evidence and speculative.
24	THE WITNESS: I know that there was a
25	discussion about contacting Tedros. That

Page 96

- 1 responsibility was not put on me. I believe it was
- 2 predominantly -- I'm not 100 percent certain, but I
- 3 think with some degree -- I wouldn't say certainty,
- 4 but I tend to believe it was Jeremy's responsibility
- 5 to be the one to contact and reach out to Tedros and
- 6 explain to him what these deliberations were.
- 7 BY MR. SAUER:
- Q. I'm going to give you a another document
- 9 marked Exhibit 8.
- 10 (FAUCI Exhibit No. 8 was marked for
- 11 identification.)
- MR. KIRSCHNER: Counsel, do you have
- 13 copies for us?
- 14 BY MR. SAUER:
- 15 Q. Do you recall communicating -- before you
- 16 look at the document, do you recall having any
- 17 communication with Dr. Tedros about the concerns that
- 18 were raised in --
- 19 A. No. I don't recall having any
- 20 communications directly, or even indirectly, with
- 21 Tedros.
- Q. Did you have any input on, you know,
- 23 having the World Health Organization get involved in
- 24 this issue of any kind?
- 25 A. I don't specifically recall. But one of

Page 97

- 1 the theme and the spirit of the discussion on the
- 2 phone call on February 9th, either before or after or
- 3 during the phone call, was that it would be important
- 4 to alert, or let in at least to the discussions,
- 5 important individuals, including the director general
- 6 of WHO.
- 7 Q. Can you look at this Exhibit 8 that's in
- 8 front of you, and with this one, can we start at the
- 9 back starting at the last page can you turn one page
- 10 forward to the second-to-last page?
- 11 MR. KIRSCHNER: Again, as I've objected
- 12 beforehand, I would please let the witness have an
- opportunity to familiarize himself with this document
- 14 prior to asking questions.
- 15 THE WITNESS: So I'm looking at something
- 16 that says "von an" -- this is, I guess, a German "to"
- 17 and "from."
- 18 BY MR. SAUER:
- 19 Q. I think so. Are you on the second-to-last
- 20 page of the document?
- 21 A. I think so. The one that has "von,"
- 22 Jeremy Farrar. And "an," Fauci, Vallance, CC:
- 23 Dorsten, Coopman --
- Q. Those are the participants in the call
- 25 there in the cc line.

Page 98

Τ	Α.	Right.

- 2 Q. Down there, second-to-last paragraph,
- 3 there's a one-sentence paragraph there that begins
- 4 there in Jeremy Farrar's e-mail, "I do know there are
- 5 papers being prepared."
- 6 Do you see that?
- 7 A. "I know there are papers being prepared.
- 8 There will be media interest and there already is
- 9 chat on Twitter and WeChat."
- 10 Q. And Twitter and WeChat are social media
- 11 platforms; correct?
- 12 A. Yes, I quess so. I don't know about
- 13 WeChat, but I know what Twitter is. I don't know.
- 14 O. You don't know what WeChat is?
- 15 A. I don't do social media so I'm not
- 16 familiar with them.
- 17 O. Is that a Chinese-based social media
- 18 platform?
- 19 A. I don't know.
- Q. Okay. Do you remember Jeremy raising
- 21 concerns about the chat on Twitter and WeChat or
- 22 other social media platforms about the virus's
- 23 origins?
- A. No. I'm not -- this is not ringing a bell
- 25 with me.

Page 99

1	Q. Well, let me ask you this: Did you ever
2	have concerns about what people might be saying on
3	social media about the virus's origin?
4	MR. KIRSCHNER: Objection. Ambiguous.
5	THE WITNESS: You know, I'm so dissociated
6	from social media. I don't have a Twitter account.
7	I don't do Facebook. I don't do any of that, so I'm
8	not familiar with that. I've never gotten involved
9	in any of that.
10	BY MR. SAUER:
11	Q. Do you know anyone who works for a social
12	media platform?
13	A. Do I know somebody who works for a social
14	media platform.
15	Q. Or at this time?
16	A. Well, I've had communications with
17	Mark Zuckerberg in the past who was I've done, I
18	believe, three outward FaceTime discussions
19	encouraging people to get vaccinated.
20	Q. Do you know anyone else who works for a
21	social media platform other than Mark Zuckerberg?
22	A. When you say do I know somebody who works?
23	Q. Like, do you have acquaintances, people
24	that you know, who work at social media platforms?
25	A. Well, a person who used to work as a

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 100

1	software e	ngineer for Twitter was my daughter.
2	Q.	Oh, your daughter worked for Twitter?
3	Α.	She used to, yes.
4	Q.	Did you ever when she was working at
5	Twitter, d	id you ever discuss with her the content of
6	stuff post	ed on social media platforms?
7	A.	No.
8	Q.	Did you ever discuss with her the origins
9	of the vir	us or concerns about the origins of the
10	virus?	
11	A.	No, she has no interest in that.
12	Q.	Was she what was her role in Twitter?
13	Α.	I believe she was a software engineer.
14	Q.	Does she still work at Twitter?
15	A.	No.
16	Q.	When did she stop?
17	A.	Over a year ago.
18	Q.	Do you know anyone else who works at a
19	social med	ia platform
20	Α.	No.
21	Q.	other than Mark Zuckerberg and your
22	daughter?	
23		THE REPORTER: Please slow down.
24		THE WITNESS: Do I know anyone else who
25	works at a	social media platform? To my knowledge,

**Page 101** 

1	no, I think I mean, I have done a number of
2	podcasts and interviews on Instagram, but I don't
3	think those people work for a social media platform.
4	I mean, I've done Instagrams with
5	Steph Curry Steph Curry. I don't think he works
6	for a media. He's a basketball player. But he uses
7	his his Instagram account to get me to talk with
8	him about encouraging people to get vaccinated.
9	Q. Can you go back to that exhibit in front
10	of you, Exhibit 8? We're on the second-to-last page.
11	Can you flip forward two pages, and on the top there,
12	there's another e-mail from Jeremy Farrar beginning
13	"My view is completely neutral on this."
14	Do you see that?
15	MR. KIRSCHNER: Dr. Fauci, I think it's
16	the page before.
17	THE WITNESS: This one?
18	MR. KIRSCHNER: No, I think you jumped too
19	much.
20	THE WITNESS: I jumped too much?
21	MR. KIRSCHNER: No, it's this page, I
22	think. Oh, nope. I was wrong. Sorry.
23	THE WITNESS: I'm sorry. Just hold on for
24	a second. "My view is completely" yeah, I got it.
25	I'm on the right page.

**Page 102** 

1	BY MR. SAUER:
2	Q. And that next line below that, do you see
3	where Jeremy says, "I do know these questions are
4	being asked by politicians citing ^ starting the
5	scientific literature and certainly on social and
6	mainstream media."
7	Do you see that?
8	A. Yeah. (Reading to himself.)
9	Q. Do you see that?
10	A. Let me finish reading it. One second.
11	But who's the e-mail to? I'm sorry. Is
12	this
13	Q. I'm just curious if you remember
14	Jeremy raising concerns about expressions on social
15	media about the origins of the virus in this time
16	frame?
17	A. I don't I don't recall anything about
18	social media. I think Jeremy and I believe he
19	says it really very well here that what he was
20	afraid of that people would be speculating and
21	blaming people, blaming the Chinese, and and that
22	only will increase tensions and reduce cooperation
23	which is necessary to really continue to pursue what
24	actually happened in order to prepare for and prevent
25	similar things from happening in the future.

**Page 103** 

Fax: 314.644.1334

1 And I think if you look at the e-mail, he 2 says, "A respected body convening a group now to 3 consider the evolutionary origins with an open mind, neutral, and in a transparent way could prevent wild 4 5 claims being made." I think it was Jeremy trying to be the honest broker and saying let's do this 6 7 properly. 0. And he's prepare -- he was concerned about 9 wild claims being made on traditional and social 10 media. Is that how you read it? 11 Α. Well, I guess so. I mean, I -- let me see 12 if he says "social media" here. Like I said, I'm kind of dissociated from social media. I don't -- I 13 14 don't even know how to access a tweet. 15 Were you ever concerned about what people 16 would be saying on social media about the origins of 17 the virus? 18 Α. I'm concerned about, you know, there being 19 misinformation or disinformation that would 20 interfere with our trying to save the lives of people 21 throughout the world, which happens when people 22 spread false claims. 2.3 0. Including about the origins of the virus 24 specifically? 25 Α. I mean, I think that there's a lot of

**Page 104** 

- 1 discussions about the origins of the virus, and we've
- 2 got to keep an open mind about that.
- 3 Q. You mention that you're concerned about
- 4 misinformation and disinformation about the virus
- 5 spreading?
- 6 A. No, I didn't say that.
- 7 Q. Okay.
- 8 A. That's not what I said.
- 9 Q. What'd you say?
- 10 A. I said misinformation and disinformation,
- 11 and misinformation can be that Bill Gates and I put a
- 12 chip in the vaccine which prevents people from
- 13 getting vaccinated and perhaps leads to their losing
- 14 their lives. That's what I get concerned about as a
- 15 physician and a scientist, that misinformation and/or
- 16 disinformation can lead to loss of life, and I'm a
- 17 physician and that troubles me.
- 18 Q. And it troubles you that those kinds of
- 19 claims are being made on social media in particular?
- 20 A. I didn't mention social media.
- 21 **Q.** Does it?
- 22 A. I mean, that's part of the way information
- 23 is disseminated.
- Q. Can you take the page that's in front of
- you, and we're going to turn forward five more pages.

**Page 105** 

Fax: 314.644.1334

1 So we're really on the second page of the document 2 now. 3 Second page. Okay. Moving forward. Α. 4 On the middle of that page, do you see an 0. 5 e-mail from you on Sunday, 2nd February 2020, at 15:30? 6 7 "Jeremy, sorry I took so long." Is that Α. 8 it? 9 That's the one, yeah. Q. 10 You say here in that second sentence --11 Α. Right. 12 -- "Like all of us, I do not know how this Q. 13 evolved"? 14 Α. Right. 15 0. Do you see that? 16 Where I say, "And so many people and the 17 threat of further distortions on social media," yeah. 18 Q. Yeah. Were you concerned about the 19 further distortions on social media --20 Α. Well --21 -- the day after the conference call? Q. 2.2 I guess I was. I said it here in the 2.3 e-mail that I was concerned about the further 24 distortions. 25 What -- what distortions on social media 0.

Page 106

1	were you concerned about? Was that the people
2	expressing
3	A. Wild wild speculations and accusations,
4	you know, blaming the Chinese and talking about their
5	deliberately or accidentally which certainly is a
6	possibility. There was no evidence of that at the
7	time, and that's what I was concerned about. And I
8	think we were all concerned about that because if you
9	put this e-mail juxtaposed against the statement of
10	Jeremy about wanting to have a situation where we get
11	down to the truth and people in good faith trying to
12	figure out what was going on, certainly there are
13	distortions on social media. Social media says I put
14	a chip into the vaccine so that I can monitor people.
15	That's a distortion.
16	Q. In that same in that same e-mail, if
17	you look down there, you go on to say immediately
18	after the reference to further distortions on social
19	media, and you say, "It's essential that we move
20	quickly."
21	Do you see that?
22	A. Right.
23	Q. And then "Hopefully we can get the WHO to
24	convene"; correct?
25	A. Right.

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 107

1	Q. Do you know what you were talking about
2	there? What were you
3	A. I'm talking about getting down to the
4	facts because when the facts come out, that counters
5	distortions wherever that distortion is, speaking
6	here or on social media or in any way, and what I was
7	referring to is that we've got to get WHO to convene
8	an unbiased body of people to try and thoroughly
9	examine the information so we can get to the truth,
10	and when you get to the truth quickly and I said,
11	"It is essential that we move quickly."
12	Q. Did that happen
13	A. And when the truth comes quickly, then you
14	can avert and avoid distortions when you don't have
15	the information out.
16	Q. Did that happen? Was there actually a
17	group convened by the WHO?
18	A. You know, I'm not sure where that went
19	quite frankly.
20	Q. Did you have any further involvement in
21	that suggestion?
22	A. I think we all felt we should get the WHO
23	involved since that's the natural organization when
24	you have something that has international
25	implications.

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 108

1	Q. If you look in the e-mail above Jeremy's
2	response to you and Francis Collins, it says, "Tedros
3	and Bernard have apparently gone into conclave."
4	Who is Tedros?
5	A. Tedros is the director general of the WHO.
6	Q. And who is Bernard?
7	A. I don't know his last name. I do know,
8	but I keep forgetting. Bernard, it's a German last
9	name. Bernard is one of the high ranking officials
10	at WHO, I believe, if it's the same Bernard that I'm
11	thinking of. There is a Bernard, and I'm
12	embarrassed that I forgot his last name, but if this
13	is the Bernard who I think it is, it is a close
14	senior associate of Tedros.
15	Q. What does it mean when they say they have
16	gone into conclave? Does that mean they are
17	unavailable?
18	MR. KIRSCHNER: Objection. Calls for
19	speculative speculation.
20	THE WITNESS: Yeah. I have no idea where
21	they'd go.^ I I would never use a terminology
22	"I'm going into conclave." I wouldn't know what that
23	means.
24	BY MR. SAUER:
25	Q. He goes Jeremy goes on to say, "They

**Page 109** 

- 1 need to decide today, in my view."
- Do you know what he's -- what he -- what
- 3 are they supposed to decide that day?
- 4 A. I do not know what they were supposed to
- 5 decide.
- 6 Q. Can you -- and then he goes on to say, "If
- 7 they do prevaricate, I would appreciate a call with
- 8 you later tonight or tomorrow to think how we might
- 9 take forward"; correct?
- 10 A. Boy, Jeremy must have been having a bad
- 11 day. He's using words like conclave and prevaricate.
- 12 I don't even know what he's talking about.
- Q. Well, let me ask you this: Was there a
- 14 discussion of having a follow-up call with you and
- 15 Jeremy and Francis Collins about what steps you would
- 16 take if the WHO didn't convene a group to study the
- virus's origins?
- 18 MR. KIRSCHNER: Objection.
- 19 Mischaracterizes the evidence. Assumes evidence not
- 20 in the record.
- 21 BY MR. SAUER:
- Q. Was there any follow-up call between you,
- 23 Jeremy Farrar, and Francis Collins?
- 24 A. I don't think so. I know that my feeling
- 25 at the time was that Jeremy was going to take the

**Page 110** 

- 1 bull and run with it regarding getting the
- 2 WHO involved. And my involvement or input into the
- 3 WHO I think diminished if not stopped at that time.
- 4 So I really would doubt that there was any
- 5 further communication between me and the WHO about
- 6 this. This was fundamentally Jeremy's lane, if you
- 7 want to call it that.
- 8 BY MR. SAUER:
- 9 Q. Can you turn to the first page of this
- 10 document? Another e-mail from Jeremy. This one
- 11 copies you, Dr. Tedros, Francis Collins, and Bernard
- 12 Shortlander?
- 13 A. That's him. Shortlander. We got it.
- Q. Down in -- you see a list of bullet points
- in this e-mail from Jeremy?
- 16 A. Yes.
- 17 Q. Are -- okay. And about halfway down,
- 18 there's a bullet point that says, "Gathering interest
- 19 evidence in the science literature and in mainstream
- and social media to questions of the origins of the
- 21 virus."
- 22 Do you see that?
- 23 A. Yes.
- Q. Are you aware of Jeremy discussing with
- 25 the WHO the concern that there be social media

**Page 111** 

-	
1	discussion of the origins of the virus?
2	A. I have no recollection or information
3	about Jeremy's discussions with the WHO involving
4	anything including social media. And I see this here
5	in an e-mail, but I I really have no additional
6	further information about Jeremy's gathering interest
7	evidence in the science literature regarding the
8	origin, no.
9	Q. You're being handed another document
10	marked Exhibit 9.
11	(FAUCI Exhibit No. 9 was marked for
12	identification.)
13	BY MR. SAUER:
14	Q. Do you see the second page of this
15	document?
16	A. Yes.
17	Q. You've got an e-mail there at the top to
18	Francis Collins and Jeremy Farrar where you say,
19	"Agree. Very thoughtful summary and analysis. We
20	really need to get WHO moving on getting the
21	convening started." Correct?
22	A. Right.
23	Q. Why did you say that to Jeremy and Francis
24	Collins?
25	MR. KIRSCHNER: Objection. Again, I would

**Page 112** 

- 1 ask that Dr. Fauci have an opportunity to familiarize
- 2 himself with this document.
- 3 THE WITNESS: Well, I'm looking at this
- 4 e-mail and it says, "Agree, very thoughtful summary
- 5 and analysis." And I don't recall what that summary
- 6 and analysis was. I get hundreds, if not thousands,
- 7 of documents thrown in front of me. I don't recall.
- 8 So I said, "I agree, very thoughtful summary and
- 9 analysis." But I don't recall today what that
- 10 summary and analysis was.
- 11 BY MR. SAUER:
- 12 Q. Can you look at the page before the first
- page of the document?
- 14 A. Yes.
- 15 O. Here's an e-mail from Eddie Holmes to
- 16 Jeremy Farrar; correct?
- 17 A. Right.
- 18 Q. "And here's our summary so far. It will
- 19 be edited further." Correct?
- 20 A. Correct.
- Q. Was this a summary of the paper they were
- 22 drafting as a result of the conference call?
- 23 MR. KIRSCHNER: Objection. Calls for
- 24 speculation.
- 25 BY MR. SAUER:

Page 113

1	Q. If you know?
2	A. I do not know what the summary was for,
3	whether it was a summary of the discussion at the
4	meeting, or whether it was the summary of what the
5	deliberations were following the meeting. I really
6	don't know.
7	Q. He goes on to say in the next line, "It's
8	fundamental science and completely neutral as
9	written"; correct?
10	A. That's what he says.
11	Q. And then he says, "Did not mention other
12	anomalies as this will make us look like loons."
13	Do you see that?
14	A. Yeah.
15	Q. Do you know what he's referring to?
16	MR. KIRSCHNER: Objection. Calls for
17	speculation.
18	BY MR. SAUER:
19	Q. Do you know?
20	A. I do not know what he is referring to.
21	Q. Were anomalies in the virus discussed on
22	that call that you participated in on February 1st?
23	A. You know, I'm not really sure what you
24	mean by the word "anomalies." It could mean a number
25	of things. Unusual observations about the virus.

Page 114

1	I'm not really sure. I really don't understand very
2	well what Eddie was referring to when he wrote this
3	e-mail to Jeremy, so
4	Q. Were you e-mailed drafts of a paper that
5	Eddie prepared as a result of that meeting?
6	A. I was Francis and I got I believe
7	I'm trying to recall accurately, but it's I think
8	this is the case. I'm not 100 percent sure that
9	we were given copies of a draft of a manuscript at
10	some point that was very fundamentally evolutionary
11	virology, which is not my lane.
12	So I remember getting a paper looking at
13	it. I don't believe I had any substantive comments
14	on it, just by reading it. Because that's not my
15	lane, evolutionary virology.
16	Q. Can you look at this next document which
17	we've marked Exhibit 10?
18	(FAUCI Exhibit No. 10 was marked for
19	identification.)
20	MR. KIRSCHNER: I wanted to make a
21	standing objection that these documents that are
22	being marked as exhibits are merging a lot of
23	documents together and we have I object to the
24	extent that this is mischaracterizing the record by
25	putting documents together that may or may not be

**Page 115** 

- 1 together, and I just want to say there's been several
- 2 exhibits along these lines, including Exhibit 10.
- 3 BY MR. SAUER:
- 4 Q. Can you look at the second page of Exhibit
- 5 **10, Dr. Fauci?**
- 6 A. Yeah.
- 7 Q. And this is an e-mail chain on Tuesday,
- 8 February 4th, between you, Francis Collins, and
- 9 Jeremy Farrar; correct?
- 10 A. Yes.
- 11 Q. At the bottom of the e-mail of this page,
- 12 the e-mail from you says, "Question mark, question
- mark, serial passage in ACE2 transgenic mice."
- 14 Do you see that?
- MR. KIRSCHNER: Again, I ask that you give
- 16 Dr. Fauci an opportunity to familiarize himself with
- 17 this document.
- THE WITNESS: Well, I'm not sure --
- 19 there's so many different things going on here, I'm
- 20 not sure what anybody is referring to here.
- 21 BY MR. SAUER:
- Q. Do you know what you're referring to? Do
- you remember referring to serial passage in ACE2
- 24 transgenic mice in connection with that call?
- 25 A. No.

**Page 116** 

1	Q. Do you know what that phrase means?
2	A. Serial passage means you sequentially
3	passage a virus in mice; right?
4	Q. In other words, is that another way of
5	having the virus gain function?
6	A. It's possible. You could decrease
7	function, you could gain function. You could do any
8	of a number of things. And I don't recall or
9	remember why or even to what I was even referring
10	when I said, "Question mark, question mark, serial
11	passage in ACE2 transgenic mice."
12	I don't recall that at all.
13	Q. Jeremy responded, "Exactly" and then
14	further up, Francis Collins says, "Surely that
15	wouldn't be done in a BSL-2 lab," question mark.
16	Do you see that?
17	A. Right.
18	Q. Do you know why Francis Collins raised
19	that issue?
20	MR. KIRSCHNER: Objection. Calls for
21	speculation.
22	THE WITNESS: I don't know why he did it
23	because I don't know the context in which he's
24	talking. I would imagine if Francis is saying if
25	you're going to do in vivo studies with a virus that

**Page 117** 

Fax: 314.644.1334

- 1 might have some danger to it, that you would want to
- 2 do it in a higher level of containment, but I
- 3 don't -- I have to say I don't know what they're
- 4 talking about on these e-mails, and it doesn't ring a
- 5 bell with me at all.
- 6 BY MR. SAUER:
- 7 Q. Do you know whether that the -- whether
- 8 the research that was done by Peter Daszak and Shi
- 9 Zhengli in the Wuhan Institute of Virology was done
- 10 at a BSL-2 safety level?
- 11 A. When you're dealing with pseudo viruses
- 12 and in vitro things, it is generally done in a BSL-2.
- 13 Q. So is serial passage in ACE2 transgenic
- 14 mice generally done at BSL-2?
- 15 A. Well, it depends. Each different country,
- 16 I believe, has their own level of restrictions about
- 17 where -- at what level of restriction a particular
- 18 experiment is done, in general.
- And again, I'm hesitant to go there
- 20 because that's not my area of expertise. But in
- 21 general, when you're dealing with the situation where
- 22 you need to take extra precautions in an in vivo
- 23 experiment, that you would do it in a BSL-3. But
- 24 again, having said that, I am not sure of what the
- 25 connection between these different e-mails are

LEXITAS LEGAL Phone: 1.800.280.3376

Page 118

1	referring to.
2	Q. Above that, it says, "Wild West" and
3	that's from the e-mail from Jeremy in response to
4	Francis; correct?
5	A. Right.
6	Q. Did Jeremy have an understanding that
7	to do the kind of research being referred to
8	A. Right.
9	Q at BSL-2
10	A. Right. Yeah.
11	Q safety conditions would be the Wild
12	West?
13	MR. KIRSCHNER: Objection. Calls for
14	speculation.
15	THE WITNESS: I actually don't know what
16	Jeremy is referring to when he says, "Wild West."
17	BY MR. SAUER:
18	Q. Did you have concerns about
19	performing gain-of-function research on viruses in
20	BSL-2 conditions?
21	MR. KIRSCHNER: Objection. Ambiguous.
22	THE WITNESS: No. You're a using the term
23	gain-of-function which as I mentioned earlier in the
24	discussion has such a broad range of interpretation
25	that you would have to specifically tell me what

**Page 119** 

Fax: 314.644.1334

1 experiment you're referring to. BY MR. SAUER: 2 3 0. How about the experiment set forth in, I think it was Exhibit 2, the 2015 Shi and Baric 4 5 paper, would those experiments be the sort to --6 would be --Α. Yeah. Q. -- appropriate to perform at BSL-2 9 functions -- sorry -- BSL-2 conditions? 10 I have not familiarized myself with that Α. 11 paper. I don't know if I ever even read it 12 carefully. It would take me probably an hour to read through the paper to make a determination of what 13 14 particular level of function -- not function, level 15 of restriction it would be. 16 So I don't think I could answer that 17 question right now. 18 Q. I'm handing you an Exhibit 11. Do you see 19 that? 20 I don't have anything in front of me yet. Α. 21 MR. KIRSCHNER: Counsel, could I have a 22 copy? MR. SAUER: Yeah. 2.3 24 (Dr. Fauci Exhibit No. 11 was marked for identification.) 25

**Page 120** 

Fax: 314.644.1334

1 BY MR. SAUER: Can you turn to the second page of this 2 Q. 3 document? And is this an e-mail on February 7th of 4 2020 from Jeremy to you and Francis Collins with the 5 subject line "revised draft"? 6 Α. Yeah. 7 0. And it says, "Attachment: Summary, Feb 7 8 PDF"; right? 9 Α. Right. Is this -- did Jeremy send you a draft 10 Q. 11 of -- a paper that Eddie Holmes was working on that 12 arose from the February 1st conference call? 13 Α. You know, I don't recall. I believe --14 and, again, this is vague -- that a draft of a 15 summary of something was sent to me. My recollection 16 is I really didn't have any meaningful comments on it 17 because it is, again, if I -- if it is a draft of 18 what it might have been, it would be involved in a 19 lot of complicated evolutionary virology that is not my lane. 20 2.1 Q. Turn to the next page, the actual 2.2 attachment. Do you see where it says "overview" at 2.3 the very top? 24 Α. Yes. 25 MR. KIRSCHNER: Counsel, you say this is

**Page 121** 

Fax: 314.644.1334

1 the actual attachment. I wanted to point out that is 2 your characterization of it. There's nothing 3 indicating that it is necessarily the --4 MR. SAUER: This is produced by NIH in 5 response to FOIA requests --6 MR. KIRSCHNER: I -- I understand, but --7 but there's -- I'm not saying -- I'm just saying for the record, it's not clear. 9 BY MR. SAUER: 10 Q. Under overview, do you see the third 11 sentence that's bolded beginning "Analysis of the 12 virus"? 13 Α. Yes. 14 That bolded sentence says, "Analysis of Ο. 15 the virus genome sequences clearly demonstrates that 16 the virus is not a laboratory construct or 17 experimentally manipulated virus"; correct? 18 Α. Correct. 19 Was that a conclusion that you and Q. 20 Jeremy and Francis Collins discussed in this time 21 frame? 2.2 As I mentioned before, I don't find -- I 2.3 am not qualified since I am not an evolutionary virologist to make any kind of definitive 24 25 determination about whether a genome could or could

**Page 122** 

1	not be a laboratory construct or experimentally
2	manipulative.
3	I have relied, as anyone would, with
4	highly qualified, respected evolutionary virologists
5	to come to that conclusion or not.
6	Q. Were you involved in the response to the
7	various FOIA requests for your e-mails from NIAID and
8	
	NIH?
9	A. I'm I don't understand what you mean
10	was I involved in them. I don't a FOIA request
11	does not come to me, and I look through my e-mails
12	and give the e-mails that they ask for. We have a
13	system at the NIH where FOIA requests come in and a
14	different component of the institutes tap into the
15	e-mails and provide the e-mails that are requested.
16	I don't decide which e-mails go and don't go.
17	Q. Do you approve redactions to them?
18	A. I never redact I don't redact things.
19	Q. So you don't have any involvement in
20	deciding what gets redacted and what doesn't?
21	A. I have no involvement in what gets
22	redacted. It gets redacted at multiple levels beyond
23	my beyond me.
24	
25	(FAUCI Exhibit No. 12 was marked for

**Page 123** 

1	identification.)
2	BY MR. SAUER:
3	Q. If you look at the first page of this
4	document?
5	A. Yes.
6	Q. And that's an e-mail, again, chain on
7	February 4th between Jeremy Farrar, you, and
8	Francis Collins; right?
9	A. Yes, I see that.
10	Q. And the attachment is called
11	"Summary.DOCX"; right?
12	A. Right.
13	Q. And he says, "Please treat in confidence.
14	A very rough first draft from Eddie and team. They
15	will send on an edited, cleaner version later today";
16	correct?
17	A. Correct.
18	Q. So you testified earlier that the
19	consensus of the call on September 1st was that they
20	needed to take more time to consider the arguments
21	back and forth; correct?
22	A. It wasn't September.
23	Q. I'm sorry. January.
24	A. Yes.
25	Q. Okay. And then by February 4th, the

**Page 124** 

- 1 following Tuesday after that Saturday call, you had
- 2 received a rough first draft of a -- a paper to be
- 3 published as a result -- or to be authored --
- 4 A. Right.
- 5 O. -- as a result of that; correct?
- A. It says, "Please treat confidence. A very
- 7 rough draft." So it looks like they did send it to
- 8 me. Right.
- 9 Q. And do you remember getting that draft?
- 10 A. I don't recall specifically getting it,
- 11 but as I mentioned, if I did, I wouldn't have much
- 12 input into it since it's a draft, I'm sure, that
- involves very complicated evolutionary virology of
- 14 which I'm not an expert.
- 15 Q. And in the -- Jeremy had forwarded to you
- lower down on that page the same e-mail we looked at
- a moment ago where Eddie Holmes says, "Did not
- 18 mention other anomalies as this will make us look
- 19 **like the^ "?**
- 20 A. Right.
- 21 Q. Do you recall reviewing this draft?
- 22 A. I might have looked at it, but I certainly
- 23 didn't make any meaningful comments since this is
- 24 outside of my lane of expertise.
- 25 Q. If you can turn to the next page -- or

**Page 125** 

4	
1	actually stay on that page for a minute.
2	Jeremy says, "Pushing WHO again today"
3	there in the top near the top of the page.
4	Do you see where that is?
5	A. I'm sorry. Top of the first page?
6	Q. Yeah.
7	A. And what are you referring to?
8	Q. Second paragraph of Jeremy's e-mail at the
9	top of the page to you and Francis Collins. It says,
10	"Pushing WHO again today"; correct?
11	A. Yes.
12	Q. Were you involved in any communications
13	with the WHO at that time to try to get them to act
14	on this project?
15	MR. KIRSCHNER: Objection. Asked and
16	answered.
17	THE WITNESS: To my recollection, I didn't
18	have direct involvement with the WHO, not to my
19	recollection.
20	BY MR. SAUER:
21	Q. Next page, second page of this document is
22	another e-mail from you we've seen before, right,
23	where you say we really need to get
24	A. Right.
25	Q WHO moving?

Page 126

1	A. Right.
2	Q. Does this jog your memory at all? Do you
3	remember being involved in trying to get the WHO to
4	act?
5	A. The context of this exchange and the theme
6	of the discussion, although I, myself, did not
7	directly get involved in interactions with WHO on
8	this, was that we all felt that given the convening
9	power and the status of WHO, that we wanted to get
10	them involved because we wanted to make sure that
11	this was an open and transparent discussion that
12	involved international global health authority.
13	So it is perfectly consistent and
14	compatible that I would say we really need to get WHO
15	moving on getting the convening involved because we
16	wanted an open convening so that evidence and data
17	could be openly discussed. That was the theme of
18	everything that was going on at the time.
19	Q. Can you turn ahead to the second-to-last
20	page of this document?
21	A. Yes.
22	Q. And this is an e-mail on Tuesday,
23	February 4th, from Jeremy to you and Francis Collins
24	with an attachment called "Summary.PDF"; right?
25	A. Correct.

**Page 127** 

1	Q. And this says it just says "tidied up";
2	correct?
3	A. Yes.
4	Q. Did he send you a second draft that same
5	day the 4th that was, quote, tidied up?
6	A. I don't recall.
7	Q. You don't know if he sent you a second
8	draft? Does this e-mail jog your recollection?
9	A. The e-mail does very little to jog my
10	recollection. Again, I had very little input or even
11	interpretation of the the the information
12	because it was in an area that is not my area of
13	expertise. I don't know what he means by tidied up.
14	Usually
15	Q. Can you turn to the next I'm not asking
16	you about that. Can you turn to the next page
17	MR. KIRSCHNER: Counsel, please don't
18	interrupt please don't interrupt the witness.
19	Just he's
20	BY MR. SAUER:
21	Q. I'm going to ask you to listen to
22	questions that I'm asking
23	A. I'm listening.
24	Q and answer the question that I'm asking
25	without going on long tangents. Can you do that,

Page 128

1	mlaasa2
1	please?
2	MR. KIRSCHNER: I
3	THE WITNESS: I'd be happy to. I don't
4	think I'm going on long tangents, but I'm trying to
5	put things
6	BY MR. SAUER:
7	Q. Well, can you turn
8	A into appropriate context.
9	Q. Can you turn to the next page of the
10	document?
11	A. Yes.
12	Q. This is the last page. This is a
13	February 5th e-mail from Jeremy to you and Francis;
14	correct?
15	A. It says, "Tony and Francis, the revised
16	draft from Eddie copied here."
17	Q. And so he sent you a third draft on
18	February 5th?
19	A. Right.
20	Q. Two drafts on the 4th and a third draft on
21	the 5th; correct?
22	A. I'm not keeping up with the different
23	ones. So I can't say "correct" because you're going
24	really fast.
25	Q. And you recall from the prior exhibit that

**Page 129** 

Fax: 314.644.1334

1 there was another draft that was sent to you on 2 February 7th; correct? It appears that there were a couple of 3 Α. 4 drafts that were sent back and forth. 5 And those were -- when you say "a couple," Q. 6 it's about four so far; correct? I can't say. At least a couple. I don't 7 8 know exactly how many. 9 Were you aware during the same time frame Q. 10 that Peter Daszak was organizing a statement for 11 The Lancet --12 MR. KIRSCHNER: Objection. BY MR. SAUER: 13 14 -- about the origins of the virus? 0. 15 MR. KIRSCHNER: Objection. Speculative, 16 also vaque. 17 THE WITNESS: I don't recall. 18 BY MR. SAUER: 19 Are you aware that a -- a letter was Q. 20 published in The Lancet in February of 2020 organized 21 by Peter Daszak? 2.2 You know, I really don't recall this. 2.3 Again, getting to my statement about context, you're talking about a period of time when thousands of 24 25 things come across my desk. So I don't -- I don't

Page 130

1	recall anything specific about something that
2	Peter Daszak may or may not have written for Lancet.
3	If I saw it, perhaps, not guaranteed, it
4	might jog my memory, but I don't recall that right
5	now.
6	Q. I'm handing you Exhibit 13.
7	(FAUCI Exhibit No. 13 was marked for
8	identification.)
9	MR. KIRSCHNER: May I ask the witness if
10	he needs a break or if he's okay.
11	THE WITNESS: I'm okay.
12	BY MR. SAUER:
13	Q. Can you turn to the third page of this
14	document?
15	A. Third page.
16	Q. And the top half of this page there's a
17	e-mail from Jeremy to that begins "Francis and
18	Tony"; correct? Do you see that e-mail?
19	A. I'm reading it. Yeah.
20	Q. In that third bullet point in his e-mail,
21	his e-mail is talking about contact with WHO again;
22	correct?
23	A. Correct.
24	Q. There's been a number of e-mails. We
25	talked about that already; correct?

**Page 131** 

1	7	77 ]	
1	/\	$v \triangle a n$	
	Α.	Yeah.	

- Q. Third bullet point in his e-mail, he says,
- 3 "We can have a call this week with the core group of
- 4 that to frame the work of the group including if you
- 5 could join."
- 6 A. Right.
- 7 Q. And I take it he's inviting you and
- 8 Francis Collins to join a call to discuss framing the
- 9 work of the WHO convened group?
- 10 A. Right.
- 11 Q. Is that right?
- 12 A. Right.
- 13 Q. Did you have that call?
- 14 A. I don't recall. Like I said before, this
- was mostly a Jeremy-led thing, and I don't recall
- 16 having a call with WHO. It's possible that we did,
- 17 but I don't recall.
- 18 Q. Two bullet points down, it says, "With
- names to be put forward into the group from us,
- 20 and pressure on this group from your and our teams
- 21 next week." Correct?
- 22 A. That's what it says.
- Q. First half of that line, it talks about,
- 24 "Names put forward into the group from us." Did you
- 25 put forward names for this group for the WHO, or do

Page 132

1	you recall doing that?
2	A. I think, if you go back and when you
3	say "recall," I recall because the first page of the
4	cluster of e-mails that you just sent me is an e-mail
5	from Jeremy to me and Francis saying, "Thank you.
6	Pardis is great, respected by everyone."
7	He's referring to Pardis Sabeti. And as
8	the e-mail jogs my memory, I believe I made the
9	suggestion that if you want to have another expert on
10	coronavirus evolution for the working group that
11	I assume is the group in the second bullet of the
12	e-mail from Jeremy to Francis and I, where it says,
13	"They have asked for names to sit on that group.
14	Please do send any names," and I believe that in
15	response not I believe.
16	It looks clearly obvious that in response
17	to that e-mail request from Jeremy, I said, "I left
18	out an important name for the group, Pardis Sabeti at
19	the Broad Institute of MIT and Harvard."
20	And Jeremy writes back, "Thank you.
21	Pardis is great. Respected by everyone."
22	Q. And you had provided top half of the
23	second page of the document, you had provided the
24	list to Jeremy
25	A. Right.

Page 133

1	Q of people to include in the WHO's work?
2	A. Correct.
3	Q. How did you come up with these names? Did
4	you talk to anyone before proposing them to Jeremy?
5	A. I don't believe I did. I just I may
6	have. I just I don't recall. It's likely because
7	these are people, some of whom I know well and I
8	probably asked around my institute for other people
9	who are fluent in molecular virology.
10	Q. How about Joseph DeRisi, third name on the
11	list, at the Chan Zuckerberg Biohub. What's the Chan
12	Zuckerberg Biohub?
13	A. I haven't referred it as Biohub, but the
14	Chan Zuckerberg has supported research institutions
15	at the University of California at San Francisco.
16	That might be what he's referring to, because
17	Q. This is he this is you; right? This is
18	your e-mail?
19	A. Yeah. But again these are names that
20	were given, I believed, even though the e-mail is
21	from me to Jeremy, several of these names, I almost
22	certainly got by asking members of my institute, such
23	as people in the division of microbiology and
24	infectious diseases for some names of people who
25	might actually be able to be contributory to the

Page 134

_	
1	working group.
2	Let me give you some examples so you can
3	be clarified. Harold Varmus I know very well.
4	Former Nobel Prize winner and former director of the
5	NIH.
6	Q. I'm really not asking you to go through
7	the whole list. I just want to focus on
8	A. Well, I want to put it into a context.
9	Q. I'm going to ask you to listen to the
10	question that I'm asking and answer that question.
11	This is an extremely long answer that is
12	absolutely nonresponsive. I just asked you about
13	Joseph DeRisi. Did you originate that name?
14	MR. KIRSCHNER: I will say before
15	Dr. Fauci responds, if he has to provide proper
16	context, he provides proper context. You can ask
17	your question, and then Dr. Fauci will provide his
18	response.
19	THE WITNESS: Yeah, it's very important to
20	me to provide the context because there are certain
21	names on this list that I don't even recognize.
22	BY MR. SAUER:
23	Q. How about Joseph DeRisi?
24	A. I don't recognize that name. It was
25	almost certainly given to me by someone in my

Page 135

1	institute. And the reason
2	Q. How about the name the name below?
3	A. I'm sorry. I got to finish.
4	Q. Go ahead.
5	A. This is context, sir.
6	I don't recognize Joseph DeRisi. I may
7	have heard of him. I know Harold Varmus well. I
8	know Dan Gannon well. I don't know Eugene Koonin
9	well.
10	So the point that I'm putting into context
11	is that it is highly likely that these names were
12	given to me in part by others.
13	So you're asking about Joseph DeRisi, and
14	Joseph DeRisi's name does not ring a bell.
15	Q. How about Pardis Sabeti on the page
16	before?
17	A. Pardis Sabeti does. She's a well-known
18	virologist.
19	Q. Did you talk to her before you sent her
20	e-mail to Jeremy for inclusion in the WHO group?
21	A. Unlikely that I pulled Pardis. I likely
22	just know her well enough that I would have put her
23	name in. But perhaps I did call her. But unlikely
24	that I did. She's such a well-known figure in
25	molecular virology that it is not unusual for me to

**Page 136** 

1	say, "Of course include Pardis Sabeti."
2	Q. How about Don Gannon?
3	A. Don Gannon is well-known person.
4	Q. Did you talk to him before you put his
5	name on this list to Jeremy?
6	A. I don't believe I did. I don't believe I
7	spoke to anyone on this list. I just pulled the
8	names out. Some of which I knew, like Varmus and
9	Nabel, and some of which were very likely given to me
10	by my staff.
11	Q. Turn back to the third page of the
12	document, Jeremy's e-mail to you and Francis. In the
13	third bullet point we talked about earlier, it talks
14	about having a call to, quote, frame the work of the
15	group.
16	Do you know what he was referring to when
17	he was asking you or he wanted to frame the work
18	of the group?
19	A. I can't say exactly that I know what he
20	means by frame the work of the group, but in
21	experience in dealing with a number of working
22	groups, when you frame the work of the group, you
23	usually start off by saying, "What is the theme and
24	what is the question we're asking? Let's frame the
25	discussion. What's the issue at hand?"

**Page 137** 

1	Q. Do you recall any discussions about
2	wanting to the frame the work of the WHO group?
3	A. I don't recall anything about framing it,
4	but
5	Q. Two bullet points lower down, you see
6	there's a bullet point about the WHO, Jeremy says
7	he refers to pressure on this group from your and
8	our teams next week.
9	Do you know what pressure he's referring
10	to?
11	A. I don't.
12	MR. KIRSCHNER: Objection.
13	Mischaracterizes the record.
14	THE WITNESS: I don't know what Jeremy is
15	referring to when he says pressure on this group.
16	BY MR. SAUER:
17	Q. Do you recall any discussion of having
18	anybody pressure the WHO in its work related to this
19	origins of the virus investigation?
20	A. I don't have any inkling at all of
21	pressuring them. The one thing that's clear from the
22	e-mails and my recollection is that everyone wanted
23	the WHO to get involved because of their convening
24	power and their credibility. We all wanted to make
25	this an open discussion, and the WHO was the most

**Page 138** 

Fax: 314.644.1334

1 appropriate forum for an open discussion. 2 So I don't think a belief had anything to 3 do with pressuring the WHO to do anything, merely to 4 get them to meet. 5 You're sniffling. You sure you don't have 6 a cold. 7 Exhibit 14? Q. (FAUCI Exhibit No. 14 was marked for 9 identification.) 10 MR. KIRSCHNER: Counsel, can I have 11 copies? BY MR. SAUER: 12 13 Q. Can you -- during this same time frame 14 we've been talking about, was there also a discussion 15 of having the WHO sponsor a trip to China to 16 investigate the virus? 17 MR. KIRSCHNER: Objection. Calls for 18 speculation. 19 THE WITNESS: You know, I don't recall. 20 You're asking, Mr. Sauer, about during this 21 discussion, was there discussion about WHO going to 2.2 China. 2.3 Well, I know now, memory-wise, 24 that WHO did send a group to China. BY MR. SAUER: 25

Page 139

1	O Did that many include Cliff Ione of ways
1	Q. Did that group include Cliff Lane of your
2	staff?
3	A. Let me answer the question. The question:
4	Did I know about it then? And I'm saying right now,
5	I don't recall, at this particular time, whether they
6	were talking about a group going to China.
7	I do know that they wanted to put together
8	a WHO group and they may have and they likely did ask
9	HHS, who asked NIH, who would be a good person to go
10	to China to see you know, to get some information
11	about what exactly evolved in China.
12	Q. Did you make a recommendation about who
13	would be a good person to go to China around February
14	2020?
15	A. I believe I recommended Dr. Clifford Lane.
16	I recommended or it was obvious because he's a very
17	well-known, competent person. So it is highly likely
18	that I recommended him. Though I don't specifically
19	remember, it would be very compatible with the
20	process that I would recommend him.
21	Q. Do you remember why you were sent an
22	e-mail that says, "WHO advance team on way to China,
23	Tedros tweet"?
24	A. No idea.
25	Q. You believe you may have recommended Cliff

**Page 140** 

Fax: 314.644.1334

- 1 Lane for that -- for that trip, but you don't know
- 2 for sure?
- 3 A. It's highly likely I would recommend him
- 4 if anyone asked me who would go on an international
- 5 trip. Dr. Lane has extensive experience in dealing
- 6 at the international level with a number of
- 7 countries, including the work he did in Africa with
- 8 Ebola and in Southeast Asia. So he's a very
- 9 experienced person at the international level.
- 10 It's entirely likely, if not very likely,
- 11 that I would have recommended him.
- 12 Q. Did he actually attend that trip?
- 13 A. Yes, he did.
- 14 Q. During February of 2020 in the kind of
- 15 month we've been talking about, did you make any
- 16 public statements about the origins of the virus?
- 17 A. That's a very broad question. I don't
- 18 recall if I did.
- 19 Q. Okay. Well, did you have any -- did you
- 20 have any contact with Peter Daszak or conversations
- with him about the origins of the virus?
- 22 A. I don't recall. I may have, but I don't
- 23 recall.
- Q. You testified earlier that you don't
- 25 really know Peter Daszak; is that right?

LEXITAS LEGAL Phone: 1.800.280.3376

Page 141

1	A. I don't know him very well at all.
2	Q. Have you ever done a joint podcast with
3	him?
4	A. You know, that was brought it was
5	interesting. I think someone recently I don't
6	know when whether it was our discussion or not. I
7	don't remember brought up that I did do some sort
8	of an interview with him, but if it had not been
9	brought to my attention, I would not have remembered
10	it. I've done several hundred podcasts, maybe
11	several hundred podcasts.
12	(FAUCI Exhibit No. 15 was marked for
13	identification.)
14	BY MR. SAUER:
15	Q. I'm handing you Exhibit 15.
16	Does this document jog your memory of
17	doing a podcast with Newt Gingrich and Peter Daszak
18	on February 9th, 2020?
19	A. Well, there's an advertisement that said
20	that I'm Newt Gingrich's guest. If you had not put
21	this in front of me, I likely would not have
22	remembered it. Like I said, I've done at least
23	several hundred podcasts over the last couple of
24	years.
25	Q. Do you remember this one in particular now

Page 142

1	that you see this? Do you remember doing this
2	podcast?
3	A. I don't I don't remember it
4	specifically, but since the e-mail indicates that the
5	podcast occurred, I don't even say I vaguely remember
6	that podcast. Like I said, I've done many podcasts.
7	Q. At the top you say, "Definitely for the
8	director's page." What are you referring to? What's
9	the director's page?
10	A. Whenever we do a media thing or a podcast
11	or a paper that comes out that the people who are
12	interested in the goings on of the National Institute
13	of Allergy and Infectious Diseases, we sometimes put
14	it on the director's page, which is the link when you
15	go to NIH.gov and then NIAID.gov, you get the
16	director's page, and on that are various links for
17	people to access things that we may have done.
18	Q. I'm handing you a document that's marked
19	Exhibit 16.
20	(FAUCI Exhibit No. 16 was marked for
21	identification.)
22	BY MR. SAUER:
23	Q. And this is an informal transcription of
24	some of your remarks in that podcast.
25	Do you see at the top there it says

Page 143

1	there's a timestamp, 18:48, Newt. Do you see that?
2	A. Yes.
3	Q. And it quotes Newt Gingrich as saying, "I
4	don't know if you had access to enough information
5	from the Chinese, but as you know, there is sort of
6	an urban legend that there is a biological warfare
7	center in Wuhan and that the coronavirus escaped from
8	that. Do you have any sense where it probably came
9	<pre>from"; correct?</pre>
10	MR. KIRSCHNER: Objection. Lack of
11	foundation.
12	BY MR. SAUER:
13	Q. Is that what it says?
14	A. You just read it correctly, yes.
15	Q. And then the transcript reports you as
16	responding at 19:06: "Well, I think ultimately we
17	know that these things come from an animal reservoir.
18	I heard these conspiracy theories and like all
19	conspiracy theories, Newt, they're just conspiracy
20	theories."
21	Do you see that?
22	A. Yes, I do.
23	Q. Do you recall making that comment on
24	Newt Gingrich's podcast?
25	MR. KIRSCHNER: Objection. Lack of

Page 144

1	foundation.
2	THE WITNESS: I don't recall making it,
3	but if this is a correct transcript, then it's clear
4	that I made that statement, but I don't recall making
5	that statement.
6	BY MR. SAUER:
7	Q. Do you recall thinking on February 9th,
8	2020, that it was, quote or that we know these
9	things come from an animal reservoir?
10	A. The background of saying that we know
11	things come from an animal reservoir because the
12	history of the evolution of new microbes from an
13	animal reservoir to a human is very clear. I could
14	give you a number of examples, but one in particular
15	to save time is that SARS-CoV-1, very similar
16	circumstances to SARS-CoV-2, was for a while not
17	knowing what it evolved, but it became clear that it
18	went from a bat to a civet cat to a human. So very,
19	very similar
20	Q. Can I direct your attention to another ^
21	page, if I may?
22	A. Yeah.
23	Q. At 34:30 Newt says you see halfway
24	down, second bullet point?
25	MR. KIRSCHNER: Counsel, I would ask for

Page 145

1	you not to interrupt the witness.					
2	MR. SAUER: He was giving a completely					
3	nonresponsive answer. I'm just asking					
4	THE WITNESS: No, actually I was I was					
5	responding to the issue of what you mean by coming					
6	from an animal reservoir, and what I was saying is					
7	that my statement that things and I'll quote the					
8	exact words "these things come from an animal					
9	reservoir," and the context of that is, is ample					
10	historical experience that these things					
11	overwhelmingly come from an animal reservoir. I was					
12	putting it into context.					
13	BY MR. SAUER:					
14	Q. Thank you for that.					
15	Can I direct your attention now to the					
16	second bullet point beginning 34:30?					
17	Do you see that?					
18	A. Yes. Yeah.					
19	Q. Where Newt says, the coronavirus probably					
20	came from one of the flea markets, although there was					
21	a secondary rumor that there is a biological weapons					
22	laboratory in Wuhan					
23	THE REPORTER: I'm sorry, Counsel. Can					
24	you slow down?					
25	BY MR. SAUER:					

**Page 146** 

1	Q. There is a secondary rumor that there is a
2	biological weapons laboratory in Wuhan and it may
3	have come from there. Is it your sense that it's
4	almost certain that it came from an animal to human
5	transition transmission. Do you see that?
6	A. I do.
7	Q. And then the transcript quotes Daszak
8	saying, "All the evidence says that is what
9	happened"; is that right?
10	MR. KIRSCHNER: Objection. Lack of
11	foundation. Speculative.
12	THE WITNESS: That's what it says. It
13	says, Daszak, quote, "All the evidence say that is
14	what happened."
15	BY MR. SAUER:
16	Q. Do you recall Daszak saying that?
17	MR. KIRSCHNER: Again, objection. Lack of
18	foundation.
19	THE WITNESS: I don't recall hardly
20	anything about this interview since, as I mentioned,
21	I give hundreds of podcasts. So I cannot say that I
22	recall Daszak making that statement, though, if this
23	transcript is correct, it appears that he has made
24	the statement.
25	BY MR. SAUER:

Page 147

1	Q. Does this jog your recollection of having
2	any communications with Daszak about the origins of
3	the virus in February of 2020?
4	Do you remember any such communication?
5	A. I told you before that I did not remember
6	any direct conversations with him about the origin,
7	and I said I very well might have had conversations,
8	but I don't specifically remember conversations. If
9	you are implying, understandably, that being on a
10	podcast with Dr. Daszak in which the origins were
11	discussed, if that constitutes a discussion with him
12	about it, I guess I had a discussion, but at the time
13	you asked the question, I did not recall having a
14	discussion with him about the origins.
15	Q. How about Dr. Ralph Baric? We talked
16	about him earlier. Did you say you knew him or not?
17	A. I know of him. I wouldn't say I know him.
18	I'm not sure. I may have met him at a meeting or
19	not. I certainly know who he is. He's a
20	well-established scientist. I cannot say for certain
21	if I've ever met him.
22	Q. Okay. Did you ever so you don't recall
23	ever having a one-on-one meeting with him of any
24	kind?
25	A. I don't recall. It's possible. I have

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 148

1	meetings with hundreds, if not thousands, of
2	scientists over the years that I've been at this
3	position.
4	Q. I'm handing you Exhibit 17.
5	MR. KIRSCHNER: Counsel, I would like to
6	take a break soon. Are we kind of finishing up a
7	line of questioning or
8	MR. SAUER: Yeah, we can do that after the
9	exhibit, if that's what you want.
10	MR. KIRSCHNER: Okay. Can I have the
11	exhibit myself?
12	(FAUCI Exhibit No. 17 was marked for
13	identification.)
14	THE WITNESS: So is this 17?
15	MR. SAUER: Yeah.
16	THE WITNESS: Thank you.
17	BY MR. SAUER:
18	Q. Do you see this exhibit is a page from
19	your official Outlook calendar dated February 11th,
20	2020?
21	A. Right.
22	Q. And then if you look at 2:30 p.m. in the
23	afternoon that day, there's a meeting marked that
24	says, "Hold meeting with Dr. Ralph Baric."
25	Do you see that?

Page 149

1	A. I do.
2	Q. And indicated on it is that the invitation
3	came from Emily sorry Emily Erbelding; correct?
4	A. Correct.
5	Q. Was that did that meeting occur? Did
6	you and Emily have a meeting with Dr. Ralph Baric on
7	February 11th, 2020?
8	MR. KIRSCHNER: Objection. Speculative.
9	THE WITNESS: You know, I don't recall the
10	meeting, but it's on my calendar. And as I mentioned
11	a moment ago, I might have had a meeting with him. I
12	don't recall.
13	Getting into context, it says 7A-18, which
14	is our conference room. If one goes back and looks,
15	I have literally hundreds of meetings in 7A-18 with
16	scientists who we fund, who we don't fund, who come
17	in and visit the NIH.
18	BY MR. SAUER:
19	Q. What did you discuss in this meeting, if
20	you remember?
21	A. I don't recall the discussion that we had
22	at 2:30 on February the 11th, 2020. I just don't
23	recall it.
24	MR. SAUER: We can take a break there, if
25	you want?
1	

Page 150

1	THE WITNESS: Sure.						
2	THE VIDEOGRAPHER: Okay. Stand by. The						
3	time is 11:09 a.m., and we're going off the record.						
4	(Recess.)						
5	THE VIDEOGRAPHER: The time is 11:21 a.m.,						
6	and we're back on the record.						
7	BY MR. SAUER:						
8	Q. Dr. Fauci, I want to circle back to						
9	something you said a little while ago before I						
10	forget. You said that misinformation and						
11	disinformation can lead to loss of life; correct?						
12	A. Right.						
13	Q. And I think that was in the context of						
14	talking about the misinformation and disinformation						
15	on social media, among other things; is that correct?						
16	A. However it's disseminated, it can lead to						
17	loss of life.						
18	Q. Is it your view that misinformation and						
19	disinformation on social media can lead to loss of						
20	life?						
21	THE WITNESS: What's the matter?						
22	THE COURT REPORTER: Nothing.						
23	THE WITNESS: You're shaking your head.						
24	THE COURT REPORTER: I need counsel to						
25	slow down.						

**Page 151** 

- 1 BY MR. SAUER:
- 2 Q. Is it your view that misinformation and
- 3 disinformation on social media can lead to loss of
- 4 life?
- 5 A. I think in any situation where egregious
- 6 misinformation such as some of the ones I referred to
- 7 before, such as information that would discourage
- 8 people from getting vaccinated, that in my mind,
- 9 would be a way that life that could otherwise have
- 10 been saved would be lost, if people were persuaded
- 11 not to pursue a life-saving intervention.
- 12 Q. Do you think that there should be steps
- taken to curb the spread of misinformation and
- 14 disinformation?
- 15 A. You know, that's not my area. I'm very
- 16 well aware of the concept of freedom of speech. The
- 17 area of the curtailment of that is something that is
- 18 not in my area of the expertise. Those are legal and
- 19 other things. And I really don't have any opinion on
- 20 that.
- 21 Q. Have you ever contacted a social media
- 22 company and asked them to remove misinformation from
- 23 one of their platforms?
- A. No, I have not.
- 25 Q. Is that something you ever discussed with

**Page 152** 

1	Mark Zuckerberg?
2	A. To my knowledge, we have not my
3	discussions with Mark Zuckerberg were very clearly
4	directed at getting me on some Facebook podcast to
5	encourage people to get vaccinated. That was the
6	extent of our conversations.
7	Q. Has anyone on your staff, you know, at
8	NIAID, ever reached out to a social media platform to
9	ask them to take content down or to block content in
10	any way?
11	MR. KIRSCHNER: Objection. Speculative.
12	THE WITNESS: To my knowledge, no. But
13	again, I don't know everything that goes on, but
14	certainly nothing that I was made aware of that they
15	were doing.
16	BY MR. SAUER:
17	Q. Let me give you Exhibit 18.
18	(FAUCI Exhibit No. 18 was marked for
19	identification.)
20	BY MR. SAUER:
21	Q. Do you see this short e-mail from Ian
22	Lipkin dated February 11th, 2020?
23	MR. KIRSCHNER: Objection. Lack of
24	foundation.
25	THE WITNESS: To whom was the e-mail

**Page 153** 

Fax: 314.644.1334

1 written to? 2 BY MR. SAUER: 3 0. Do you know if you were copied on this 4 e-mail? 5 Well, let me read it first, and then I'll Α. 6 see. 7 Is this an e-mail from Ian to me? Q. That's my question. Do you know if this 9 is an e-mail from Ian to you? 10 You know, I can't say for sure. I mean, Α. 11 again, just in the spirit of the context that I've 12 been trying to establish here, I average a couple of thousand e-mails a day. So this could have been --13 14 Do you have any recollection of this one? 0. 15 I don't have a recollection of it. 16 entirely possible that Ian wrote this to me. 17 communicates with me -- I wouldn't say a lot, but 18 enough to recognize an e-mail when -- and I will send it, I'll read it, but I don't recognize this 19 particular e-mail. 20 2.1 0. Can I direct your attention to the last 2.2 sentence where Ian says, "Given the scale of the bat 2.3 CO research pursued there -- that is to say at the institute in Wuhan -- and the site of the emergence 24 25 of the first human cases, we have a nightmare of

**Page 154** 

1	circumstantial evidence to assess."				
2	Do you see that?				
3	A. I do.				
4	Q. Do you know what he is talking about?				
5	MR. KIRSCHNER: Objection. Speculative.				
6	BY MR. SAUER:				
7	Q. If you know.				
8	A. I am not certain of what he's referring				
9	to. I could surmise what he is referring to is				
10	that and I think it has to do with circumstantial				
11	evidence, is that whenever you have a situation when				
12	research is being done and you might have an				
13	outbreak, then there will be always people who				
14	immediately jump on and say, "Well, this could have				
15	had to do with the research."				
16	Q. Did you think it was a nightmare of				
17	circumstantial evidence, these factors he's referring				
18	to, given that there's a lot of bat coronavirus				
19	research pursued at the Institute in Wuhan, and that				
20	the first human cases emerged in Wuhan, you view that				
21	as a nightmare of circumstantial evidence?				
22	MR. KIRSCHNER: Objection. Vague.				
23	Ambiguous. Compound.				
24	THE WITNESS: I don't at least that's				
25	not my style to think in terms of circumstantial				

**Page 155** 

1	evidence. I think anyone who is involved in the
2	field knows that when there's an outbreak, there's
3	always a concern of how did it happen? What
4	happened?
5	And when you have an element that there is
6	a research institution involved, there is always
7	speculation that it has something to do with research
8	institution. I mean, we have been in situations
9	where people questioned what's going on up in
10	Frederick, Maryland, even though there's nothing
11	going on in Frederick, Maryland, to my knowledge,
12	that is of any concern that people always refer to as
13	"Oh, there's that kind of research going on."
14	BY MR. SAUER:
15	Q. Would it be a nightmare if it turned out
16	that, in fact, that the virus had escaped
17	accidentally escaped from a lab in Wuhan?
18	A. You know, again, you're use the word
19	"nightmare," you know, kind of a a sort of a vague
20	thing that means different things to different
21	people.
22	Q. How would you describe it?
23	A. I mean if and I have to emphasize "if,"
24	and I believe the evidence weighs much more toward a
25	natural occurrence, even though you always keep an
1	

**Page 156** 

Fax: 314.644.1334

- 1 open mind as to what the origin and etiology is,
- 2 certainly if that happened, then the purpose of
- 3 knowing that is try and make sure, looking forward,
- 4 that those things don't happen again. The purpose of
- 5 trying to determine the origin of an outbreak is to
- 6 see what you can do, looking forward, to prevent it
- 7 from happening again and it goes both ways. If it's
- 8 a factual occurrence, then you want to make sure that
- 9 you get good animal human surveillance.
- 10 Q. How about it was not a natural occurrence
- on the hypothetical, and it, in fact, escaped from
- 12 the lab and in fact that the research that had
- 13 created the virus was partly funded by NIAID, would
- 14 that be a nightmare scenario? Can you pick a word
- 15 that would describe the scenario to your knowledge?
- 16 A. Well, I'm going to go to context because
- 17 you're asking a question that I think needs to be
- 18 explained. If you look at the molecular makeup of
- 19 SARS-CoV-2 and you look at the viruses that were
- 20 studied under the auspices and funding of the
- 21 subaward to the Wuhan Institute, those bat viruses
- 22 evaluated by anyone with even a reasonable
- 23 acquaintance with evolutionary virology would tell
- 24 you that given those viruses that they worked on,
- 25 reported on, and published on was so far removed from

LEXITAS LEGAL Phone: 1.800.280.3376

**Page 157** 

1	SARS-CoV-2, that it would be molecularly impossible,
2	even if people tried to manipulate them to become
3	SARS-CoV-2 they wouldn't become SARS-CoV-2.
4	So the idea of conflating research that's
5	funded by NIH to look at in a surveillance way the
6	bat viruses that were circulating in that area, you
7	can talk to any unbiased molecular virologist and you
8	can say that the evolutionary difference between
9	those viruses and SARS-CoV-2 would make it
10	essentially impossible to have this turn into this.
11	And what happens, is when you talked about
12	laboratory leaks and the things you're referring to
13	here, people inappropriately conflate that with
14	research funded by the NIH. And it's apples and
15	oranges.
16	Could something have, quote, leaked out of
17	a Chinese lab? I have always kept an open mind that
18	that is possible. Could it have happened by the
19	experiments that were done and reported that were
20	funded by the NIH? Getting back to what I said a
21	moment ago, molecularly, that could not have
22	happened.
23	Q. What about experiments that were done but
24	weren't reported. For example, are you aware that a
25	whole large number of genomic sequences were pulled

**Page 158** 

1	down in September of 2019 from the Wuhan Institute of
2	Virology's website? Are you aware of that? It's a
3	-
	yes or no question.
4	MR. KIRSCHNER: Objection. Lack of
5	foundation.
6	THE WITNESS: Tell me what you're
7	referring to.
8	BY MR. SAUER:
9	Q. Well, are you aware that genomic sequences
10	of viruses were removed from publicly available
11	databases in September of 2019 at the Wuhan Institute
12	of Virology?
13	A. I am aware of that context. Those
14	sequences were also, even though they were removed
15	from a bank that has nothing do with my institute,
16	those sequences were published in the literature.
17	So it isn't as if they were unknown.
18	Q. Let me ask you this. Actually, let me
19	give you another exhibit.
20	(FAUCI Exhibit No. 19 was marked for
21	identification.)
22	BY MR. SAUER:
23	Q. I'm handing you Exhibit 20.
24	MR. KIRSCHNER: Twenty or 19?
25	MR. SAUER: You're right. It's 19.

**Page 159** 

- 1 BY MR. SAUER:
- 2 Q. Do you recognize this as the preprint
- 3 version of the proximal origin of SARS-CoV-2 dated
- 4 February 17th of 2020?
- 5 A. Yeah, this looks like the preprint that
- 6 antedated the full papers that were published in the
- 7 peer-reviewed literature. This is a preprint.
- 8 Q. Did you review the preprint when it came
- 9 out? Did anyone send it to you? Do you know?
- 10 MR. KIRSCHNER: Objection. Asked and
- 11 answered.
- 12 BY MR. SAUER:
- 13 Q. Do you know?
- 14 A. Again, I -- a lot of things get sent to
- 15 me. I -- it likely is that they probably sent a copy
- of this to Dr. Collins and I, though I don't
- 17 specifically recall it.
- 18 Q. Do you know if you reviewed it when the
- 19 preprint came out?
- 20 MR. KIRSCHNER: Objection. Asked and
- answered.
- 22 THE WITNESS: It -- it depends. I think I
- 23 answered that question before, did I not?
- 24 BY MR. SAUER:
- Q. I'm just asking you again. I don't

**Page 160** 

Temenber what you sard	1	remember	what	you	said
------------------------	---	----------	------	-----	------

- 2 A. Well, let me try and remember and make
- 3 sure that it's both true and consistent, that it is
- 4 likely that this was sent to me. When you say review
- 5 a paper, review means different things to different
- 6 people.
- 7 Did I look through it? Yes. Did
- 8 I fully understand the molecular virology of it?
- 9 Unlikely, because I'm not an evolutionary virologist.
- 10 Did I make any substantive comments on it? Unlikely,
- 11 because that would not be my position since I'm not
- 12 an evolutionary virologist.
- 13 Q. Now, you have been copied on four drafts
- of this paper prior to this on February 4th, 5th, and
- 15 7th; correct?
- 16 A. Correct.
- 17 Q. Those drafts were sent to you by
- 18 Jeremy Farrar as written up by Eddie Holmes? Do you
- 19 recall that?
- 20 A. I'm not sure it was written up by
- 21 Eddie Holmes, but it was sent from me, I believe.
- 22 You showed me an -- you showed me a lot of e-mails
- 23 and papers before. I don't have an exact
- 24 recollection of the name of the person who sent it
- 25 versus the one who was referred to, but the names of

**Page 161** 

- 1 Eddie Holmes and Jeremy Farrar are certainly
- 2 associated with the paper.
- 3 Q. And, in fact, if you look at the author
- 4 line, there's five authors associated with it;
- 5 correct?
- 6 A. Yes.
- 7 Q. And all of those people are on that
- 8 February 1st call at 2:00 p.m. organized by
- 9 Jeremy Farrar; correct?
- 10 A. I believe so. I -- yeah, I believe so,
- 11 but I'm not a hundred percent sure. Was he and
- 12 Lipkin on the call? He might have been. I know that
- 13 the others very likely were on the call.
- 14 Q. Is that Ian Lipkin who one week -- or six
- days earlier had sent an e-mail saying that we have a
- 16 nightmare of circumstantial evidence to address?
- 17 MR. KIRSCHNER: Objection. Lack of
- 18 foundation.
- 19 BY MR. SAUER:
- 20 O. Is that the same human?
- 21 A. Well, Ian Lipkin is Ian Lipkin. There
- 22 aren't a lot of Ian Lipkins that I know.
- 23 Q. Can you turn to the second page of the
- document? Second paragraph, last sentence, it says,
- 25 "Importantly, this analysis provides evidence that

**Page 162** 

- SARS-CoV-2 is not a laboratory ^ construct nor a
- 2 purposely manipulated virus"; correct?
- 3 A. Correct.
- 4 Q. Did you have any discussions with any of
- 5 these authors about that conclusion?
- 6 MR. KIRSCHNER: Objection. Asked and
- 7 answered.
- 8 THE WITNESS: I don't recall whether I had
- 9 a discussion with the authors about that last
- 10 statement. When I looked at the paper for things
- 11 that you understand are clear sentences like that and
- 12 not necessarily things like Figure 1, which go into
- 13 the mutations and contact residues, et cetera. So I
- 14 am certain that having looked at it, I was aware of
- 15 what their conclusion was. I don't recall discussing
- 16 specifically that conclusion with them.
- 17 BY MR. SAUER:
- 18 Q. How about with Francis Collins? Did you
- 19 discuss it with him?
- 20 A. It's possible. I mean, Francis and I know
- 21 each other very well. He's the director of NIH. I
- 22 would not be surprised if I had in the discussion a
- 23 mention of and perhaps discussion of the conclusion
- 24 of that paper.
- Q. How about with Jeremy Farrar? Did you

**Page 163** 

1	have any discussions with him about the conclusion?
2	A. I don't recall. I would not be surprised
3	
	if I did, but I don't specifically recall. It would
4	be much more likely that I had a conversation of that
5	type with Dr. Collins, possibly with Dr. Farrar, but
6	I don't know for sure.
7	Q. I'm handing you Exhibit 20.
8	(FAUCI Exhibit No. 20 was marked for
9	identification.)
10	BY MR. SAUER:
11	Q. Do you see this article from the NIH
12	record entitled "NIAID's Lane Discusses WHO COVID-19
13	Mission to China"?
14	A. And what's the question, sir? I'm sorry.
15	Q. I'm just saying do you see this?
16	A. Yes, I do see it.
17	Q. Okay. And then if you look at the first
18	paragraph, it's talking about Dr. Cliff Lane, which
19	is the patient in that WHO mission we talked about
20	earlier; correct?
21	A. Correct.
22	Q. Could you turn to the fifth page of the
23	document, bottom paragraph? There's a quote from
24	Mr. Lane. Do you see that?
25	MR. KIRSCHNER: Objection. I would ask

that Dr. Fauci have an -- an opportunity to

### **DR. ANTHONY FAUCI 11/23/2022**

**Page 164** 

Fax: 314.644.1334

- familiarize himself with this document. 2 3 MR. SAUER: I'm just asking if he sees 4 that -- that quote on the bottom of Page 5. 5 THE WITNESS: Is it the last paragraph? BY MR. SAUER: 6 7 Q. Yeah, beginning "The Chinese were 8 managing"? 9 Α. Yes. And Mr. Lane, after returning from the 10 Q. 11 trip, said the Chinese were managing this in a very 12 structured, organized way; correct? 13 MR. KIRSCHNER: Objection. Lack of 14 foundation.
- 15 BY MR. SAUER:

1

- 16 Q. Is that what it says?
- 17 A. That's what the sentence says on this
- 18 report on Page 5. That's what the NIH record --
- 19 report says, yes.
- 20 Q. And the quote goes on to quote Mr. Lane as
- 21 saying, "When we got there, the outbreak was already
- 22 coming under control in China. The measures they put
- in place appear to be working. I think that they
- 24 felt there were lessons learned they wanted to share
- with the rest of the world"; correct?

**Page 165** 

1	A. Correct.
2	Q. Did you discuss Mr. Lane's experience on
3	the trip with him when he got back from the WHO trip?
4	A. The answer is I did, and it relates really
5	a lot to what the sentence what he said.
6	Dr. Lane was very impressed about how from a clinical
7	public health standpoint, the Chinese were handling
8	the isolation, the contact tracing, the building of
9	facilities to take care of people, and that's what I
10	believed he meant when he said were managing this in
11	a very structured, organized way.
12	Q. And he goes on in that last sentence on
13	that page to say, "From what I saw in China, we may
14	have to go to as extreme a degree of social
15	distancing to help bring our outbreak under control";
16	correct?
17	A. Correct.
18	Q. So he drew the conclusion that there might
19	have to be extreme, in his word, measures to mandate
20	social distancing to bring the outbreak under
21	control; correct?
22	A. That's what this is implying, yes.
23	Q. Did he discuss that with you when he came
24	back from the trip?
25	A. He might have. I don't recall the exact

**Page 166** 

Fax: 314.644.1334

- 1 sentence, but he did discuss with me that the Chinese
- 2 had a very organized way of trying to contain the
- 3 spread in Wuhan and elsewhere. He didn't get
- 4 a chance to go to Wuhan, but he was in Beijing, and I
- 5 believe other cities -- at least Beijing -- and he
- 6 mentioned that they had a very organized,
- 7 well-regimented way of handling the outbreak.
- 8 Q. And so he had a kind of positive reaction
- 9 to that. There might be lessons to be learned for
- 10 the United States in its response to the outbreak;
- 11 correct?
- 12 MR. KIRSCHNER: Objection. Vaque.
- 13 Ambiguous.
- 14 BY MR. SAUER:
- 15 O. Correct?
- 16 A. I believe Dr. Lane came to the conclusion
- 17 that when you have a widespread respiratory disease
- 18 that a very common and effective way to curtail the
- 19 rapid spread of the disease is by implementing social
- 20 distancing measures.
- 21 Q. Did you agree with that conclusion when
- you discussed it with him when he came back?
- 23 A. I wasn't there and I didn't see it, but
- 24 Dr. Lane is a very astute clinician, and I have every
- 25 reason to believe that his evaluation of the

LEXITAS LEGAL Phone: 1.800.280.3376

**Page 167** 

Fax: 314.644.1334

1 situation was accurate and correct. 2 Q. Do you know if he communicated with 3 Chinese officials when he was on that trip? I don't know for sure whether 4 Α. 5 he communicated with Chinese officials on the trip. 6 So you -- would you know the identities of 0. 7 any Chinese officials he may have communicated with? 8 MR. KIRSCHNER: Objection. Speculative. 9 THE WITNESS: I don't recall discussions 10 about -- he may have. Again, this was a few years 11 ago. He may have had discussions with them. I -- I 12 don't know if he did or not. BY MR. SAUER: 13 14 I'm going to give you another exhibit, 21. 0. 15 (FAUCI Exhibit No. 21 was marked for 16 identification.) BY MR. SAUER: 17 18 Q. Just real briefly, you see this is an 19 e-mail from Cliff Lane dated 22nd February 2020; 20 correct? 21 Α. Correct. 2.2 And in the first line of the e-mail he Q. 2.3 said, "China has demonstrated this infection can be 24 controlled, albeit at great cost"; correct? 25 Α. Right.

Page 168

1	Q. In your discussions with him, did he
2	discuss controlling the infection at great cost?
3	A. Again, I don't recall the precise nature
4	of the conversation that I had with Dr. Lane, but I
5	believe what he was referring to is that you have
6	to that you can control it, and by great cost, I
7	believe he was referring to extreme methods.
8	And the Chinese, indeed, went to extreme
9	methods to do that.
10	Q. And those extreme methods include very
11	aggressive lockdowns, for example
12	A. Yeah, but the lockdowns were the types of
13	lockdowns that were really quite extreme. They would
14	essentially lock people in their homes, which was
15	extreme to do that.
16	Q. Did you come to believe that extreme
17	measures would be required to control the spread of
18	the virus?
19	MR. KIRSCHNER: Objection. Vague.
20	Ambiguous.
21	THE WITNESS: When you're talking about
22	the virus here in the United States?
23	BY MR. SAUER:
24	Q. Correct.
25	A. It was my opinion that social distancing

**Page 169** 

1	would be very important when you have a respiratory
2	virus that is spreading widely through a community
3	causing an extraordinary amount of suffering and
4	death. Getting to context, I refer specifically that
5	early on in the epidemic when New York got hit very
6	badly, there were freezer and cooler trucks that were
7	loaded with dead bodies from the hospital. That is
8	an unprecedented extreme issue that we all felt
9	strongly, those of us involved in the discussions and
10	the public health recommendations, that social
11	distancing was imperative so that our hospitals would
12	not be overrun, and that we would be in a situation
13	where we would have to almost triage the decision of
14	who would live and who would die.
15	When you get to that extreme, social
16	distancing, even by somewhat difficult means, is
17	warranted to save lives.
18	Q. Did you think that social distancing
19	I'm talking about this time frame of around February
20	of 2020 did you think that social distancing would
21	have to include only high-risk individuals or would
22	it apply to society as a whole?
23	MR. KIRSCHNER: Objection. Vague.
24	THE WITNESS: When you're when you're
25	dealing with a respiratory illness that has the

**Page 170** 

- 1 potential to kill a lot of people -- we've lost over
- 2 one million people in this country -- in order to
- 3 have an effective interruption, which would almost
- 4 certainly be on a temporary basis, but to interrupt
- 5 this enormous explosion of infections that we were
- 6 seeing, you would have to involve essentially the
- 7 entire community.
- 8 BY MR. SAUER:
- 9 Q. Let me hand you Exhibit 22.
- 10 (FAUCI Exhibit No. 22 was marked for
- 11 identification.)
- 12 BY MR. SAUER:
- 13 Q. And this is an e-mail chain involving you,
- 14 Christian Anderson, Jeremy Farrar, and Francis
- 15 Collins; right?
- 16 A. Yeah.
- 17 O. And then it also includes the other
- 18 authors of that "Proximal Origins of COVID-19" paper
- 19 that we looked at earlier in the preprint version?
- 20 A. Yeah.
- Q. If you look at that, just a little way
- down the March 6th, 2020 4:23 p.m. e-mail from
- 23 Anderson. Do you see that?
- 24 A. Right.
- Q. He says, "Dear Jeremy, Tony and Francis,

Page 171

1	Thank you again for your advice and leadership as
2	we've been working through the SARS-CoV-2 origin
3	paper; correct?
4	A. Correct.
5	Q. And Jeremy is Jeremy Farrar; correct?
6	A. Correct.
7	Q. Tony is you?
8	A. Yeah.
9	Q. And Francis is Francis Collins, right?
10	A. Correct.
11	Q. And what advice and leadership did you
12	provide, if any, on the preparation of that paper?
13	A. Very little.
14	Q. So you don't know what he's talking about
15	when he says thank you?
16	A. No. I think that Jeremy is being
17	courteous, as he is wont to be. I mean "advice"
18	could be and "leadership" could be we really got
19	to get information out. Thank you for the effort
20	you've put into it. Advice and leadership, to my
21	recollection, had very little to do with substantive
22	input into the paper.
23	Q. And that second
24	A. And we did not have substantive input into
25	the paper.
l	

**Page 172** 

Fax: 314.644.1334

1 And below that, it says, "Please let me Q. 2 know if you have any comments, suggestions or 3 questions about the paper or the press release"; 4 correct? 5 Α. Correct. 6 So he invited you to have comments on the 0. 7 paper because we're still waiting for proofs? 8 Α. Right. 9 So there was still time to make changes to 0. 10 it; correct? 11 Α. Yeah. And there were no -- to my recollection, any substantive input into the paper. 12 13 Q. Do you recall making comments on it at any 14 time --15 MR. KIRSCHNER: Objection. Asked and 16 answered. BY MR. SAUER: 17 18 Q. Do you? 19 I don't recall making any substantive 20 comments on the paper. I may have made a comment 21 that "nice job," which is very courteous, but doesn't 2.2 mean that I had a substantive input into the paper. 2.3 I did not. 24 (FAUCI Exhibit No. 23 was marked for 25 identification.)

**Page 173** 

- 1 BY MR. SAUER:
- 2 Q. Exhibit 23. The first stage -- page of
- 3 this document is an e-mail from you to
- 4 Mark Zuckerberg; correct?
- 5 A. Yeah. The reason I'm smiling, you're
- 6 jumping around here, but that's okay. We're good.
- 7 Fake left. All right. Let's go.
- 8 Q. Is an e-mail to you from Mark Zuckerberg;
- 9 correct?
- 10 A. Correct.
- 11 Q. The top one is dated February 27, 2020.
- 12 A. Right.
- Q. And he writes to you, "Tony, I was glad to
- 14 hear your statement about the COVID-19 vaccine," and
- 15 so forth.
- 16 A. Right.
- Q. Were you already on a first-name basis
- with Mark Zuckerberg on February 27?
- 19 A. You know, a lot of people call me Tony who
- 20 have never even met me before.
- Q. Had you met him before this e-mail was
- 22 sent?
- 23 A. I don't recall what the first time I met
- 24 Mark Zuckerberg. I actually don't think -- maybe
- 25 not. Again, context, I meet thousands of people.

**Page 174** 

Fax: 314.644.1334

- 1 I'm not sure I've ever met him in person. I've been
- 2 on Zooms and Facebook things with him, but it could
- 3 not be at all unusual -- it happens every day -- that
- 4 people who have never met me refer to me as Tony.
- 5 I'm a rather informal person.
- 6 Q. Do you have relationships with researchers
- 7 at the Chan Zuckerberg Institute?
- 8 A. If the Chan Zuckerberg Institute that
- 9 you're referring to is the San Francisco General
- 10 Hospital.
- 11 Q. The one you described earlier.
- 12 A. Yeah because remember -- yeah, that's the
- 13 thing, Mr. Sauer. I'm not really clear on -- I'm not
- 14 really guite sure what Bio Club is. I do know that
- 15 Chan Zuckerberg supports the San Francisco General
- 16 Hospital. And I know Chan Zuckerberg in the context
- of the University of California, San Francisco
- 18 General Hospital.
- 19 Q. And do you have relationships with
- 20 researchers at that hospital?
- 21 MR. KIRSCHNER: Objection. Vague and
- 22 ambiguous.
- 23 BY MR. SAUER:
- Q. If I could finish the question.
- 25 A. Again, I'm not sure what you mean by

LEXITAS LEGAL Phone: 1.800.280.3376

**Page 175** 

Fax: 314.644.1334

1 relationship. I know, to varying degrees of familiarity ranging from knowing who they are to 2 3 being able to recognize them at a meeting and say 4 hello, to knowing them over the years in our 5 interactions in the medical and scientific community, but the answer to your question is: I can't pull out 6 7 people. I mean, I know researchers who are at the San Francisco General Hospital, for sure. I've 9 dealt -- our institute deals with them regularly. 10 Do you remember the first time you met Q. 11 Mark Zuckerberg? 12 I don't remember specifically, but I Α. 13 believe it was on a Zoom call. I don't believe I've 14 ever physically -- I may have. Could be. I don't 15 know for sure, but I don't think I've physically 16 interacted with him. I believe I have seen him on 17 multiple times that we've interacted on Facebook 18 Zoom-type podcasts. 19 Did any of those Zooms predate the Q. 20 outbreak of COVID-19? 21 Α. I don't think so. I mean, I don't -- I've 2.2 heard of Mark Zuckerberg -- obviously, he's a famous 2.3 person, but I don't recall -- again, I could have run

specifically recall running into Mark Zuckerberg

into him prior to the outbreak, but I don't

24

25

**Page 176** 

before. It's possible. 1 2 Can you turn to the third page of this Q. 3 There's another e-mail from document? 4 Mark Zuckerberg dated March 15th of 2020. 5 Do you see that? 6 MR. KIRSCHNER: The page before. 7 THE WITNESS: The one in the middle of the 8 page? 9 MR. KIRSCHNER: No, I think it's --10 BY MR. SAUER: 11 Q. Third page of the document? 12 Α. Third page of the document, yes. 13 MR. KIRSCHNER: Again, I would ask for 14 Dr. Fauci to have an opportunity to familiarize 15 himself with this e-mail prior to asking any 16 questions. BY MR. SAUER: 17 I just want to ask a quick question about 18 Q. 19 the paragraph that begins, "I'm also doing a series 20 of live-streamed Q and As." 21 Do you see that? 2.2 Yeah. I see it. Just let me read it. Α. 2.3 Yeah.

A with Mark Zuckerberg as he invited you to do in

Did you, in fact, do a live stream Q and

Fax: 314.644.1334

Q.

24

25

Page 177

1	this one in this paragraph?
2	A. I believe I did. I did a three I think
3	three is correct. Three live stream Facebook-type Q
4	and As where he would ask me important questions
5	you know, why is it important to be careful with, you
6	know, public health measures. Tell us the truth.
7	Now, what is the virus? What do you mean? How does
8	it spread? Things like that.
9	Q. Next paragraph down, "Finally, we have
10	allocated technical resources and millions of dollars
11	of free ad credits for the U.S. Government to use for
12	PSAs to get its message out over the platform"?
13	A. That's what he says, right.
14	Q. And the platform refers to Facebook, I
15	guess?
16	A. I guess so.
17	Q. Did you accept that offer that Facebook
18	would donate millions of dollars of free ad credit?
19	A. No, I don't have the authority to accept
20	outside money like that. It would have to go through
21	a different channel. And I don't believe though
22	I'm not 100 percent certain I don't believe that
23	there was any money that was given from the
24	Zuckerberg to the United States government to do
25	PSAs. It's possible, but it certainly didn't happen

**Page 178** 

- 1 to my knowledge. I don't recall money being given
- 2 for PSAs. I recall the offer to help get information
- 3 out, but I don't recall -- again, could have
- 4 happened, possible. But I don't recall.
- 5 Q. Exhibit 24 --
- 6 MR. KIRSCHNER: Counsel, before we go to
- 7 Exhibit 24, I've noticed on this exhibit it looks
- 8 like a phone number that I want to make sure is
- 9 redacted before it becomes a public record. It looks
- 10 like a personal cell phone for Mark Zuckerberg.
- 11 MR. SAUER: This is a document as we
- 12 received it from the government.
- 13 MR. KIRSCHNER: And it's marked
- 14 confidential.
- MR. SAUER: We have no objection to that.
- 16 BY MR. SAUER:
- 17 O. And Exhibit 24?
- 18 (FAUCI Exhibit No. 24 was marked for
- 19 identification.)
- 20 BY MR. SAUER:
- 21 Q. Is this the actual published version of
- 22 the "Proximal Origin of SARS-CoV-2"?
- 23 A. I don't have anything in front of me.
- Q. Oh, sorry. Is this the published version
- of the "Proximal Origin of SARS-CoV-2" that was

Page 179

1	published online on March 17th of 2020.
2	MR. KIRSCHNER: Objection.
3	Mischaracterizes the evidence. Just to make the
4	record clear, you're saying March 17th.
5	MR. SAUER: If you look at the last page
6	in the far right column, at the very top, it says,
7	"Published online 17 March, 2020." Do you see that?
8	MR. KIRSCHNER: Okay. I see that. Thank
9	you.
10	THE WITNESS: This appears to be the
11	Nature Medicine it says Nature Medicine, Volume
12	27, April 2020, on the bottom of the paper so I would
13	imagine this is the original, published,
14	peer-reviewed article that appeared in Nature
15	Medicine.
16	BY MR. SAUER:
17	Q. So this is the published version of the
18	one that Dr. Anderson had sent you the preprint
19	version of a few days earlier; correct?
20	A. Well, I can't say exactly that it is. I
21	do know that it would be standard to have a preprint
22	usually in Med Archive. And it had the same title,
23	the "Proximate Origin of SARS-CoV-2," and the authors
24	appear to be the same, so I would make a reasonable
25	assumption that Exhibit 24 is the peer-reviewed

Page 180

1	version of the preprint that you showed me before.
2	Q. And the first page, second paragraph?
3	A. Yes.
4	Q. Last sentence. "Our analyses clearly show
5	that SARS-CoV-2 is not a laboratory construct or a
6	<pre>purposely manipulated virus;" correct?</pre>
7	A. That's what it says.
8	Q. Did you have any input in formulating that
9	conclusion between the time you got the preprint
10	version from Dr. Anderson on March 8 and then the
11	publication online on March 17?
12	A. Mm-hmm.^ this is a conclusion of the
13	authors. I'm not really sure of what you're saying
14	did I have any input. I don't recall conversation
15	that we had and as I mentioned before, my input
16	into the formulation of this was minimal, if at all.
17	I remember reading through it.
18	And I'm not quite sure what you mean that
19	I have substantial input into the conclusion. That
20	conclusion was based on the analysis by the authors
21	of this paper.
22	Q. Did you have any communications at all
23	about that about any communications at all
24	about that conclusion in that time frame from
25	March 8th to March 17th?

Page 181

1	A. Conversations with whom?
2	Q. With anybody.
3	A. You know, I don't recall specific
4	conversations, but we read the preprint and,
5	therefore, we knew what the conclusion was, and I'm
6	sure that that conclusion was discussed. So I would
7	not be surprised at all following the initial
8	preprint that I discussed the conclusion of these
9	authors that this is not a laboratory construct or a
10	purposely manipulated virus.
11	I wouldn't be surprised if I did discuss
12	this with people since it already was out in public
13	knowledge in the preprint. So the question, did I
14	discuss this between the preprint and now? I would
15	not be surprised if I did.
16	Q. Do you know anyone you discussed it with?
17	Do you remember?
18	A. I can't specifically remember anyone I
19	discussed it with, but, as I said, given the fact
20	that it was out in the preprint literature, it is
21	likely, and I'm not surprised if I did, discuss it.
22	It was being discussed widely.
23	Q. I'm handing you Exhibit 26.
24	MR. KIRSCHNER: I think we're on 25.
25	MR. SAUER: Oh, sorry. That was it.

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

**Page 182** 

Fax: 314.644.1334

1 Twenty-five. 2 (FAUCI Exhibit No. 25 was marked for 3 identification.) 4 BY MR. SAUER: 5 Is this a copy of a blog that Q. 6 Francis Collins, the NIH director, published on 7 March 26th, 2020? MR. KIRSCHNER: Objection. Speculative. 9 BY MR. SAUER: 10 Is that what appears to be on the cover? Q. 11 Α. The cover states it was a NIH director's 12 blog posted on March 26th, 2020, by Dr. Francis Collins. So I have no reason to believe that that's 13 14 not what actually occurred. That this blog was put 15 up on his director's page. 16 Can you look at the second page of the 0. 17 document, the beginning of the blog? 18 Α. Yes. 19 You see where Director Collins says, "Some Q. 20 folks are even making outrageous claims that the new 21 coronavirus causing the pandemic was engineered in a 2.2 lab"? 2.3 Α. I'm sorry. Where -- we are -- where are 24 we? 25 Ο. Second page.

Page 183

1	A. This here?
2	Q. First full paragraph.
3	MR. KIRSCHNER: Again, I would ask for
4	Dr. Fauci to have an opportunity to familiarize
5	himself with this document.
6	THE WITNESS: Yeah. Let me read that
7	paragraph, please.
8	Yes. I've read the paragraph. What's the
9	question?
10	BY MR. SAUER:
11	Q. You see where it says, "Some folks are
12	even making outrageous claims that the new
13	coronavirus causing the pandemic was engineered in a
14	lab"?
15	A. Yes, I see that.
16	Q. And he goes on to say, "A new study
17	debunks such claims by providing scientific evidence
18	that this novel coronavirus arose naturally";
19	correct?
20	A. Correct.
21	Q. In the immediate following paragraph,
22	he describes that as reassuring findings and refers
23	to the Nature Medicine article we just looked at;
24	right?
25	A. Correct.

Page 184

1	Q. Were you aware that Francis Collins was
2	publishing a blog addressing the Nature Medicine
3	article "Proximal Origins of COVID-19"?
4	MR. KIRSCHNER: Objection. Lack of
5	foundation.
6	BY MR. SAUER:
7	Q. Were you aware?
8	A. Was I aware that he was preparing it? I
9	don't think so. I might have been, but I doubt it.
10	Someone likely would have brought this to my
11	attention. I don't recall reading this. I don't
12	read every NIH director's blog. It is conceivable,
13	maybe likely, that I did read it, but I was not to
14	my knowledge maybe he mentioned something to me
15	that I forgot that he was going to write a blog, but
16	it doesn't ring a bell in my mind that he was
17	planning to write a blog. But, you know, Francis
18	writes a lot. I wouldn't be surprised if he
19	mentioned he was going to do a blog, but this does
20	not ring a bell. It's clear that he did it and if he
21	did it, I likely saw it.
22	Q. You don't recall discussing it with him
23	beforehand in any way before he published it?
24	A. You know, again, I might have discussed it
25	with him, but I don't recall specifically discussing

Page 185

1	it with him.
2	Q. I'm handing you Exhibit 26. Was there
3	were you aware of media coverage of the article when
4	it came out?
5	MR. KIRSCHNER: Can you please wait until
6	Dr. Fauci has the exhibit in front of him? Also I
7	only have one person okay. What exhibit number is
8	this?
9	MR. SAUER: Twenty-six.
10	MR. KIRSCHNER: I apologize, Mr. Sauer,
11	but can you once Dr. Fauci has the exhibit, can
12	you restate the question?
13	THE WITNESS: So this is I have two
14	things here.
15	MR. KIRSCHNER: Oh, I have one copy.
16	THE WITNESS: So this is
17	(FAUCI Exhibit No. 26 was marked for
18	identification.)
19	BY MR. SAUER:
20	Q. Do you see this ABC News article
21	designated at the top of the page entitled "Sorry,
22	conspiracy theorists. Study concludes COVID-19 is
23	not a laboratory construct."
24	Do you see that?
25	A. I see it, yes.
	<del>-</del>

Page 186

1	Q. And then it it's dated March 27th,
2	2020, the day after the NIH director's blog that we
3	<pre>just looked at; correct?</pre>
4	A. Correct.
5	Q. Did you communicate with the media about
6	the Nature Medicine article when it came out at all?
7	A. You know, I don't recall communicating
8	with the media about that. I might have, but I don't
9	specifically recall communicating with the media
10	about it.
11	Q. Do you know if Dr. Collins communicated
12	with the media about it?
13	A. I don't know if he did.
14	Q. Do you know if anyone in the NIAID staff,
15	the staff that you oversee, communicated with the
16	media about it?
17	A. I don't recall if they did or did not.
18	They might have, but I don't recall.
19	Q. Did Dr. Collins ever contact you about the
20	Nature Medicine article after this his March 26th
21	blog?
22	MR. KIRSCHNER: Objection. Vague.
23	Ambiguous. Lack of foundation.
24	THE WITNESS: You're asking if he
25	contacted me about the Nature Medicine article. I

**Page 187** 

1	don't remember a specific contact, but since it's a
2	published article, I wouldn't be surprised if somehow
3	or other Dr. Collins commented to me about it or I
4	commented to him about it. But I don't specifically
5	recall any significant discussion. Again, we might
6	have. That would not be surprising to me.
7	BY MR. SAUER:
8	Q. I'm handing we're handing you
9	Exhibit 26.
10	(FAUCI Exhibit No. 27 was marked for
11	identification.)
12	THE WITNESS: I have Exhibit 26. You're
13	talking about 27.
14	BY MR. SAUER:
15	Q. Sorry. Twenty-seven. You're right.
16	A. Francis Collins to me, CC.
17	Q. Do you recognize this e-mail?
18	MR. KIRSCHNER: Objection
19	THE WITNESS: I have to read it.
20	MR. KIRSCHNER: I would ask for
21	Dr. Fauci to have an opportunity
22	THE WITNESS: I have to read it.
23	MR. KIRSCHNER: to familiarize himself
24	with the document.
25	THE WITNESS: Yes, I've read it.

Page 188

1	BY MR. SAUER:
2	Q. Do you recall getting this e-mail from
3	Dr. Collins on April 14th, 2020 at 5:02 p.m.?
4	A. Again, I'm very sorry, but you're talking
5	about e-mails several years ago. I don't recall
6	specifically this e-mail. You're putting an e-mail
7	in front of me that's from Francis to me, and I'm
8	reading what it says. I don't recall seeing this,
9	but I know that Francis clearly was concerned that
10	there'd be misinformation out and he wanted and
11	that's why he asked: "Any more we can do as the
12	national academy to weigh in?"
13	Q. In particular in the first paragraph there
14	he says to you, "Wondering if there is something NIH
15	can do to help us put down this very destructive
16	conspiracy with what seems to be growing momentum";
17	correct?
18	A. Right.
19	Q. Have you ever described the lab leak
20	theory of the origins of COVID as a very destructive
21	conspiracy to you?
22	A. Specifically, to me I mean, it's here
23	in this e-mail, but I just think that my little bit
24	of a hyperbole on his part about, you know, using
25	words like destructive conspiracy, I think Francis

Page 189

1	felt and you'll have to ask Francis about that
2	but I believe he felt that the data and you go to
3	the third paragraph in that e-mail he said, "I
4	hoped that the Nature Medicine article on the genomic
5	sequence would settle this."
6	So what I believe Francis was saying that
7	the scientific data strongly point to a natural
8	occurrence, and there's a lot of, you know,
9	discussion by some that this is clearly a deliberate
10	development of a virus that could harm people, and
11	Francis in the e-mail appears to be disturbed saying,
12	the scientific data shown in Nature Medicine we hoped
13	would settle this, and that's why he's concerned.
14	The words that he used, I don't recall him
15	using those words in public in person to person to
16	me, but he clearly used those words in this e-mail.
17	Q. You said a few things there. To
18	understand what Dr. Collins meant when he sent this
19	e-mail and the various other e-mails, you said you
20	really have to ask Dr. Collins about that?
21	A. Yeah.
22	Q. Is that fair to say?
23	MR. KIRSCHNER: Objection.
24	Mischaracterizes the evidence and also
25	THE WITNESS: No, I mean, you're asking me

**Page 190** 

- 1 about something he said, and I think the natural
- 2 thing is why don't you ask the guy who said it?
- 3 BY MR. SAUER:
- 4 Q. Fair enough. And then if you look there
- 5 to the link, he's got a link there to a Bret Baier
- 6 report that's entitled "Sources increasingly
- 7 confident coronavirus outbreak started in a
- 8 Wuhan lab"; correct?
- 9 A. I'm sorry. What -- is this the --
- 10 Q. First page?
- 11 A. I can't read it.
- 12 Q. Yeah, directly.
- 13 A. I can't see Bret Baier. I can't read the
- 14 rest of it.
- Q. Well, let me ask you this: Dr. Collins,
- 16 at the end of it says, "Anything more we can do? Ask
- 17 the National Academy to weigh in?" Correct?
- 18 A. Right.
- 19 Q. So he's asking you if there is anything
- 20 more that you and he and Cliff Lane and the others
- 21 copied can do to try to put this destructive
- 22 conspiracy, in his words, to rest; correct?
- 23 A. I think if you look at -- I mean, I'm not
- 24 sure exactly. I don't recall this e-mail, so I'm not
- 25 sure what he was implying. But reading it now, I

Page 191

1	concentrate on the next-to-last paragraph, what he
2	said.
3	"I had hoped the Nature Medicine article
4	on the genomic sequence would settle this, but it
5	probably didn't get much visibility." And it is
6	conceivable that what he is saying is that this is a
7	scientific, peer-reviewed article. It's not
8	surmising. It's not extrapolation. It's just a
9	peer-reviewed scientific article that he feels didn't
10	get a proper amount of visibility.
11	And in the next sentence, he says, "How
12	can we get it to get more visibility? Perhaps ask
13	the National Academy to weigh in and review the
14	evidence to give the evidence more visibility. I
15	think this is typical Francis, who's is a very solid
16	scientist, wanting to stick with the scientific data
17	as opposed to discussions of hypotheses with no
18	basis.
19	Q. Did you take any steps to increase the
20	visibility of the article after this?
21	A. Not to my knowledge. I don't think so. I
22	was busy with a lot of other things.
23	Q. I'm sure you were very busy. Did you
24	respond to the e-mail?
25	A. I don't recall if I did. You're probably

**Page 192** 

Fax: 314.644.1334

- 1 going to show me an e-mail where I did. 2 Q. Can you look at the next page? 3 Α. Yeah. 4 Next day, April 17, 2022, you respond to 0. 5 that e-mail, saying, quote, "I would not do anything 6 about this right now. It is a shiny object that will 7 ^ correct? go away." Α. Right. 9 What did you mean when you said, "I would Q. 10 not" -- "I would not do anything about this right 11 now." Were you saying you don't want to take any 12 steps to increase the visibility of --No. I think we should let the 13 Α. Right.
- Q. And you said it is a shiny object --

Nature Medicine article speak for itself is what I

17 A. Right.

meant.

14

15

- 18 Q. -- that will go away in time?
- 19 A. Right.
- Q. What did you mean by that?
- 21 A. By shiny object I mean something that
- 22 people tend to really get excited about. It's very
- 23 exciting to say, "Well, this thing was manufactured
- 24 by the Chinese and they threw it out into the world."
- 25 That's a shiny object.

Page 193

1	If you say that, it gets discussed all
2	over the world. That's a shiny object. And I was
3	referring to the fact that I stick, as a scientist,
4	with the science. And invariably, the science
5	prevails.
6	So what I was referring to is that I don't
7	think you should do anything about it right now. Let
8	the Nature Medicine and the data essentially prevail.
9	And this issue of with no proof at all,
10	people stating this is likely manufactured by the
11	Chinese and released, that's what I meant by a shiny
12	object, it's something with no evidence but a lot of
13	pizzazz to it if you say it. And that's what I was
14	referring to.
15	Q. Tying back to your earlier comment, do you
16	think that that theory was a form of misinformation
17	or disinformation that could lead to loss of life?
18	MR. KIRSCHNER: Objection. Vague.
19	Ambiguous.
20	THE WITNESS: No. I'm not sure.
21	BY MR. SAUER:
22	Q. Well, Dr. Collins described it as a very
23	destructive conspiracy.
24	A. Correct.
25	Q. And I take it that's the destructive

Page 194

1	conspiracy theory that the virus originated from a
2	lab?
3	A. Right, right.
4	Q. Did you view that theory as a form of
5	misinformation or disinformation that could lead to
6	the loss of life?
7	A. It could be misinformation. Remember,
8	misinformation are things that are untrue, not
9	necessarily deliberately, you know, propagated as
10	untrue, whereas disinformation is when you know it's
11	wrong and you still spread it.
12	So this very well might be, at least at
13	the time there was no indication that this was
14	correct information. So let me categorize it that
15	way.
16	So for someone or anyone to be going
17	around spreading that this clearly is something that
18	was made by the Chinese and released in society and
19	killed a lot people, that would be misinformation
20	because there's no evidence that that's the case.
21	And the second part of your question was
22	that could lead to a number of other things. When
23	you pursue misinformation and disinformation, often
24	you take away from the effort of pursuing something
25	that is in the line of correct information.
1	

Page 195

1	Q. Did you take any further steps after that
2	e-mail to increase the visibility or the public
3	awareness of the Nature Medicine article?
4	MR. KIRSCHNER: Objection. Asked and
5	answered.
6	THE WITNESS: Again, I'm not really sure
7	what you mean. When the paper came out, it was a
8	peer-reviewed scientific analysis that came to a
9	conclusion that we've already discussed.
10	Did I discuss this with people since this
11	was a topic of considerable concern, likely I did.
12	If you're asking did I do anything to promote the
13	dissemination of that, I don't think I went out of my
14	way, as I mentioned and you agreed, I'm a really busy
15	person. I have a lot of other things to do. I don't
16	think I made this something that was a high level of
17	priority for me.
18	BY MR. SAUER:
19	Q. You don't think you made let me ask you
20	this: You knew what Nature Medicine article he was
21	talking about, right?
22	A. Yeah.
23	Q. And in particular, this is the article
24	that has Christian Anderson as a corresponding
25	author?

Page 196

1	A.	Right.
2	Q.	Correct?
3	Α.	Correct.
4	Q.	This is the article where he, you know,
5	you had be	een sent at least four drafts of it, based
6	on the e-r	mails we saw previously; correct?
7	Α.	That's the same one of which I had very
8	little inp	out into, yeah.
9	Q.	And this is the article that Christian
10	Anderson h	nad sent you a preprint and had said thank
11	you for yo	our advice and leadership about the article;
12	correct?	
13		MR. KIRSCHNER: Objection.
14	Mischaract	terizes the evidence.
15	BY MR. SAU	JER:
16	Q.	Correct?
17	Α.	It's the article that we discussed before.
18	Q.	Proximal Origins of COVID-19?
19	Α.	Yes.
20	Q.	Exhibit 28.
21		(FAUCI Exhibit No. 28 was marked for
22	identifica	ation.)
23	BY MR. SAU	JER:
24	Q.	And this is a excerpt from the transcript
25	of the Co	ronavirus Task Force press briefing in the

**Page 197** 

1	White House dated April 17th, 2020; correct?
2	MR. KIRSCHNER: Objection.
3	THE WITNESS: That's what it says on the
4	top of the piece of paper of Exhibit 28, it says
5	"Remarks by President Trump, Vice President Pence,
6	and members of the Coronavirus Task Force."
7	BY MR. SAUER:
8	Q. At that time, you were a member of the
9	Coronavirus Task Force; correct?
10	A. That is correct.
11	Q. And you participated in this briefing with
12	the president and the vice president; correct?
13	MR. KIRSCHNER: Objection. I would ask
14	Dr. Fauci have an opportunity to familiarize himself
15	with this document.
16	THE WITNESS: I'm looking at the document
17	now. And as I scan, I see on page 44 of 48, that it
18	says Dr. Fauci, and it says something that it looks
19	like I said at the press this looks like a
20	transcript, which it looks like it is, then clearly I
21	participated in that because my name is here.
22	BY MR. SAUER:
23	Q. And if you look little bit above that on
24	that second page, there's a question from a member of
25	the media saying, "Mr. President, I wanted to ask

Page 198

1	Dr. Fauci, could you address the suggestions or
2	concerns that the virus was somehow manmade, possibly
3	came out of a laboratory in China?" Correct?
4	A. That's what it says.
5	Q. And the president says to you, "Want to
6	go?" Correct?
7	A. That's what the president said.
8	Q. And then the reporter repeated, addressing
9	you. "You studied this virus. What are the
10	prospects of that?" Right?
11	A. That's what the question said.
12	Q. And your response to that was, "There was
13	a study recently that we can make available to you
14	where a group of highly qualified evolutionary
15	virologists looked at the sequences there and the
16	sequences in bats as they evolved. And the mutations
17	that it took to get to the point where it is now is
18	totally consistent with a jump of a species from an
19	animal to a human"; correct?
20	A. That's what it says.
21	Q. Do you remember saying that?
22	A. I don't recall. I was at as you
23	probably know, multiple, multiple White House press
24	conferences. I have no reason to doubt that the
25	transcript is not accurate, and it looks like that's

**Page 199** 

- 1 what I said. So I would imagine I said it.
- 2 Q. And this is April 17, which is the same
- 3 day that you had e-mailed Dr. Collins this last
- 4 exhibit saying this theory is a shiny toy that will
- 5 go away in time. Correct?
- 6 A. Shiny object.
- 7 Q. Sorry. Shiny object that will go away in
- 8 time.
- 9 MR. KIRSCHNER: Objection. Lack of
- 10 foundation.
- 11 THE WITNESS: You know, I would have to go
- 12 back and look where -- you're asking me if it was the
- 13 same date. And I have to look here. The date on
- 14 Exhibit 27 is 17th of April. And this is the date of
- 15 the press conference, yes. So it's the same date.
- 16 Yeah.
- 17 BY MR. SAUER:
- 18 Q. And I've watched the video of this
- 19 particular comment?
- 20 A. Yeah.
- Q. And I noted in watching the video that,
- 22 when you said that sentence about totally consistent,
- you pause and use that phrase, "totally consistent"
- 24 with emphasis.
- 25 A. Right.

Page 200

1	Q. Do you remember doing that?
2	A. I don't remember doing that. Like I said,
3	it's one of many, many, many press conferences. So I
4	don't remember a pause of a statement I made in one
5	of dozens and dozens of press conferences.
6	Q. And you have given many, to be sure. But
7	do you remember saying the mutations that it took to
8	get to the point where it is now pause for
9	emphasis is totally consistent with a jump from
10	species, from animal to human. You don't remember
11	that?
12	MR. KIRSCHNER: Objection. Lack of
13	foundation.
14	THE WITNESS: I don't remember pauses in
15	the hundreds of conferences that I've been at.
16	BY MR. SAUER:
17	Q. You went on to say, "So the paper will be
18	available. I don't have the authors right now, but
19	we can make that available to you"; correct?
20	A. Right.
21	Q. This is the same paper that, on the same
22	day, you had been e-mailing with Dr. Collins about in
23	the previous exhibit; correct?
24	A. I'm a little bit confused with your
25	question. I'm not sure what you mean. Is the

**Page 201** 

Fax: 314.644.1334

1 paper --2 What paper are you referring to here in Q. 3 your comments from the White House podium at the task 4 force briefing on April 17th? Do you know? 5 Α. I don't know. I assume it was the Nature 6 Medicine paper. I don't know. I think it was. 7 Q. Did you make the paper available to any 8 reporters after this press conference? 9 Not to my knowledge. 10 MR. KIRSCHNER: Mr. Sauer, how long do you want to go before lunch? 11 MR. SAUER: Why don't we do one more 12 exhibit. 13 14 THE WITNESS: Okay. 15 BY MR. SAUER: 16 0. Exhibit 29. 17 (FAUCI Exhibit No. 29 was marked for 18 identification.) 19 BY MR. SAUER: 20 If you'll look at the bottom of this page, 0. 21 did you receive an e-mail on April 19th, 2020, from a 22 reporter at the Washington -- at The Times asking: 2.3 "Dr. Fauci on Friday said he would share a scientific 24 paper with the press on the origin of the 25 coronavirus. Can you please help me get a copy of

**Page 202** 

1	that paper?" Do you recall that?
2	A. This is Bill Bill Gertz's e-mail to
3	Katie. I don't recall it, but I'm looking up ahead
4	and I this is I guess this is Katie Miller, if
5	I'm not mistaken, who is the vice president's press
6	person. I think that's probably who it was. It
7	doesn't say who it's to or from, and then up above I
8	sent a link. So that that may be the papers we're
9	talking about.
10	Q. Did you send the link to Bill in there in
11	the first line of the e-mail, directly to Bill?
12	A. Yeah. He asked for the scientific paper
13	in the press briefing that you asked for. That may
14	have been the press person that asked the question,
15	and it looks like Katie Miller, who is the press
16	person for the Vice President Pence,
17	probably contacted me. I don't see a connecting
18	e-mail here, but she probably contacted me and said,
19	would you send the links to the paper to Bill Gertz,
20	and it looks like I did. It says here, "Bill, here
21	are the links to the scientific papers and a
22	commentary about the papers."
23	So there are two aspects here. There is
24	the original paper that came online that I believe
25	was not yet out or maybe just did come out and a

**Page 203** 

Fax: 314.644.1334

1 commentary on it in the journal Cell, yes. 2 Q. And the first paper is, in fact, the 3 proximal origin of SARS-CoV-2 --4 Α. Right. 5 -- the Nature Medicine paper that we've 6 talked about? 7 It looks -- yes, it says here Nature Medicine April 2020. That is the paper that is the 9 peer-reviewed version of the original preprint that came out earlier. 10 11 Q. And then the other two citations are both authored by Eddie Holmes who was --12 13 Α. Right. 14 -- involved in drafting that paper; 0. 15 correct? 16 Α. Right. 17 MR. SAUER: Let's take a break there. 18 THE VIDEOGRAPHER: The time is 12:27 p.m., 19 and we're going off the record. 20 (Recess.) 21 THE VIDEOGRAPHER: The time is 1:19 p.m., 2.2 and we're back on the record. 2.3 BY MR. SAUER: 24 Q. Dr. Fauci, I'm handing you Exhibit 30. 25 (FAUCI Exhibit No. 30 was marked for

Page 204

1	identification.)
2	BY MR. SAUER:
3	Q. You see this is an e-mail at the top from
4	you to Peter Daszak dated at dated April 19th,
5	2020?
6	A. Yes.
7	Q. And you're responding to an e-mail from
8	him the day before, April 18th, 2020; correct?
9	A. Correct.
10	Q. And his e-mail was the day after that
11	coronavirus task force press conference that we
12	looked at, the previous exhibit; correct?
13	A. Right.
14	Q. And he said, "Tony, CC'ing David so that
15	you might pass this on to Tony once he has a spare
16	sec"; correct?
17	A. Correct.
18	Q. Is David a reference to David Morens?
19	A. That's true, yes.
20	Q. Who is David Morens?
21	A. David Morens is a person who works at
22	NIAID, is a scientist, been with us for a very long
23	time.
24	Q. Does he know Peter Daszak?
25	A. I believe he does.

**Page 205** 

1	Q. Do you know Peter Daszak?
2	A. You know
3	
	MR. KIRSCHNER: Objection. Asked and
4	answered.
5	THE WITNESS: Yeah. To the extent that
6	I've answered that multiple times, I'm acquainted in
7	the sense of I have seen him once or twice. I don't
8	have a friendship or a relationship, if you want to
9	call it that, with him. I'm just aware of him, and
10	I've seen him a couple of times. I think I did a
11	podcast once where he was another member of the
12	podcast group.
13	BY MR. SAUER:
14	Q. These other people he copies, Erik Stemmy,
15	Emily Erbelding, and Aleksei Chmura, are they all
16	people that work on your staff at NIAID?
17	A. Erik Stemmy does for sure. Emily does for
18	sure. I believe Aleksei Chmura does also, but I'm
19	not 100 percent sure. I believe that person does.
20	I've seen his name circulated around in in
21	correspondence in our institute, but for sure
22	Erik Stemmy and Emily Erbelding work at NIAID.
23	Q. Do you know how he got all your e-mail
24	addresses?
25	MR. KIRSCHNER: Objection. Calls for

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

**Page 206** 

- 1 speculation.
- 2 BY MR. SAUER:
- 3 Q. For example, do you know how he got your
- 4 e-mail address?
- 5 A. How Peter Daszak got my e-mail address?
- 6 O. Yeah.
- 7 A. It's pretty easy to get an e-mail address.
- 8 You just go on to the global NIH and you can get it.
- 9 Q. That's publicly available, your e-mail
- 10 address?
- 11 A. Oh, totally.
- 12 Q. Even though it's redacted under B6 in this
- 13 document?
- 14 MR. KIRSCHNER: Objection. Argumentative.
- 15 BY MR. SAUER:
- 16 Q. You may answer.
- 17 A. I don't know what you're talking about.
- 18 You don't redact a website. If you go on to the NIH
- 19 global, you can find my e-mail address.
- 20 Q. You responded to this the day after you
- 21 received it saying, "Many thanks for your kind note";
- 22 correct?
- 23 A. Right. That's a very typical response of
- 24 mine. I can show you 45,000 e-mails that say thank
- 25 you for your kind note.

**Page 207** 

1	Q. You say you get about 2,000 e-mails a day?
2	A. I get yeah, some days some days a
3	thousand, two thousand, some days several hundred.
4	Q. Do you respond to all of them like that?
5	A. No, no. The the ones that are
6	irrelevant and what's the right word for them
7	the ones that I don't really need to see.
8	Q. That's how you respond to them?
9	A. I don't respond no, to this? No. I
10	don't respond to every one of my e-mails. I get a
11	lot of e-mails from a number of different sources
12	that are completely distracting and irrelevant to me,
13	but when an e-mail comes through, we got people
14	think I should see from a legitimate scientist,
15	they let it through and then I see it.
16	Q. And that Peter Daszak is a legitimate
17	scientist in that category. Fair to say?
18	MR. KIRSCHNER: Objection. Vague.
19	THE WITNESS: Peter Daszak is a is a
20	grantee of NIAID. So it would be perfectly
21	appropriate to let an e-mail from a grantee of NIAID
22	through to me.
23	BY MR. SAUER:
24	Q. Are you aware that generally, that
25	after your comments at the White House April 17th,

**Page 208** 

1	coronavirus task force briefing speech about the lab
2	leak hypothesis was censored on social media?
3	Are you aware of that?
4	MR. KIRSCHNER: Objection. Lack of
5	foundation. Vague.
6	MR. SAUER: I've asked him if he's aware
7	of it.
8	BY MR. SAUER:
9	Q. Are you aware of it?
10	A. I'm not aware of suppression of speech on
11	social media to my knowledge. If if it was
12	brought to my attention, it went (unreportable
13	sound.) I I don't recall being aware of
14	suppression of anything.
15	Q. Were you were you aware that Twitter,
16	for example, removed content that suggested the virus
17	may have escaped from a lab?
18	MR. KIRSCHNER: Objection. Lack of
19	foundation.
20	BY MR. SAUER:
21	Q. If you know?
22	A. You know, I don't know for sure. I can
23	say I am not aware of it. It may be someone somehow
24	sent me one of the thousands of e-mails and said,
25	"Hey, this is happening," but I was not aware to the

**Page 209** 

- 1 point of noting it in my memory that Twitter or any
- 2 other social media was suppressing anything.
- 3 O. Exhibit 31.
- 4 (FAUCI Exhibit No. 31 was marked for
- 5 identification.)
- 6 BY MR. SAUER:
- 7 Q. Here's a report in The Hill, if you see
- 8 that at the top, headline is Twitter suspends
- 9 accounts of Chinese virologist who
- 10 claimed coronavirus was made in the lab; correct?
- 11 A. That's what it says.
- 12 Q. Does this incident ring a bell? Were you
- 13 aware of an incident like this which --
- 14 THE REPORTER: Counsel, please slow down.
- 15 BY MR. SAUER:
- 16 Q. Were you aware of a -- Twitter suspending
- 17 the account of a Chinese virologist --
- 18 A. Yeah.
- 19 Q. -- who claimed it was removed from a lab?
- 20 A. You know, Mr. Sauer, I might have -- been
- 21 brought to my attention then. I don't recall this.
- 22 If you show me this now and ask me the question: Do
- 23 you recall this? I'd have to say I don't recall.
- Is it possible that back then somebody
- 25 said, "Hey, you know, Twitter suspended a Chinese

**Page 210** 

1	virologist's account," and I would have went, ah,
2	okay, and move on to the other things I do in life.
3	This is not something that would be
4	catching my attention because, you know, the social
5	media and Twitter, I told you, I don't have a Twitter
6	account. I don't tweet. I don't do Facebook. I
7	don't do anything. So social media stuff, I don't
8	really pay that much attention to.
9	Q. Exhibit 33?
10	MR. KIRSCHNER: Thirty-two.
11	MR. SAUER: Thirty-two.
12	(FAUCI Exhibit No. 32 was marked for
13	identification.)
14	BY MR. SAUER:
15	Q. Is this a document from Meta entitled,
16	"Update on our work to keep people informed and limit
17	misinformation about COVID-19"?
18	MR. KIRSCHNER: Objection. Lack of
19	foundation. Speculative.
20	BY MR. SAUER:
21	Q. Is that what it says on the front of it?
22	A. The title say "Meta," and it says, "Update
23	on our work to keep people informed and limit
24	misinformation about COVID-19."
25	Q. Third page of this document, can you turn
Ī	

**Page 211** 

1	to that?
2	A. Page 3. Okay. All right.
3	Q. It says at the top, the very first line,
4 :	mostly across, "We are expanding the list of
5	false claims we will remove to include additional
6	debunked claims"?
7	A. I'm sorry. What where is it?
8	Q. Top page.
9	A. "We are expanding," the middle of the
10	sentence. Okay. I got it.
11	Q. "We will remove to include
12	additional debunked claims about the coronavirus and
13	vaccine"; correct?
14	MR. KIRSCHNER: I object. I'd like to
15	have Dr. Fauci to have a moment to familiarize
16	himself with this document.
17	THE WITNESS: So I'm not is this
18	what is Meta? That is a ^ Facebook.
19	BY MR. SAUER:
20	Q. Let me cut past all that. If you look at
21	the top of page 3, there's a reference to removing
22	debunked claims in that first bullet point that
23	COVID-19 is manmade or manufactured. Generally, were
24	you aware that Meta, which controlled Facebook and
25	Instagram, changed its policy alleging that it would

**Page 212** 

1	remove its content alleging that COVID-19 is
2	manufactured or manmade?
3	A. I don't recall being aware of this
4	some again, when you say were you aware, you're
5	talking a couple of years ago. Could someone have
6	passed me in the hall and said, "By the way, were you
7	aware that Meta did this?" Would have been one of
8	10,000 things that that was said to me that day. I
9	don't recall being aware of anything that Meta did.
10	In fact, I didn't even know what the Meta was.
11	Q. You've heard of Facebook; right?
12	A. If I yeah, I understand now. Somebody
13	told me that they are part of Facebook or own
14	Facebook or something like that.
15	Q. Exhibit 33.
16	(FAUCI Exhibit No. 33 was marked for
17	identification.)
18	BY MR. SAUER:
19	Q. Very briefly oh, sorry.
20	Very briefly, this article is headlined
21	"Facebook Censors Award-Winning Journalist for
22	Criticizing the WHO." Is that correct?
23	A. That's what this title of Exhibit 33 says.
24	Q. And the article referred to a man named
25	Ian Birrel, B-i-r-r-e-l. Have you ever heard of him?

**Page 213** 

1	A. I don't recall of ever hearing of Ian
2	Birrel. Maybe back then somebody said something
3	about him. But right now, I wouldn't know. It says
4	here a multiaward-winning investigative reporter.
5	But if it hadn't said that, I wouldn't know who Ian
6	Birrel is.
7	Q. Did you ever have any communications with
8	anybody removing speech about the lab leak theory of
9	the origins of the COVID from social media platforms?
10	A. I don't recall ever having any
11	conversation. But again, no, I would say it would be
12	unlike me because I don't get involved in that sort
13	of stuff. Like I said, my association with social
14	media is almost zero. I don't have an account. I
15	don't tweet. I don't pay attention to social media.
16	I wouldn't know how to access a tweet if you paid me.
17	Q. Exhibit 34.
18	(FAUCI Exhibit No. 34 was marked for
19	identification.)
20	BY MR. SAUER:
21	Q. During 2020, was there a controversy about

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

the effectiveness of hydroxychloroquine in treatment

MR. KIRSCHNER: Objection. Vague.

Fax: 314.644.1334

of COVID-19?

Ambiguous.

22

23

24

25

**Page 214** 

1	THE WITNESS: There were claims that
2	hydroxychloroquine was effective against coronavirus.
3	BY MR. SAUER:
4	Q. And did you disagree with those claims?
5	A. I did.
6	Q. What was your basis for disagreeing with
7	those claims?
8	A. Lack of any evidence whatsoever that
9	hydroxychloroquine was effective against coronavirus,
10	followed by clinical studies that showed that, in
11	fact, was not effective against hydroxychloroquine ^
12	and statements by clinical trials guideline groups
13	stating explicitly that there's no evidence
14	whatsoever that hydroxychloroquine works against
15	coronavirus.
16	Q. Did you you're referring to the studies
17	and so forth. Did you collect those studies yourself
18	and review them or did someone collect them for you?
19	MR. KIRSCHNER: Objection. Assumes
20	evidence not in the record.
21	THE WITNESS: What studies are you
22	referring to?
23	MR. SAUER: Well, I think you referred to
24	studies.
25	THE WITNESS: Well, there were claims

**Page 215** 

- 1 based on anecdotal data. And if you look at the
- 2 record, it was clear that when people made definitive
- 3 claims about efficacy based on anecdotal data that's
- 4 not scientific, that does not indicate that a drug is
- 5 effective.
- 6 Subsequently, papers were published
- 7 showing a lack of effect of hydroxychloroquine.
- 8 BY MR. SAUER:
- 9 Q. And my question is: Did you do all this
- 10 research yourself where you are getting all the
- 11 studies --
- 12 A. No.
- 13 Q. -- or did someone else do the research for
- 14 you?
- 15 A. I don't do research myself on the efficacy
- of drugs. The research is performed by researchers
- 17 who publish their data in peer-reviewed journals, and
- 18 that's how you get information that's applicable to
- 19 the real world.
- Q. Did you have discussions with others in
- 21 NIAID about the efficacy of hydroxychloroquine?
- 22 A. The subject of the hydroxychloroquine and
- 23 the claims based on no data that hydroxychloroquine
- 24 was effective against coronavirus was a topic of
- 25 discussions on and off, both in NIAID and in the

**Page 216** 

- 1 scientific community in general.
- Q. Who did you discuss it with at NIAID, to
- 3 your recollection?
- 4 A. I'm sure I discussed it with a number of
- 5 people. Probably Dr. Cliff Lane, who was the
- 6 clinical director of my institute. It's likely that
- 7 I discussed the efficacy of hydroxychloroquine with
- 8 him.
- 9 Q. Anyone else within NIAID?
- 10 A. I'm -- I would imagine there were other
- 11 people. I don't specifically recall. But given the
- 12 fact that Cliff Lane is one of the top infectious
- disease clinicians in the country and happens to be
- 14 my clinical director and the director of my division
- of clinical research, it is highly likely that I had
- 16 that discussion with him.
- 17 Q. How about outside of NIAID? Anyone else
- within government that you discussed its efficacy
- 19 with?
- 20 A. I can't say for sure. As I mentioned, it
- 21 was a topic of considerable discussion. So I would
- 22 not be surprised if somehow you pulled out a piece of
- 23 paper where I spoke to someone about it. It was a
- 24 very important subject because hydroxychloroquine can
- 25 have some deleterious effects in people, and it was

**Page 217** 

Fax: 314.644.1334

- 1 concern within the established medical community that
- 2 based on claims based on no data, anecdotal data at
- 3 best that hydroxychloroguine works, that people would
- 4 be taking it, in which it does not help, but
- 5 possibly harms them.
- 6 Q. Is that one of the pieces of
- 7 misinformation or disinformation that may cause loss
- 8 of lives that you referred to earlier, in your view?
- 9 A. The claim, based on no data, juxtaposed on
- 10 clear-cut clinical data showing that
- 11 hydroxychloroquine does not work. If one propagates
- 12 this concept that hydroxychloroquine is highly
- 13 effective and people take it based on that
- 14 information, which is incorrect, yes, that would be
- 15 misinformation or even disinformation that could lead
- 16 people to take a drug that would not help them, that
- 17 could possibly hurt them.
- 18 Q. Did you make a series of public statements
- 19 about the efficacy of hydroxychloroquine in the
- 20 **summer of 2020?**
- 21 A. I don't know when I made it, whether it
- 22 was the spring or the summer, but I definitely made
- 23 public statements. I recall, when people asked at a
- 24 White House press conference whether
- 25 hydroxychloroquine worked, and I said those data are

LEXITAS LEGAL Phone: 1.800.280.3376

**Page 218** 

- 1 anecdotal, and there's not definitive proof that it
- 2 works. So I have made public statements in places
- 3 like a White House press conference.
- 4 Q. Just looking at the exhibit in front of
- 5 you. This is a Politico article entitled, "Fauci:
- 6 Hydroxychloroquine not effective against
- 7 coronavirus." Correct?
- 8 A. That's what the title says, yes.
- 9 Q. And then the second page of it gives a
- 10 date of May 22nd, 2020. Correct?
- 11 A. Correct.
- 12 Q. And in the second paragraph there, it
- 13 quotes you as saying, "The scientific data is really
- quite evident now about lack of efficacy; correct?
- 15 A. Correct.
- 16 Q. And the next page, when you said that,
- you're referring to the hydroxychloroquine; correct?
- 18 A. I quess so. I quess if the topic of
- 19 discussion was hydroxychloroquine, it isn't
- 20 explicitly stated hydroxychloroquine, but in the
- 21 antecedent paragraph, the author, Zachary Brennan,
- 22 is referring to hydroxychloroguine. So I would
- 23 imagine that I was also referring to
- 24 hydroxychloroquine.
- Q. And the next page, third page, it says,

**Page 219** 

1	"Fauci's comments come days after the Lancet
2	published"
3	(Discussion off the record.)
4	THE VIDEOGRAPHER: The time is 1:37 p.m.
5	(Recess taken.)
6	THE VIDEOGRAPHER: The time is 1:38 p.m.
7	and we're back on the record.
8	BY MR. SAUER:
9	Q. Turning your attention to the third page
10	there, it says, "Fauci's comments come days after you
11	The Lancet published a 96,000-patient observational
12	study that concluded that hydroxychloroquine has no
13	effect on COVID-19 and may have even caused some
14	harm"; correct?
15	A. That's what it says, yes.
16	Q. It says that was that, in fact, the
17	basis of your statement that the scientific data is
18	really now quite evident about lack of efficacy?
19	A. That could be. Again, you're going back a
20	couple of years. It is quite consistent with that.
21	I can't say definitively that that was the specific
22	study that I was referring to. There was information
23	coming from a number of studies, some of which were
24	negative studies that showed that it did not work.
25	And others were positive studies to show that it did

**Page 220** 

Fax: 314.644.1334

- not work. 2 So this could have been the study that I
- was referring to. I'm not 100 percent certain. 3
- 4 In the time frame, was there discussion 0.
- 5 of -- was there a situation with the FDA first in
- 6 March of 2020 issuing an EUA as to
- 7 hydroxychloroquine? Did that occur, do you recall?
- I don't recall exactly when, but I -- and
- 9 again, you're going back and they may have -- I think
- 10 they did, but I'm not 100 percent sure, that they did
- 11 issue an EUA for the emergency use of
- 12 hydroxychloroquine, but I believe that that EUA was
- subsequently pulled back. 13
- 14 Would that have been in June of 2020? 0.
- 15 Α. Could possibly have been. I don't recall
- 16 exactly.

1

- 17 Were you consulted in that process by the 0.
- FDA? Did you have any input on the decision by the 18
- 19 FDA to revoke the EUA?
- I don't recall. It is possible that I was 20 Α.
- 21 but I don't recall.
- 2.2 Do you have any recollection of why the Q.
- 2.3 EUA was revoked?
- 24 Α. I don't have any recollection now of why
- 25 it was revoked then, but I would imagine, as the data

**Page 221** 

- 1 accumulated, that clinical trials showed a lack of
- 2 efficacy.
- 3 The criteria for an emergency use
- 4 authorization that a drug that has not been proven to
- 5 be effective, that the potential benefit of the drug
- 6 might outweigh the risk.
- 7 If data comes in to show that there's no
- 8 benefit for the drug, then that would be a basis for
- 9 pulling back on the EUA.
- 10 Q. Next 35.
- 11 (FAUCI Exhibit No. 35 was marked for
- 12 identification.)
- 13 BY MR. SAUER:
- 14 Q. Is this The Lancet study that was referred
- 15 to in the Politico article that we just discussed, to
- 16 your knowledge?
- 17 MR. KIRSCHNER: Objection. Lack of
- 18 foundation.
- 19 BY MR. SAUER:
- 20 Q. If you know?
- 21 A. I don't know if it's the same article, to
- 22 be honest with you.
- Q. If you look on the front page of this
- 24 exhibit on the right?
- 25 A. Yeah.

**Page 222** 

1	Q. Do you see where it says at the top the
2	very top, "Published online May 22nd, 2020"?
3	A. Okay.
4	Q. The word "May" is under the D and
5	retracted.^ Do you see that?
6	A. Yeah.
7	Q. And that's five days before that Politico
8	article dated May 27th?
9	A. Right.
10	Q. And the Politico article referred to a
11	study in The Lancet that surveyed 96,000 patients;
12	correct?
13	A. That's what the Politico article says.
14	Q. And if you look at the third paragraph
15	here in the summary, the very beginning of it, it
16	says, "Findings: 96,032
17	A. Yeah.
18	Q patients
19	A. Right.
20	Q are discussed"?
21	Then this study was later retracted;
22	correct?
23	A. Well, it says "retracted" across the
24	front. I don't recall it being retracted, but if it
25	says "retracted"

**Page 223** 

1	Q. Were you aware that it was retracted at
2	the time? Do you have any recollection of that?
3	MR. KIRSCHNER: Objection. Lack of
4	foundation.
5	BY MR. SAUER:
6	Q. If you know?
7	A. I don't recall it being retracted. I
8	might have at the time heard that it was retracted,
9	but it wasn't the only paper that was on
10	hydroxychloroquine.
11	BY MR. SAUER:
12	Q. Did you was your opinion based
13	on other papers as well?
14	A. My I mean, I'm thinking back, then,
15	my my opinion of the effect of hydroxychloroquine
16	was based on accumulating data from a number of
17	studies. I don't recall specifically what those
18	studies are now.
19	Q. Some of obviously not every doctor
20	agreed with your views on hydroxychloroquine;
21	correct?
22	MR. KIRSCHNER: Objection. Argumentative.
23	THE WITNESS: Not every doctor agreed. I
24	don't think every doctor in the world agrees on
25	everything, but I'm sure there was some doctors who

**Page 224** 

- 1 disagreed with it despite the fact that the evidence
- 2 was ample, accumulating, and continued to accumulate
- 3 that hydroxychloroquine was not effective.
- 4 BY MR. SAUER:
- 5 Q. Were you aware that there were doctors who
- 6 continued to prescribe it for their patients with
- 7 COVID?
- 8 A. I heard that doctors were continuing to
- 9 prescribe it.
- 10 Q. If a doctor makes that clinical judgment
- 11 with respect to their patient, are you qualified to
- 12 second guess that clinical judgment?
- 13 MR. KIRSCHNER: Objection. Argumentative.
- 14 THE WITNESS: I don't -- I don't know what
- 15 you're talking about. Am I qualified to -- what do
- 16 you mean by qualified to question?
- 17 BY MR. SAUER:
- 18 Q. Well, do you have qualifications --
- 19 A. There's no -- you mean, like, a written
- 20 statement that says you are qualified to -- I'm not
- 21 sure what you mean am I qualified to.
- Q. What is your qualification to second guess
- 23 a decision that's made between a doctor and their
- 24 individual patient about the prescription of
- 25 hydroxychloroguine for -- to treat COVID?

**Page 225** 

1	A. Well, I mean, you're using the word
2	"second guess." If a physician is prescribing a
3	medication that has no benefit and can clearly cause
4	harm, that would make me pause as to whether or not
5	that was an appropriate thing. When you say "second
6	guess," I'm wondering what you mean. Second guess,
7	go out and demonstrate in front of his or her office?
8	No, that's not it, but I can certainly have an
9	opinion that if a physician prescribes a medication
10	with no proven efficacy and clearcut potential
11	toxicity, then I would be concerned about that
12	because as a physician, I never want to see a patient
13	harmed by an intervention that has no benefit to
14	begin with.
15	Q. Were you aware or do you recall that in
16	July of 2020, a couple of months after the your
17	statement that from Politico that we talked about,
18	there were a group of doctors who had a posted a
19	video in front of the Supreme Court touting the
20	what they perceived as the benefits of
21	hydroxychloroquine?
22	MR. KIRSCHNER: Objection. Lack of
23	foundation.
24	THE WITNESS: I don't recall. I do
25	vaguely recall a group of doctors I forgot who

**Page 226** 

- 1 they called themselves -- got up and were talking
- 2 about a bunch of things regarding COVID. I don't
- 3 precisely recall what they were saying.
- 4 BY MR. SAUER:
- 5 O. You don't remember --
- 6 A. I think at the time I knew what they were
- 7 saying, but quite frankly, I've forgotten what they
- 8 were saying.
- 9 O. Exhibit 36.
- 10 (FAUCI Exhibit No. 36 was marked for
- 11 identification.)
- 12 BY MR. SAUER:
- 13 Q. Do you recall appearing on Good Morning
- 14 America around July 27th or 28th of 2020?
- 15 A. No. I don't recall. Do you know how many
- 16 times I've appeared on television?
- 17 Q. I'm just asking if you remember this
- 18 particular one, sir.
- 19 A. Yeah, I don't recall.
- 20 Q. Can you turn to the fourth page -- or
- 21 fifth page of this document?
- MR. KIRSCHNER: What -- what -- the top of
- 23 the page, Mr. Sauer?
- MR. SAUER: There's white space and
- 25 then it says, "Responding to questions about an

**Page 227** 

1	antimalarial drug."
2	MR. KIRSCHNER: I would ask for Dr. Fauci
3	to have the time to familiarize himself with this
4	document.
5	THE WITNESS: Yes. What about it?
6	BY MR. SAUER:
7	Q. And sorry. That that quote on
8	Page 5, you said on Good Morning America, "The
9	overwhelming prevailing clinical trials that have
10	looked at the efficacy of hydroxychloroquine have
11	indicated that it is not effective in coronavirus
12	disease"; correct?
13	A. Right. Correct.
14	Q. And do you recall those comments being
15	made in response to a video of doctors they called
16	themselves America's Frontline Doctors
17	A. Right.
18	Q appearing on the I think the steps
19	of the Supreme Court
20	A. Right.
21	Q and touting the perceived benefits of
22	that drug?
23	A. Right.
24	Q. Do you remember that?
25	A. Let's make sure we get the connections

**Page 228** 

- 1 right. I do recall a group of doctors that were in
- 2 front of the Supreme Court. I guess there were six
- 3 or seven of them. One, I believe, was an
- 4 African-American woman, female physician, if I'm not
- 5 mistaken. Could be. I think that -- I think that's
- 6 the group that we were referring to who were in front
- 7 of the Supreme Court making a bit of statements. I
- 8 don't precisely recall what they were talking about,
- 9 but I know that in general the people who were
- 10 watching that were concerned about the -- the truth
- 11 of what they were saying. They were making -- I
- don't recall specifically what they were saying, but
- 13 there was some concern about the accuracy of what
- 14 they were saying.
- 15 **O.** Exhibit 37.
- 16 (FAUCI Exhibit No. 37 was marked for
- 17 identification.)
- 18 MR. KIRSCHNER: Mr. Sauer, I have one
- 19 version of this. Do you have two versions of that?
- THE WITNESS: I have one.
- 21 MR. KIRSCHNER: That's fine. What number
- 22 are we on?
- 23 BY MR. SAUER:
- 24 Q. This is a -- is this a Bret Baier article
- with the headline "Fauci uncensored:

**Page 229** 

Fax: 314.644.1334

1 Hydroxychloroquine video. A bunch of people spouting 2 something that isn't true" 3 Α. That's what it says. 4 And the next -- if you look at the second 0. 5 page, just look at the first paragraph of this --6 this report. It quotes you appearing on MSNBC's 7 Andrea Mitchell Reports saying that a video 8 re-tweeted by President Trump that featured doctors 9 at a press conference touting hydroxychloroquine as a 10 coronavirus treatment was, quote, "people spouting 11 something that isn't true"; correct? 12 Α. That's what it says here. 13 Q. Do you recall saying that? 14 MR. KIRSCHNER: Objection. Lack of 15 foundation. 16 THE WITNESS: You know, I certainly may have said that. Yes, I think the general impression 17 18 that if one looked at the video, some -- I recall --I don't know exactly, but it was pretty clear among 19 physicians and those involved that what was being 20 2.1 said on the steps in many respects didn't make much 2.2 medical sense. 2.3 BY MR. SAUER: 24 Q. In your review, what was being said was

> LEXITAS LEGAL Phone: 1.800.280.3376

that misinformation or disinformation that could lead

25

**Page 230** 

1	to loss of lives?
2	A. Well, it's possible. I don't recall
3	exactly. If you want to play the tape for me and we
4	could go over it, and I could then properly answer
5	your question. I just know that there was a lot of
6	negative response on the overwhelming representation
7	of the medical community that was said on that press
8	conference on the steps, I believe, of the
9	Supreme Court. It was really quite unorthodox.
10	Q. I'm sorry. I didn't really follow what
11	you just said. You said there was an
12	overwhelming medical response
13	A. In general, if you were to take a poll of
14	physicians in established medical centers throughout
15	the country and have them look at the tape of what
16	was being said at that time, I believe it's not
17	been proven, but I believe you would find that the
18	overwhelming majority would find that what was said
19	there really didn't make much medical sense.
20	Q. Did you take such a poll at the time?
21	A. I did not, but I know my community and
22	everyone who has ever looked at that just raised
23	their eyebrows and said what the heck are they
24	talking about?
25	Q. You say you know your community. Who in

**Page 231** 

1	your community did you discuss the efficacy of
2	hydroxychloroquine with?
3	A. We discussed the efficacy of
4	hydroxychloroquine with a number of people in the
5	community.
6	Q. Can you name one?
7	A. Yeah, I can name a whole group.
8	Q. Please do.
9	A. We we have clinical trials I want to
10	get the correct name of it. It's the NIH Treatment
11	Guidelines Panel. The Treatment Guidelines Panel is
12	made up of, oh, I would say a total,
13	mostly physicians and health care providers, of about
14	40-plus individuals who are representative of the
15	infectious diseases community throughout the country.
16	Most of them are the chiefs of infectious
17	diseases throughout the medical centers in the
18	country. Harvard, Cornell, San Francisco. These are
19	the real leaders in infectious diseases in the
20	country. They came to a determination based on an
21	examination of all the literature that
22	hydroxychloroquine had no evidence at all of
23	efficacy.
24	Q. When was that determination made?
25	A. I don't know the exact date, but it is a

**Page 232** 

- 1 group that can easily be asked about when that
- 2 occurred and you could find out on the record, but it
- 3 was very, very clear that that was the case that they
- 4 felt that way.
- 5 They kept an open mind, but they looked at
- 6 the literature and said that they really felt that
- 7 there was no evidence at all that
- 8 hydroxychloroquine -- and it isn't an individual
- 9 person. It's a treatment guidelines panels that
- 10 represents the leadership of infectious diseases in
- 11 the entire country.
- 12 Q. I'm going to give you Exhibit 38.
- 13 (FAUCI Exhibit No. 38 was marked for
- 14 identification.)
- 15 BY MR. SAUER:
- 16 Q. Do you see this Breitbart report that
- says Facebook/Google/YouTube/Twitter censor viral
- video of doctors, Capitol Hill Coronavirus press
- 19 conference?
- 20 A. Yes. I see that, another Breitbart
- 21 statement.
- 22 Q. And then can you turn to the third page
- of -- actually can you see what the date of this
- 24 report is?
- 25 A. The date. Let me see.

Page 233

1	Q. Actually, if you turn to the third page
2	there at the top, is the date, July 27, 2020.
3	A. Correct.
4	Q. So this is within a day of the comments
5	your comments to Good Morning America and Andrea
6	Mitchell that we just talked about. Correct?
7	MR. KIRSCHNER: Objection, lack of
8	foundation.
9	BY MR. SAUER:
10	Q. Is that correct?
11	A. I'm getting confused about dates here. So
12	let's go back, and what's the date of the Andrea
13	Mitchell thing?
14	Q. If you look at the last two exhibits,
15	July 28th was your comment on Good Morning America.
16	Or the 27th.
17	A. On Tuesday, well the news article here, it
18	says: Updated July 28th. So I assume that the
19	statement was either July 28th or it was reported on
20	July 28th and the statement was July 27th. I can't
21	tell from this exhibit.
22	Q. So it would be within a day of this
23	article we're looking at now, that's page 127;
24	correct?
25	A. Correct.

Page 234

1	Q. Okay. So staying on the third page, the
2	report says Facebook entered a ^ video posted by
3	Breitbart News earlier today, which was the
4	top-performing Facebook post in the world Monday
5	afternoon of a press conference in DC held by the
6	group, America's Frontline Doctors. You see that?
7	A. I see that, yes.
8	Q. And that group and press conference has
9	been saying that that group and press conference
10	that you were disagreeing with in your two prior
11	statements; correct?
12	MR. KIRSCHNER: Objection. Lack of
13	foundation. Speculative.
14	BY MR. SAUER:
15	Q. Your two prior statements to Andrea
16	Mitchell and to Good Morning America; correct?
17	MR. KIRSCHNER: Again, objection. Lack of
18	foundation. Speculative.
19	THE WITNESS: It is likely it was that. I
20	can't say absolutely for sure, but if you were
21	talking about the press conference by a group of
22	doctors on the steps of wherever, the Capitol or the
23	Supreme Court, and I was referring to that, it is
24	likely that's what I was referring to but I can't say
25	for sure. I don't have a precise recollection of

**Page 235** 

Fax: 314.644.1334

1 that. 2 BY MR. SAUER: 3 0. Looking down on this page, do you see 4 under that big paragraph, there's a smaller paragraph 5 that says, "The video accumulated over 17 million 6 views during the eight hours it was hosted on 7 Facebook." Α. Correct. 9 Does the widespread dissemination of this Q. 10 video touting the benefits of hydroxychloroquine, 11 would that trouble you as a doctor who was concerned 12 about --13 MR. KIRSCHNER: Objection. 14 BY MR. SAUER: 15 -- misinformation and disinformation being 0. 16 disseminated? 17 MR. KIRSCHNER: Objection. Lack of foundation. 18 19 THE WITNESS: You know, I don't really pay 20 much attention to the quantity. Like I said, for 21 maybe now the ninth or tenth time, I don't get 2.2 involved in social media stuff. I don't follow -- I 2.3 wouldn't even know how to access how many views 24 something has, so --BY MR. SAUER: 25

**Page 236** 

1	Q. If you were aware that a video did have 17
2	million views, would that you bother you as a doctor
3	who is concerned about the dissemination of
4	misinformation and disinformation about COVID
5	treatments?
6	MR. KIRSCHNER: Objection.
7	THE WITNESS: I don't know what 17 million
8	views means. What's the denominator? Is 17 million
9	a large amount? Is it a small amount? I don't go on
10	social media, so I don't know what 17 million views
11	means.
12	BY MR. SAUER:
13	Q. So that doesn't bother you or you have no
14	opinion one way or the other on that question; fair
15	to say?
16	A. Well, I don't know how to quantitate the
17	number of views with whatever it is, the point you're
18	trying to make.
19	Q. But those 17 million people watching that
20	video, were those doctors standing on the steps of
21	the Supreme Court and touted the benefits of
22	hydroxychloroquine, would that bother you?
23	A. It would likely bother me if a very large
24	number of people were given information that was
25	not only based on no data, but in which data actually

**Page 237** 

- 1 showed that those statements were untrue.
- 2 As a physician who takes care of patients
- 3 and cares about the health of patients, I think that
- 4 information that spreads falseness not based on data,
- 5 as physician would be troublesome to me. What does
- 6 troublesome mean? Would I do anything about it? Not
- 7 necessarily at all. But it's just I don't like false
- 8 information that hurts patients.
- 9 Q. Could you turn two pages forward in that
- 10 document, please?
- MR. KIRSCHNER: When you say two pages
- 12 forward, you mean page 5 of 19?
- 13 MR. SAUER: Correct.
- 14 THE WITNESS: Okay. What do you want me
- 15 to look at?
- 16 BY MR. SAUER:
- 17 Q. Fourth paragraph down, there's a quote on
- 18 the Facebook copy, stating, "We removed the video for
- 19 sharing false information about curious and treatment
- 20 for treatment of COVID-19?"
- 21 A. That's what it says.
- 22 MR. SAUER: Objection. Lack of
- 23 foundation.
- 24 BY MR. SAUER:
- Q. Are you aware of anyone communicating with

Page 238

1	Facebook about that decision to remove the video?
2	A. I don't recall anybody communicating with
3	them about that. Could have been, but I don't recall
4	anybody I don't recall anybody communicating with
5	the social media people.
6	Q. Do you recall anyone at NIAID
7	communicating with social media people?
8	A. To my recollection, I don't recall. But I
9	don't know everything that everybody does. But I
10	don't recall anybody communicating with social media.
11	Q. Were you aware of anyone associated with
12	the federal government communicating with Facebook
13	about that decision?
14	A. I don't recall anyone in the federal
15	government that I know. They might have. Possible.
16	But I don't recall specifically anyone in the federal
17	government communicating with them.
18	Like I said, I don't pay attention to
19	those types of things. I have a really important day
20	job that I work at, so
21	Q. How about any other topics, setting aside
22	this America's Frontline Doctors, are you aware of
23	anyone the U.S. Government communicating with social
24	media platforms about what can and can't be posted on
25	their platform?

Page 239

1	A. You know, I have to say I don't recall any
2	of that. I mean, it could be that back then someone
3	did and brought it to my attention, but I don't
4	recall any federal official or anybody communicating
5	directly with social media. That doesn't ring a bell
6	for me now. That doesn't mean it hasn't happened.
7	It just doesn't ring a bell to me right now.
8	Q. Can you turn one page forward in this
9	exhibit, in that first full paragraph that goes all
10	the way across the page. "Facebook's decision to
11	censor the Livestream was quickly followed by
12	YouTube, the Google-owned video sharing platform"?
13	A. Yes, I knew of that.
14	Q. Or at the time, were you aware of Google
15	or YouTube pulling down this video about
16	hydroxychloroquine?
17	MR. KIRSCHNER: Objection. Asked and
18	answered.
19	BY MR. SAUER:
20	Q. Were you aware?
21	A. Well, as I've said multiple times, I don't
22	pay attention to what social media organizations like
23	Google and YouTube and Twitter, and all that, what
24	they do because I'm not involved in that.
25	So was I aware could someone have

**Page 240** 

- 1 cursorily mentioned to me that they did? Possibly.
- 2 And it probably went over my head, because that's not
- 3 something that I pay attention to.
- 4 Q. Next paragraph down, following Facebook
- 5 and YouTube's removal of the video, Twitter follows
- 6 suit, removing Breitbart News's Periscope Livestream
- 7 of the press conference; correct?
- 8 A. Where is that? What paragraph? I'm
- 9 sorry.
- 10 Q. Immediately below, there's a two line?
- 11 A. Yeah, I'm on the wrong page.
- MR. KIRSCHNER: Dr. Fauci is on page 7 of
- 13 16. Turn back another page.
- 14 THE WITNESS: Okay. And what's the
- 15 paragraph, Mr. Sauer, you're talking about?
- 16 Yes, Twitter followed suit, removing
- 17 Breitbart's Periscope, whatever that is. Jack
- 18 Dorsey's platform also -- yeah.
- 19 BY MR. SAUER:
- 20 Q. Same question. Were you aware at the time
- 21 that Twitter followed suit with Facebook and YouTube
- 22 and pulled this video down?
- 23 MR. KIRSCHNER: Objection. Lack of
- 24 foundation.
- 25 BY MR. SAUER:

**Page 241** 

1	Q. Were you aware?
2	A. I was not aware, to my knowledge, and when
3	you say aware, it's possible that somebody walking in
4	the hall said, "Hey, did you hear this happened?"
5	Very likely, I would have paid no attention. Because
6	like I said, I do not get involved in any way with
7	social media. I don't have an account, I don't
8	tweet, I don't Facebook, and I don't pay attention to
9	that.
10	So you keep asking questions about am
11	I aware of what's going on with people putting things
12	down, I don't pay attention to what gets put up and
13	put down on social media.
14	Q. Are you generally aware of the terms of
15	service about content moderation on the social media
16	platform? Do you know anything about them?
17	A. Terms of service?
18	Q. Their policies with respect to what people
19	can and can post to social media. Do you have any
20	knowledge of what those policies say?
21	A. I'm not even knowing what you're talking
22	about. The answer would be, like I said I'll
23	repeat it again. I don't pay attention to social
24	media issues. That's something I don't do. I don't
25	follow it. I don't have an account. I don't follow

I don't even know what the condition is.

**Page 242** 

Fax: 314.644.1334

- Q. Never once?

  A. Well, I can't say never ever. I'm sure

  when you're in a place where there's thousands of

  people, and you get thousands of e-mails, somebody
  - 6 somewhere is going to say something and I'm going to
  - 7 say, "Oh, good."

1

- 8 So if you're going to show me one time
- 9 where someone mentions, good. Show me.
- 10 **Q.** Exhibit 39.
- 11 (FAUCI Exhibit No. 39 was marked for
- 12 identification.)
- 13 BY MR. SAUER:
- 14 Q. This is a report from the Washington
- 15 Standard entitled "America's Frontline Doctors
- 16 website shut down." Do you see that?
- 17 A. Yeah.
- 18 Q. And right there in the front page it
- indicates that this is dated August 1st, 2020?
- 20 A. Right.
- Q. So this is just a couple of days after the
- 22 report about their video being pulled off Twitter,
- 23 Facebook and YouTube; correct?
- MR. KIRSCHNER: Objection. Lack of
- 25 foundation.

Page 243

1	THE WITNESS: I'm sorry. I'm getting
2	confused here. So it says the Washington Standard
3	America's Frontline Doctors website shuts down on the
4	first page. Now, what's the next issue you're
5	pointing out to me?
6	BY MR. SAUER:
7	Q. Is the date of it August 1st, 2020?
8	A. Yes, it is.
9	Q. Were you aware of their website being
10	taken down by their web hosting provider?
11	MR. KIRSCHNER: Objection. Lack of
12	foundation.
13	THE WITNESS: I don't recall that. I
14	might have been aware. Someone may have pointed it
15	out to me, but that's not something, as I say, that
16	would normally attract my attention or my interest.
17	I could have been aware, but, again, I concentrate on
18	other things besides this.
19	BY MR. SAUER:
20	Q. Do you still you testified about your
21	views about the efficacy of hydroxychloroquine. Is
22	that still your view today that there's still no
23	evidence of its efficacy?
24	A. Correct.
25	Q. Are you aware of any metaanalyses of the

**Page 244** 

Fax: 314.644.1334

1 studies that have been done on a global scale of the 2 efficacy of hydroxychloroquine? I'm not specifically aware of that, but 3 Α. 4 there really are some real ^ failings of 5 metaanalyses, and when you get statisticians to look 6 at them, they often debunk some of those 7 metaanalyses. 8 Q. Do you recall saying in connection with 9 the discussion of hydroxychloroquine that a 10 randomized double blind placebo based study is the 11 gold standard? 12 That is the gold standard for everything. Α. It isn't always needed, but for the most part, it's 13 14 the gold standard. 15 Do you remember criticizing publicly a --16 a study done by -- a sort of real-time study done by 17 practitioners of the Henry Ford Medical Center who 18 has about a thousand participants that found an 19 observational benefit to hydroxychloroguine? 20 MR. KIRSCHNER: Objection. Lack of 2.1 foundation. 2.2 BY MR. SAUER: 2.3 Do you remember that? Q. 24 Α. I don't recall. It's possible. I see a

lot of studies, hundreds and hundreds of studies

25

**Page 245** 

- 1 that come across my desk. Some that are put there,
- 2 some that I find myself. So I can't say for sure
- 3 what my opinion or comment was on any given study.
- 4 O. Exhibit 40.
- 5 (FAUCI Exhibit No. 40 was marked for
- 6 identification.)
- 7 BY MR. SAUER:
- 8 Q. Is this the first page of a meta-analysis
- 9 of the studies addressing the efficacy of
- 10 hydroxychloroquine? Is that what it appears to be?
- 11 A. This is confusing. Global HCQ/CQ studies.
- 12 Let me read this paragraph first.
- I'm not sure what the summary is saying.
- 14 Negative evaluations typically ignore treatment
- 15 delay. Some in vitro evidence suggests that
- 16 therapeutical level could not be reached, however,
- 17 that was incorrect.
- 18 Q. Let's just focus on that first sentence
- 19 for a minute, would you, where it says, 449 HCQ
- 20 COVID-19 studies; correct?
- 21 A. Right.
- 22 Q. HCQ is a common -- a Shortlander for
- 23 hydroxychloroquine; correct?
- 24 A. Right.
- 25 O. And it indicates there's -- 351 of these

Page 246

_	
1	449 studies are peer reviewed; correct?
2	MR. KIRSCHNER: Objection. Lack of
3	foundation.
4	BY MR. SAUER:
5	Q. Is that what it says?
6	A. 351 peer reviewed, 371 comparing treatment
7	and control groups. Late treatment in high dosages
8	may be harmful while early treatment consistently
9	shows positive results.
10	Q. Just focusing on that comparing treatment
11	and control groups, is that a description of a
12	placebo based double blind study?
13	A. Well, it's not
14	MR. KIRSCHNER: Objection
15	BY MR. SAUER:
16	Q. To your understanding?
17	A. To my
18	MR. KIRSCHNER: Objection. Speculative.
19	THE WITNESS: I'm not sure what they're
20	referring to. There's a difference between a
21	treatment and a control group versus a randomized
22	placebo control group. Lack of randomization very
23	infrequently leads to confusing, if not inaccurate,
24	results. It depends on what the control group was.
25	If it was a historical control, you want to make sure

**Page 247** 

- 1 that there were no confounding variables in the
- 2 control group that could have skewed the data, and
- 3 that's the reason why I said if you look at the
- 4 preponderance of evaluation of these studies by
- 5 groups such as the NIH clinical trials guideline
- 6 group, they come to the conclusion that the studies
- 7 that claim efficacy are statistically not valid
- 8 studies.
- 9 BY MR. SAUER:
- 10 Q. Would that apply to all 371 studies here
- 11 that are reported to --
- 12 A. If --
- 13 Q. If I may finish my question, please?
- 14 A. Oh. Please, go ahead.
- 15 Q. 371 comparing treatment and control groups
- 16 that indicates that early treatment, that is,
- 17 receiving hydroxychloroquine early within the course
- 18 of infection with the virus, consistently shows
- 19 positive results?
- 20 A. Yeah. That's what this says. I would
- 21 have go to back, take a look at the study, and
- 22 consult with our statisticians, who I believe were
- 23 the ones that looked at the study and allowed
- 24 the treatment guidelines panel, which, as I said, is
- comprised of anywhere from 30 to 40 of the top

**Page 248** 

Fax: 314.644.1334

- 1 infectious disease physicians in the country, have
- 2 still come to the conclusion that there's no evidence
- 3 that hydroxychloroquine works and that, in fact, it
- 4 can harm.
- 5 **O.** But that --
- A. So you can show me this study, and I don't
- 7 see the study. It would probably take, when you talk
- 8 about meta-analysis, a long period of time to look at
- 9 each thing. What are they referring to as a control
- 10 group? Is it randomized or is it not randomized?
- 11 All of those factors play a major role in the
- 12 validity or not of a study.
- 13 Q. Are you familiar with the Great Barrington
- 14 Declaration?
- 15 A. Yes, I am.
- 16 Q. What is the Great Barrington Declaration?
- 17 A. It's a declaration signed by a number of
- 18 people who proposed letting the virus circulate in
- 19 the community with the statement that you can protect
- 20 vulnerable people and if you let the virus circulate
- 21 freely, that you would get what's called herd
- 22 immunity, and then ultimately the virus would
- 23 essentially go to such a low level because of herd
- 24 immunity.
- 25 Q. And if you look at Exhibit 40 in front of

LEXITAS LEGAL Phone: 1.800.280.3376

Page 249

1	you, is that a copy of the Great Barrington
2	Declaration?
3	MR. KIRSCHNER: I think is this
4	Exhibit 41 or 40?
5	MR. SAUER: Forty-one, I apologize.
6	(FAUCI Exhibit No. 41 was marked for
7	identification.)
8	BY MR. SAUER:
9	Q. Looking at Exhibit 41 in front of you, is
10	that a copy of the Great Barrington Declaration?
11	A. Well, it says on the front page Great
12	Barrington Declaration. I'm not sure if it is. I
13	have no reason to believe it isn't.
14	Q. Did you ever review the Great Barrington
15	Declaration?
16	A. I have read it some time ago.
17	Q. Flipping ahead to the third page where it
18	says the Great Barrington Declaration at the top,
19	does that look like the Great Barrington Declaration?
20	MR. KIRSCHNER: Objection. Lack of
21	foundation.
22	THE WITNESS: What page are we on? Three
23	of 13?
24	BY MR. SAUER:
25	Q. Correct.

Page 250

1		
	1	A. It says the Great Barrington Declaration.
	2	Q. And is this familiar to you? You said
	3	you've read it before?
	4	A. I read it some time ago when it first came
	5	out.
	6	Q. At the end of the first paragraph there it
	7	just talks about recommending an approach called
	8	focus protection; correct?
	9	A. Right.
	10	Q. And is that what you described earlier
	11	as
	12	A. Right.
	13	Q by circulating among certain
	14	populations
	15	A. Right.
	16	Q while trying to provide targeted
	17	protection for more vulnerable population?
	18	A. I believe that's what they're referring
	19	to.
	20	Q. You this was published on October 4th,
	21	2020; correct?
	22	MR. KIRSCHNER: Objection. Lack of
	23	foundation.
	24	THE WITNESS: I don't know when it
	25	was published, to be honest with you.
1		

**Page 251** 

- 1 BY MR. SAUER:
- Q. Well, flip ahead to Page 5 of 13 at the
- 3 very top.
- 4 A. It says on October 4th, the declaration
- 5 was authored and signed.
- 6 Q. Okay. So that's when at least it purports
- 7 to have been executed?
- 8 A. Right.
- 9 Q. Were you -- when did you become aware of
- 10 it after it was published?
- 11 A. I don't recall.
- 12 Q. Would it have been soon after that to your
- 13 knowledge?
- 14 A. Possibly. I don't recall.
- 15 Q. Do you know these three scientists who are
- 16 listed as the leaders of it -- or the authors of it,
- 17 Dr. Martin Kulldorff, Dr. Sunetra Gupta, and
- 18 Dr. Jay Bhattacharya?
- MR. KIRSCHNER: Objection. Vague.
- 20 BY MR. SAUER:
- 21 Q. Do you know them?
- 22 A. I don't know them. I know their names now
- 23 because it's been kicked around a fair amount over
- 24 the last -- period of time. I don't -- I don't know
- 25 them.

**Page 252** 

1	Q. You did and you didn't were you
2	familiar with them or their reputations at the time
3	that this was published?
4	A. I don't know them so I'm not familiar with
5	them.
6	Q. Okay. Flipping ahead to Page 8 of 13.
7	There's a list in the list of joiners there,
8	second from the bottom, it lists Dr. Michael Levitt
9	at Stanford?
10	A. Yes.
11	Q. And he was a Nobel Prize winner?
12	A. Correct.
13	Q. Do you know him?
14	A. I don't know him. I've heard of him. I
15	don't know him.
16	Q. You said earlier, I think, that you don't
17	recall how you first became aware of the Great
18	Barrington Declaration?
19	A. I can't say the moment I became aware of
20	it. I don't recall. I became aware of it. I don't
21	know precisely when I became aware of it.
22	Q. Do you remember the context in which you
23	became aware of it? Was it raised to you by a
24	colleague or surfing the internet or something like
25	that?
Ī	

**Page 253** 

Fax: 314.644.1334

1 Α. I don't recall how that -- how that 2 occurred. 3 MR. KIRSCHNER: I would like to, Mr. Sauer, take a break in the next five minutes. 4 Do 5 you want to take a break now or do you want to take a break after the next exhibit. 6 7 MR. SAUER: Let's do it now. 8 THE VIDEOGRAPHER: Okay. Time is 2:17 9 p.m. and we're going off the record. 10 (Recess taken.) 11 THE VIDEOGRAPHER: The time is 2:28 p.m. 12 and we're back on the record. BY MR. SAUER: 13 14 Exhibit 42. 0. 15 (FAUCI Exhibit No. 42 was marked for 16 identification.) BY MR. SAUER: 17 18 Q. Dr. Fauci, do you recognize this e-mail 19 dated October 8th, 2020, at 2:31 p.m.? 20 MR. KIRSCHNER: Objection. Lack of 2.1 foundation. 2.2 THE WITNESS: I don't recognize it like I 2.3 remember it, but it's sitting right in front of me and it's an e-mail from Francis Collins to myself and 2.4 Cliff Lane, with a copy to Larry Tabak. So I'll read 25

**Page 254** 

```
it and see what it says. Yes, I've read it.
    BY MR. SAUER:
               Do you remember getting this e-mail?
         Q.
               Yeah. Vaguely, yeah.
 5
               Dr. Collins sent it to you on October 4th,
 6
    four days after the Great Barrington Declaration was
 7
    offered; correct?
 8
               MR. KIRSCHNER: Objection. It says
 9
    October 8th on it.
    BY MR. SAUER:
10
11
         Q.
               Sorry. He sent it to you on October 8,
    after the Great Barrington Declaration was offered on
12
13
    October 4th. Correct?
14
         Α.
              Correct.
15
          Q.
              And he sent it to you and Cliff Lane;
16
    correct?
         A. Correct.
17
18
               And he says, "Hi, Tony and Cliff. See
    https://urldefense.com/v3/ https://gbdeclaration.org ;!!
20
    NtP9J7iH11vXGg!OfjQ3HS19TPlz9Q r-u4RtZWR1naETdrZpFm3si212
21
    NbcloUbvSz3asoQn-18Dm2C-z5uDtNV26mSJ8uMD5iM6vYqN78 3ajww$ "; correct?
22
         A. Correct.
23
               And is that a reference to the Great
24
    Barrington Declaration?
25
               I believe so. I believe so. I would
```

**Page 255** 

Fax: 314.644.1334

1 imagine. It's a link and it says gbdeclaration, so I 2 would imagine. 3 0. Did you read the Great Barrington 4 Declaration for the first time when you got this 5 e-mail? Or do you not know? I don't recall. 6 Α. 7 0. Did you click on that link when you got 8 the e-mail? 9 I don't recall. Α. He goes on to say, "This proposal from the 10 Q. 11 three fringe epidemiologists who met with the 12 Secretary"; right? 13 Were you aware of those three authors of 14 the Great Barrington Declaration meeting with the 15 Secretary? 16 I don't recall. This may have been my 17 first awareness of it, or I could have been 18 peripherally aware of it at the time. I can't say 19 for sure. 20 So you don't know -- when he refers to 0. 2.1 the three fringe epidemiologists, is he referring to 22 a prior conversation or communication where you 2.3 discussed them with him, if you know? 24 MR. KIRSCHNER: Objection, speculative. 25 THE WITNESS: I don't know.

**Page 256** 

1	BY MR. SAUER:
2	Q. You don't remember?
3	A. No.
4	Q. Do you recall Dr. Bhattacharya, Gupta and
5	Dr. Kulldorff meeting with Secretary Azar?
6	A. You know, I don't. I think after the
7	fact, I would have known because Francis said they
8	did. It is very likely, although I'm not 100 percent
9	sure that the meeting of the epidemiologists, authors
10	of the declaration with the Secretary, this was very
11	likely the first time it was brought to my attention,
12	although I can't say for sure. I would imagine
13	again, getting back to context, this is not something
14	that I would have been paying a lot of attention to.
15	I was knee deep in trying to do things like develop a
16	vaccine that wound up saving the lives of millions of
17	people. That's what I was doing at the time.
18	So an e-mail like this may not have
19	necessarily risen to the top of my awareness and
20	interest.
21	Q. So he goes on to say, "You believe that
22	this didn't catch your interest at the time that you
23	received it"?
24	MR. KIRSCHNER: Objection.
25	Mischaracterizes his testimony.

**Page 257** 

Fax: 314.644.1334

1 THE WITNESS: I don't know if it did or 2 I wouldn't imagine that I would be 3 overwhelmingly interested. I may have responded. 4 I'm sure you're going to pull out my e-mail and show 5 my response. But I don't recall -- this is an e-mail 6 from Francis just bringing it to my attention. 7 don't recall what, if any, was my response to this. 0. It seems to be getting a lot of attention 9 and even a cosignature from a Nobel Prize winner, 10 Mike Levitt at Stanford. 11 Α. Right. 12 And that was the person we referred to a Q. 13 minute ago. 14 Α. Yes. 15 Then Dr. Collins goes on to say, "There Ο. 16 needs to be a quick and devastating published 17 takedown of his premises." 18 Do you know what he's referring to when he 19 talks about a quick and devastating takedown? 20 MR. KIRSCHNER: Objection. Speculative. 2.1 BY MR. SAUER: 2.2 Q. If you know. 2.3 I do not know what he was referring to. Α. 24 would imagine I was thinking that someone would take 25 the counterargument of what the premise was, and I

**Page 258** 

- 1 believe, you know, knowing now what's in the
- 2 declaration, the premise that you could actually
- 3 selectively target susceptible people and protect
- 4 them and yet let the virus spread through society
- 5 without doing considerable damage.
- I would imagine that that is the premise
- 7 that Dr. Collins felt was an invalid assumption.
- 8 Q. And did you discuss this with him at the
- 9 time? Did you talk to him about getting a quick and
- 10 devastating published takedown of the Great
- 11 Barrington Declaration?
- 12 A. I don't recall. You know, quick and
- devastating takedown, that doesn't sound like some
- 14 terminologies that I would use. So I don't believe I
- 15 had a conversation about that specific.
- 16 Q. And so you don't know specifically what he
- meant?
- 18 A. I don't know specifically what he meant.
- 19 But knowing Francis, he is a scholar. He's likely
- 20 talking about writing a scholarly article to contest
- 21 some of the premises. That's what I would imagine
- 22 Francis is referring to. That would be his style.
- 23 That if someone writes an article that he
- 24 disagrees with, that he would write a counterargument
- 25 to challenge the premises. Again, I don't know for

Page 259

1	sure, but knowing Francis, I believe that's what he
2	means, to provide a counterargument.
3	Q. Do you know for sure, then, what he meant
4	or we would ask him if if you know?
5	MR. KIRSCHNER: Objection. Speculative.
6	THE WITNESS: Again, I'm not sure
7	again, I'm not 100 percent sure. You can never be
8	sure what's in someone's mind, but knowing Francis,
9	he is a scholar, a fair person. Highly respected in
10	the community. When he talks about premises, just
11	the way he would with a scientific article with
12	scientific data, if he had an issue with it, he would
13	write a scholarly article to try and challenge it.
14	And I believe that's what he's referring
15	to.
16	BY MR. SAUER:
17	Q. Okay. He goes on in the e-mail to say, "I
18	don't see anything like that online yet. Is it
19	underway?" Do you see that?
20	A. I see that.
21	Q. Why would he think that you and Cliff Lane
22	would know whether or not there was a swift and
23	devastating takedown of this declaration underway?
24	MR. KIRSCHNER: Objection. Speculative.
25	THE WITNESS: Certainly speculative. I

**Page 260** 

1	don't know what he meant. I just think he was
2	speaking bluntly. I don't think he was specifically
3	pointing to us to have known if there was something
4	online. He scours the online better than we do.
5	He's got an entire staff that does that.
6	So I think it was a just a casual comment,
7	"Hey, you guys. Did you see anything online yet?"
8	BY MR. SAUER:
9	Q. And he says not "Is there something up
10	there?" He says, "Is it underway?"
11	Did he have any reason to think that you
12	guys might be working on
13	A. Absolutely not.
14	Q. Let me finish the question of some kind
15	of refutation of the Great Barrington Declaration?
16	A. No. This is not something I would
17	be involved in. As I told you, I have a very
18	important day job that is running a \$6.4 billion
19	institute. I would not be involved in examining this
20	and doing something that would, quote, counter it.
21	Q. Do you know why he copied Cliff Lane on
22	this e-mail with you?
23	MR. KIRSCHNER: Objection. Speculative.
24	THE WITNESS: I don't know why he copied
25	

**Page 261** 

- 1 director of the Institute, the deputy director for
- 2 clinical research, and a highly -- what's the right
- 3 word -- respected clinical scientist in the
- 4 institute.
- 5 So it would not be unusual for Francis to
- 6 send me an e-mail and have Cliff Lane, as my deputy
- 7 director for clinical research, be copied.
- 8 That would not be surprising.
- 9 BY MR. SAUER:
- 10 Q. Is Cliff Lane the same one who went on the
- 11 WHO-sponsored trip to China in February of 2020 that
- we talked about this morning?
- 13 MR. KIRSCHNER: Objection. Asked and
- 14 answered.
- 15 BY MR. SAUER:
- 16 Q. Is he the same guy?
- 17 A. Cliff Lane is the same person, and the
- 18 same motivation that led to his going to China was
- 19 probably the same motivation that Francis copied him
- in the e-mail, that he's highly respected and well
- 21 thought of and a very knowledgeable physician
- 22 scientist.
- Q. When he came back from China, he was the
- one who had reported about China -- I think he called
- 25 them extreme lockdown measures being effective in

Page 262

1	controlling the spread of the virus. Do you recall
2	that?
3	MR. KIRSCHNER: Objection. Asked and
4	answered.
5	THE WITNESS: I answered that question,
6	but he was the one that said social distancing that
7	they have done was, in fact, effective. He believes
8	in curtailing the spread of the virus.
9	BY MR. SAUER:
10	Q. Do you recall any discussions between you,
11	Francis Collin, and Cliff Lane in that time frame
12	of him returning from the WHO-sponsored trip to China
13	that related to the efficacy of extreme lockdown
14	measures or extreme social distancing measures?
15	A. We're going back to the same question. I
16	think I answered that. I think
17	Q. I'm just asking if you had any discussions
18	on that topic that I just described, you, Cliff Lane,
19	and Francis Collins back when Cliff Lane returned
20	from the trip to China?
21	A. Did we have any discussions about the
22	efficacy of of severe social distancing on
23	shutting down to spread a virus?
24	Q. Correct.
25	A. It's entirely possible that we had that

**Page 263** 

- 1 conversation. I don't specifically recall that
- 2 conversation, but it would not be unusual. Cliff
- 3 went to China, and we wanted to find out what was
- 4 going on there to see if there could be any lessons
- 5 learned from what they were doing compared to what
- 6 we're doing.
- 7 O. Exhibit 43.
- 8 (FAUCI Exhibit No. 43 was marked for
- 9 identification.)
- 10 BY MR. SAUER:
- 11 Q. Do you recognize this e-mail exchange also
- dated October 8th, 2020?
- 13 A. You know, you say do I recognize it.
- 14 Q. Do you remember it?
- 15 A. I don't remember it, but now that you've
- 16 put it in front of me, it's got my name on it next to
- 17 "from" and Francis next to "to." So I get back to my
- 18 statement before. I receive literally thousands of
- 19 e-mails, many of which get screened. So I generally
- 20 wind up seeing only a few hundred.
- I don't remember this one specifically,
- 22 but clearly it was sent by me to Francis.
- 23 Q. And to the same list of recipients on his
- e-mail to you that was in the previous exhibit;
- 25 correct?

Page 264

1	A. Right.
2	Q. And you said to him, "Francis, I'm pasting
3	in below a piece from The Wire ^ that debunks this
4	theory"; correct?
5	A. That's what it says.
6	Q. If you look at the top, your the
7	subject line is the Great Barrington Declaration;
8	correct?
9	A. Correct.
10	Q. And Francis responds to you "Excellent";
11	correct?
12	A. That's what it says.
13	Q. You've pasted in here an article from
14	Wired magazine by Matt Reynolds; right?
15	A. Yes.
16	Q. How did you find that?
17	A. I don't recall.
18	Q. Did someone find it for you or did you
19	Google it yourself?
20	A. I don't recall.
21	Q. Do you know this author Matt Reynolds?
22	A. Doesn't ring a bell. I may have run into
23	him or interacted with him in the past, but doesn't
24	come out jump out of the page at me.
25	Q. Did you have any communications with

Page 265

Fax: 314.644.1334

1	w D 11 1 C 1 11: 1 11: 1: 1: 1 0
1	Mr. Reynolds before he published this article?
2	A. I don't recall.
3	Q. Do you know of anyone at NIAID
4	communicating with him before publishing this
5	article?
6	A. I don't recall.
7	Q. Do you know Gregg Gonsalves?
8	A. I do.
9	Q. Who is he?
10	A. Gregg Gonsalves is the person on the
11	faculty of the Yale School of Public Health, I
12	believe, certainly Yale University of New Haven, who
13	formerly was a member of the AIDS activist group
14	ACT UP, and then a member of the therapy group, TAG,
15	treatment action group, of ACT UP.
16	Q. How long have you known him?
17	A. I've known Gregg since the first decade of
18	HIV. So I would imagine that would likely be
19	sometime in late 1980s, early 1990.
20	Q. Is he a friend of yours?
21	A. Well, it depends on what you mean by a
22	friend. He's someone I know. He's an associate. I
23	think he's a solid person. He cares deeply about
24	public health.
25	Yeah, I again, it depends on definition

LEXITAS LEGAL Phone: 1.800.280.3376

**Page 266** 

Fax: 314.644.1334

1 of friend or not. He's somebody that's more than just hello. I mean, I've -- I've interacted with him 2 3 a fair amount. 4 0. Exhibit 44. 5 (FAUCI Exhibit No. 44 was marked for 6 identification.) 7 BY MR. SAUER: Q. Another e-mail chain between you, 9 Francis Collins, and Cliff Lane regarding the Great 10 Barrington Declaration; correct? 11 MR. KIRSCHNER: Objection. Lack of 12 foundation. 13 THE WITNESS: This is an e-mail from me to 14 Francis in which I forwarded to him a commentary or a 15 Twitter, I guess, a commentary by Gregg Gonsalves 16 concerning the idea of herd immunity and focused 17 protection. BY MR. SAUER: 18 19 Q. And you said above -- sending that, you 20 said, "another refutation of the herd immunity 21 approach"; right? 2.2 Α. Correct. 2.3 0. And this is also addressing essentially 24 the approach -- the herd immunity approach, are you 25 there referring to the approach espoused by the

**Page 267** 

1	authors of the Great Barrington Declaration?
2	A. Could be. I would imagine it was, but,
3	you know, since herd immunity was a significant
4	component of the declaration, I don't see specific
5	reference to the declaration here, but it is
6	compatible with this being referring to the
7	declaration, though I I don't see any specific
8	indication of it.
9	Q. Can you turn to the second page of this
10	document? In the Gonsalves article, the second
11	paragraph begins "However, after some
12	acknowledgment." Do you see that?
13	A. Yes.
14	Q. And if you go about five lines down,
15	there's a sentence beginning "Fast forward to this
16	week." Do you see that?
17	A. Yes.
18	Q. It says, "Fast forward to this week where
19	one of the Harvard professors in question,
20	Martin Kulldorff, along with Dr. Jay Bhattacharya
21	from Stanford University and Sunetra Gupta from the
22	University of Oxford were in DC meeting with
23	Scott Atlas ^ and Health and Human Services as
24	secretary Alex Azar ^ ?
25	A. Yes.

**Page 268** 

1	Q. And then it goes on to say they were
2	promoting their new focus protection strategy;
3	correct?
4	A. That's what it says.
5	Q. And focus protection is a phrase used in
6	the Great Barrington Declaration; correct?
7	A. That's correct.
8	Q. Did you have any communications with
9	Gregg Gonsalves before he wrote this piece?
10	A. I don't recall. I might have. I don't
11	recall specifically having any communications with
12	Gregg before he wrote this. I might have, but I
13	don't know. It doesn't come out at me as something I
14	remember having a communication with him.
15	Q. Do you do you remember consulting
16	him consulting with you or anyone at NIAID staff in
17	any way about his piece on this?
18	A. You know, I don't recall. It's possible,
19	but I don't recall.
20	Q. Do you know what Francis Collins was going
21	to do with this information? You're sending him
22	these articles refuting the Great Barrington
23	Declaration. What was his plan to do with them?
24	MR. KIRSCHNER: Objection. Speculation.
25	THE WITNESS: I don't know what his

**Page 269** 

- 1 plan -- I think he was getting back to a prior e-mail
- 2 that you showed me. He was wondering what the
- 3 community in general's response was to the Great
- 4 Barrington Declaration, and I believe, if I can
- 5 recall from a few moments -- minutes ago when he was
- 6 talking -- is anybody else refuting this premise?
- 7 That's one of the things he asked in an e-mail he
- 8 sent to me.
- 9 So I would imagine -- I'm trying to piece
- 10 it together -- that the things that I forwarded to
- 11 Francis were in response to his question "Is anybody
- 12 else refuting this premise?" And this looks like a
- 13 refutation that I forwarded to him on October 8th and
- 14 then on that same day what Gregg Gonsalves tweeted.
- 15 BY MR. SAUER:
- 16 Q. Do you know if Francis Collins has any
- 17 contacts or acquaintances that work for social media
- 18 companies?
- 19 MR. KIRSCHNER: Objection. Calls for
- 20 speculation.
- 21 THE WITNESS: I don't know of
- 22 Francis Collins's connection to any -- I don't know
- 23 of it. I mean, whether he does or not, I don't -- I
- 24 don't -- I have no knowledge of that.
- 25 BY MR. SAUER:

Page 270

1	Q. Does he have social media accounts?
2	A. His office does. I think he tweets. I
3	have heard he tweets. Since I don't have a Twitter
4	account, I don't see tweets.
5	Q. Exhibit 45.
6	MR. KIRSCHNER: Yes.
7	(FAUCI Exhibit No. 45 was marked for
8	identification.)
9	BY MR. SAUER:
10	Q. Before we before we get to this
11	exhibit, has Dr. Collins ever discussed with you the
12	content of matters posted on social media that you
13	recall?
14	A. I'm sorry. What's the question again?
15	Q. Has Dr. Collins ever discussed with you
16	the content of speech posted on social media?
17	MR. KIRSCHNER: Objection. Ambiguous.
18	THE WITNESS: You know, I'm I'm not
19	sure.
20	BY MR. SAUER:
21	Q. Has he ever discussed with you any
22	communications that he or his staff has had with
23	social media companies?
24	A. Not specifically that I can recall. He
25	may have but, again, it's not something that rings a

**Page 271** 

Fax: 314.644.1334

1 bell with me that I would remember. Can you look briefly at the exhibit in 2 Q. 3 front of you, Exhibit 45? 4 Α. Right. 5 This is a Washington Post article dated Q. 6 October 14th, 2020? 7 Α. Right. Q. And the headline is "Proposal to hasten 9 herd immunity to the coronavirus grabs White House attention but appalls the top scientists"; correct? 10 11 Α. Correct. 12 If you go to the fourth paragraph on the 0. first page, Dr. Collins quoted in this article --13 14 MR. KIRSCHNER: Again, I would ask for 15 Dr. Fauci to have an opportunity to familiarize 16 himself with this document. 17 THE WITNESS: Just give me a sec. 18 BY MR. SAUER: 19 Q. Do you see that -- the fourth paragraph on 20 the first page, where it says that, "A senior 21 administration official told reporters in a 22 background briefing called Monday that the proposed 2.3 strategy, which has been denounced by other

and, quote, dangerous by NIH director Francis

infectious disease experts and called, quote, fringe,

24

25

Page 272

1	Collins."
2	Do you see that?
3	A. Yes.
4	Q. Did you consult with Dr. Collins before he
5	told the Washington Post that this was a fringe and
6	dangerous idea?
7	A. Yes.
8	MR. KIRSCHNER: Objection. Lack of
9	foundation.
10	THE WITNESS: Yeah. I'm not sure of the
11	connections because it's saying here, "which has been
12	denounced by other infectious disease experts and
13	called fringe and dangerous," whether Francis spoke
14	to Joel directly and said it was fringe and dangerous
15	or whether Joel was reporting on statements that
16	Francis Collins made not directly to him, but he may
17	have heard of statements that Francis made.
18	BY MR. SAUER:
19	Q. Why don't we flip ahead to page 4 of this
20	document 4 of 6 in the bottom left corner? You
21	A. Four of 5.
22	Q. Page 4 of 5?
23	A. Got it.
24	Q. You see that third full paragraph?
25	There's a quotation from Dr. Collins that says, "What

**Page 273** 

1	
1	I'm worried about with this is it's being presented
2	as a major alternative view that's held by large
3	numbers of experts in the scientific community."
4	That is not true, correct?
5	MR. KIRSCHNER: Objection. Lack of
6	foundation.
7	THE WITNESS: That's what this says.
8	BY MR. SAUER:
9	Q. And he goes on to say in the next
10	paragraph, "This is a fringe component of
11	epidemiology. This is not mainstream science. It's
12	dangerous." Correct?
13	MR. KIRSCHNER: Objection. Lack of
14	foundation.
15	THE WITNESS: Well, I'm reading the quote
16	from Dr. Collins.
17	BY MR. SAUER:
18	Q. Did he consult with you before he gave
19	that quote or made those statements to the Washington
20	Post?
21	MR. KIRSCHNER: Objection. Lack of
22	foundation.
23	THE WITNESS: I can't say for sure whether
24	he consulted with me or spoke to me about it. It was
25	clear how Dr. Collins felt about the premise of the

**Page 274** 

- 1 declaration. He felt that it was, in fact, an
- 2 ill-founded premise, and that it would be dangerous
- 3 because it would lead to the unnecessary infection,
- 4 sickness, hospitalization, and death of larger
- 5 numbers of people if you pulled back and let the
- 6 virus freely circulate, even if you tried to protect
- 7 targeted populations.
- 8 BY MR. SAUER:
- 9 Q. Did he think it would be dangerous if
- 10 those communications were conducted on social media
- 11 platforms?
- MR. KIRSCHNER: Objection, speculative.
- 13 BY MR. SAUER:
- 14 Q. To your knowledge?
- 15 A. To my knowledge, I don't see a connection
- 16 here with what he's saying and things being spread on
- 17 social media, but perhaps, since a lot of things get
- 18 spread on social media, I'm sure that -- I'm not
- 19 sure, but that could have been something that he was
- 20 concerned about.
- 21 Q. Did you ever discuss that with him, his
- 22 concerns about it circulating on social media?
- MR. KIRSCHNER: Objection. Asked and
- 24 answered.
- THE WITNESS: You know, we've been down

**Page 275** 

Fax: 314.644.1334

1 that question before. And I said, "I'm not certain at all." 2 3 I've had discussions with Dr. Collins a 4 few years ago about these issues and I don't know if 5 we discussed the implications of social media on it. BY MR. SAUER: 6 7 0. Did you become aware -- did he -- did he 8 let's do the next exhibit, 46? 9 (FAUCI Exhibit No. 46 was marked for 10 identification.) 11 BY MR. SAUER: 12 On October 13th at 3:36 p.m., did Q. 13 Dr. Collins send you and some others a link to the 14 Washington Post article that we just looked at? 15 The link on the bottom, is that the same 16 article? I don't know if it is. Let me see if the

Q. So this is on October 13th, which would be

link is the same. "COVID herd immunity 2020," yeah,

it looks like it's the link to the article that we

- 21 the day after -- or no -- strike that. So he e-mails
- you and others and says, "My quotes in the article
- are accurate but will not be appreciated in the White
- 24 House"; correct?

were referring to.

25 A. It says here, "My quotes are accurate, but

17

18

19

**Page 276** 

- 1 will not be appreciated in the White House."
- 2 Q. Did he discuss with you whether the White
- 3 House would approve the quotes he made about
- 4 the Great Barrington Declaration?
- 5 A. I don't recall him discussing whether they
- 6 would be appreciated or not, but he clearly states in
- 7 the e-mail to me -- is it to me? Yes, to me and
- 8 others -- that his quotes are accurate. Namely, that
- 9 he rejects the premise of herd immunity, but that
- 10 will not be appreciated in the White House.
- 11 Q. And you responded, "They are too busy with
- 12 other things to worry about this"?
- 13 A. Right.
- 14 Q. What you said was entirely correct?
- 15 A. Right.
- 16 Q. So was it your view at the time that the
- 17 Great Barrington Declaration was a fringe and
- 18 dangerous idea?
- 19 A. I'm not sure I would have categorized it
- 20 like that. I would say that the premise, I believe,
- 21 is invalid. And the invalid premise of
- 22 essentially letting the virus freely circulate under
- 23 the assumption which has already been proven to
- 24 be incorrect with the one million deaths that we've
- 25 had in the country, that the premise of allowing the

**Page 277** 

- 1 virus to freely circulate is a premise that is
- 2 invalid because it is not possible to
- 3 selectively protect all the vulnerable people.
- 4 Q. Do you think --
- 5 A. So I agree that the premise of the Great
- 6 Barrington Declaration is ill-founded and incorrect
- 7 and I'm joined by the overwhelming majority of
- 8 physicians, public health officials, and
- 9 epidemiologists.
- 10 Q. Do you think it's nonsense?
- 11 A. You know, you're putting words. It could
- 12 be nonsense. In fact, I believe that you're going to
- 13 show me an e-mail shortly in which I call it
- 14 nonsense, you know.
- 15 Q. Why don't we go with that?
- 16 A. Okay.
- 17 **O.** Exhibit 47.
- 18 A. All right. Thank you.
- 19 (FAUCI Exhibit No. 47 was marked for
- 20 identification.)
- 21 BY MR. SAUER:
- 22 Q. Is this a -- can you look at that?
- 23 A. I see it.
- Q. Can you see this is an NBC News article
- 25 **dated October 15, 2020.**

**Page 278** 

1	A. Correct.
2	Q. And the headline says, "Dr. Fauci says
3	letting the coronavirus spread to achieve herd
4	immunity is, quote, nonsense, and quote, dangerous."
5	Correct?
6	A. That is correct.
7	Q. Turn to the third page of the document in
8	the first full paragraph.
9	A. Right.
10	Q. You describe the view of letting everybody
11	get infected and then we'll have herd immunity. And
12	you say, "Quite frankly, that is nonsense and anybody
13	who knows anything about epidemiology will tell you
14	that that is nonsense and very dangerous." Correct?
15	A. That is correct.
16	Q. Were those the statements that you made at
17	the time?
18	A. That's the quote there. I have no reason
19	to believe that it's a misquote.
20	Q. Do you still believe that?
21	A. Do I believe that the Barrington
22	Declaration premise of letting the virus rip
23	through society and infect people, leading to their
24	illness, hospitalization, and death is nonsense and
25	dangerous? I still do.

**Page 279** 

1	Q.	Are you an epidemiologist?
2	Α.	I'm an infectious disease person with some
3	pretty go	od experience in epidemiology.
4	Q.	Is Dr. Bhattacharya an epidemiologist?
5	Α.	I don't know. I guess you'll have to look
6	up his cre	edentials. I don't know precisely his
7	credentia	ls.
8	Q.	How about Dr. Kulldorff?
9	Α.	Again, I'm not familiar offhand with their
10	qualifica <sup>.</sup>	tions.
11	Q.	So your statement was made within two days
12	of Dr. Co	llins' statement?
13	Α.	Right.
14	Q.	With the Washington Post; correct?
15	Α.	Right.
16	Q.	Did you coordinate with making those
17	statement	s, discussing with each other that you were
18	going to	make these statements criticizing the Great
19	Barrington	n Declaration, other than the e-mails you've
20	already s	een?
21	Α.	I don't believe so, but I don't no, I'm
22	not tha	at's not our style to be coordinating
23	things.	I don't know it's possible we discussed
l		

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

In this same time frame, did you become

it, depending on what your coordination is.

Q.

24

25

**Page 280** 

Fax: 314.644.1334

1 aware that the Great Barrington Declaration was being 2 censored in social media? 3 I'm not aware of anything being censored. 4 Like I said multiple times -- and I'll repeat it 5 again -- I don't follow what goes on on social media, 6 censoring or otherwise. That's not something that I 7 pay attention to. (FAUCI Exhibit No. 48 was marked for 9 identification.) BY MR. SAUER: 10 11 Would you look at exhibit 48. And is this Q. 12 an article from the website Spiked entitled, "Why has 13 Google censored the Great Barrington Declaration?" 14 MR. KIRSCHNER: Objection. Lack of 15 foundation. 16 THE WITNESS: The first page says: 17 has Google censored the Great Barrington Declaration? BY MR. SAUER: 18 19 Without going into details of the article, Q. 20 were you aware that there were reports that Google 21 had deboosted the Great Barrington Declaration in the 22 search results. So if you search for it on Google, 2.3 the declaration itself would be buried in the results 24 and you would only get articles that were critical of 25 it, like for example, the Washington Post article

Page 281

1	that quoted Francis Collins and the NBC?
2	MR. KIRSCHNER: Objection. Lack of
3	foundation and compound. Many compounds.
4	BY MR. SAUER:
5	Q. Did you know about that?
6	A. Could you repeat ^ the specific question.
7	Did I know about what?
8	Q. Did you know about the fact that the Great
9	Barrington Declaration had been deboosted in people's
10	search results in the same time frame?
11	MR. KIRSCHNER: Objection. Lack of
12	foundation.
13	BY MR. SAUER:
14	Q. Did you know?
15	A. I believe not. It is possible that
16	someone walking by the hall mentioned that to me.
17	But as I mentioned to you, I don't pay much attention
18	to what goes on in social media, and I certainly
19	would not have had this plop up on my radar screen so
20	I would say, "I can't say 100 percent," but it is
21	highly unlikely that I am aware was aware of, or
22	if I was, I paid any attention to this thing of
23	Google censoring the Great Barrington.
24	I don't pay attention to that whole
25	culture of social media censoring or not censoring.

Page 282

1	I've said that maybe 50 times today. That's not what
2	I do.
3	Q. Let me ask you a new question then.
4	A. Sure.
5	Q. Are you familiar with the social media
6	platform Reddit?
7	A. Reddit?
8	Q. R-e-d-d-i-t?
9	A. I'm heard the that term, but
10	Q. Are you aware that Reddit also censored
11	the Great Barrington Declaration, along with Google?
12	MR. KIRSCHNER: Objection. Lack of
13	foundation.
14	BY MR. SAUER:
15	Q. If you know.
16	A. Again, I'm not even sure what Reddit is,
17	and so I don't think I could be aware of its
18	censoring. If I did was aware at one time, I
19	certainly didn't register it as something that I
20	would want to remember.
21	Q. Have you ever heard of YouTube?
22	A. Have I ever heard of YouTube? Yes, I
23	have. There you go. I've heard of one thing, yeah.
24	Q. Were you aware that YouTube actually
25	amended its terms of service in October of 2020 to

**Page 283** 

Fax: 314.644.1334

1 clarify that it would remove content related to the 2 Great Barrington Declaration? 3 MR. KIRSCHNER: Objection. Lack of 4 foundation. 5 BY MR. SAUER: 6 0. Do you know? 7 I don't know for sure whether someone pointed that out to me, but, again, with the 9 repetitive theme that I keep saying if I was aware of 10 it, I would not have paid much attention to it. 11 Q. Exhibit 49. 12 (FAUCI Exhibit No. 49 was marked for 13 identification.) 14 BY MR. SAUER: 15 This is a copy of YouTube's online site 16 admissions relations ' policy. Have you ever seen 17 it before? 18 Not to my recollection, no. 19 And on the second page, there's a kind of Q. 20 rolling chronology. Do you see on the second page in 2.1 the far left it indicates 2020 in the middle? 2.2 Α. Yeah. 2.3 Ο. And then there's various links. So if you 24 go on to the third page, there's one from October 25 of 2020 called fighting misinformation?

Page 284

1	A. Yeah.
2	Q. And that indicates in kind of one sentence
3 <b>th</b> a	at they have updated their COVID-19 medical
4 mis	sinformation policy in October of 2020; correct?
5	A. Correct. It looks that way.
6	Q. Exhibit 50.
7	(Dr. Fauci Exhibit No. 50 was marked for
8 <b>id</b>	entification.)
9	THE WITNESS: I'm sorry. What what was
10 the	e question? I didn't see any question.
11 BY	MR. SAUER:
12	Q. Oh, I was now I was going to give you
13 <b>wh</b> a	at you get when you click on that. That's
14 <b>Ex</b> l	nibit 50.
15	A. Okay.
16	Q. Did I slide over an extra copy to you?
17 <b>Oh</b>	, no. Here it is. Sorry.
18	I take it you've never seen this sort of
19 <b>do</b>	cument before either, Exhibit 50, the sort of
20 <b>de</b> f	tailed version of the COVID-19 medical
21 <b>mi</b> s	sinformation policy that you're privy ^ to?
22	A. No. I don't recall ever seeing this
23 be:	fore.
24	Q. Can you go to Page 4 of 5, the fourth
25 <b>bu</b> :	llet point from the bottom on the list of items

**Page 285** 

Fax: 314.644.1334

- 1 that YouTube does not allow on its platform, quote, 2 "Claims that achieving herd immunity through natural 3 infection is safer than vaccinating the population." 4 Do you see that? 5 Α. I see it, yes. 6 Is that a claim that paraphrases the Q. 7 recommendations in the Great Barrington Declaration? 8 MR. KIRSCHNER: Objection. Speculative. 9 THE WITNESS: You know, I'm not sure. 10 know that the Great Barrington Declaration promotes 11 the concept of herd immunity through natural 12 infection. I am not certain -- I don't recall if they specifically mention that it's safer than 13 14 vaccinating the population. It might.
- 16 Q. Did you have any knowledge of any update
- 17 to YouTube's terms of service in October of 2020 to
- 18 add that as a disfavored claim?
- 19 MR. KIRSCHNER: Objection. Asked and
- answered.

15

21 BY MR. SAUER:

BY MR. SAUER:

- 22 Q. Did you? Yes or no?
- 23 A. Not to my knowledge. It doesn't ring a
- 24 bell.
- 25 Q. Do you know of anyone who communicated to

**Page 286** 

1	YouTube abo	out that topic?
2	A.	Not to my knowledge.
3	Q.	Exhibit 51.
4		(FAUCI Exhibit No. 51 was marked for
5	identificat	tion.)
6	BY MR. SAU	ER:
7	Q.	This is Meta's online misinformation
8	policy, and	d I think we talked about earlier how Meta
9	is the comp	pany that
10	Α.	Now I know what Meta is. We can proceed.
11	Q.	It's Facebook and Instagram.
12	Α.	Yes. Okay.
13	Q.	And the CEO of Meta is someone you're on a
14	first-name	basis with, a man called Mark Zuckerberg;
15	is that con	rrect?
16		MR. KIRSCHNER: Objection.
17	Mischaracte	erizes the evidence.
18		THE WITNESS: Yeah, right. I'm on a
19	first-name	basis with a lot of people.
20	BY MR. SAU	ER:
21	Q.	Apparently. Did you do some PSAs with
22	Mark Zucke	rberg back in March of 2015?
23	A.	I don't know
24	Q.	I'm sorry. March of 2020?
25	A.	I'm not sure of the date, but I did some

**Page 287** 

- 1 Facebook PSAs encouraging people to get vaccinated
- 2 and answering questions about the virus.
- 3 Q. And in your interrogatory responses, you
- 4 identify 13 communications with Mark Zuckerberg
- 5 consisting of both e-mails and phone calls.
- 6 Do you recall that?
- 7 A. Interrogatories, when you and I were
- 8 talking -- what is he talking about?
- 9 MR. KIRSCHNER: Well, Dr. Fauci, I would
- 10 ask not to talk about -- about our communications.
- 11 THE WITNESS: Yeah. I'm not sure what you
- 12 mean by "interrogatory." What is that?
- 13 BY MR. SAUER:
- 14 Q. Did you prepare information in response to
- 15 written discovery requests in this case identifying
- 16 13 communications with Mark Zuckerberg during 2020?
- 17 MR. KIRSCHNER: Mr. Sauer, if you have a
- 18 document to show Dr. Fauci, I would ask that you
- 19 show --
- THE WITNESS: Yeah, I'm not sure what
- 21 you're talking about. Interrogatory about -- show
- 22 me something, and I'll tell you.
- 23 BY MR. SAUER:
- Q. Do you dispute that you had 13
- 25 conversations -- or communications with

Page 288

1	Mark Zuckerberg in 2020?
2	A. I don't know how many I had. I do know
3	some time ago that of the many, many, many thousands
4	of e-mails of mine that were FOIA'd, that someone
5	mentioned that there were e-mails between Mark and I.
6	And I don't know how many there were so I can't
7	answer the question completely accurately.
8	Q. Let me ask you this. Can you turn to
9	Page 4 of 12?
10	A. And remind me what's this this is the
11	misinformation policy document of
12	Q. Meta.
13	A. Meta, okay.
14	Q. Page 4 of 12 under Roman II, harmful
15	health misinformation, there's a bullet in bold
16	saying "Misinformation about vaccines"; correct?
17	A. Right.
18	Q. And it says, "We remove misinformation
19	primarily about vaccines when public health
20	authorities conclude that the information is
21	false and likely to directly contribute to imminent
22	<pre>vaccine refusals"; correct?</pre>
23	A. Correct.
24	Q. Are you one of the public health
25	authorities whose conclusions Meta relies on when

**Page 289** 

1	they're deciding to remove information?
2	MR. KIRSCHNER: Objection. Speculative.
3	THE WITNESS: I have no idea who the
4	public health authority is.
5	BY MR. SAUER:
6	Q. Did you ever have a conversation with
7	Mark Zuckerberg where he told you that you're a
8	respected public health authority?
9	A. Did I ever have a conversation with Mark
10	saying that I was a respected public health
11	authority?
12	Q. Or something like that.
13	A. My conversations with Mark are documented
14	on the PSAs that we have. I'm not sure whether he
15	said now I'm going to introduce the public health
16	authority. I'm not sure about that.
17	Q. How about in the phone calls you had with
18	him?
19	A. The phone calls, I believe, were related
20	to saying, you know, look forward to being on the PSA
21	with you. You got any questions about the technical
22	aspects of it or stuff like that. I don't think
23	there was anything more substantiative than that on
24	the e-mails.
25	Q. Did anyone ever say to you that you're a

**Page 290** 

- 1 public health authority that platforms like Meta and
- Facebook and so forth would rely on in --
- 3 A. Not to my knowledge.
- 4 Q. If I may finish -- may rely on in
- 5 modulating content on their platform?
- A. No, no. To my knowledge, I've never had
- 7 anyone mention me and my authority or my reputation
- 8 that has anything to do with influencing social media
- 9 platforms.
- 10 Q. After the Great Barrington Declaration was
- 11 published, did you ever communicate with anyone at
- 12 Stanford about it?
- 13 A. I don't recall. It's possible. Like I
- 14 say, I made thousands of phone calls and thousands of
- 15 e-mails. I may have, but I doubt it.
- 16 Q. Well, more generally, do you recall
- 17 communicating with anyone outside of the government
- 18 and aside from the reporters that quoted you about
- 19 the Great Barrington Declaration and its approach?
- 20 A. Outside of government, I don't know.
- 21 That's possible, but I don't recall.
- Q. How about do you know a man named Dr. Phil
- 23 Pizzo or Pizzo? P-I-Z-Z-O --
- 24 A. I do. I do.
- 25 **O.** Who is he?

Page 291

1	A. Phil Pizzo is a pediatric infectious
2	disease expert who used to be at the NIH who then
3	went on to become the dean at the School of Medicine
4	at Stanford who now, I believe, is either dean
5	emeritus or professor emeritus at Stanford.
6	Q. And did you know him from his time at the
7	NIH?
8	A. I did.
9	Q. So you've known him for decades, then?
10	A. Yes.
11	Q. Did you ever contact him to discuss the
12	Great Barrington Declaration?
13	A. I don't recall. That's possible.
14	Q. Is it possible you had a conversation with
15	him about Dr. Jay Bhattacharya also at Stanford?
16	A. I don't recall.
17	Q. How about Lloyd Minor? Who's that?
18	Someone named Dr. Lloyd Minor?
19	A. I've heard the name. I it doesn't ring
20	a bell of any connection.
21	Q. How about Mark Tessier-Lavigne? Do you
22	know him?
23	A. Mark is the current president of Stanford.
24	Q. Did you ever have a conversation with him?
25	MR. KIRSCHNER: Objection. Vague.

**Page 292** 

Fax: 314.644.1334

1 THE WITNESS: Yeah. I don't know what you mean by a conversation with him. He used to be at 2 3 the Rockefeller Institution. I had conversations --4 scientific conversations with him, and I met him at 5 meetings. 6 So I'm not sure what you mean. Yeah, I've 7 had conversations with Mark, but I don't recall the content of the conversation. 9 BY MR. SAUER: 10 Have you ever discussed the Great Q. 11 Barrington Declaration with him? Or --12 Α. Not my knowledge. 13 Q. How about the focused protection or herd 14 immunity approaches? 15 I don't recall. These are possible. 16 not ringing a bell when you're asking that question. 17 How about any of the following names: 0. 18 Harry Greenberg? Do you know him? 19 Harry Greenberg is the scientist who used Α. 20 to be at the NIH and is still now at Stanford. 2.1 Did you ever talk to him about focused 0. 22 protection or herd immunity? 2.3 I doubt it. I can't say 100 percent, but Α. I doubt it. I don't recall discussing this issue 2.4 25 with these people, but it's possible it came up in a

**Page 293** 

- 1 discussion about something else, but I don't recall.
- Q. How about Jack Rowe, R-o-w-e? Do you know
- 3 him?
- 4 A. I know Jack. I don't know him well. He
- 5 used to be the CEO of a medical center maybe in
- 6 New York. I'm not sure.
- 7 Q. Do you know a scientist with the last name
- 8 of Ioannides, I-o-a-n-n-i-d-e-s?
- 9 A. I've heard of him. I don't know him.
- 10 I've heard the name Ioannides, but I don't know him.
- 11 Q. Are you are familiar with a serial
- 12 prevalence study of people in Santa Clara County from
- 13 March of 2020? It was done by him and some others.
- MR. KIRSCHNER: Objection. Vague.
- 15 THE WITNESS: No. It doesn't ring a bell.
- 16 BY MR. SAUER:
- Q. So you don't remember there being a study
- 18 of the people in Santa Clara County early in the
- 19 pandemic to assess how widespread the virus already
- 20 was at that time?
- 21 A. Again, I get hundreds and hundreds of
- 22 studies that come across my desk. It is possible
- 23 that someone brought such a study to my attention,
- 24 but I don't specifically recall it.
- 25 **O. Exhibit 52.**

Page 294

1	MR. KIRSCHNER: What time are we at?
2	THE VIDEOGRAPHER: 5:41.
3	MR. KIRSCHNER: What exhibit number is
4	this?
5	MR. SAUER: 52.
6	(FAUCI Exhibit No. 52 was marked for
7	identification.)
8	BY MR. SAUER:
9	Q. Is this an e-mail from Greg Folkers to you
10	dated November 2nd, 2020?
11	A. Me to Greg, November the 2nd. Greg to me,
12	November the 1st.
13	Q. Gotcha. So on November 1st, he sent you
14	a list of articles and highlighted the three he found
15	most useful?
16	A. Right.
17	MR. KIRSCHNER: Is there a question,
18	Counsel?
19	BY MR. SAUER:
20	Q. Is that what he did in this e-mail?
21	A. It appears in this e-mail that he has sent
22	me, it looks like blanks maybe or at least titles of
23	articles let me read them see what connection
24	there is to the article.
25	(Reading.) "Herd Immunity, the false

Page 295

1	premise of the herd immunity."
2	Yeah, there's a bunch of articles to
3	from different scientific and lay press.
4	Q. And these are all articles that are
5	critical of the herd immunity approach of the Great
6	Barrington Declaration; correct?
7	A. Right.
8	Q. Do you know why Greg sent you these?
9	A. I don't recall. Greg would probably send
10	me something that I've asked for. So somehow, back
11	then, a couple of years ago, I asked for articles
12	concerning herd immunity and I believe he sent them.
13	Q. Did you forward these on to Francis
14	Collins?
15	Sorry. Were you still talking?
16	A. Yeah. I mean, I don't know. This would
17	be something Greg would do if I asked him to get some
18	articles for me. And looks like I likely and I
19	don't see the e-mail requesting them. I either
20	e-mailed him or called him up, or walked in his
21	office and said, "Get some articles on the issue of
22	herd immunity." Yes, so
23	Q. Did you ever communicate with the authors
24	of any of these articles about this topic?
25	A. I don't recall. I'm looking at the people

**Page 296** 

- 1 here and I don't recognize the names, except for John
- 2 Barry and Gregg Gonsalves and ^^ Michelle -- some
- 3 people I know and I -- some people I've never heard
- 4 of. I don't recall if I communicated with any of
- 5 them about these articles.
- 6 Q. Which one do you know? Do you know John
- 7 Barry?
- 8 A. I know John Barry.
- 9 Q. And who else do you know?
- 10 A. All right. Let's go through the list.
- 11 John Barry.
- 12 I've been interviewed by Apoorva
- 13 Mandavilli and Sheryl Stolberg, two reporters for the
- 14 New York Times.
- 15 I've met Mark Lipschitz. I don't know him
- 16 well. I know Gregg Gonsalves, Carlos del Rio, and
- 17 Rochelle Walensky well.
- 18 Q. Did you communicate with any of those
- 19 people about the Great Barrington Declaration in any
- 20 connection?
- 21 A. I don't recall. I mean --
- 22 Q. Did you ever take any steps to ensure
- 23 there would be an online criticism of the Great
- 24 Barrington Declaration in any --
- MR. KIRSCHNER: Objection. Asked and

Page 297

1	answered.
2	THE WITNESS: I don't ever recall I
3	don't recall ever taking any steps to do anything
4	online or influence online criticism of them. I just
5	knew how I felt personally about the Great Barrington
6	Declaration and we already discussed that. I felt
7	that it was and is misguided and could lead to the
8	unnecessary infection, hospitalization, and death of
9	individuals if you follow the premise of the Great
10	Barrington Declaration.
11	BY MR. SAUER:
12	Q. Did you share that view with the people in
13	the media other than the ones we talked about?
14	A. I don't recall necessarily what I said to
15	people in the media, but my opinion of the nature of
16	the premise of the Great Barrington Declaration, I
17	believe, is reasonably well known and shared by a
18	very large number of scientists throughout the
19	country, as actually stated in some of these
20	articles.
21	Q. Are there large numbers of scientists who
22	disagree with your view, who signed the Great
23	Barrington Declaration?
24	MR. KIRSCHNER: Objection. Vague.
25	THE WITNESS: I haven't quantitated the

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

**Page 298** 

- 1 number of people. I haven't done a
- 2 quantitative study on the number of people who agree
- 3 with it. But I can tell you that I interact with a
- 4 lot of scientists in the country. And
- 5 overwhelmingly, they disagree with it.
- 6 BY MR. SAUER:
- 7 Q. Does that include the 15,000 who signed
- 8 it?
- 9 MR. KIRSCHNER: Objection. Argumentative.
- THE WITNESS: Yes.
- 11 BY MR. SAUER:
- 12 Q. It does or does not?
- 13 A. I haven't even looked at the names of the
- 14 15,000 who signed it. A lot of people sign petitions
- and are not fully aware of what the implications of
- 16 those petitions are.
- 17 **O.** Exhibit 53.
- 18 (FAUCI Exhibit No. 53 was marked for
- 19 identification.)
- 20 BY MR. SAUER:
- 21 Q. Can you turn to the second page of this
- 22 e-mail chain on the bottom half? Do you see there's
- 23 an e-mail from someone at Twitter to a Carol Crawford
- 24 dated March 14th of 2020?
- 25 A. Right.

Page 299

1	MR. KIRSCHNER: I would ask for Dr. Fauci
2	to be able to familiarize himself with this document.
3	THE WITNESS: I'm all confused. I don't
4	recognize anything on this piece of paper.
5	BY MR. SAUER:
6	Q. Could you just point to the part where I'm
7	pointing to where there's an e-mail from someone at
8	Twitter to a ^^ Carol Cross?
9	A. Right.
10	Q. And this other client is @anthonyfauci_
11	account. Correct?
12	A. Right. Yes.
13	Q. And the Twitter person says, "Hi CDC team.
14	A few folks have flagged this account to me wondering
15	if it's real or not. Is it a legitimate account?"
16	Do you see that?
17	A. Yes.
18	Q. And there's a reference to an Anthony
19	Fauci Twitter account; correct?
20	A. Right.
21	Q. And then if you go up above, you see Carol
22	Crawford on March 14th, the response I'm adding
23	someone at NIH and someone at HHS to verify that.
24	A. Right.
25	Q. And then if you go further up on the page,

Page 300

1	the NIH person, Scott Prince. Do you know him?
2	A. No. I mean, it says here, "Deputy
3	director for public information." You know, I have
4	about six thousand employees work for me. I don't
5	recognize this name.
6	Q. But he works in NIH?
7	A. Yeah.
8	Q. Is that fair to say?
9	A. Yeah. He probably works in Building
10	1 which is the NIH director's office. Not my it
11	doesn't say NIAID, which means he doesn't work for
12	me.
13	Q. And he e-mailed Twitter back, and said,
14	"Fake/Imposter handle," and then in all caps,
15	"Please remove, exclamation point, exclamation point,
16	exclamation point." Correct?
17	A. That's what it says right here.
18	Q. Were you aware that staff at the NIH were
19	communicating with Twitter about removing accounts
20	from Twitter because they were impersonating you?
21	A. I don't I kind of vaguely recall that
22	there was a fake account of people using my name
23	under false pretenses. I'm not 100 percent sure what
24	they did about it. I'm sure that when they found out
25	that it was a false account, that they would want it

**Page 301** 

- 1 to be removed. I didn't say remove it. I believe I
- 2 have a communication staff that I'm sure, if they
- 3 found out it was a false and misleading account, that
- 4 they would want it to be removed.
- 5 Q. And would your communication staff contact
- 6 the social media platforms to have that false and
- 7 misleading content removed?
- 8 MR. KIRSCHNER: Objection. Speculative.
- 9 THE WITNESS: I don't know how they would
- 10 do it. Again, I said I don't pay attention to things
- 11 related to social media accounts.
- 12 BY MR. SAUER:
- 13 Q. Who's in your communication staff?
- 14 A. A lot of people.
- 15 Q. Can you name -- who's the leader of it?
- 16 A. Courtney Billet.
- Q. Okay. Did you ever tell Courtney Billet
- 18 to communicate with a social media platform about
- 19 taking down an imposter account or fake account?
- 20 MR. KIRSCHNER: Objection. Asked and
- 21 answered.
- 22 THE WITNESS: I don't recall doing it, but
- 23 I assume, when Courtney found out that it was an
- 24 imposter handle, that she would have asked to take it
- 25 down herself, possibly without even telling me except

**Page 302** 

- 1 to say, "There's an imposter account on you. We'll take care of it." Something like that. 2 BY MR. SAUER: 3 4 Do you remember her having that Ο. 5 conversation with you? 6 Α. I don't specifically remember it, but I 7 vaguely remember somebody mentioning something about an imposter account. I didn't even know what 9 an imposter account was. And I likely would have said, "Well, how can they do that?" 10 11 And I found out that people do 12 imposter accounts, so I don't get involved in searching for them or doing anything about them. 13 14 have an entire communication staff that worries about 15 that. 16 To be clear, your entire communication 17 staff worries about things like false and misleading 18 accounts like this on social media? 19 MR. KIRSCHNER: Objection.
- 20 Mischaracterizes the evidence -- or the testimony.
- 21 THE WITNESS: My staff worries about me,
- 22 not other people's accounts and what's spread on
- other people's -- they don't worry about -- they work
- 24 for me. They don't scour the social media looking
- 25 for things that may or may not be true.

**Page 303** 

Fax: 314.644.1334

1 BY MR. SAUER: 2 Do they scour social media looking for Q. 3 imposter accounts or ^ accounts --4 Α. I don't think they spend time looking for 5 them, but when someone like Lauren Duvall says, "Hey, 6 we have an Anthony -- @Anthony Fauci," and brings it 7 to the attention of the NIH, then they would 8 obviously be concerned about an imposter account. 9 Turn to the first page. The HHS official 0. says, "Thanks, Lauren. Is there anything else you 10 11 can do to block other variations of his name from 12 impersonations so we don't have this occur again"; 13 correct? 14 Objection. MR. KIRSCHNER: Speculative. 15 THE WITNESS: It says, "Thanks, Lauren." 16 They're trying to make sure that other people don't 17 impersonate me. BY MR. SAUER: 18 19 Q. Correct. 20 I think impersonating me is a bad thing, 21 isn't it? I think so. 2.2 Perhaps. If you go further up on 2.3 March 14th, it says -- the Twitter official responds, 24 "Will freeze this at -- @ handle and some other 25 variations so no one can talk on that"; correct?

**Page 304** 

Fax: 314.644.1334

1 Α. That's what it says. 2 Q. So they would freeze a number of different 3 account handles to make sure that no one uses them to 4 impersonate you? 5 Α. I don't know what this -- I don't know what this statement means. I don't -- I know it says 6 will freeze the @ handle and some other variations of the @ handle. I don't know what they're referring 9 to. 10 Let's do another exhibit. Q. 11 I think what they're trying to say 12 possibly is that someone is impersonating me and that's a bad thing, and they're trying to stop it. 13 14 Correct. Specifically they're trying to 0. 15 stop it by removing accounts from the social media 16 platform Twitter; correct? 17 MR. KIRSCHNER: Objection. Speculative. 18 THE WITNESS: I'm not sure where you're 19 going with this, but I believe if someone is saying 20 they're Fauci and they're not, that that would 2.1 be disturbing to my communication staff. 2.2 BY MR. SAUER: 2.3 0. Exhibit 54. 24 (FAUCI Exhibit No. 54 was marked for 25 identification.)

Page 305

1	BY MR. SAUER:
2	Q. Can you look at the third page of this
3	e-mail chain? At the very bottom there's an e-mail
4	from someone called Nicole Burkholtz or Burkes.
5	Do you see that?
6	A. Nicole Berkowitz, yes.
7	Q. Do you know who she is?
8	A. I don't recognize the name.
9	Q. And if you look at this e-mail, if you
10	look up at the top of this e-mail, it looks like she
11	sent an e-mail to the NIH.gov list?
12	A. It looks that way, yes.
13	Q. Do you know what that list is?
14	MR. KIRSCHNER: Objection. Spec
15	BY MR. SAUER:
16	Q. F
17	MR. KIRSCHNER: Sorry.
18	BY MR. SAUER:
19	Q. FCN@list.NIH.gov?
20	A. No, I don't know what that is. I mean, it
21	says "NIH.gov" so it has something to do with the
22	NIH, but I don't really know what FCN@list is.
23	Q. Third paragraph down in her e-mail there
24	she says, "Reason for the request, I have come across
25	a very misleading YouTube video titled "How to Kill

**Page 306** 

- 1 Coronavirus" that because of the unfortunate
- 2 placement of the ad banner and the algorithm which
- 3 chose my ad makes it look like this is a CDC video on
- 4 COVID-19"; correct?
- 5 MR. KIRSCHNER: Objection. Lack of
- 6 foundation, and I would ask for Dr. Fauci to have an
- 7 opportunity to familiarize himself with this
- 8 document.
- 9 THE WITNESS: Yeah. Let me read it. Hold
- 10 on.
- 11 BY MR. SAUER:
- 12 Q. Do you see that reference?
- 13 A. I don't know what this is. This looks
- 14 like a CDC thing. Let me read it carefully so that I
- 15 can answer your question.
- Okay. So what's the question? I'm sorry.
- 17 Q. Were you aware of someone -- or do you see
- 18 where she refer -- describes the content of the video
- 19 she's looked at as incredibly dangerous information?
- 20 A. Yeah, and I want to make sure I'm not
- 21 confused. So she is an NIH -- who is she?
- 22 Q. I think if you look at the next page,
- 23 she's identified as a communications lead for the
- 24 EPA. Do you see that?
- 25 A. Where's that next page?

Page 307

1		
1	Q.	The very next page. The one we're looking
2	at.	
3	Α.	This one? EPA.gov.
4	Q.	Yeah.
5	Α.	Environmental Protection Agency; right?
6	Q.	Let me ask you this: Did you have any
7	knowledge	of someone from the EPA consulting with an
8	NIH list t	o try and find a contact at social media to
9	have dange	rous information taken out?
10	Α.	I don't have any recollection of any of
11	this.	
12	Q.	Let's move on to another exhibit.
13	A.	I don't even know what you're talking
14	about.	
15		(FAUCI Exhibit No. 55 was marked for
16	identifica	tion.)
17	BY MR. SAU	ER:
18	Q.	Here's an e-mail chain from April of 2020.
19	Can you tu	rn to the second-to-last page where there's
20	an e-mail	from someone called Judith Lavelle of NIAID
21	sent to Fa	cebook?
22	Α.	Yeah.
23	Q.	And here do you know who Judith Lavelle
24	is?	
25	Α.	She it says NIAID, NIH. So I'm the

Page 308

1	director of NIAID. So she obviously works in my
2	multi-thousand-person institute. So maybe I've run
3	into her, and I don't know exactly what she does.
4	Q. And the next page it indicates she's a
5	technical writer editor in her signature block.
6	Do you see that?
7	A. Right. And she's located at Fishers Lane,
8	which is not the building that you and I are now
9	sitting in. So it is unlikely I would have run into
10	her.
11	Q. She's copied on this e-mail someone called
12	Jennifer Routh at the last CRC. Do you see that?
13	A. Yes.
14	Q. Who is Jennifer Routh?
15	A. Jennifer Routh is a member of my
16	communications staff.
17	Q. Is Judith Lavelle a member of your
18	communications staff?
19	A. Let me look. It says Judith Lavelle,
20	technical writer editor. So that would probably put
21	her in the communications staff.

THE WITNESS: Well, that's what technical 25

MR. KIRSCHNER: Objection.

Q. Okay. So she is on the communications

22

24

23 **team?** 

**Page 309** 

- 1 writers generally fall under, the broad group of
- 2 communications all under Courtney Billet.
- 3 BY MR. SAUER:
- 4 Q. And she's e-mailed Facebook and said, "We
- 5 wanted to flag a few more fake Dr. Fauci accounts on
- 6 Facebook and Instagram for you." Do you see that?
- 7 A. Yes.
- 8 Q. And she says she's also reported them from
- 9 at NIAID and her personal Facebook account; correct?
- 10 A. Correct.
- 11 Q. And there's a list of about eight accounts
- 12 there in this e-mail?
- 13 A. Correct.
- 14 Q. And then if you flip to the next page,
- 15 there's another one called Dr. Fauci the hero where
- she says, "I think this one may be fine as a fan page
- 17 but just as a reminder that it could have been more
- 18 clear"; correct?
- 19 A. That's what it says.
- 20 Q. So really you -- were you aware that, in
- 21 fact, your communications staff was flagging many
- 22 fake accounts from Facebook to have them removed?
- 23 A. I was not aware that they were flagging
- 24 many accounts, but from looking at this, they are
- 25 trying to get rid of fake accounts because fake

**Page 310** 

1	accounts are bad things, I believe.
2	Q. "They" are "they" are your
3	communications staff, right, when you say "they are
4	working to remove fake accounts"?
5	MR. KIRSCHNER: Objection.
6	Mischaracterizes testimony.
7	THE WITNESS: Yeah. I'm not sure what
8	you're saying or what you're getting at, but I'm
9	reading here that there are people that are using my
10	name falsely and creating fake accounts which people
11	in the communications staff saying that this is
12	troubling because they're doing things like selling
13	masks and doing things like that.
14	So I think that that would be kind of
15	appropriate for my communications staff to be
16	concerned when people are falsely impersonating me.
17	BY MR. SAUER:
18	Q. Are some of them parody accounts?
19	MR. KIRSCHNER: Objection. Speculative.
20	THE WITNESS: Who?
21	BY MR. SAUER:
22	Q. Parody.
23	If I may finish the question?
24	Are some of them parody accounts?
25	MR. KIRSCHNER: Objection. Speculative.

**Page 311** 

Fax: 314.644.1334

1 THE WITNESS: What is a parody account? 2 BY MR. SAUER: 3 0. Someone pretending to be you in a way 4 that's ironic or making a point. 5 MR. KIRSCHNER: Again, objection. 6 Speculative. 7 THE WITNESS: I don't know what these are. 8 I just got a bunch of links to them. I'm not sure 9 what they are. BY MR. SAUER: 10 11 Q. And there's one more. She sent a second 12 e-mail flagging one more -- apologies for one more in 13 the middle of that page. Do you see that? 14 Α. Apologies for one more, right. 15 And then the -- directly above that, the 0. 16 Facebook person responds, "Hi, all, flagged this for 17 the fake accounts team and they have confirmed that 18 all but two accounts were removed for the 19 impersonation of Dr. Fauci"; correct? 20 Α. Right. Right. Impersonation are bad 21 things. 2.2 And bad things should be removed from Q. 2.3 social media on your --2.4 Α. No. I mean, I think when someone says 25 they're me and they're not me, I think someone should

Page 312

1	
1	take a close look at that.
2	Q. Should someone take a close look at other
3	false statements on social media?
4	A. That's not my lane. I don't I never
5	get involved in that, nor do I concentrate on that,
6	so I don't have an opinion on that. Like I've told
7	you maybe now, I can repeat it for the hundredth
8	time, I really don't get involved in social media
9	issues.
10	Q. Do people on your communication staff get
11	involved in social media issues regarding false
12	information or misinformation?
13	A. Not to my knowledge.
14	Q. If I may finish my question.
15	Other than impersonation accounts?
16	MR. KIRSCHNER: Objection. Speculative.
17	THE WITNESS: To my knowledge, they don't
18	get involved in trying to influence social media in
19	any way. But when someone impersonates me, I think
20	it's totally appropriate for them to be concerned
21	about that.
22	MR. KIRSCHNER: And after this, can we
23	take a break?
24	MR. SAUER: Why don't we do that now?
25	THE VIDEOGRAPHER: The time is 3:39 p.m.

Page 313

1	and we are going off the record.
2	(Recess.)
3	THE VIDEOGRAPHER: The time is 3:55 p.m.
4	and we're back on the record.
5	BY MR. SAUER:
6	Q. Dr. Fauci, do you know Sylvia Burwell?
7	A. I do.
8	Q. Who's that?
9	A. Sylvia Burwell is the former Secretary of
10	the Department of Health and Human Services and the
11	current president of American University.
12	Q. Did she e-mail you in February of 2020
13	asking whether she should wear a mask if she was
14	traveling in an airport in the early stages of the
15	pandemic?
16	MR. KIRSCHNER: Objection. Speculative.
17	THE WITNESS: Sylvia has, over the past
18	couple of years, asked me advice about personal
19	safety during the COVID-19 pandemic.
20	BY MR. SAUER:
21	Q. And in particular, in February of 2020,
22	did she e-mail you and say, "I am traveling to
23	redacted folks are suggesting I take a mask
24	through the airport. Is this something I should do?"
25	MR. KIRSCHNER: Objection. Lack of

Page 314

1	foundation.
2	THE WITNESS: You know, I don't recall
3	specifically that. I I do know that Sylvia has
4	called me over the last couple of years asking me
5	questions about health. I don't specifically recall
6	that.
7	BY MR. SAUER:
8	Q. Do you recall writing this in response:
9	"Masks are really for infected people to prevent them
10	from spreading infection to people who are not
11	infected, rather than protecting uninfected people
12	from acquiring infection. The typical mask you buy
13	in the drugstore is not really effective in keeping
14	out virus, which is small enough to pass through
15	material. It might, however, provide some slight
16	benefit in keep out gross droplets if someone coughs
17	or sneezes on you. I do not recommend that you wear
18	a mask, particularly since you're going to a low risk
19	location."
20	Do you recall writing that?
21	MR. KIRSCHNER: Objection. Lack of
22	foundation.
23	THE WITNESS: I vaguely recall talking to
24	her about certain safety issues regarding masks.
25	BY MR. SAUER:

Page 315

1	Q. Do you specifically recall recommending
2	that she not wear a mask as she's traveling
3	A. If that's an accurate I mean, you're
4	asking if I recall?
5	Q. Yeah.
6	A. I don't recall. I mean, these things
7	thousands of things happen. If you show me an e-mail
8	that has my name and the proper identification and I
9	said that, I would not argue with you. It would not
10	be out of the question that at that time in the
11	outbreak, I would have said that.
12	Q. In fact, you made several statements that
13	are similar to that at that time frame; fair to say?
14	A. Yeah.
15	Q. Saying that masks are not effective
16	A. Yeah.
17	Q in keeping out the virus, and I don't
18	recommend you wear masks, in February of 2020?
19	A. Yeah, in the very early months prior to
20	our understanding of the virus and its modality of
21	transmission, I, the surgeon general, and the CDC
22	were not recommending masks for people for three
23	reasons. I'd be happy to tell you those three
24	reasons.
25	Q. Please do.

**Page 316** 

1	A. The three reasons are as follows: There
2	was this understanding and discussion that the best
3	masks that we used in hospitals were in short supply,
4	and if people did a run on masks and bought them all,
5	that masks would not be available for the people in
6	the medical community who needed them; point number
7	one.
8	Point number two, there was no evidence at
9	the time or any studies that showed outside of the
10	medical environment, i.e., in a hospital or in an
11	ICU, that masks actually worked in protecting
12	transmission or acquisition. At the time, there were
13	no studies. And thirdly, we were not aware at the
14	time that 50 to 60 percent of the transmission occur
15	from someone who is without symptoms, either someone
16	who never will develop symptoms or someone who is in
17	the presymptomatic stage.
18	So based on those three considerations,
19	both myself, the surgeon general, and the CDC were
20	saying you really don't need to wear masks. Then
21	things changed. Three things changed: A, it was
22	clear that there was not a shortage, and that if
23	people wore masks, they would not be taking masks
24	away from the medical community. Two, it became
25	clear that there was an asymptomatic spread of

Page 317

1	of of virus where people walking around not
2	knowing they're infected were spreading virus. And
3	then three, it became clear let me see. It was
4	three? There was asymptomatic spread oh.
5	Evidence began accumulating that masks actually
6	work in preventing acquisition and transmission.
7	So the three reasons that I might have
8	said and did say if that is correct that you
9	don't need to wear a mask now, particularly in a low
10	risk situation, the basis for those statements
11	dramatically changed over a period of time, which
12	then made me be a very vocal proponent of wearing
13	masks.
14	Q. And you became a vocal proponent as soon
15	as April 3rd of 2020 correct when you joined a
16	universal recommendation
17	A. Right.
18	Q a recommendation for universal masking;
19	correct?
20	A. I'm not sure of the dates, why
21	Q. How many studies were done between
22	February of 2020, when you e-mailed Ms. Burwell and
23	told her that "the typical mask you buy in the
24	drugstore is not really effective in keeping out
25	virus, which is small enough to pass through the

**Page 318** 

- 1 material," between when you said that and April 3rd
- of 2020, what studies were done of the efficacy of
- 3 masks --
- 4 A. Yeah.
- 5 Q. -- in preventing the spread of -- of
- 6 **COVID-19?**
- 7 MR. KIRSCHNER: Objection. Speculative.
- 8 THE WITNESS: I could find those and --
- 9 and get them for you, but I don't have them in my
- 10 fingertips right now.
- 11 BY MR. SAUER:
- Q. Who'd you consult with about the efficacy
- of masks during that time period? Who'd you talk to
- in the government about it?
- 15 A. I don't recall who I spoke to.
- 16 Q. Did your opinion on masking change based
- 17 on new information and new scientific evidence that
- 18 came forward?
- 19 A. I believe it did, yes.
- Q. Was there disputes about the efficacy of
- 21 masking at that time?
- MR. KIRSCHNER: Objection. Vague.
- 23 BY MR. SAUER:
- Q. For example, on March 31st, 2020, where
- you forwarded a -- a study showing that masking is

**Page 319** 

- ineffective; a review of masking on March 31st, 2020 that said there was no evidence that masks works --
- 3 that masks worked?
- 4 MR. KIRSCHNER: Objection. Lack of
- 5 foundation.
- THE WITNESS: Yeah, I don't recall that,
- 7 so I'm not able to answer that accurately, I believe.
- 8 BY MR. SAUER:
- 9 Q. Is it important for that kind of
- development of your view that you had access to both
- 11 sides of that debate?
- 12 MR. KIRSCHNER: Objection. Lack of
- 13 foundation. Vague.
- 14 THE WITNESS: You always have access to
- 15 both sides of the debate.
- 16 BY MR. SAUER:
- 17 Q. Do you? In science, do you always have
- 18 access to both sides of the debate?
- 19 A. Most of time.
- 20 Q. Is that important for people --
- 21 A. Yeah.
- 22 Q. -- to have access to both sides of the
- 23 **debate?**
- 24 A. Yeah, and then you make a decision based
- on your judgment based on the preponderance of the

**Page 320** 

1	correct data.
2	Q. Right. And so you would look at the
3	studies
4	A. Yeah.
5	Q that come one way
6	A. Yeah.
7	Q or the opinions
8	A. Sure.
9	Q one way and look at the studies that go
10	the other way? Is that
11	A. Yeah, but often there are studies that
12	when you subject them to proper physical statistical
13	analysis, that the conclusions don't hold up; that
14	happens often. So you've got to be careful when
15	you're looking at one study versus another that it
16	goes through the proper statistical analysis and
17	there's proper design.
18	Q. Part of the reason that you recommended
19	against masking in February was to avoid too many
20	people going out and buying masks to ensure that they
21	were available for
22	A. That was one of the reasons, yes.
23	Q to be available for healthcare
24	providers; correct?
25	A. That was one of the reasons is that we

**Page 321** 

1	were told multiple times at the coronavirus task
2	force meeting, that there was a shortage of masks,
3	and that if, in fact, there was a run on the purchase
4	of masks, that that could potentially lead to a
5	shortage for the healthcare providers that really
6	needed them.
7	Q. So the recommendation you gave as to masks
8	was motivated in part by not wanting people to go out
9	and and buy a bunch of masks, so that the people
10	who really needed them wouldn't have them?
11	A. That was one of the considerations that
12	was discussed at the coronavirus task force, that
13	there was a shortage of masks, which led to a lot of
14	activities of trying to increase the supply of masks,
15	either by importing them because many of the masks
16	were made outside of the United States, increasing
17	production of masks, or using alternative masks, such
18	as cloth masks. So the the discussion, the
19	dialogue the discussion at the time was that there
20	is a shortage of masks. We were trying desperately
21	to get masks as well other personal protective
22	equipment into the country, and there was a concern
23	that there was a shortage of them. That was one of
24	the considerations which went into a lack of
25	promoting, go out and buy masks and wear masks.

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

**Page 322** 

1	Q. Were there placebo-based, randomized,
2	double-blind studies of the efficacy of masking that
3	were done between February and April of 2020?
4	A. I don't recall. I'd have to go back and
5	take a close look at the literature. I don't recall.
6	Q. Have you seen any studies that contradict
7	the efficacy of masking?
8	A. There were some studies early on I
9	don't know the dates of them that made the
10	statement that masks were not effective. When those
11	studies were subject to statistical scrutinization,
12	they were felt to be not definitive.
13	Subsequent to that time, there have been
14	studies to indicate that in situations where mask
15	wearing was compared to not mask wearing, that masks
16	clearly have an effect.
17	Q. In a situation like this, a debate about
18	the efficacy of mask wearing, is it important for
19	people to have access to both sides of the debate but
20	to propose to expose the different viewpoints
21	reflected in the debate?
22	MR. KIRSCHNER: Objection. Argumentative.
23	BY MR. SAUER:
24	Q. Is it important?
25	A. Is it important for people? I think it's

**Page 323** 

- 1 important for people to have all of the information that's available. 2 3 0. And so they can assess what's good information and what's bad information? 4 5 Well, you know, it depends. Α. Yeah. Ιf information is clearly inadequate and statistically 6 7 not sound, there can be a danger in people who don't have the ability or the experience of being able to 9 understand that it's a flawed study, that that's when 10 the literature is self-correcting. Science is 11 self-correcting. 12 So if you have something that makes a certain statement based on data that isn't 13 14 statistically significant, that often there are 15 studies that come out and examine that and do 16 proper statistical analysis to try and get the real 17 truth of what the data are showing. 18 MR. SAUER: Can you give the witness 19 Exhibit 56? (FAUCI Exhibit No. 56 was marked for 20 2.1 identification.) 2.2 BY MR. SAUER:
- 25 Here's an e-mail chain from October

It's right there. We marked it before the

Fax: 314.644.1334

break.

Q.

2.3

24

Page 324

1 of 2020. Do you see that at the top?
2 A. October 30th, 2020, from Jen Routh?
3 Q. Yeah, and she's on your communications
4 team; is that right?
5 A. Correct.
6 Q. And she's e-mailing with people some
7 people from with Google.com e-mail addresses in
8 the "to" line?
9 A. Yeah. There's Google, yeah.
10 Q. And then she's copying Courtney Billet,
11 who is the head of your communications team; correct?
12 A. Correct.
Q. And the second page of this e-mail, can
14 you turn to that? There's an e-mail from that
15 this chain begins with an e-mail from a Sandra Sitar
16 from NIAID; correct?
17 A. Right.
18 Q. Do you know who she is?
19 A. It says director of communications,
20 clinical trials program, VRC. I don't recognize the
21 name, but the signature block indicates she is part
22 of the vaccine research center at NIAID.
Q. And she's e-mailing Jen Jennifer Routh
24 saying, "As I mentioned, Jan and the Google team are
25 hoping to connect on vaccine communications,

**Page 325** 

1	specifically misinformation."
2	Do you see that? It's the second full
3	paragraph on this page.
4	MR. KIRSCHNER: Objection. Lack of
5	foundation. Mischaracterizes the evidence.
6	BY MR. SAUER:
7	Q. Do you see where Sandra writes that Jen
8	and the Google team are hoping to connect on vaccine
9	communications, specifically misinformation?
10	A. I'm reading it, yeah.
11	Q. Did your communications team communicate
12	with the Google, YouTube team about vaccine
13	misinformation?
14	MR. KIRSCHNER: Objection. Speculative.
15	THE WITNESS: Not to my knowledge. I
16	don't I don't know if they did. I have no
17	knowledge that they did.
18	BY MR. SAUER:
19	Q. Page before this, go to the first page;
20	e-mailing from the Google person, says, "Hi, Sandra
21	and Jen, thank you so much for reaching out. It
22	would be great to find a time early next week for a
23	quick call on vaccine communications."
24	Do you know if your team had that call in
25	October 30th of 2020 or thereabouts with Google about
20	occoder John or 2020 or energabouts wrom Google about

**Page 326** 

_	
1	vaccine communications?
2	MR. KIRSCHNER: Objection. Speculative.
3	BY MR. SAUER:
4	Q. Do you know?
5	A. Not to my knowledge.
6	Q. Did you
7	A. I don't recall that, no.
8	Q. Did you authorize them to talk to Google
9	about vaccine communications including
10	misinformation or, actually, specifically
11	misinformation?
12	A. That would be unlikely that I would
13	authorize or not authorize someone to do that, again.
14	Q. You don't believe you authorized your
15	communication team to communicate with Google about
16	vaccine misinformation?
17	A. When you say "authorize," I'm it
18	doesn't work it doesn't work that way in the
19	institute. The communication team would if they
20	were going to do it, they would do it.
21	Q. Okay. So they would just do this on their
22	own to the extent they did it?
23	A. Yeah. I don't think that they would need
24	my permission to communicate with people. That's
25	that's their job.

**Page 327** 

1	Q. And then Jan sorry Jen Routh then
2	looped in Courtney Billet, who's the head of your
3	communications team; correct? At the very top of the
4	e-mail?
5	MR. KIRSCHNER: Objection. Speculative.
6	BY MR. SAUER:
7	Q. Where it says, "Hi, Jen, I'm adding
8	Courtney Billet, Director of the Office of
9	Communications and Government Relations at NIAID"
10	A. Right.
11	Q "to talk about vaccine communications."
12	She's Courtney Billet is the director of your
13	whole communications team; right?
14	A. Right. Yes, she is.
15	Q. And you never discussed with her having
16	communications with Google about vaccine
17	misinformation?
18	MR. KIRSCHNER: Objection. Asked and
19	answered.
20	THE WITNESS: I don't recall having
21	specific conversations with Courtney about
22	communicating with Google.
23	BY MR. SAUER:
24	Q. Exhibit 57.
25	(FAUCI Exhibit No. 57 was marked for

**Page 328** 

1	identification.)
2	(Discussion off the record.)
3	BY MR. SAUER:
4	Q. Just briefly, if you look at the second
5	page of this exhibit, do you see an e-mail from
6	someone called Clarke Humphrey?
7	A. Clarke Humphrey, July 2021. Okay.
8	Q. The second page do you know who
9	Clarke Humphrey is?
10	A. She Clarke, I believe, is one of the
11	communications people at the White House.
12	Q. And she e-mailed to at Facebook in July
13	of 2021 saying, "Hi there, any way we can get
14	this pulled down? It is not actually one of ours,"
15	with a link to an Instagram account called
16	Anthony Fauci official; correct?
17	A. It says, "Subject: Deactivating the fake
18	Fauci IG," which I would imagine is Instagram. I
19	don't know if that's what that is.
20	Q. Were you aware that the White House was
21	communicating with Facebook to have accounts with
22	your name taken down?
23	A. The only thing I remember is someone
24	mentioning that there's fake stuff impersonating me
25	going on. I don't specifically recall who

Page 329

1	specifically was asked to address that problem of
2	people impersonating me, but I know that there was
3	some talk. Someone mentioned to me in my group that
4	there's an impersonation of you going on out there.
5	I don't recall anything specific except
6	that they're obviously trying to do something about
7	it.
8	Q. And, in fact, they succeeded, it looks
9	like, where Carrie Adams says, "This account has been
10	removed. Thank you for flagging," in the second
11	e-mail on the first page. Do you see that?
12	A. "This account has been removed. Thank you
13	for flagging." So they removed a spurious, fake
14	account, which I think was a good thing
15	Q. At the request of the
16	A because those accounts are bad.
17	Q. At the request of the White House?
18	MR. KIRSCHNER: Objection. Speculative.
19	BY MR. SAUER:
20	Q. Or Clarke Humphrey, the digital director
21	for the White House?
22	Is that your understanding of that e-mail?
23	MR. KIRSCHNER: Objection. Speculative.
24	THE WITNESS: I wasn't even know you were
25	asking me questions. Clarke Humphrey is at the White

Page 330

Fax: 314.644.1334

1 House, and there was communication that there was a 2 fake, impersonating Fauci Instagram that was 3 deactivated. BY MR. SAUER: 5 Can you look at Exhibit 58? Q. 6 (FAUCI Exhibit No. 58 was marked for 7 identification.) THE WITNESS: Okay. 9 BY MR. SAUER: 10 Q. Here is an e-mail chain between people at 11 Google and people at the CDC that include 12 Carol Crawford; correct? 13 Hold on. Carol Crawford of the CDC; Α. 14 So I'm -- there's a bunch of e-mails here. 15 So what -- what do you want -- you want me to read 16 this and then you'll ask your question or --17 Q. I just want to ask you on the first 18 page, do you see there's an e-mail from 19 Catherine Jamal of the CDC; right? 20 Α. Right. 2.1 Q. And she's sending it to two people at 22 Facebook and copying Carol Crawford; correct? 2.3 Copy Carol Crawford, yes. Α. 24 And it says -- the subject is: Q. 25 Ivermectin questions for the CDC; correct?

**Page 331** 

1	A. Correct.
2	Q. And in that e-mail, this Ms. Jamal
3	notifies or gives Facebook the CDC's position on
4	three claims: The claim that ivermectin
5	ivermectin is effective in treating COVID with the
6	answer that that is not accurate; correct? That's
7	the first item.
8	A. That's Item Number 1. That's what it
9	says: Ivermectin is effective in treating COVID.
10	And, I believe is this what the CDC said, "Answer
11	is not accurate"? I would imagine that that's what
12	they typed in.
13	Q. Yeah, and if you look at each of those
14	A. Yeah.
15	Q what they're citing for their claim
16	that ivermectin the claim about ivermectin's
17	effectiveness is not accurate
18	A. Right.
19	Q is they link to something from the NIH;
20	correct?
21	MR. KIRSCHNER: Objection. Speculative.
22	THE WITNESS: I see a guideline that says:
23	Practice guideline, COVID-19 guideline, treatment
24	management.

Fax: 314.644.1334

25 BY MR. SAUER:

**Page 332** 

Fax: 314.644.1334

1 And do you see something before that or Q. 2 nearly before that where it says: Ivermectin 3 COVID-19 treatment guidelines, and then in 4 parentheses NIH.gov? 5 Α. Yeah. 6 Were you aware that the CDC citing NIH 0. 7 provided information to debunk claims about efficacy 8 of ivermectin to Facebook? 9 MR. KIRSCHNER: Objection. Lack of 10 foundation. 11 BY MR. SAUER: 12 Q. Were you aware? 13 Α. I was -- I was not aware of this, but this 14 is not surprising. Just a second somebody is -- just 15 let me --16 I was not aware, but it's not surprising 17 that organizations, including the CDC, would use the 18 treatment guidelines of the NIH, which is, as I 19 mentioned before in a prior question you asked me, 20 it's a group of, you know, up to 40 people who are 2.1 infectious disease experts from throughout the 2.2 country, usually the chiefs of infectious diseases at 2.3 various medical centers throughout the country. it's not at all surprising that when people want to 24 25 find out what the latest documented information and

**Page 333** 

- 1 clinical opinions among the top infectious disease
- 2 people, that they would refer to or access the
- 3 treatment guidelines.
- 4 Q. Would it be surprising if the social media
- 5 platforms also relied on the public statements of
- 6 someone like yourself on matters of health policy for
- 7 their own decisions?
- 8 MR. KIRSCHNER: Objection. Speculative.
- 9 BY MR. SAUER:
- 10 Q. You just said it would not be surprising
- if they relied on the published NIH guidelines --
- 12 A. Right.
- 13 Q. -- to debunk --
- 14 A. Right.
- 15 O. -- ivermectin claims. Would it be
- surprising if they relied on public statements by
- 17 Dr. Fauci about the efficacy of --
- 18 A. I don't think that --
- 19 Q. -- ivermectin?
- 20 A. I don't think that would have as much
- 21 weight as the measured, scholarly analysis of
- 22 hundreds of articles that the treatment guideline
- 23 panel -- so the weight of the opinion of 30 to 40
- 24 infectious diseases experts would likely carry
- 25 considerably more weight than the statement by an

Page 334

Fax: 314.644.1334

1 individual physician or scientist. 2 Multiple times today you've characterized 3 your opinions as reflecting and reporting on the 4 consensus of that 40 scholars --5 Α. Right. 6 Ο. -- and if you make a public statement, is 7 it surprising if social media platforms take your public statement and view it as reflecting knowledge 9 of that kind of consensus of government experts or 10 public health authorities? 11 MR. KIRSCHNER: Objection. Speculative. 12 Compound. 13 THE WITNESS: Yeah, I'm not -- it's a 14 convoluted question. I'm not sure really what the 15 point you're making. BY MR. SAUER: 16 17 Exhibit 59. Q. 18 Α. Yeah. 19 Q. Have ever heard of -- sorry. 20 (FAUCI Exhibit No. 59 was marked for 2.1 identification.) 2.2 BY MR. SAUER: 2.3 Have you ever heard of Alex Berenson? Q. 2.4 I've heard of him. I'm not sure -- I'm Α. 25 trying to remember what context, but now you've put

Page 335

1	this in front of me, and it it's the person who
2	says that the White House demanded Twitter ban ban
3	me months before the company did so. I had never
4	heard of who Alex Berenson was before this, but I
5	mean, not before this but I had heard that there was
6	an issue that he was complaining that he was being
7	banned. I don't even know who who he is.
8	Q. What what issue did you hear about?
9	A. I think he was complaining that he was
10	being muzzled or something. I something like
11	that. Again, I don't pay attention to these social
12	media things of people getting banned or impeded or
13	what have you. That's not an interest of mine.
14	Q. Can you look at the second paragraph of
15	this document, Exhibit 59?
16	A. Yes.
17	Q. See how it says you know, in this
18	subset post by Alex Berenson, he says, "In a White
19	House meeting in April 2021, four months
20	before Twitter suspended my account, the company
21	faced one really tough question about why Alex
22	Berenson hadn't been kicked off the platform."
23	Do you recall you were the White House
24	chief medical advisor in April of 2021; correct?
25	A. Yes.

Page 336

1	Q. Do you recall any communications or
2	discussion of Alex Berenson, as a vaccine critic,
3	being on Twitter, or being booted off Twitter?
4	A. I don't recall that, no.
5	Q. Do you remember were you aware of any
6	meeting between do you know who Andy Slavitt is or
7	Slavitt?
8	A. Andy Slavitt for a relatively small period
9	of time was a part of the coronavirus team. He was
10	at the White House a fair amount, and then he left,
11	and I forgot where he went, but he was with the group
12	at the White House for a few months.
13	Q. How about Rob Flaherty? Do you know who
14	that is?
15	A. No. I know Andy Slavitt. I don't know
16	Rob Flaherty.
17	Q. Do you know who the digital director is at
18	the White House, coronavirus response team?
19	A. Digital? I thought that was Clarke, or
20	maybe Clarke reports to the director.
21	Q. Let me ask you this: Were you aware of a
22	meeting between Andy Slavitt, Rob Flaherty, and
23	people at Twitter in April of 2021 to discuss vaccine
24	misinformation?
25	MR. KIRSCHNER: Objection. Lack of

**Page 337** 

Fax: 314.644.1334

1 foundation. BY MR. SAUER: 2 3 0. Were you aware of it? I don't recall. I mean, you're bringing 4 Α. 5 it up. It doesn't ring a bell that I was aware of 6 it. 7 Can you turn to the third page of this Q. document? At the very bottom, in the Twitter 9 employee Slack message thread, it says: Andy 10 Slavitt -- it says, "They really wanted to know about 11 Alex Berenson"; the very bottom post. Do you see 12 that? 13 Α. Yes. 14 And then it says, "Andy Slavitt suggested 15 they had seen data viz that had showed he was the 16 epicenter of the disinfo that radiated outwards to 17 the persuadable public." 18 Do you see that? 19 Yeah. Α. 20 Were you aware of any discussions of Q. 21 someone on Twitter who was, you know, an epicenter of 2.2 disinformation radiating outward to the 2.3 persuadable public about vaccines? 24 MR. KIRSCHNER: Objection. Lack of foundation. 25

Page 338

1	THE WITNESS: You know, you're asking me
2	if I was aware of I mean, there was always talk
3	about misinformation and disinformation. I'm not
4	aware of any connection, to my memory. Maybe someone
5	casually mentioned it of you know, I don't even
6	know the connection, whether An Berenson was
7	no. I mean, this does this does not ring a bell
8	to me, to be honest with you.
9	BY MR. SAUER:
10	Q. Well, do you remember any discussions more
11	generally of misinformation and disinformation on
12	social media leading to vaccine hesitancy?
13	A. You know, there's a lot of different
14	discussions about misinformation. You're making a
15	connection between misinformation and something about
16	social media. It's all blob about misinformation.
17	Q. Well, let's take the whole blob. What
18	sort of discussions were there about misinformation?
19	You say there's discussions about
20	A. Well, I'll give you an example.
21	Q. Yeah, that'd be great.
22	A. The misinformation that Bill Gates and I
23	put a chip in the vaccine to monitor people, and,
24	therefore, people should not get vaccinated. I think
25	that falls under the category of disinformation.

Page 339

1	Q. Or misinformation if people honestly
2	A. No, this is dis
3	Q. Okay.
4	A. Because I didn't put a chip, so this dis.
5	Q. I think they're both false right mis
6	and dis are both incorrect
7	A. Yeah, yeah
8	Q under your definition.
9	A. Yeah, but
10	Q. You testified to earlier
11	A. Yeah, right, but the disinformation
12	MR. KIRSCHNER: Please let the witness
13	finish.
14	THE WITNESS: Yeah, but the disinformation
15	is when you deliberately get propagate information
16	that you know to be true.^ there's no evidence
17	because it isn't true that I put a chip in the
18	vaccine. So I think that qualifies as
19	disinformation.
20	BY MR. SAUER:
21	Q. Were there discussions of that with your
22	colleagues at the White House about that particular
23	issue of trying to stop the spread of that kind of
24	disinformation?
25	A. No, no, I you know, you just said

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

**Page 340** 

- 1 something important. I never engaged in any
- 2 discussion about stopping the spread. It just was
- 3 been disconcerted that there's so much disinformation
- 4 going on out there. I don't recall, to my knowledge,
- 5 that I got involved in any discussions about stopping
- 6 or blocking things.
- 7 Q. So your testimony is that you were never
- 8 involved in any discussions about stopping the spread
- 9 of disinformation --
- 10 A. Not -- no.
- 11 Q. If I may finish the question. So your
- 12 recollection is that you have never been involved in
- any discussions about stopping the spread of
- disinformation, whether on social media or elsewhere?
- 15 A. I don't recall. Someone may have
- 16 mentioned that we should be stopping misinformation,
- 17 but I don't recall specifically that I was involved
- in interfering with the dissemination, not to my
- 19 recollection. Like I said, someone may have made a
- 20 mention of that, but I didn't put it squarely on my
- 21 radar screen.
- 22 (FAUCI Exhibit No. 60 was marked for
- 23 identification.)
- 24 BY MR. SAUER:
- Q. If you'd look at Exhibit 60, is this a

**Page 341** 

1	report from The Hill dated July 11th of 2021?
2	A. Yes.
3	Q. And if you turn to it reports on some
4	of your public comments on a Sunday talk show
5	correct I think on CNN State of the Union?
6	MR. KIRSCHNER: I would ask for the
7	witness to be able to familiarize himself.
8	THE WITNESS: I have to I have to read
9	this before I make any comments, so I'm going to read
10	the whole thing.
11	BY MR. SAUER:
12	Q. You'll see there at the top of the second
13	page of the document
14	A. Yes.
15	Q. Where it says, "Fauci was responding to a
16	clip of conservative author Alex Berenson, who spoke
17	at CPAC on Saturday"; correct?
18	A. Correct.
19	Q. Does that jog your memory as to who
20	Alex Berenson is?
21	A. It does jog my memory to who he is because
22	at that time, they were talking about this CPAC where
23	people were cheering on not taking a lifesaving
24	intervention. And it says in this Exhibit 60, Fauci
25	was responding to a clip of conservative author

**Page 342** 

- 1 Alex Berenson who spoke at CPAC.
- 2 So it looks like on the show, the Sunday
- 3 show, that they showed me a clip of this person who I
- 4 very likely had not heard of before saying that,
- 5 quote -- they quote Berenson, "The government was
- 6 hoping that they could sort of sucker 90 percent of
- 7 the population into getting vaccinated, and it isn't
- 8 happening," he added, to applause.
- 9 Q. And then you made a response to that on
- 10 CNN State of the Union where you described it as
- 11 horrifying; correct?
- 12 A. Yeah.
- 13 Q. It quotes you as saying, "It's
- 14 horrifying." Is that what you said?
- 15 A. Well, this is the quote that they're
- 16 saying here. I don't recall saying it's horrifying,
- 17 but I have no reason to believe that CNN would
- 18 misquote me.
- 19 Q. And they went on to -- or The Hill -- it
- 20 goes on to say in the next paragraph that "Fauci said
- 21 it was almost frightening for people to say they
- 22 don't want health officials to save their lives";
- 23 right?
- 24 A. That's what it says that I said. I have
- 25 no reason to believe that's not what I said.

Page 343

1	Q. Were there any discussions before you made
2	these comments on CNN State of the Union on in
3	July of 2021, were there any did you have any
4	discussions with anyone in the government about
5	making statements to criticize Alex Berenson in any
6	way?
7	A. I don't recall. Again, the context of
8	this "almost frightening for people to say," if one
9	looks at the data comparing the hospitalizations and
10	deaths of vaccinated people and unvaccinated people,
11	it is overwhelmingly weighted towards unvaccinated
12	people. So someone cheering to the statement that
13	you shouldn't be vaccinating people, I think is
14	really very much contrary to the principles of good
15	public health.
16	Q. Before you made those comments, do you
17	recall discussing Alex Berenson with anyone in the
18	<pre>government?</pre>
19	A. I don't recall that. It is possible, but,
20	again, Alex Berenson rings the bell here when you
21	show me this clip. But, again, I I don't recall
22	any necessary discussions with him. They may have
23	occurred, but I don't recall.
24	Q. Exhibit 61. Five days oh, sorry.
25	(FAUCI Exhibit No. 61 was marked for

**Page 344** 

Fax: 314.644.1334

1 identification.) 2 BY MR. SAUER: 3 0. You see this is a New York Times report 4 dated five days later on July 16th of 2021? 5 Α. I don't see the date. Yeah, July 16th, 2021. 6 7 MR. KIRSCHNER: Just to clarify the record, it also says it was updated July 19th, 2021. 8 9 THE WITNESS: Right. 10 BY MR. SAUER: 11 Q. And the first line says, "President Biden 12 unleashed his growing frustration with Social Media 13 on Friday saying that platforms like Facebook were 14 killing people by allowing disinformation about the 15 coronavirus vaccine to spread online"; correct? 16 Α. That's what the first sentence says. 17 Do you recall the president saying that, 0. that social media companies are, quote, "killing 18 19 people"? 20 I don't recall him saying that, but this 2.1 is reported by the New York Times saying that that's 2.2 what he said. So I have no reason to believe that he 2.3 did not say that, but I don't specifically recall him 24 saying that specific comment. I may -- I may have 25 been aware of it when he said it, but I don't recall

Page 345

1	now that he said it except when you put this
2	statement in front of me.
3	Q. Do you recall any discussions with anyone
4	in the government of how disinformation or
5	misinformation on social media platforms are killing
6	people?
7	A. Well, it is very clear that, as I've said
8	multiple times before, that misinformation and
9	disinformation, particularly that encourages people
10	to avoid lifesaving interventions, can certainly
11	result in the unnecessary death of people whose lives
12	would have been saved. So when misinformation and
13	disinformation leads people to avoid a lifesaving
14	intervention, that is equivalent to contributing to
15	the death of that person.
16	Q. My question was: Do you recall discussing
17	that with anyone in the government in this time
18	frame?
19	MR. KIRSCHNER: Objection. Lack of
20	foundation. Vague.
21	THE WITNESS: You know, when you say
22	"anyone in the government," I have often said that
23	misinformation and disinformation is the enemy of
24	public health. Could I have said it to someone in
25	the government? It is certainly possible that I did

**Page 346** 

- 1 because I do feel strongly that misinformation and
- 2 disinformation, when it leads to people avoiding
- 3 lifesaving interventions, can be deadly.
- 4 BY MR. SAUER:
- 5 Q. Misinformation and disinformation are the
- 6 enemy of public health you said just now?
- 7 A. Yeah.
- 8 Q. Is that true when they are propagated on
- 9 social media platforms, on your view? Yes or no?
- 10 A. If social media is propagating
- 11 disinformation that leads to the death of people by
- 12 encouraging them to avoid lifesaving interventions, I
- 13 believe that's contrary to public health.
- 14 Q. Can you look at Exhibit 62?
- 15 (FAUCI Exhibit No. 62 was marked for
- 16 identification.)
- 17 MR. KIRSCHNER: Can I get a copy, Counsel?
- 18 There's -- I don't know what this is.
- MR. SAUER: Oh.
- 20 BY MR. SAUER:
- 21 Q. Do you know who Scott Gottlieb is?
- 22 A. I do.
- Q. Do you know him personally?
- 24 A. Well, I've met him. I -- I don't socially
- 25 interact with him. I know him because for a time he

**Page 347** 

- 1 was the commissioner of the FDA, and currently he is
- 2 frequently on CBS Sunday Morning shows commenting on
- 3 COVID-19 and other health matters.
- 4 Q. In 2021, did you have any communications
- 5 with him about vaccines or misinformation?
- 6 MR. KIRSCHNER: Objection. Compound.
- 7 BY MR. SAUER:
- 8 Q. Do you recall communicating with him in
- 9 any way in the summer of 2021?
- 10 A. You know, I may have, but I don't recall.
- 11 I communicate with hundreds, if not many more people.
- 12 So I don't recall specifically. But if you showed me
- 13 a document of some sort that showed I communicated
- 14 with him, I would not be surprised.
- 15 Q. Why don't you look at the Exhibit 62 on
- 16 the first page in the middle of that page? Do you
- see there's a -- you see this is another subset post
- 18 by Alex Berenson talking about how he was banned from
- 19 Twitter, generally?
- 20 A. I'm sorry. What paragraph are you
- 21 referring to?
- 22 Q. I'll tell you, will you look at that --
- that kind of e-mail that's pasted in the middle
- 24 of the page --
- 25 A. Pasted in the middle -- oh, the pasted

Page 348

1	e-mail.
2	Q. The one that shows
3	A. Scott Gottlieb to someone that has been
4	redacted.
5	Q. Someone at Twitter?
6	A. Yeah.
7	Q. And he's forwarded a posting by
8	Alex Berenson that's critical of you; right? "Quite
9	frankly," said Alex Berenson, "the arrogance of
10	Anthony Fauci and what it means for the rest of us";
11	correct?
12	A. So Berenson said the arrogance of
13	Anthony Fauci and what it means for the rest of us?
14	Q. And then Gottlieb forwarded that to
15	someone at Twitter; correct?
16	MR. KIRSCHNER: Objection. Lack of
17	foundation.
18	THE WITNESS: Yeah. So I want to make
19	sure I understand what you're saying. So this is
20	a this is a tweet from Berenson calling me
21	arrogant, and then it's Scott forwarding the tweet to
22	Twitter saying this is what is promoted on Twitter
23	and this is why Tony needs a security detail?
24	BY MR. SAUER:
25	Q. Correct, yeah. Tony is a reference to

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

Page 349

1	you, I presume?
2	A. There's a lot of Tonys around, but I guess
3	he's talking about me.
4	Q. I mean, that's the one that's referred in
5	the e-mail.
6	A. Right.
7	Q. Did you ever have a discussion with
8	Scott Gottlieb about needing a security detail
9	because of the things that people posted about you on
10	the Internet?
11	A. I don't recall having that discussion with
12	him, but it is possible in a discussion I had with
13	him that it's no secret that I have a security
14	detail. My life has been threatened multiple times.
15	So I might have discussed that I need a security
16	detail with him, but I that doesn't ring a bell as
17	something unless there was a reason for me to I
18	don't usually talk to people about my security
19	detail.
20	Q. He refers to you as "Tony" in this
21	e-mail
22	A. Everybody refers to me as Tony. We
23	said we got that established before.
24	Q. Is there somebody at Twitter who was on a
25	first-name basis with you? I would refer to you as
l	

**Page 350** 

1	Dr. Fauci
2	A. Yeah.
3	Q if I was sending it to someone who
4	didn't know you. Is there someone who works for
5	Twitter who who you're on a first-name basis with?
6	A. Scott Scott refers to me as Tony, but I
7	don't see anybody on Twitter referring to me as Tony.
8	Q. He's referring you to some unidentified
9	person
10	A. But he's using his own
11	Q. If I may finish the question?
12	A. Yeah, yeah. Sure. Sorry.
13	Q. He's referring to you as Tony to some
14	unidentified person at Twitter?
15	A. Right.
16	Q. Are you on a first-name basis with anyone
17	who works at Twitter? Yes or no?
18	A. Am I on a first-name basis of anyone who
19	works at Twitter?
20	Q. Correct. That's my question.
21	A. Well, right now, no, but when my daughter
22	worked at Twitter, I was on a first-name basis with
23	her.
24	Q. Did she work at Twitter in August 24th
25	of 2021?

**Page 351** 

- 1 A. I don't recall. She may have already left
- 2 then.
- 3 Q. Did anyone else -- have you ever been on a
- 4 first-name basis with anyone else who worked at
- 5 Twitter?
- 6 A. Not that I know of. Not that I know of.
- 7 I mean, I'm trying to think of people that I know at
- 8 Twitter, and the only person that I've really known
- 9 that works at Twitter, I believe, is my daughter.
- 10 Q. Did you have any communications with -- at
- 11 this time, Scott Gottlieb was on the board of Pfizer;
- 12 is that right?
- 13 A. He might -- I know he's on -- I believe --
- I believe he's on the board of Pfizer. I don't know
- 15 if he was on the board of Pfizer at this time.
- 16 Q. Did you have any communications with him
- in connection with the development of the vaccines
- 18 that you talked about earlier?
- 19 A. You know, I don't know. I mean, we talk
- 20 about the development of vaccines all the time.
- 21 Vaccines was a big subject of discussion from the
- 22 time we began developing the vaccines; right? In a
- 23 few weeks into January we began developing the
- 24 vaccine. So we spoke about vaccine development a
- 25 lot. Did -- would I have mentioned vaccine

**Page 352** 

- 1 development to Scott? I don't see any reason why I
- 2 would not, but I don't specifically recall discussing
- 3 vaccine development with Scott.
- 4 Q. How about discussing any speech on the
- 5 internet that would lead to vaccine hesitancy? Did
- 6 you discuss that with him?
- 7 MR. KIRSCHNER: Objection. Vaque.
- 8 THE WITNESS: You know, again, I don't --
- 9 I don't recall specific conversations with Scott
- 10 about hardly anything.
- 11 BY MR. SAUER:
- 12 Q. How about Alex Berenson? Did you ever
- 13 discuss Alex Berenson with Scott Gottlieb?
- 14 A. You know, again, you had mentioned before,
- 15 I -- Alex Berenson doesn't ring a bell. It's
- 16 possible associated with some of the things you
- 17 showed me before, but I don't recall discussing
- 18 Alex Berenson with Scott Gottlieb.
- 19 Q. Exhibit 63.
- 20 (FAUCI Exhibit No. 63 was marked for
- 21 identification.)
- 22 BY MR. SAUER:
- 23 Q. Who is Ezekiel J. Emmanuel?
- A. Ezekiel J, better known as Zeke Emmanuel,
- 25 is a vice provost at the University of Pennsylvania

**Page 353** 

- 1 and was at a time and might still be the director of
- 2 the division or program of medical ethics.
- 3 Q. At the university? At that university?
- 4 A. At the University of Pennsylvania.
- 5 Q. In this e-mail chain, he says to you on
- 6 the second to last page, "I'm a bit perplexed by your
- 7 seeming strong endorsement of remdesivir. Was it
- 8 just a bit forced? My reading of the data were weak
- 9 and in normal times for normal disease. It is not
- 10 enough to approve and very likely to really impact
- 11 COVID-19 disease pattern regardless of supply
- 12 issues."
- Do you see that?
- 14 A. Yeah.
- 15 Q. And what were you talking -- what was he
- 16 talking about there?
- 17 MR. KIRSCHNER: Objection. Again, I ask
- 18 for Dr. Fauci to have an opportunity to familiarize
- 19 himself with this document.
- 20 THE WITNESS: So there was a clinical
- 21 trial that showed a modest effect but nonetheless a
- 22 clear but modest effect of remdesivir, which is an
- 23 antiviral drug used for the treatment of COVID-19.
- 24 And when the announcement came out of the clinical
- 25 trial, I believe, I said this is a good thing that we

Page 354

1	have a drug when we had no other drugs. This is well
2	before Paxlovid, so we had no good drugs for COVID.
3	And when the study came out, I was pleased that we
4	had a drug that at least had a modest effect. Zeke,
5	who is a good person, said my reading of the data
6	were weak and normal times for normal disease, not
7	enough to approve, yada, ya, and I write back, and
8	say, "Zeke, I did not strongly endorse it." I
9	specifically said that it was not a knockout drug but
10	was only a baby step in the development in the
11	direction of developing more and better drugs. I
12	said it was important because it proved in a
13	well-powered which it was "randomized" which
14	it was "placebo-controlled trial that one can
15	suppress the virus enough to see a clinical effect as
16	modest as that effect was." I do not think
17	BY MR. SAUER:
18	Q. If I may right there.
19	A that I forced anything.
20	Q. Dr. Fauci, thank you.
21	Why don't we go off the record now?
22	MR. KIRSCHNER: Okay.
23	THE VIDEOGRAPHER: Time is 4:46 p.m. and
24	we're going off the record.
25	(Recess.)

**Page 355** 

1	THE VIDEOGRAPHER: The time is 4:55 p.m.
	<u>-</u>
2	and we're back on the record.
3	BY MR. SAUER:
4	Q. Dr. Fauci, we've discussed a lot of
5	opinions today about COVID and treatments for COVID
6	and related things. For example, we talked about
7	hydroxychloroquine; we talked about masks for a while
8	and whether they're effective; we talked about the
9	origins of COVID, whether it came out of a lab; we
10	talked about vaccines and the efficacy of vaccines;
11	we talked about herd immunity. And you've made some
12	pretty strong statements in media about a lot of
13	these issues is that fair to say using strong
14	language to disagree with opinions that you disagree
15	with?
16	MR. KIRSCHNER: Objection. Vague.
17	THE WITNESS: No, I'm not sure what you
18	mean by strong language. Most of the time it was
19	measured language. I think you pointed out at one
20	point when I was talking about the premise of herd
21	immunity that I believe I said that it was nonsense
22	which is if you want to call that strong language.
23	I believe it resulted in the deaths of unnecessary
24	deaths of individuals.
25	BY MR. SAUER:

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376

**Page 356** 

1	Q. And people have disagreed with you in
2	strong language as well. For example, Alex Berenson
3	saying calling the arrogance of Dr. Fauci
4	A. Right.
5	Q and so forth.
6	Do you think people should be able to post
7	their opinions on social media, for example, about
8	the efficacy of hydroxychloroquine, even if you
9	disagree with them?
10	MR. KIRSCHNER: Objection. Compound.
11	THE WITNESS: You know, I'm not an expert
12	on what should or should not be on social media. I
13	^ audio cuts out here believe that people certainly
14	can express their opinions. I'm not an expert. I've
15	said that multiple times during the deposition. I'm
16	not a social media person.
17	BY MR. SAUER:
18	Q. Do you have an opinion about whether
19	people should be allowed to post on social media
20	opinions that you think, for example, are dangerous
21	and might lead to loss of life? What's your view on
22	that?
23	A. You know, again, you say allowed, I don't
24	know what the legal or other First Amendment issues
25	are associated with that. That's not my lane or my

area of expertise. As a physician and a scientist

**Page 357** 

Fax: 314.644.1334

- and a public health person, I'm very sensitive to the fact that disinformation, including some of the
  - 4 disinformation that we discussed that, for example,
  - 5 has people avoid lifesaving interventions, is
  - 6 dangerous to health.

1

- 7 How you -- how you counter that I think is
- 8 open to question. My way of countering false
- 9 information, and I've been on the record multiple
- 10 times as saying that, is that my approach is to try
- 11 to ^ and flood the system with the correct
- 12 information as opposed to interfering with other
- 13 people's ability to say what they want to say. And
- 14 I've said, I think, if you, in your investigations
- and your discovery, you looked into how many times
- 16 I've often said the best way to counter
- 17 misinformation and disinformation is to flood the
- 18 system with correct information.
- 19 Q. Do you think social media platforms have a
- 20 responsibility to take down dangerous misinformation
- 21 that gets posted on their platforms?
- 22 A. You know, I'm not an expert in the legal
- 23 and other aspects of that to make an informed
- 24 comment. I would leave that to experts. I told you
- 25 I'm not someone fluent in the ins and outs of what

**Page 358** 

1	could or should be on social media, so I don't really
2	have any comment on that, because that's not an area
3	that I've seriously thought about and analyzed about
4	the pros and cons of that.
5	Q. Do you think that allowing both sides to
6	openly debate their positions on hotly contested
7	issues, like the efficacy of hydroxychloroquine or
8	where the COVID-19 virus came from, do you think it's
9	important to allow both sides to freely debate those
10	issues?
11	MR. KIRSCHNER: Objection. Argumentative.
12	THE WITNESS: You know, when you say
13	allowed to debate, I think honest debate is
14	important, but when it goes beyond debate and leads
15	people who are unwitting about these things to do
16	things that are clearly detrimental to their life and
17	their safety, I find that disturbing. How you
18	mitigate against that, I would leave to other people.
19	That's not in my lane.
20	Q. Have you taken steps to mitigate against
21	it in the last two and a half years?
22	A. As I said, the theme that I've gone by is
23	the best way to counter misinformation and
24	disinformation is to flood the system with correct
25	information. That's the reason why I very often am

Page 359

1	involved with the media with writing, with
2	interviewing, with podcasts to get people to get
3	vaccinated. The most recent of which was yesterday,
4	I believe, when I was or the day before when I
5	made my final press conference at the White House and
6	my message was: Please go out for your own safety,
7	the safety of your community and your family, to go
8	out and get the updated booster.
9	That's how I counter misinformation and
10	disinformation.
11	THE VIDEOGRAPHER: That is it. That's the
12	seven hours.
13	MR. KIRSCHNER: Very well. Two things:
14	One, first, we have no questions for the witness, and
15	second of all, we want to reserve the right to read
16	and sign.
17	THE VIDEOGRAPHER: Okay. If there's no
18	further statements for record, we'll be going off.
19	The time is 5:01 p.m. on November 23rd, 2022. We are
20	going off the record completing today's video
21	recorded session.
22	(Whereupon, at 5:01 p.m., the taking of
23	the deposition ceased.)
24	
25	

Page 360

1	CERTIFICATE OF REPORTER
2	UNITED STATES OF AMERICA ) ss.:
3	STATE OF MARYLAND )
4	I, STEPHANIE BARNES, the officer
5	before whom the foregoing deposition was taken, do
6	hereby certify that the witness whose testimony
7	appears in the foregoing deposition was duly sworn by
8	me; that the testimony of said witness was taken by
9	me to the best of my ability and thereafter reduced
10	to typewriting under my direction; that I am neither
11	counsel for, related to, nor employed by any of the
12	parties for the action in which this deposition was
13	taken, and further that I am not a relative or
14	employee of any attorney or counsel employed by the
15	parties thereto, nor financially or otherwise
16	interested in the outcome of the action.
17	
18	
19	Deduntanco
20	Notary public in and for
21	the State of Maryland
22	My commission expires: 10/3/2025
23	
24	
25	

**Page 361** 

Fax: 314.644.1334

```
1
                            LEXITAS LEGAL
 2
 3
     November 28, 2022
 4
     ADAM KIRSCHNER, ESQ.
     U.S. Department of Justice
     1100 L Street, Northwest
 6
     Washington, D.C. 20530
 7
     IN RE: THE STATE OF MISSOURI, et al. v. JOSEPH R.
            BIDEN, JR., et al.
 8
     Dear Mr. Kirschner:
 9
     Please find enclosed your copies of the deposition of
     DR. ANTHONY FAUCI taken on November 23, 2022 in the
10
     above-referenced case. Also enclosed is the original
     signature page and errata sheets.
11
12
     Please have the witness read your copy of the
     transcript, indicate any changes and/or corrections
13
     desired on the errata sheets, and sign the signature
14
     page before a notary public.
15
16
     Please return the errata sheets and notarized
17
     signature page within 30 days to our office at 711 N
18
     11th Street, St. Louis, MO 63101 for filing.
19
20
     Sincerely,
21
22
23
     Lexitas Legal
2.4
25
     Enclosures
```

LEXITAS LEGAL Phone: 1.800.280.3376

**Page 362** 

1	ERRATA SHEET Witness Name: DR. ANTHONY FAUCI
2	Case Name: THE STATE OF MISSOURI, et al. v. JOSEPH R.
3	BIDEN, JR., et al. Date Taken: NOVEMBER 23, 2022
4	
5	Page # Line #
6	Should read:
7	Reason for change:
8	
9	Page # Line #
10	Should read:
11	Reason for change:
12	
13	Page # Line #
14	Should read:
15	Reason for change:
16	
17	Page # Line #
18	Should read:
19	Reason for change:
20	
21	Page # Line #
22	Should read:
23	Reason for change:
24	
25	Witness Signature:

**Page 363** 

Fax: 314.644.1334

1	STATE OF)
2	
3	COUNTY OF)
4	
5	I, DR. ANTHONY FAUCI, do hereby certify:
6	That I have read the foregoing deposition;
7	That I have made such changes in form
8	and/or substance to the within deposition as might
9	be necessary to render the same true and correct;
10	That having made such changes thereon, I
11	hereby subscribe my name to the deposition.
12	I declare under penalty of perjury that the
13	foregoing is true and correct.
14	Executed this day of,
15	20, at
16	
17	
18	
19	
20	DR. ANTHONY FAUCI
21	
22	
23	NOTARY PUBLIC
24	My Commission Expires:
25	

LEXITAS LEGAL Phone: 1.800.280.3376

	•	·		
A	143:4	accumulate	act125:13	266:23
	213:16	224:2	126:4	administer
<b>A-U-C-H</b> 30:23	235:23	accumulated	265:14,15	9:25
	319:10,14	221:1	acting 65:10	administ
<b>a.m</b> 1:20 9:4	319:18,22	235:5	action	271:21
54:8,12	322:19	accumula	265:15	admissions
55:2 58:14	333:2	223:16	360:12,16	283:16
61:14 62:14	accident	224:2	actively	adopted 27:3
68:14 69:2	106:5	317:5	64:18	27:13,14
	155 <b>:</b> 17	accuracy	activist	advance
83:17,20 84:19	account 99:6	228:13	265:13	139:22
	101:7	accurate	activities	advertis
150:3,5	209:17	36:25	321:14	141:19
<b>Aaron</b> 2:25	210:1,6	167:1	activity	<b>advice</b> 171:1
<b>ABC</b> 7:9	213:14	198:25	20:3	171:11,17
185:20	241:7,25	275:23,25	actual	171:20
ability	270:4	276:8	120:21	196:11
323:8 357:13	299:11,14	315:3	121:1	313:18
357:13	299:15,19	331:6,11	178:21	advisor
<b>able</b> 133:25	300:22,25	331:17	ad 177:11,18	10:15,18
175:3	301:3,19	accurately	306:2,3	10:20,21
299:2	301:19	114:7	Adam 3:22	335:24
319:7	302:1,8,9	288:7	9:21 361:4	Affairs
323:8	303:8	319:7	Adam.kir	38:11
341:7	304:3	accusations	4 <b>:</b> 5	affiliated
356:6	309:9	106:3	<b>Adams</b> 329:9	75:19 <b>,</b> 25
above-en	311:1	<b>ACE2</b> 115:13	<b>add</b> 285:18	affiliation
1:15	328:15	115:23	<b>added</b> 342:8	75 <b>:</b> 22
above-re	329:9,12	116:11	adding	afraid
361:10	329:14	117:13	299:22	102:20
absolutely	335 <b>:</b> 20	achieve	327:7	<b>Africa</b> 140:7
37:5	accounts	278:3	additional	African
134:12	209:9	achieving	16:8 17:17	228:4
234:20	270:1	285:2	111:5	afternoon
260:13	300:19	acknowle	211:5,12	65:23 <b>,</b> 25
abstract	301:11	267 <b>:</b> 12	address	66:2 68:10
22:25	302:12 <b>,</b> 18	acquaint	161:16	148:23
academies	302:22	20:17	198:1	234:5
17:6	303:3,3	156 <b>:</b> 23	206:4,5,7	agency 28:4
academy	304:15	acquaint	206:10,19	28:18
188:12	309:5 <b>,</b> 11	99:23	329:1	30:14 45:6
190:17	309:22,24	269:17	addresses	307 <b>:</b> 5
191:13	309:25	acquainted	55:10	aggressive
accept	310:1,4,10	205:6	205:24	168:11
177:17,19	310:18,24	acquiring	324 <b>:</b> 7	<b>ago</b> 11:1,7
access 36:15	311:17,18	314:12	addressing	11:10
37:2,9,15	312:15	acquisition	184:2	13:24 16:5
103:14	328:21	316:12	198:8	19:11
142:17	329:16	317 <b>:</b> 6	245:9	23:25

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

27:17	252 <b>:</b> 6	52 <b>:</b> 25	76:12	<b>Andy</b> 336:6,8
29:10,23	272:19	285:1	169:3	336:15,22
43:23	<b>AIDS</b> 265:13	358:9	191:10	337:9,14
44:23	airport	allowed	236:9,9	anecdotal
57:13 78:6	313:14,24	247:23	251:23	215:1,3
100:17	<b>al</b> 1:5,8 9:7	356:19 <b>,</b> 23	266:3	217:2
124:17	9:7 55:19	358:13	336:10	218:1
149:11	56:1 61:2	allowing	ample 145:9	animal
150:9	361:7,7	276:25	224:2	143:17
157:21	362:2,2	344:14	amplify 25:1	144:9,11
167:11	alarming	358:5	analyses	144:13
188:5	52:10	alternative	52:8 180:4	145:6,8,11
212:5	albeit	273:2	analysis	146:4
249:16	167:24	321:17	111:19	156:9
250:4	Aleksei	ambiguous	112:5,6,9	198:19
257:13	205:15,18	35:22	112:10	200:10
269:5	alert 97:4	71:10	121:11,14	announce
275:4	Alex 267:24	78:15	161:25	353:24
288:3	334:23	79:10 82:8	180:20	anomalies
295:11	335:4,18	99:4	195:8	113:12,21
agree 47:16	335:4,10	118:21	320:13,16	113:24
111:19	336:2	154:23	323:16	124:18
112:4,8	337:11	166:13	333:21	answer 13:7
166:21	341:16,20	168:20	analyzed	18:23
277:5	342:1	174:22	358:3	19:21
298:2	343:5,17	186:23	<b>ANANT</b> 4:9	20:21
agreed 52:14	343:20	193:19	Anant.ku	25:11
195:14	347:18	213:25	4:15	36:25
223:20,23	348:8,9	270:17	and/or	41:21,24
agreement	352:12,13	amended	104:15	47:11
73:17	352:12,13	282:25	361:12	51:22
agrees	356:2	Amendment	363:8	94:16
223:24	algorithm	356 <b>:</b> 24	Anderson	119:16
<b>ah</b> 210:1	306:2	America 7:19	34:21	127:24
ahead 17:12	alleging	226:14	43:20	134:10,11
20:19,23	211:25	227:8	44:24	139:3
48:9 49:12	212:1	233:5,15	45:13,21	145:3
52:21	Allergy	234:16	50:16,23	165:4
64:21	10:14	360:2	51:11 60:2	175:6
84:15	142:13	America's	61:19 84:6	206:16
85:24	Alliance 3:4	227:16	89:4	230:4
89:18,19	6:9 18:11	234:6	170:14,23	241:22
91:17 93:7	19:10,25	238:22	179:18	288:7
126:19	20:4,6	242:15	180:10	306:15
135:4	21:22 30:4	243:3	195:24	319:7
202:3	allocated	American	196:10	331:6,10
247:14	177:10	15:18	Andrea 229:7	answered
249:17	allow 26:14	313:11	233:5,12	63:4 88:13
251:2	28:14	amount 21:13	234:15	125:16
	•	•	•	•

LEXITAS LEGAL Phone: 1.800.280.3376

159:11,21	181 <b>:</b> 2	applicable	307:18	31:12 49:5
159:23	213:8	215:18	317:15	49:15,19
162:7	238:2,4,4	applicat	318:1	49:22 50:3
172:16	238:10	24:8	322:3	50:9 56:5
195:5	239:4	apply 169:22	335:19,24	56:21,22
205:4,6	269:6,11	247:10	336:23	57:2,9,14
239:18	278:12	appreciate	<b>apropos</b> 70:5	57:17 60:7
261:14	350:7	109:7	Archive	60:9 61:18
262:4,5,16	apologies	appreciated	179:22	61:24 62:6
274:24	311:12,14	275:23	Archives	62:13,14
285:20	apologize	276:1,6,10	7:11	65:13 66:9
297:1	90:2 93:13	approach	area 40:18	82:23
301:21	185:10	250:7	117:20	163:11
327:19	249:5	266:21,24	127:12,12	179:14
answering	Apoorva	266:24,25	151:15,17	183:23
11:19	296:12	290:19	151:13,17	184:3
12:23	appalls	295:5	157:16	185:3,20
14:12	271:10	357:10	357:1	186:6,20
48:22 53:9	apparently	approaches	358:2	186:25
287:2	108:3	292:14	argue 315:9	187:2
	286:21		Argument	189:4
answers 11:23		appropriate 46:18	206:14	191:3,7,9
antecedent	<b>appear</b> 164:23	119:8	223:22	191:3,7,9
218:21	179:24	128:8	224:13	192:14
antedated		138:1	298:9	195:3,20
159:6	appearance 38:24	207:21	322:22	195:23
Anthony 1:13	APPEARANCES	225:5	358:11	196:4,9,11
6:3 9:6	2:1	310:15	arguments	196:4,9,11
10:2,10	appeared	312:20	123:20	212:20,24
91:22	77:16	approval	arose 120:12	212:20,24
299:18	179:14	70:22	183:18	221:15,21
303:6,6	226:16	approve	arranged	222:8,10
328:16	appearing	18:24	44:15	222:13
348:10,13	226:13	122:17	arranging	228:24
361:10	227:18	276:3	44:19	233:17,23
362:1	229:6	353:10	arrogance	258:20,23
363:5,20	appears	354:7	348:9,12	259:11,13
anthonyf	129:3	approved	356:3	264:13
299:10	146:23	18:17 19:2	arrogant	265:1,5
antimala	179:10	70:1,13	348:21	267:10
227:1	182:10	April 179:12	article 6:8	271:5,13
antiviral	189:11	188:3	6:12 7:2,3	275:14,16
353:23	245:10	192:4	7:7,9,14	275:11,10
anybody	294:21	197:1	7:16,17,18	277:24
34:13	360:7	199:2,14	7:19,20,21	280:12,19
75:24	applause	201:4,21	7:22 8:3,5	280:25
77:14	342:8	203:8	8:6,17,18	294:24
115:20	apples	204:4,8	8:19,20	articles
137:18	157:14	207:25	15:15 31:7	13:24
	, ,			
	•	•	•	

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

31:17	274 <b>:</b> 23	329:25	55:17,23	9 <b>:</b> 19
62:12	285:19	338:1	56:16 61:2	360:14
268:22	295:10,11	aspects 17:3	120:7,22	attract
280:24	295:17	202:23	121:1	243:16
294:14,23	296:25	289:22	123:10	Auchincloss
295:2,4,11	301:20,24	357 <b>:</b> 23	126:24	30:21,22
295:18,21	313:18	assess 154:1	Attachments	30:21,22
295:24	327:18	293:19	55:18	54:20,24
296:5	329:1	323:3	attend	62:3 68:7
297:20	332:19	associate	140:12	69:2
333:22	asking 11:20	108:14	attention	<b>audio</b> 356:13
<b>Asia</b> 140:8	11:21	265:22	22:16	August
Asian 33:10	12:21 25:9	associated	30:10	242:19
33:19	25:14		31:17 34:3	243:7
aside 238:21	26:15	161:2,4 238:11	42:10	350 <b>:</b> 24
290:18 asked10:20	36:20,23	352:16	47:24	auspices 156:20
12:10	47:12	356:25	48:14 58:2	Australia
41:22	49:13	association 213:13	79:15	
	67:25		141:9	45:5 73:11
43:13	68:17 69:5	<b>assume</b> 85:13	144:20	<b>author</b> 161:3
48:25	69:6,8,10	86:17	145:15	195:25
58:25 63:3	87:5 <b>,</b> 6	132:11	153:21	218:21
69:7 78:5	94:15	201:5	184:11	264:21
82:20	97:14	233:18	208:12	341:16,25
88:12	127:15,22	301:23	209:21	authored
102:4	127:24	Assumes 30:5	210:4,8	124:3
125:15	133:22	109:19	213:15	203:12
132:13	134:6,10	214:19	219:9	251:5
133:8	135:13	assuming	235:20	authorities
134:12	136:17,24	18:20	238:18	288:20,25
139:9	138:20	19:18 22:8	239:3,22	334:10
140:4	145:3	49:24 70:4	240:3	authority
147:13	156:17	assumption	241:5,8,12	126:12
151:22	159:25	87:25	241:23	177:19
159:10,20	164:3	179:25	243:16	289:4,8,11
162:6	176:15	258 <b>:</b> 7	256:11,14	289:16
172:15	186:24	276:23	257:6 <b>,</b> 8	290:1,7
188:11	189:25	astute	271:10	authoriz
195:4	190:19	166:24	280 <b>:</b> 7	221:4
202:12,13	195 <b>:</b> 12	asymptom	281:17,22	authorize
202:14	199:12	316:25	281:24	326:8,13
205:3	201:22	317:4	283:10	326:13,17
208:6	226:17	<b>Atlas</b> 267:23	293:23	authorized
217:23	241:10	attached	301:10	29:14
232:1	262 <b>:</b> 17	8:22 57:17	303:7	30:14
239:17	292:16	attaching	335:11	326:14
261:13	313:13	56:12	attenuated	authors
262:3	314:4	attachment	24:24	32:10
269:7	315:4	38:18	attorney2:8	161:4
L				

LEXITAS LEGAL Phone: 1.800.280.3376

162:5,9	66:14	316:13	256:13	360:4
· ·	110:24	328:20		
170:18			261:23	Barrington
179:23	129:9,19	332:6,12	262:15,19	7:24
180:13,20	151:16	332:13,16	263:17	248:13,16
181:9	152:14	336:5,21	269:1	249:1,10
200:18	157 <b>:</b> 24	337:3,5,20	274:5	249:12,14
251:16	158:2,9,13	338:2,4	286:22	249:18,19
255:13	162:14	344:25	295:10	250:1
256:9	184:1,7,8	awareness	300:13	252:18
267:1	185:3	195:3	313:4	254:6,12
295:23	205:9	255 <b>:</b> 17	322:4	254:24
available	207:24	256:19	354:7	255:3,14
95:2	208:3,6,9	<b>Azar</b> 256:5	355:2	258:11
158:10	208:10,13	267:24	background	260:15
198:13	208:15,23		144:10	264:7
200:18,19	208:25	B	271:22	266:10
201:7	209:13,16	<b>B</b> 6:6	<b>bad</b> 109:10	267:1
206:9	211:24	B-i-r-r-e-l	303:20	268:6,22
316:5	212:3,4,7	212:25	304:13	269:4
320:21,23	212:9	<b>B6</b> 206:12	310:1	276:4,17
323:2	223:1	<b>baby</b> 354:10	311:20,22	277:6
average	224:5	<b>back</b> 35:13	323:4	278:21
153:12	225:15	54:13 64:2	329:16	279:19
averages	236:1	77:7,17	<b>badly</b> 169:6	280:1,13
36:12	237:25	78:3 83:21	Baier 190:5	280:17,21
avert 107:14	238:11,22	97:9 101:9	190:13	281:9,23
avoid 107:14	239:14,20	123:21	228:24	282:11
320:19	239:25	129:4	ban 335:2,2	283:2
345:10,13	240:20	132:2,20	bank 158:15	285:7,10
346:12	241:1,2,3	136:11	<b>banned</b> 335:7	290:10,19
357:5	241:11,14	149:14	335:12	291:12
avoiding	243:9,14	150:6,8	347:18	292:11
346:2	243:17,25	157:20	banner 306:2	295:6
award 76:6,9		165:3,24	Baric 32:12	296:19,24
Award-Wi	244:3 251:9	166:22	32:15	290:19,24
212:21	252:17,19	193:15	39:22	297:3,10
awards 36:10	252:17,19	199:12	40:11	Barry 296:2
awards 36:10	252:20,21	203:22	55:25 56:9	296:7,8,11
22:12,15	252:23	209:24		<b>based</b> 27:23
· ·	•	213:2	56:16,23	
22:18,21	275:7	219:7,19	57:12	42:7 78:8
25:19	280:1,3,20 281:21,21	220:9,13	60:23 61:2	80:6 88:22
27:10		220:9,13	62:13	89:9
31:15,22	282:10,17	223:14	71:15	180:20
33:13 34:6	282:18,24	233:14	119:4	196:5
35:16	283:9	239:2	147:15	215:1,3,23
43:23	298:15		148:24	217:2,2,9
60:22 61:1	300:18	240:13	149:6	217:13
61:4,6	306:17	247:21 253:12	Barnes 1:17	223:12,16
62:19	309:20,23	203:12	1:22 9:13	231:20
		l	l	I

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

236:25	145:16	82:20 <b>,</b> 22	281:15	244:19
230.23	164:7	87:24 89:2	289:19	314:16
244:10	182:17	89:9 92:9	291:4	benefits
246:12	222:15	96:1,4	295:12	225:20
316:18	267:15	99:18	297:17	227:21
318:16	begins 23:4	100:13	301:1	235:10
319:24,25	39:9,14	100:13	304:19	236:21
323:13	98:3	108:10	310:1	Berenson
basis 21:20	130:17	114:6,13	318:19	334:23
81:12,25	176:19	117:16	319:7	335:4,18
170:4	267:11	120:13	326:14	335:22
173:17	324:15	132:8,14	328:10	336:2
191:18	behalf 2:3	132:15	331:10	337:11
214:6	2:14,24	133:5	342:17,25	338:6
219:17	3:12,20	136:6,6	344:22	341:16,20
221:8	4:7,16	139:15,25	346:13	342:1,5
286:14,19	9:19,22	155:24	351:9,13	343:5,17
317:10	Beijing	160:21	351:14	343:20
349:25	166:4,5	161:10,10	353:25	347:18
350:5,16	belief 138:2	166:5,16	355:21,23	348:8,9,12
350:18,22	believe	166:25	356:13	348:20
351:4	14:18	168:5,7,16	359:4	352:12,13
basketball	16:13,24	175:13,13	believed	352:12,13
101:6	21:5,8,10	175:16	46:16	356:2
bat 18:6,8	24:25 26:3	177:2,21	133:20	Berkowitz
18:12	30:8 31:16	177:22	165:10	305:6
22:14 31:8	31:17	182:13	believes	Bernard
33:15,15	32:12 33:7	189:2,6	262:7	108:3,6,8
41:4,9,15	33:9,10,20	202:24	<b>bell</b> 98:24	108:9,10
43:3	34:19,20	204:25	117:5	108:11,13
144:18	36:12	205:18,19	135:14	110:11
153:22	37:13	220:12	184:16,20	<b>best</b> 15:9
154:18	40:13,15	228:3	209:12	84:10
156:21	40:22,24	230:8,16	239:5,7	217:3
157:6	43:5,22	230:17	264:22	316:2
<b>Bates</b> 52:22	44:15,21	247:22	271 <b>:</b> 1	357 <b>:</b> 16
54:3 64:24	45:15,22	249:13	285:24	358:23
<b>Baton</b> 2:21	46:15	250:18	291:20	360:9
<b>bats</b> 42:14	57 <b>:</b> 19	254:25,25	292:16	Bethesda
43:1 58:1	63:22 <b>,</b> 23	256:21	293:15	1:11,19
198:16	66:2 <b>,</b> 20	258:1,14	337 <b>:</b> 5	4:24 9:12
<b>began</b> 317:5	67:5,6,16	259:1,14	338:7	<b>better</b> 12:4
351:22,23	72:12	265:12	343:20	58:23
beginning	73:11 75:4	269:4	349:16	79:17
31:24 32:1	75:8,8,15	276:20	352 <b>:</b> 15	260:4
32:4 34:4	75:15 76:2	277:12	benefit	352 <b>:</b> 24
34:4,14,15	77:4 78:4	278:19,20	15:15,17	354 <b>:</b> 11
101:12	78:19 80:4	278:21	221:5,8	beyond
121:11	81:8,20,23	279:21	225:3,13	122:22,23

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

358:14	353:6,8	52 <b>:</b> 23	271:22	132:11
Bhattach	blaming	72:23	briefly	136:13
2:25	102:21,21	75:11	167:18	137:5,6
251:18	106:4	86:19,20	212:19,20	144:24
256:4	blanks	115:11	271:2	145:16
267:20	294:22	163:23	328:4	211:22
279:4	blathering	164:4	bring 44:9	284:25
291:15	74:4	179:12	165:15,20	288:15
Biden 1:8	<b>blind</b> 244:10	201:20	bringing	<b>bunch</b> 226:2
9:7 10:16	246:12	252:8	64:4 257:6	229:1
344:11	<b>blob</b> 338:16	272:20	337:4	295:2
361:7	338:17	275:15	brings 303:6	311:8
362:2	<b>block</b> 152:9	284:25	<b>broad</b> 24:7	321:9
<b>big</b> 22:25	303:11	298:22	24:11,23	330:14
235:4	308:5	305:3	118:24	buried
351:21	324 <b>:</b> 21	337:8,11	132:19	280:23
<b>Bill</b> 104:11	blocking	bought 316:4	140:17	<b>Burkes</b> 305:4
202:2,2,10	340:6	Box 3:15	309:1	Burkholtz
202:11,19	<b>blog</b> 7:8	Boy 109:10	<b>broker</b> 103:6	305:4
202:20	182:5,12	Branch 4:21	brought 30:9	<b>Burns</b> 3:13
338:22	182:14,17	<b>break</b> 83:16	30:9 31:17	3:14
<b>Billet</b> 38:9	184:2,12	130:10	39:3 42:21	Burwell
301:16,17	184:15,17	148:6	46:2,19,20	313:6,9
309:2	184:19	149:24	46:23 58:2	317 <b>:</b> 22
324:10	186:2,21	203:17	141:4,7,9	<b>busy</b> 191:22
327:2,8,12	bluntly	253:4,5,6	184:10	191 <b>:</b> 23
billion 72:1	260:2	312:23	208:12	195:14
260:18	board 351:11	323:24	209:21	276:11
Bio 174:14	351:14 <b>,</b> 15	Breitbart	239:3	<b>buy</b> 314:12
Biohub	<b>Bob</b> 35:12,14	7:20,21	256:11	317 <b>:</b> 23
133:11,12	50:24 51:5	232:16,20	293:23	321:9,25
133:13	51:6	234:3	<b>BSL-2</b> 116:15	buying
biological	<b>bodies</b> 169:7	240:6	117:10,12	320:20
143:6	<b>body</b> 39:8	Breitbart's	117:14	buzz-buzz
145:21	103:2	240:17	118:9,20	78:21
146:2	107:8	Brennan	119:8,9	
biology	<b>bold</b> 288:15	218:21	<b>BSL-3</b> 117:23	C
15:11	bolded	<b>Bret</b> 190:5	Budget 22:1	<b>c</b> 3:13 6:1
biosafety	121:11,14	190:13	22:2	9:1
16:22,22	booster	228:24	building	calendar
Birrel	359:8	briefed	1:19 4:23	6:25 66:23
212:25	<b>booted</b> 336:3	59:12 71:3	165:8	67 <b>:</b> 2
213:2,6	<b>bother</b> 236:2	briefing	300:9	148:19
<b>bit</b> 26:24	236:13,22	39:3 43:6	308:8	149:10
78:6	236:23	196:25	<b>bull</b> 110:1	California
188:23	<b>bottom</b> 23:3	197:11	bullet	133:15
197:23	23:6,8,9	201:4	110:14,18	174:17
200:24	26:20	202:13	130:20	<b>call</b> 10:24
228:7	47 <b>:</b> 25	208:1	131:2,18	34:18,22
			l	

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

35:9 43:20	131:3,8,13	118:13	361:10	332:6 <b>,</b> 17
44:2,3,8	131:16	138:17	362:2	CDC's 331:3
44:14,18	135:23	205:25	cases 153:25	ceased
45:24	136:14	269:19	154:20	359 <b>:</b> 23
46:13,21	161:8,12	287:5	casual 21:18	<b>cell</b> 58:17
51:20	161:13	289:17,19	260:6	59:1
58:19 59:1	173:19	290:14	casually	178:10
59:22 60:1	175:13	capacity	338:5	203:1
63:10,13	205:9	12:19	<b>cat</b> 144:18	censor
63:16,20	277:13	18:18	catch 84:18	232:17
64:6,11,13	325:23,24	25:19	84:22	239:11
66:16,18	355:22	Capitol	256:22	censored
66:23 67:4	<b>called</b> 1:14	232:18	catching	208:2
73:21	10:3 13:15	234:22	210:4	280:2,3,13
74:20 75:3	18:5 20:11	caps 300:14	categori	280:17
75:5,10	33:14	caps 300.14 care 17:11	24:12	282:10
77:1,2,4	37:25 61:2	165:9	categorize	censoring
77:1,2,4	62:22	231:13	194:14	280:6
78:10,23	123:10	237:13	categorized	281:23,25
79:5,24	126:24	302:2	276:19	281:25
80:18,22	226:1	careful	category	282:18
81:17,18	227:15	11:14	207:17	Censors
82:14,18	248:21	13:11	338:25	212:21
83:3 85:5	250:7	80:12	Catherine	<b>center</b> 1:19
85:8,20	261:24	177:5	330:19	4:22 9:12
86:8,13,16	271:22,24	320:14	<b>cause</b> 217:7	143:7
86:17	272:13	carefully	225:3	244:17
87:23 88:2	283:25	18:16 78:7	caused	293:5
89:10 90:9	286:14	80:11,25	219:13	324:22
90:21 91:2	295:20	81:9	causing	centers 35:7
91:5,7,7	305:4	119:12	169:3	230:14
91:11,13	307:20	306:14	182:21	231:17
92:10,13	308:11	<b>cares</b> 237:3	183:13	332:23
92:20,23	309:15	265:23	<b>CBS</b> 347:2	<b>CEO</b> 76:3
92:24 93:2	314:4	Carlos	cc 38:14	286:13
93:5 94:4	328:6,15	296:16	55:5 97:22	293:5
94:6 95:2	calling	Carol 298:23	97 <b>:</b> 25	certain 27:4
95:8,14	348:20	299:8,21	187:16	27 <b>:</b> 24
97:2,3,24	356 <b>:</b> 3	330:12,13	CC'd55:6,9	29:10 30:7
105:21	<b>calls</b> 24:4	330:22,23	55:13	32:9 33:9
109:7,14	24:17	Carolina	CC'ing	33:24
109:22	29:18	32:13,20	204:14	44:21 45:7
110:7	35:21	<b>Carrie</b> 329:9	CDC 299:13	96:2
112:22	41:11 46:4	<b>carry</b> 333:24	306:3,14	134:20
113:22	62:7 87:22	<b>case</b> 1:7 9:8	315 <b>:</b> 21	146:4
115:24	108:18	44:9 114:8	316:19	147:20
120:12	112:23	194:20	330:11,13	154 <b>:</b> 8
123:19	113:16	232:3	330:19 <b>,</b> 25	162:14
124:1	116:20	287 <b>:</b> 15	331:10	177 <b>:</b> 22

LEXITAS LEGAL
Phone: 1.800.280.3376 Fax: 314.644.1334

220:3	298:22	335:24	339:4,17	331 <b>:</b> 15
250:13	305:3	chiefs	Chmura	332:6
275:1	307:18	231:16	205:15,18	City 2:10
285:12	323:25	332:22	<b>chose</b> 306:3	40:23
314:24	324:15	China 34:7	Christian	<b>civet</b> 144:18
323:13	330:10	41:3 42:15	34:21	Civil 3:4
certainly	353:5	42:21 43:1	43:20 44:4	<b>claim</b> 217:9
11:16,22	challenge	57 <b>:</b> 22	44:5,23	247:7
12:8 16:25	258 <b>:</b> 25	59:14,17	45:13,14	285:6,18
22:17,18	259:13	62:21	45:21,21	331:4,15
31:24 33:3	<b>Chan</b> 133:11	63:17,19	45:23	331:16
56:3,15,17	133:11,14	67:15 <b>,</b> 17	46:10 48:3	claimed
64:17	174:7,8,15	67:18 <b>,</b> 22	50:8 60:2	209:10,19
72:12,16	174:16	70:11,18	61:18,20	<b>claims</b> 103:5
74:9 81:22	<b>chance</b> 166:4	71:4,24	74:25 81:8	103:9,22
83:4 91:4	change 52:9	138:15 <b>,</b> 22	81:22 84:6	104:19
102:5	318:16	138:24	170:14	182 <b>:</b> 20
106:5,12	362:7 <b>,</b> 11	139:6,10	195:24	183:12 <b>,</b> 17
124:22	362:15 <b>,</b> 19	139:11,13	196:9	211:5,6,12
133:22	362:23	139:22	CHRISTOPHER	211:22
134:25	changed	163:13	4:18	214:1,4,7
147:19	211:25	164:22	Christop	214:25
152:14	316:21,21	165:13	4:25	215:3,23
156:2	317:11	167:23	chronology	217:2
161:1	changes	198:3	283:20	285:2
170:4	172:9	261:11,18	circle 150:8	331:4
177:25	361 <b>:</b> 12	261:23,24	circulate	332 <b>:</b> 7
225:8	363:7,10	262:12,20	248:18,20	333:15
229:16	channel	263:3	274:6	Clara 293:12
259:25	177:21	Chinese	276:22	293:18
265:12	characte	102:21	277:1	clarified
281:18	121:2	106:4	circulated	134:3
282:19	characte	143:5	205:20	clarify
345:10,25	20:17 42:9	157:17	circulating	11:18
356:13	characte	164:7,11	31:7 157:6	44:12
certainty	334:2	165:7	250:13	283:1
96:3	chat 98:9,21	166:1	274:22	344:7
CERTIFICATE 360:1	chatting 84:24	167:3,5,7 168:8	circumst	clarity 11:15 17:8
certify	85 <b>:</b> 13	192:24	144:16	17:14
360:6	check 91:12	193:11	circumst	65:18
363:5	check 91:12	194:18	154:1,10	Clarke 328:6
cetera 39:23	341:23	209:9,17	154:17,21	328:7,9,10
162:13	343:12	209:25	154:17,21	329:20,25
chain 94:10	<b>chief</b> 10:15	Chinese	161:16	336:19,20
115:7	10:17 38:3	98:17	citations	<b>clause</b> 27:25
123:6	38:23 47:2	<b>chip</b> 104:12	203:11	cleaner
170:13	75:14,16	106:14	<b>cities</b> 166:5	123:15
266:8	76:4	338:23	citing 102:4	<b>clear</b> 17:16
	<del>-</del>		9	
		•	•	•

LEXITAS LEGAL Phone: 1.800.280.3376

21:20	190:20	51:13 52:1	collection	269:16
80:15 87:5	216:5,12	52:7,16	84:3	270:11,15
121:8	253 <b>:</b> 25	closer 81:1	Collin	271:13
137:21	254:15,18	81:2	262:11	272:1,4,16
144:3,13	259:21	closest	Collins	272:25
144:17	260:21,25	70:17	13:14 15:7	273:16,25
162:11	260:25	<b>cloth</b> 321:18	66:15 67:6	275 <b>:</b> 3,13
174:13	261:6,10	<b>Club</b> 174:14	67:9,12,14	281:1
179:4	261:17	<b>clues</b> 49:16	67:20 68:1	295:14
184:20	262:11,18	50:3	75:5 82:23	Collins'
215:2	262:19	cluster 31:7	84:8 89:22	279:12
229:19	263:2	39:14	91:1 92:3	Collins's
232:3	266:9	132:4	93:5,11	269:22
273:25	Clifford	<b>CNBC</b> 8:5	94:2,11,21	Columbia
302:16	139:15	<b>CNN</b> 341:5	108:2	40:12,24
309:18	clinical	342:10,17	109:15,23	<b>column</b> 179:6
316:22,25	165:6	343:2	110:11	<b>come</b> 14:5,20
317:3	214:10,12	coauthor	111:18,24	22:20 78:7
345:7	216:6,14	13:14,19	115:8	81:3,6
353:22	216:15	Coauthored	116:14,18	107:4
clear-cut	217:10	56 <b>:</b> 7	120:4	122:5,11
217:10	221:1	coauthors	121:20	122:13
clearcut	224:10,12	35:18	123:8	129:25
225:10	227:9	56:23	125:9	133:3
clearly 21:4	231:9	<b>Cohen</b> 49:6	126:23	143:17
60:25	247:5	49:16 50:9	131:8	144:9,11
82:25	260:25	61:18,24	159:16	145:8,11
121:15	261:2,3,7	62:14	162:18	146:3
132:16	324:20	cohorts	163:5	149:16
152:3	333:1	42:14 43:1	170:15	168:16
180:4	353:20,24	cold 138:6	171:9	202:25
188:9	354:15	collabor	182:6,13	219:1,10
189:9,16	clinician	37:6,10	182:19	245:1
194:17	166:24	collabor	184:1	247:6 248:2
197:20 225:3	clinicians 216:13	37:8 58:24 collabor	186:11,19 187:3,16	248:2 264:24
263:22	clip 341:16	59:13	188:3	268:13
276:6	341:25	collabor	189:18,20	293:22
322:16	342:3	37:11	190:15	305:24
323:6	343:21	42:17	193:22	320:5
358:16	<b>close</b> 39:13	collater	199:3	323:15
<b>click</b> 255:7	76:17	17:3	200:22	comes 107:13
284:13	84:24	colleague	253:24	142:11
client	85:16	252:24	254:5	207:13
299:10	86:19,19	colleagues	257 <b>:</b> 15	221:7
Cliff139:1	108:13	40:9	258:7	coming 145:5
139:25	312:1,2	339:22	262:19	164:22
163:18	322:5	collect	266:9	219:23
167:19	closely	214:17,18	268:20	comment
	_	<u>'</u>		

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376

143:23	communic	287:4,10	343:9	151 <b>:</b> 16
172:20	167:2,5,7	287:16,25	compatible	217:12
193:15	186:11,15	306:23	70:25 78:2	285:11
199:19	285:25	308:16,18	81:14 82:1	concern
233:15	296:4	308:21,22	82:25	34:23 35:2
245:3	347:13	309:2,21	126:14	35:10
		•		
260:6	communic	310:3,11	139:19	43:18 46:2
344:24	153:17	310:15	267:6	51:19
357:24	communic	324:3,11	competent	52:10,13
358:2	96:15	324:19,25	139:17	52:18
commentary	186:7,9	325:9,11	complaining	62:23 63:8
202:22	237:25	325:23	335:6,9	67:13,13
203:1	238:2,4,7	326:1 <b>,</b> 9	completely	70:21 71:5
266:14,15	238:10,12	327:3,9,11	59 <b>:</b> 20	71:14
commented	238:17,23	327:13,16	80:16	78:10,20
187:3,4	239:4	328:11	101:13,24	79:13 <b>,</b> 15
commenting	265 <b>:</b> 4	336:1	113:8	80:5,9,13
347:2	290:17	347 <b>:</b> 4	145:2	80:15 <b>,</b> 16
comments	300:19	351:10 <b>,</b> 16	207:12	81:12,13
114:13	327 <b>:</b> 22	community	288:7	110:25
120:16	328:21	28:9,10	completing	155:3,12
124:23	347:8	58:1 169:2	359:20	195:11
160:10	communic	170:7	complicated	217:1
172:2,6,13	38:11 83:9	175:5	120:19	228:13
172:20	96:17	216:1	124:13	321:22
201:3	110:5	217:1	component	concerned
207:25	147:4	230:7,21	122:14	59:16 <b>,</b> 19
207:25 219:1,10	147:4 255:22	230:7,21 230:25	_	59:16,19 103:8,15
	255:22 268:14		122:14	· ·
219:1,10	255 <b>:</b> 22	230:25	122:14 267:4	103:8,15
219:1,10 227:14	255:22 268:14	230:25 231:1,5,15	122:14 267:4 273:10	103:8,15 103:18
219:1,10 227:14 233:4,5	255:22 268:14 301:2,5,13	230:25 231:1,5,15 248:19	122:14 267:4 273:10 compound	103:8,15 103:18 104:3,14
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10	230:25 231:1,5,15 248:19 259:10 269:3 273:3	122:14 267:4 273:10 <b>compound</b> 154:23 281:3 334:12	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9
219:1,10 227:14 233:4,5 341:4,9 343:2,16	255:22 268:14 301:2,5,13 302:14,16 304:21	230:25 231:1,5,15 248:19 259:10 269:3	122:14 267:4 273:10 compound 154:23 281:3	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10	230:25 231:1,5,15 248:19 259:10 269:3 273:3	122:14 267:4 273:10 <b>compound</b> 154:23 281:3 334:12	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies	122:14 267:4 273:10 <b>compound</b> 154:23 281:3 334:12 347:6	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7	122:14 267:4 273:10 <b>compound</b> 154:23 281:3 334:12 347:6 356:10	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24 commissi	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 communic	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10
219:1,10 227:14 233:4,5 341:4,9 343:2,16 <b>commission</b> 360:22 363:24 <b>commissi</b> 347:1	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 communic 38:6 72:7	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24 commissi 347:1 common 38:22	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 communic 38:6 72:7 82:5,13,17	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18 270:23	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3 comprised	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11 236:3
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24 commissi 347:1 common 38:22 166:18	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 <b>communic</b> 38:6 72:7 82:5,13,17 83:2,6	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18 270:23 344:18	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3 comprised 247:25	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11 236:3 274:20
219:1,10 227:14 233:4,5 341:4,9 343:2,16 <b>commission</b> 360:22 363:24 <b>commissi</b> 347:1 <b>common</b> 38:22 166:18 245:22	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 communic 38:6 72:7 82:5,13,17 83:2,6 96:20	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18 270:23 344:18 company	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3 comprised 247:25 conceivable	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11 236:3 274:20 303:8
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24 commissi 347:1 common 38:22 166:18 245:22 communicate	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 communic 38:6 72:7 82:5,13,17 83:2,6 96:20 99:16	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18 270:23 344:18 company 151:22	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3 comprised 247:25 conceivable 184:12	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11 236:3 274:20 303:8 310:16
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24 commissi 347:1 common 38:22 166:18 245:22 communicate 186:5	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 <b>communic</b> 38:6 72:7 82:5,13,17 83:2,6 96:20 99:16 125:12	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18 270:23 344:18 company 151:22 286:9	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3 comprised 247:25 conceivable 184:12 191:6	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11 236:3 274:20 303:8 310:16 312:20
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24 commissi 347:1 common 38:22 166:18 245:22 communicate 186:5 290:11	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 communic 38:6 72:7 82:5,13,17 83:2,6 96:20 99:16 125:12 147:2	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18 270:23 344:18 company 151:22 286:9 335:3,20	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3 comprised 247:25 conceivable 184:12 191:6 concentrate	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11 236:3 274:20 303:8 310:16 312:20 concerning
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24 commissi 347:1 common 38:22 166:18 245:22 communicate 186:5 290:11 295:23	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 communic 38:6 72:7 82:5,13,17 83:2,6 96:20 99:16 125:12 147:2 180:22,23	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18 270:23 344:18 company 151:22 286:9 335:3,20 compared	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3 comprised 247:25 conceivable 184:12 191:6 concentrate 191:1	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11 236:3 274:20 303:8 310:16 312:20 concerning 266:16
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24 commissi 347:1 common 38:22 166:18 245:22 communicate 186:5 290:11 295:23 296:18	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 communic 38:6 72:7 82:5,13,17 83:2,6 96:20 99:16 125:12 147:2 180:22,23 213:7	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18 270:23 344:18 company 151:22 286:9 335:3,20 compared 263:5	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3 comprised 247:25 conceivable 184:12 191:6 concentrate 191:1 243:17	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11 236:3 274:20 303:8 310:16 312:20 concerning 266:16 295:12
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24 commissi 347:1 common 38:22 166:18 245:22 communicate 186:5 290:11 295:23 296:18 301:18	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 <b>communic</b> 38:6 72:7 82:5,13,17 83:2,6 96:20 99:16 125:12 147:2 180:22,23 213:7 264:25	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18 270:23 344:18 company 151:22 286:9 335:3,20 compared 263:5 322:15	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3 comprised 247:25 conceivable 184:12 191:6 concentrate 191:1 243:17 312:5	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11 236:3 274:20 303:8 310:16 312:20 concerning 266:16 295:12 concerns
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24 commissi 347:1 common 38:22 166:18 245:22 communicate 186:5 290:11 295:23 296:18 301:18 325:11	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 <b>communic</b> 38:6 72:7 82:5,13,17 83:2,6 96:20 99:16 125:12 147:2 180:22,23 213:7 264:25 268:8,11	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18 270:23 344:18 company 151:22 286:9 335:3,20 compared 263:5 322:15 comparing	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3 comprised 247:25 conceivable 184:12 191:6 concentrate 191:1 243:17 312:5 concept	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11 236:3 274:20 303:8 310:16 312:20 concerning 266:16 295:12 concerns 34:13 79:1
219:1,10 227:14 233:4,5 341:4,9 343:2,16 commission 360:22 363:24 commissi 347:1 common 38:22 166:18 245:22 communicate 186:5 290:11 295:23 296:18 301:18 325:11 326:15,24	255:22 268:14 301:2,5,13 302:14,16 304:21 312:10 326:15,19 330:1 communic 38:6 72:7 82:5,13,17 83:2,6 96:20 99:16 125:12 147:2 180:22,23 213:7 264:25 268:8,11 270:22	230:25 231:1,5,15 248:19 259:10 269:3 273:3 316:6,24 359:7 companies 269:18 270:23 344:18 company 151:22 286:9 335:3,20 compared 263:5 322:15 comparing 246:6,10	122:14 267:4 273:10 compound 154:23 281:3 334:12 347:6 356:10 compounds 281:3 comprised 247:25 conceivable 184:12 191:6 concentrate 191:1 243:17 312:5 concept 25:19	103:8,15 103:18 104:3,14 105:18,23 106:1,7,8 188:9 189:13 225:11 228:10 235:11 236:3 274:20 303:8 310:16 312:20 concerning 266:16 295:12 concerns 34:13 79:1 89:5 96:17

LEXITAS LEGAL Phone: 1.800.280.3376

				_
102:14	85:5 86:8	247:1	123:19	construct
118:18	86:13	confused	334:4,9	121:16
198:2	87 <b>:</b> 22	26:10	conseque	122:1
274:22	90:12 91:2	33:10 53:2	88:19	162:1
conclave	94:4,6	53:22	conserva	180:5
108:3,16	105:21	61 <b>:</b> 25	341:16,25	181:9
108:22	112:22	200:24	consider	185:23
109:11	120:12	233:11	103:3	consult
conclude	149:14	243:2	123:20	247:22
288:20	199:15	299:3	consider	272:4
concluded	201:8	306:21	195:11	273:18
219:12	204:11	confusing	216:21	318:12
concludes	217:24	16:10	258:5	consulted
185:22	218:3	17:15	consider	220:17
conclusion	229:9	245:11	333:25	273:24
78:8 81:1	230:8	246:23	consider	consulting
81:4,7,11	232:19	Congratu	316:18	268:15,16
82:24	234:5,8,9	11:2	321:11,24	307 <b>:</b> 7
121:19	234:21	Congress	considered	contact
122:5	240:7	31:19	28:15 30:1	95:20 96:5
162:5,15	359:5	82:21	46:16	130:21
162:16,23	conferences	congress	consistent	140:20
163:1	198:24	39:2	56:3,15,17	162:13
165:18	200:3,5,15	connect	56:19	165:8
166:16,21	confidence	324:25	71:21	186:19
180:9,12	73:16,22	325:8	91:10	187:1
180:19,20	74:8,13	connected	126:13	291:11
180:24	88:8,11	75 <b>:</b> 9	160:3	301 <b>:</b> 5
181:5,6,8	123:13	connecting	198:18	307 <b>:</b> 8
195:9	124:6	202:17	199:22,23	contacted
247:6	confident	connection	200:9	151 <b>:</b> 21
248:2	190:7	20:3,18,25	219:20	186:25
conclusions	confiden	115:24	consiste	202:17,18
288:25	7:6 8:11	117:25	246:8	contacting
320:13	8:12,13,14	244:8	247:18	95:25
concrete	8:15,16	269:22	consisting	contacts
16:18	178:14	274:15	287:5	269:17
condition	confiden	291:20	conspiracy	contain
242:1	73:24	294:23	78:12	166:2
conditions	configur	296:20	143:18,19	containment
15:3,19	34:23	338:4,6,15	143:19	117:2
118:11,20	82:25	351:17	185:22	content
119:9 conducted	confirmed 311:17	connections 227:25	188:16,21 188:25	21:17 100:5
9:11 30:4	conflate	271:25 272:11	188:25	152:9,9
274:10	157:13	cons 81:10		208:16
conducting	conflating	358:4	193:23 194:1	212:1
15:4	157:4	consensus	constitutes	241:15
conference	confounding	80:18	147:11	270:12,16
COULTELEUGE	Controunding	00.10	<u> </u>	∠ / ∪ • ±∠ <b>,</b> ± ∪
	1	<u> </u>	ı	I

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

283:1	contribu	152 <b>:</b> 6	324:10	correct
290:5	345:14	181:1,4	330:22	14:23 33:7
292:8	contribu	287:25	core 131:3	41:5,21
301:7	133:25	289:13	Cornell	48:5 51:17
306:18	control 35:7	292:3,4,7	231:18	54:19,21
contest	164:22	327:21	corner	54:23
258:20	165:15,21	352:9	272:20	56:21,25
contested	168:6,17	convoluted	coronavirus	58:14,17
358:6	246:7,11	334:14	18:6,8,12	60:23
context	246:21,22	cooler169:6	22:14 34:7	61:15
12:22	246:24,25	cooperation	41:3,4,10	68:14
14:23,25	247:2,15	102:22	41:15	77:13 84:6
15:6 29:25	248:9	Coopman	42:21	84:7,18
31:18	controlled	97:23	49:16	85:2,3
47:19	167:24	coordinate	59:18	86:5 88:8
116:23	211:24	279:16	60:14	90:23,24
126:5	controlling	coordina	70:20	92:4,15,17
128:8	168:2	279:22	72:14	93:12
129:23	262:1	coordina	132:10	94:11,22
134:8,16	controversy	279:24	143:7	95:3,4,11
134:16,20	213:21	copied	145:19	98:11
135:5,10	convene	128:16	154:18	106:24
145:9,12	106:24	153:3	182:21	109:9
149:13	107:7	160:13	183:13,18	111:21
150:13	109:16	190:21	190:7	112:16,19
153:11	convened	260:21,24	196:25	112:20
156:16	107:17	261:7,19	197:6,9	113:9
158:13	131:9	308:11	201:25	115:9
169:4	convening	<b>copies</b> 17:25	204:11	118:4
173:25	103:2	96:13	208:1	121:17,18
174:16	111:21	110:11	209:10	123:16,17
252:22	126:8,15	114:9	211:12	123:21
256:13	126:16	138:11	214:2,9,15	124:5
334:25	137:23	205:14	215:24	125:10
343:7	conversa	361:9	218:7	126:25
continue	163:4	copy 119:22	227:11	127 <b>:</b> 2
27:24	168:4	159:15	229:10	128:14,21
102:23	180:14	182:5	232:18	128:23
continued	213:11	185:15	271:9	129:2,6
224:2,6	255:22	201:25	278:3	130:18,22
continuing	258:15	237:18	306:1	130:23,25
224:8	263:1,2	249:1,10	321:1,12	131:21
contradict	289:6,9	253:25	336:9,18	133:2
322:6	291:14,24	283:15	344:15	143:9
contrary	292:2,8	284:16	coronavi	144:3
343:14	302:5	330:23	67 <b>:</b> 22	146:23
346:13	conversa	346:17	coronavi	149:3,4
contribute	140:20	361:12	31:8 33:16	150:11,15
288:21	147:6,7,8	copying	37:4 39:24	160:15,16
	, ,	•••		,
	=	=	-	-

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

161:5,9	233:3,6,10	327:3	94:13	13:3 23:3
162:2,3	233:24,25	328:16	96:12	28:25
163:20,21	234:11,16	330:12,22	119:21	29:24
164:12,25	235:8	330:25	120:25	30:12 34:9
165:1,16	237:13	331:1,6,20	127:17	34:11
165:17,21	240:7	335:24	138:10	52:17
166:11,15	242:23	341:5,17	144:25	61:12 71:1
167:1,20	243:24	341:18	145:23	129:3,5,7
167:21,24	245:20,23	342:11	148:5	141:23
168:24	246:1	344:15	150:24	153:12
171:3,4,5	249:25	348:11,15	178:6	205:10
171:6,10	250:8,21	348:25	209:14	212:5
172:4,5,10	252:12	350:20	294:18	219:20
173:4,9,10	254:7,13	357:11,18	346:17	225:16
177:3	254:14,16	358:24	360:11,14	242:21
179:19	254:17,21	363:9,13	count 53:25	295:11
180:6	254:22	corrections	counter 78:1	313:18
183:19,20	262:24	361:12	260:20	314:4
183:25	263:25	correctly	357:7,16	course 93:5
186:3,4	264:4,8,9	70:5	358:23	136:1
188:17	264:11	143:14	359:9	247:17
190:8,17	266:10,22	correspo	countera	court 1:1
190:22	268:3,6,7	205:21	257:25	9:10,24
192:7	271:10,11	correspo	258:24	12:10
193:24	273:4,12	195:24	259:2	17:23
194:14,25	275:24	CORY 5:2	countering	26:23
196:2,3,6	276:14	cosignature	357:8	60:18
196:12,16	278:1,5,6	257:9	counters	74:15
197:1,9,10	278:14,15	cost 167:24	107:4	150:22,24
197:12	279:14	168:2,6	countries	225:19
198:3,6,19	284:4,5	coughs	140:7	227:19
199:5	286:15	314:16	country 46:8	228:2,7
200:19,23	288:16,22	counsel1:14	117:15	230:9
203:15	288:23	4:19 6:2	170:2	234:23
204:8,9,12	295:6	9:16 10:3	216:13	236:21
204:16,17	299:11,19	10:6 12:15	230:15	courteous
206:22	300:16	14:8 17:25	231:15,18	171:17
209:10	303:13,19	26:13,24	231:20	172:21
211:13	303:25	42:1 43:11	232:11	Courtney
212:22	304:14,16	47:18	248:1	38:9
218:7,10	306:4	52:24 53:1	276 <b>:</b> 25	301:16,17
218:11,14	309:9,10	54:2 60:18	297:19	301:23
218:15,17	309:13,18	65:19	298:4	309:2
219:14	311:19	68:15	321:22	324:10
222:12,22	317:8,15	69:10 73:2	332:22,23	327:2,8,12
223:21	317:19	74:15	County	327:21
227:12,13	320:1,24	76:16	293:12,18	CoV 23:5,11
229:11	324:5,11	90:10	363:3	39:15
231:10	324 <b>:</b> 12 <b>,</b> 16	93:22	couple 11:1	<b>cover</b> 182:10
			_	

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376

	_	_		
182:11	create 15:5	65 <b>:</b> 10	40:10 41:2	243:7
coverage	24:24	347:1	117:8	286:25
185:3	78:21	Curry 101:5	129:10,21	344:5
covers 22:25	created	101:5	130:2	362:3
COVID 40:17	156:13	cursorily	140:20,25	<b>dated</b> 72:24
42:16	creating	240:1	141:17	148:19
188:20	310:10	curtail	146:7,13	152:22
213:9	creation	166:18	146:16,22	159:3
224:7,25	59:18	curtailing	147:2,10	167:19
226:2	credentials	262:8	204:4,24	173:11
236:4	279:6,7	curtailment	205:1	176:4
275:17	credibility	151:17	206:5	186:1
331:5,9	137:24	<b>cut</b> 211:20	207:16,19	197:1
354:2	credit	cuts 356:13	data 37:2,9	204:4,4
355:5,5,9	177:18	cutting 42:2	37:15 80:4	222:8
COVID-19	credits		80:6,10,11	242:19
31:25	177:11	D	126:16	253:19
163:12	criteria	<b>D</b> 2:5,7 9:1	189:2,7,12	263:12
170:18	221:3	222:4	191:16	271:5
173:14	<b>critic</b> 336:2	<b>D.C</b> 3:7 4:3	193:8	277 <b>:</b> 25
175:20	critical	361:6	215:1,3,17	294:10
184:3	27:24	<b>damage</b> 258:5	215:23	298:24
185:22	280:24	Dan 135:8	217:2,2,9	341:1
196:18	295:5	danger 117:1	217:10,25	344:4
210:17,24	348:8	323:7	218:13	dates 22:23
211:23	criticism	dangerous	219:17	44:17
212:1	296:23	14:6,20,24	220:25	233:11
213:23	297:4	15:2,5,23	221:7	317:20
219:13	criticize	17:3 24:1	223:16	322:9
237:20	343:5	271:25	236:25,25	daughter
245:20	criticizing	272:6,13	237:4	100:1,2,22
284:3,20	212:22	272:14	247:2	350:21
306:4	244:15	273 <b>:</b> 12	259:12	351:9
313:19	279:18	274:2,9	320:1	<b>David</b> 204:14
318:6	Cross 299:8	276 <b>:</b> 18	323:13,17	204:18,18
331:23	culture	278:4,14	337:15	204:20,21
332:3	281:25	278 <b>:</b> 25	343:9	day 44:15
347:3	<b>curb</b> 151:13	306:19	353:8	46:21
353:11,23	curious	307:9	354 <b>:</b> 5	51:21 59:1
358:8	102:13	356 <b>:</b> 20	databases	59:4 61:6
<b>CPAC</b> 341:17	237:19	357:6 <b>,</b> 20	158:11	63:20 66:3
341:22	current	Daniel 9:14	<b>date</b> 58:11	66:24
342:1	10:11 48:5	dark 59:21	73 <b>:</b> 12	67:13 <b>,</b> 14
Crawford	49:22	<b>Daszak</b> 20:11	199:13,13	67 <b>:</b> 20
298:23	50:11	20:13,15	199:14,15	85:10 86:8
299:22	61:23	21:8,16,21	218:10	105:21
330:12,13	291:23	35:17 36:2	231:25	109:3,11
330:22,23	313:11	36:14 37:1	232:23,25	127:5
<b>CRC</b> 308:12	currently	37:6 39:22	233:2,12	148:23
			,	
	-	-	-	-

LEXITAS LEGAL
Phone: 1.800.280.3376 Fax: 314.644.1334

153:13	dean 291:3,4	220:18	declare	demonstrate
174:3	Dear 170:25	224:23	363:12	225:7
186:2	361:8	238:1,13	decrease	demonstr
192:4	<b>death</b> 169:4	239:10	116:6	167:23
199:3	274:4	319:24	<b>deep</b> 256:15	demonstr
200:22	278:24	decisions	deeply	121:15
204:8,10	297:8	333:7	265:23	DENNIS 5:2
206:20	345:11,15	declaration	Defendant	denominator
207:1	346:11	7:24	1:14 3:20	236:8
212:8	deaths	248:14,16	4:7,16	denounced
233:4,22	276:24	248:17	defendants	271:23
238:19	343:10	249:2,10	1:9 9:23	272:12
260:18	355:23,24	249:12,15	define 16:7	Department
269:14	debate	249:18,19	definitely	2:19 3:20
275:21	319:11,15	250:1	142:7	4:1,7,10
359:4	319:18,23	251 <b>:</b> 4	217:22	9:22
363:14	322:17,19	252:18	definition	313:10
days 34:9,11	322:21	254:6,12	265:25	361:5
52:17	358:6,9,13	254:24	339:8	depending
60:15 85:5	358:13,14	255:4,14	definitive	279:24
161:15	debating	256:10	16:19	depends
179:19	77:11	258:2,11	121:24	117:15
207:2,2,3	deboosted	259:23	215:2	159:22
219:1,10	280:21	260:15	218:1	246:24
222:7	281:9	264 <b>:</b> 7	322:12	265:21,25
242:21	<b>debunk</b> 244:6	266:10	definiti	323:5
254:6	332 <b>:</b> 7	267:1,4,5	219:21	deposition
279:11	333:13	267:7	degree 74:2	1:13 9:5
343:24	debunked	268:6,23	96:3	9:11 11:3
344:4	211:6,12	269:4	165:14	12:19,22
361:17	211:22	274:1	degrees	13:2 47:7
<b>DC</b> 234:5	debunks	276:4,17	175:1	356:15
267:22	183 <b>:</b> 17	277:6	<b>del</b> 296:16	359:23
deactivated	264:3	278:22	<b>delay</b> 245:15	360:5,7,12
330:3	decade	279:19	deleterious	361:9
Deactiva	265:17	280:1,13	216:25	363:6,8,11
328:17	decades	280:17,21	deliberate	<b>deputy</b> 29:2
<b>dead</b> 169:7	291:9	280:23	189:9	29:12
<b>deadly</b> 346:3	December 6:8	281:9	delibera	30:18,20
<b>deal</b> 21:19	13:20 34:8	282:11	106:5	30:25
dealing	34:10	283:2	194:9	54:25
33:18	decide 64:7	285:7 <b>,</b> 10	339:15	57:18 65:9
88:17	109:1,3,5	290:10,19	delibera	261:1,6
117:11,21	122:16	291:12	27:23 96:6	300:2
136:21	deciding	292:11	113:5	DeRisi
140:5	122:20	295:6	delibera	133:10
169:25	289:1	296:19,24	25:25	134:13,23
<b>deals</b> 175:9	decision	297:6,10	demanded	135:6,13
<b>dealt</b> 175:9	169:13	297:16,23	335:2	DeRisi's

LEXITAS LEGAL Phone: 1.800.280.3376

				. 1
135:14	details 6:10	122:14	66:15	discovery
describe	19:10	128:22	70:15	287:15
57:1,6	90:12	155:20,20	72:18 75:6	357:15
155:22	280:19	160:5,5	76:3 91:5	discredit
156:15	determin	177:21	95:6,9,17	79:2
278:10	16:6	207:11	97:5 108:5	discuss
described	119:13	295:3	134:4	44:11,19
33:14	121:25	304:2	162:21	88:24
38:15 57:7	231:20,24	322:20	182:6,19	89:14
82:15	determine	338:13	216:6,14	100:5,8
174:11	70:23	difficult	216:14	131:8
188:19	80:12	169:16	261:1,1,7	149:19
193:22	156:5	digital	271:25	162:19
250:10	determines	329:20	300:3	165:2,23
262:18	28:4	336:17,19	308:1	166:1
342:10	detrimental	diminished	324:19	168:2
describes	358:16	110:3	327:8,12	181:11,14
183:22	devastating	direct 34:3	329:20	181:21
306:18	257:16,19	47:24	336:17,20	195:10
describing	258:10,13	125:18	353 <b>:</b> 1	216:2
57:9	259:23	144:20	director's	231:1
description	develop	145:15	142:8,9,14	258:8
246:11	256 <b>:</b> 15	147:6	142:16	274:21
design	316:16	153:21	182:11,15	276:2
320:17	developed	directed	184:12	291:11
designated	17:8 27:19	152 <b>:</b> 4	186:2	336:23
185:21	developing	directing	300:10	352:6 <b>,</b> 13
desired	351:22,23	48:13	directors	discussed
361:13	354 <b>:</b> 11	direction	30:19	67:12 <b>,</b> 14
<b>desk</b> 22:19	development	1:23 53:19	dis 339:2,4	67:19 <b>,</b> 25
22:20 29:5	189:10	354 <b>:</b> 11	339:6	78:19 79:7
129:25	319:10	360:10	disagree	79:11
245:1	351:17 <b>,</b> 20	directly	214:4	113:21
293:22	351 <b>:</b> 24	36:8 38:8	297:22	121:20
desperately	352:1,3	96:20	298:5	126:17
321:20	354 <b>:</b> 10	126:7	355:14,14	147:11
despite	dialogue	190:12	356:9	151 <b>:</b> 25
224:1	321:19	202:11	disagreed	166:22
destructive	<b>die</b> 169:14	239:5	224:1	181:6,8,16
188:15,20	difference	272:14,16	356 <b>:</b> 1	181:19,22
188:25	157 <b>:</b> 8	288:21	disagreeing	184:24
190:21	246:20	311:15	214:6	193:1
193:23,25	different	director	234:10	195:9
detail 77:24	15:1 58:24	10:13,24	disagrees	196:17
348:23	65:17	10:25 29:1	258:24	216:4,7,18
349:8,14	73:12	30:25 35:7	disconce	221:15
349:16,19	90:11	38:10,17	340:3	222:20
detailed	115:19	38:19 46:9	discourage	231:3
284:20	117:15,25	65:9,10	151:7	255 <b>:</b> 23
	<u> </u>	<u> </u>	<u> </u>	l

LEXITAS LEGAL Phone: 1.800.280.3376

270:21	147:14	46:8,17	344:14	9 <b>:</b> 10
275:5	149:21	166:17,19	345:4,9,13	disturbed
279:23	162:9,22	216:13	345:23	189:11
292:10	162:23	227:12	346:2,5,11	disturbing
297:6	187:5	248:1	357:3,4,17	304:21
321:12	189:9	271:24	358:24	358:17
327:15	216:16,21	272:12	359:10	diversion
349:15	218:19	279:2	dispute	80:7
355:4	219:3	291:2	66:25	diverting
357:4	220:4	332:21	287:24	79:15
Discusses	244:9	333:1	disputes	division 1:3
163:12	293:1	353:9,11	318:20	4:20 9:11
discussing	316:2	354:6	dissemin	30:19
77:11	321:18,19	diseases	88:25	70:15
90:25	328:2	10:14	104:23	70:13
110:24	336:2	46:10,14	150:16	133:23
162:15	340:2	70:16	235:16	216:14
184:22,25	349:7,11	72:19	dissemin	353:2
276:5	349:12	133:24	195:13	doctor
279:17	351:21	142:13	235:9	223:19,23
292:24	discussions	231:15,17	236:3	223:13,23
343:17	29:24	231:19	340:18	224:10,23
345:16	50:23	232:10	dissociated	235:11
352:2,4,17	66:14	332:22	99:5	236:2
discussion	73:20	333:24	103:13	doctors
35:15 48:5	82:17 97:4	disfavored	distancing	223:25
49:23	99:18	285:18	165:15,20	224:5,8
50:11 52:2	104:1	disinfo	166:20	225:18,25
54:10	111:3	337:16	168:25	227:15,16
61:23	137:1	disinfor	169:11,16	228:1
63:23,24	152:3	103:19	169:18,20	229:8
64:1,19	162:4	104:4,10	262:6,14	232:18
73:16,23	163:1	104:16	262:22	234:6,22
74:4 77:17	167:9,11	150:11,14	distant	236:20
78:22,25	168:1	150:19	70:23	238:22
80:17 88:1	169:9	151:3,14	distortion	242:15
95:13,25	191:17	193:17	106:15	243:3
97:1	215:20,25	194:5,10	107:5	document
109:14	262:10,17	194:23	distortions	12:10,21
111:1	262:21	217:7,15	105:17,19	13:9 14:10
113:3	275:3	229:25	105:24,25	14:18
118:24	337:20	235:15	106:13,18	17:18,24
126:6,11	338:10,14	236:4	107:5,14	18:4,7
136:25	338:18,19	337:22	distracting	25:2,7,14
137:17,25	339:21	338:3,11	207:12	25:17,24
138:1,14	340:5,8,13	338:25	distraction	26:15 31:1
138:21,21	343:1,4,22	339:11,14	79:18,22	43:13
141:6	345:3	339:19,24	District1:1	48:12,19
147:11,12	disease 35:7	340:3,9,14	1:2 9:10	48:23
ĺ	•	•	•	•

LEXITAS LEGAL Phone: 1.800.280.3376

				1
E2.20 22	200.11	07.00	110.04	075.0 10
52:20,22	288:11	97:23	119:24	275:3,13
54:5,16	299:2	dosages	134:15,17	278:2
64:21,24	306:8	246:7	139:15	279:4,8,12
68:17	335:15	double	140:5	284:7
69:12	337 <b>:</b> 8	244:10	147:10,15	287:9,18
72:21 73:4	341:13	246:12	148:24	290 <b>:</b> 22
76:20 <b>,</b> 22	347 <b>:</b> 13	double-b	149:6	291:15,18
94:14 96:8	353:19	322:2	150:8	299:1
96:16	documented	<b>doubt</b> 29:3,6	159:16	306:6
97:13 <b>,</b> 20	289:13	32:16	163:5,5,18	309:5,15
105:1	332 <b>:</b> 25	55:15,16	164:1	311:19
110:10	documents	110:4	165:6	313:6
111:9,15	12:16 13:1	184:9	166:16,24	333 <b>:</b> 17
112:2,13	13:3,4,5	198:24	168:4	350:1
114:16	25:12,13	290:15	176:14	353:18
115:17	25:12,13	292:23,24	179:18	354:20
120:3	112:7	downs 81:11	180:10	355:4
123:4	114:21,23	downs 61:11 dozen 63:25	182:12	356 <b>:</b> 3
125:4	114:21,23	dozen 63:23 dozens 200:5	183:4	361:10
126:20				362:1
	doing 11:24	200:5,5	185:6,11	
128:10	13:21	<b>Dr</b> 1:13 2:24	186:11,19	363:5,20
130:14	18:11	2:25,25	187:3,21	<b>draft</b> 114:9
132:23	42:23	6:3 9:6	188:3	120:5,10
136:12	58:10,24	10:2,11	189:18,20	120:14,17
141:16	59 <b>:</b> 25	12:18 13:1	190:15	123:14
142:18	62:21,24	14:9 15:7	193 <b>:</b> 22	124:2,7,9
161:24	70:7 <b>,</b> 18	15:7 17:22	197:14 <b>,</b> 18	124:12,21
163:23	71:23	21:8 25:9	198:1	127:4,8
164:2	132:1	26:14	199:3	128:16,17
173:3	141:17	30:21	200:22	128:20
176:3,11	142:1	37 <b>:</b> 13	201:23	129:1
176:12	152 <b>:</b> 15	38:20	203:24	drafting
178:11	176:19	43:12	211:15	112:22
182 <b>:</b> 17	200:1,2	50:16,23	216:5	203:14
183:5	256:17	51:11	227:2	<b>drafts</b> 114:4
187 <b>:</b> 24	258:5	52:25 53:8	240:12	128:20
197:15,16	260:20	54:15	251:17,17	129:4
206:13	263:5,6	68:16,24	251:18	160:13,17
210:15,25	301:22	73:3 83:14	252:8	196:5
210:15,25	302:13	83:23 89:4	252 <b>:</b> 0 253 <b>:</b> 18	dramatic
226:21	310:12,13	90:11	254 <b>:</b> 5	317:11
227:4	dollars	91:21 93:5	256:4,5	drew 165:18
237:10	177:10,18	94:14	250:4,5	Drive 1:19
	· ·			
267:10	Don 136:2,3	95:21	258:7	4:22 9:12
271:16	donate	96:17	267:20	droplets
272:20	177:18	101:15	270:11,15	314:16
278:7	Dorsey's	110:11	271:13,15	<b>drug</b> 215:4
284:19	240:18	112:1	272:4,25	217:16
287:18	Dorsten	115:5,16	273:16,25	221:4,5,8
	<u> </u>	<u> </u>	<u> </u>	

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

227:1,22	106:9,16	206:9,19	317:22	77:1,6
353:23	108:1	200:3,13	328:12	80:19
354:1,4,9	110:10,15	253:18,24	e-mailing	118:23
drugs 215:16	111:5,17	254:3	200:22	123:18
354:1,2,11	112:4,15	255:5,8	324:6,23	136:13
	114:3	256:18	324:0,23	
drugstore 314:13				140:24 147:16
314:13	115:7,11 115:12	257:4,5 259:17	<b>e-mails</b> 6:13	
			6:14,15,16	161:15
<b>due</b> 46:7	118:3	260:22	6:17,19,20	163:20
duly 1:16	120:3	261:6,20	6:21,22,23	170:19
10:4 360:7	123:6	263:11,24	7:4,5,6,10	174:11
<b>Duvall</b> 303:5	124:16	266:8,13	7:12,13,25	179:19
E	125:8,22	269:1,7	8:1,2,4,10	193:15
	126:22	276:7	8:11,12,13	203:10
<b>E</b> 6:1,6 9:1	127:8,9	277:13	8:14,15,16	217:8
9:1	128:13	294:9,20	8:21 21:14	234:3
e-mail 21:16	130:17,18	294:21	63:12 78:5	250:10
37:25 39:8	130:20,21	295:19	81:19 84:3	252:16
40:6 42:7	131:2	298:22,23	117:4,25	286:8
42:12 48:2	132:4,8,12	299:7	122:7,11	339:10
50:15,16	132:17	305:3,3,9	122:12,15	351:18
50:20	133:18,20	305:10,11	122:15,16	<b>early</b> 22:16
54:20,24	135:20	305:23	130:24	169:5
55:5,7,10	136:12	307:18,20	132:4	246:8
55:13,18	139:22	308:11	137:22	247:16,17
55:24	142:4	309:12	153:13	265:19
56:13	152:21,25	311:12	160:22	293:18
57:18 59:6	153:4,7,9	313:12,22	188:5	313:14
59:7 60:13	153:18,20	315:7	189:19	315:19
61:7,12,24	161:15	323:25	196:6	322:8
62:3 63:1	167:19,22	324:7,13	206:24	325:22
65:2 68:6	170:13,22	324:14,15	207:1,10	easily 232:1
68:9,13	173:3,8,21	327:4	207:11	Eastern 9:4
69:2,5,9	176:3,15	328:5	208:24	<b>easy</b> 206:7
72:3,13,24	187:17	329:11,22	242:5	<b>Ebola</b> 140:8
75:9 84:5	188:2,6,6	330:10,18	263:19	EcoHealth
84:13,16	188:23	331:2	275:21	6:9 18:11
85:12,23	189:3,11	347:23	279:19	19:10,24
86:1,14,19	189:16,19	348:1	287:5	20:4,6
89:20 90:8	190:24	349:5,21	288:4,5	21:22 30:4
90:20 91:6	191:24	353:5	289:24	36:4,9
92:1,2	192:1,5	e-mailed	290:15	58:9,22
93:14,15	195:2	69:23	330:14	Eddie 44:24
94:3,8,10	201:21	92:12	earlier 26:2	45:2,3,9
94:21 98:4	202:2,11	114:4	41:8 43:17	50:24 51:3
101:12	202:18	199:3	50:23	51:4 73:9
102:11	204:3,7,10	295:20	51:20	73:10,10
103:1	205:23	300:13	56:10,24	112:15
105:5,23	206:4,5,7	309:4	60:1,12,15	114:2,5
			<u> </u>	<u> </u>

LEXITAS LEGAL Phone: 1.800.280.3376

120:11	217:19	155 <b>:</b> 5	101:8	environment
123:14	218:14	elements	287 <b>:</b> 1	316:10
124:17	219:18	17:1	346:12	Environm
128:16	221:2	embarrassed	<b>ended</b> 78:4	307:5
160:18,21	225:10	108:12	endorse	<b>EPA</b> 306:24
161:1	227:10	emerged	354:8	307:7
203:12	231:1,3,23	154:20	endorsement	EPA.gov
edited	243:21,23	emergence	353 <b>:</b> 7	307:3
112:19	244:2	18:6,9,12	<b>enemy</b> 345:23	epicenter
123:15	245:9	22:14 31:9	346:6	337:16,21
editor 308:5	247:7	41:4,10,15	engaged	epidemic
308:20	262:13,22	153:24	64:18	169:5
editorial	318:2,12	emergency	340:1	epidemio
13:19	318:20	220:11	engineer	279:1,4
<b>effect</b> 29:16	322:2,7,18	221:3	100:1,13	epidemio
215:7	332:7	emeritus	engineered	255:11,21
219:13	333:17	291:5,5	34:16	256:9
223:15	355 <b>:</b> 10	<b>Emily</b> 70:14	51:15	277 <b>:</b> 9
322:16	356:8	70:14,19	89:12	epidemio
353:21 <b>,</b> 22	358 <b>:</b> 7	72:9,13,15	182 <b>:</b> 21	273 <b>:</b> 11
354:4 <b>,</b> 15	effort 12:3	72:17 <b>,</b> 18	183:13	278:13
354:16	12:5	149:3,3,6	engineering	279:3
effective	171:19	205:15,17	17:7	equipment
166:18	194:24	205:22	England 47:2	321 <b>:</b> 22
170:3	egregious	Emmanuel	enormous	equivalent
214:2,9,11	151 <b>:</b> 5	352:23 <b>,</b> 24	170:5	345:14
215:5,24	<b>eight</b> 27:16	emphasis	ensure	Erbelding
217:13	29:10,23	199:24	296:22	70:14 72:9
218:6	53:25 86:1	200:9	320:20	149:3
221:5	91:18	emphasize	entered	205:15,22
224:3	235:6	155 <b>:</b> 23	234:2	ERIC 2:6
227:11	309:11	employed	<b>entire</b> 170:7	Erik 42:16
261:25	<b>eighth</b> 52:21	40:15	232:11	205:14,17
262 <b>:</b> 7	53:5,12,14	360:11 <b>,</b> 14	260:5	205:22
314:13	54:1,15	employee	302:14,16	errata
315:15	either 24:15	337:9	entirely	361:11,13
317:24	27:14 34:8	360:14	140:10	361:16
322:10	34:10	employees	153:16	362:1
331:5,9	75:15	300:4	262:25	escaped
355:8	80:14 97:2	enclosed	276:14	79:21
effectiv	233:19	361:9,10	entitled	143:7
213:22	284:19	Enclosures	31:7	155:16,17
331:17	291:4	361:25	163:12	156:11
effects	295:19	encourage	185:21	208:17
216:25	316:15	152:5	190:6	espoused
efficacy	321:15	encourages	210:15	266:25
215:3,15	election	345:9	218:5	<b>ESQ</b> 2:5,6,7
215:21	10:20	encouraging	242:15	2:16,17,18
216:7,18	element	99:19	280:12	3:2,3,13
	l	1	l	I

LEXITAS LEGAL Phone: 1.800.280.3376

				. 1
3:22,23,24	everybody	81:3,7	229:19	263:11
3:25 4:9	28:9 67:17	evident	230:3	excited
4:18 361:4	238:9	218:14	308:3	192:22
essential	278 <b>:</b> 10	219:18	examination	exciting
54:18	349:22	evolution	1:14 6:2	192:23
58:13	everythi	78:2 81:15	10:6 78:8	exclamation
106:19	12:6 70:13	82:2	80:14	300:15,15
107:11	evidence	132:10	231:21	300:16
essentially	18:21	144:12	examine	<b>excuse</b> 53:17
37:16	19:19 22:8	evolutio	107:9	executed
157:10	30:6 36:19	44:11 45:4	323 <b>:</b> 15	251 <b>:</b> 7
168:14	49:25 57:4	45:12	examined	363:14
170:6	80:3,6	50:25 52:6	10:5 81:10	exhibit 6:7
193:8	88:20,22	52:15	examining	6:8,9,11
248:23	95:23	58:20	260:19	6:12,13,14
266:23	106:6	63:25 64:8	example	6:15,16,17
276:22	109:19,19	77:23 80:2	14:25	6:18,19,20
establish	110:19	89:13,15	36:15 87:7	6:21,22,23
153:12	111 <b>:</b> 7	103:3	157 <b>:</b> 24	6:24 <b>,</b> 25
established	126:16	114:10,15	168:11	7:1,2,3,4
59 <b>:</b> 23	146:8,13	120:19	206:3	7:5,6,7,8
217:1	154:1,11	121:23	208:16	7:9,10,11
230:14	154:17,21	122:4	280:25	7:12,13,14
349:23	155:1,24	124:13	318:24	7:15,16,17
estimate	161:16,25	156:23	338:20	7:18,19,20
32:2	179:3	157 <b>:</b> 8	355:6	7:21,22,23
<b>et</b> 1:5,8 9:7	183:17	160:9,12	356:2,7,20	7:24 <b>,</b> 25
9:7 39:23	189:24	198:14	357:4	8:1,2,3,4
55:19,25	191:14,14	evolved	examples	8:5,6,7,8
61:2	193:12	105:13	134:2	8:9,10,11
162:13	194:20	139:11	144:14	8:12,13,14
361:7 <b>,</b> 7	196:14	144:17	Excellent	8:15,16,17
362:2,2	214:8,13	198:16	90:7,19	8:18,19,20
<b>ethics</b> 353:2	214:20	<b>exact</b> 145:8	264:10	8:21 12:11
etiology	224:1	160:23	exception	12:13
156:1	231:22	165:25	27:6,9,10	13:10
<b>EUA</b> 220:6,11	232:7	231:25	27:20,25	17:19,20
220:12,19	243:23	exactly 11:8	28:2,15,16	18:4 25:3
220:23	245:15	20:17	28:22 29:5	25:4 31:2
221:9	248:2	23:21 50:4	29:8	31:3 35:19
Eugene 135:8	286:17	57:10	exceptions	37:19,21
evaluated	302:20	67:23 70:4	28:24	41:8,14
156:22	316:8	116:13	29:25	43:7,8,9
evaluation	317:5	129:8	30:10,11	47:25
166:25	318:17	136:19	30:12	49:15
247:4	319:2	139:11	excerpt	52:21 53:3
evaluations	325:5	179:20	196:24	53:6,9
245:14	339:16	190:24	exchange	56:4,13,20
evening 60:1	evidence	220:8,16	68:6 126:5	56:22
	l	l	l	I

LEXITAS LEGAL Phone: 1.800.280.3376

60:13	221:11,24	211:4,9	357 <b>:</b> 24	168:13,15
83:12,24	226:9,10		expires	168:16
83:25 96:9	228:15,16	<b>expectat</b> 50:25 52:5	360:22	169:8,15
96:10 97:7	232:12,13	experience	363:24	261:25
101:9,10	232:12,13	69:24	explain 96:6	262:13,14
		136:21	_	· ·
111:10,11	239:9		explained 156:18	extremely
114:17,18	242:10,11	140:5 145:10		134:11
115:2,4	245:4,5	165:2	explanation 52:19	eyebrows 230:23
119:4,18	248:25 249:4,6,9	279:3		
119:24			explicitly	Ezekiel
122:24,25	253:6,14	323:8	16:25	352:23,24
128:25	253:15	experienced	214:13	F
130:6,7	263:7,8,24	140:9	218:20	<b>F</b> 305:16
138:7,8	266:4,5	experiment	explosion	
141:12,15	270:5,7,11	28:12	170:5	Facebook
142:19,20	271:2,3	117:18,23	expose	99:7 152:4
148:4,9,11	275:8,9	119:1,3	322:20	174:2
148:12,18	277:17,19	experime	exposed	175:17
152:17,18	280:8,11	23:13	42:14 43:1	177:14,17
158:19,20	283:11,12	121:17	express	210:6
158:23	284:6,7,14	122:1	78:11	211:18,24
163:7,8	284:19	experiments	356:14	212:11,13
167:14,15	286:3,4	15:4 16:7	expressed	212:14,21
170:9,10	293:25	17:16	78:10	234:2,4
172:24	294:3,6	28 <b>:</b> 25	expressing	235:7
173:2	298:17 <b>,</b> 18	31:19	106:2	237:18
178:5,7,7	304:10,23	68:19	expressions	238:1,12
178:17,18	304:24	119:5	79:1	240:4,21
179:25	307:12,15	157:19,23	102:14	241:8
181:23	323:19,20	expert	extensive	242:23
182:2	327:24,25	124:14	140:5	286:11
185:2,6,7	328:5	132:9	<b>extent</b> 12:18	287:1
185:11,17	330:5,6	291:2	25:8,14	290:2
187:9,10	334:17,20	356:11 <b>,</b> 14	71:3	307:21
187:12	335:15	357 <b>:</b> 22	114:24	309:4,6,9
196:20,21	340:22,25	expertise	152:6	309 <b>:</b> 22
197:4	341:24	117:20	205:5	311:16
199:4,14	343:24,25	124:24	326:22	328:12,21
200:23	346:14 <b>,</b> 15	127:13	<b>extra</b> 51:24	330:22
201:13,16	347 <b>:</b> 15	151 <b>:</b> 18	70:22	331:3
201:17	352:19 <b>,</b> 20	357 <b>:</b> 1	117 <b>:</b> 22	332:8
203:24,25	exhibits	experts	284:16	344:13
204:12	8:22 57:24	39 <b>:</b> 23	extraord	Facebook's
209:3,4	114:22	271:24	169:3	239:10
210:9,12	115:2	272 <b>:</b> 12	extrapol	Facebook
212:15,16	233:14	273:3	191:8	177:3
212:23	existence	332:21	extreme	Facebook
213:17,18	22:22	333:24	165:14,19	232:17
218:4	expanding	334:9	168:7,8,10	<b>faced</b> 335:21
			, , , ,	
	•	•	•	•

LEXITAS LEGAL Phone: 1.800.280.3376

	_	_		
FaceTime	259:9	252:2,4	90:7 92:2	138:8
99:18	266:3	279:9	93:9,16,25	141:12
facilities	300:8	282:5	97:22	142:20
165:9	315:13	293:11	101:12	148:12
<b>fact</b> 15:10	336:10	familiarity	109:23	150:8
18:10 30:9	355:13	175 <b>:</b> 2	111:18	152:18
52:18	fairly 33:24	familiarize	112:16	158:20
59:20 64:5	44:17,21	14:9 26:14	115:9	163:8
81:5,14	<b>faith</b> 77:16	43:12	123:7	164:1
95:15	106:11	48:11 53:8	160:18	167:15
155:16	<b>fake</b> 173:7	68:16	161:1,9	170:10
156:11,12	300:22	69:11 73:4	162:25	172:24
161:3	301:19	94:14,17	163:5	176:14
176:24	309:5,22	97:13	170:14	178:18
181:19	309:25,25	112:1	171:5	182:2
193:3	310:4,10	115:16	Farrar's	183:4
203:2	311:17	164:2	76:1 98:4	185:6,11
212:10	328:17,24	176:14	fast 128:24	185:17
214:11	329:13	183:4	267:15,18	187:10,21
216:12	330:2	187:23	Fauci 1:13	196:21
219:16	Fake/Imp	197:14	6:3,7 9:6	197:14,18
224:1	300:14	211:15	10:2,10,11	198:1
248:3	<b>fall</b> 309:1	227:3	12:13,18	201:17,23
256:7	<b>falls</b> 338:25	271:15	13:1 14:9	203:24,25
262:7	<b>false</b> 103:22	299:2	17:20,22	209:4
274:1	211:5	306:7	25:4,9	210:12
277:12	237:7,19	341:7	26:14 31:3	211:15
281:8	288:21	353:18	37:21	212:16
309:21	294:25	familiar	38:20 43:9	213:18
315:12	300:23,25	119:10	43:12	218:5
321:3	301:3,6	<b>family</b> 359:7	52:25 53:8	221:11
329:8	302:17	famous	54:15	226:10
357 <b>:</b> 3	312:3,11	175:22	68:16,24	227 <b>:</b> 2
factors	339:5	<b>fan</b> 309:16	73:3 83:14	228:16,25
154:17	357 <b>:</b> 8	<b>far</b> 112:18	83:23,25	232:13
248:11	falsely	129:6	90:11	240:12
<b>facts</b> 107:4	310:10,16	156:25	91:21	242:11
107:4	falseness	179:6	94:14	245:5
factual	237:4	283:21	96:10	249:6
156:8	familiar	<b>Farrar</b> 34:19	97 <b>:</b> 22	253:15,18
faculty	18:6,10	43:21	101:15	263:8
265:11	27:2,5	44:23 60:2	111:11	266:5
failings	31:11,13	61:19,20	112:1	270:7
244:4	39:4 48:18	66:24	114:18	271 <b>:</b> 15
<b>fair</b> 189:22	63:18	72:24	115:5,16	275:9
190:4	92:10	73:21 79:8	119:24	277 <b>:</b> 19
207:17	98:16 99:8	79:12 83:3	122:25	278:2
236:14	248:13	84:16 85:9	130:7	280:8
251:23	250:2	89:21,25	134:15,17	283:12

LEXITAS LEGAL Phone: 1.800.280.3376

284:7	120:7	feeling	245:2	74:4 89:12
286:4	February	79:23	263:3	89:14
287:9,18	22:17	109:24	264:16,18	110:9
294:6	43:15	feels 47:20	307:8	112:12
298:18	44:16 55:3	191:9	318:8	123:3,14
299:1,19	61:14 66:6	<b>felt</b> 17:15	325:22	124:2
303:6	66:17 69:3	28:8 46:15	332:25	125:5
304:20,24	72:25 73:8	46:16 75:4	358:17	131:23
-	77:5 82:14			
306:6		81:25	361:9	132:3
307:15	86:2,13	107:22	findings	153:5,25
309:5,15	89:25	126:8	183:22	154:20
311:19	91:22	164:24	222:16	163:17
313:6	93:16 97:2	169:8	<b>fine</b> 47:15	167:22
323:20	105:5	189:1,2	228:21	173:2,23
327:25	113:22	232:4,6	309:16	175 <b>:</b> 10
328:16,18	115:8	258:7	fingertips	180:2
330:2,6	120:3,12	273:25	59:24	183:2
333:17	123:7,25	274:1	318:10	188:13
334:20	126:23	297:5,6	<b>finish</b> 42:12	190:10
340:22	128:13,18	322:12	46:22	202:11
341:15,24	129:2,20	<b>female</b> 228:4	49:11	203:2
342:20	139:13	Ferguson	76:19	211:3,22
343:25	140:14	92:4,6	102:10	220:5
346:15	141:18	93:12	135:3	229:5
348:10,13	144:7	<b>field</b> 63:15	174:24	239:9
350:1	147:3	64:8 155:2	247:13	243:4
352:20	148:19	<b>fifth</b> 163:22	260:14	245:8,12
353:18	149:7,22	226:21	290:4	245:18
354:20	152:22	fighting	310:23	250:4,6
355:4	159:4	283:25	312:14	252 <b>:</b> 17
356:3	160:14	figure	339:13	255:4 <b>,</b> 17
361:10	161:8	106:12	340:11	256:11
362:1	167:19	135:24	350:11	265:17
363:5 <b>,</b> 20	169:19	162:12	finishing	271:13 <b>,</b> 20
Fauci's	173:11,18	filing	148:6	278 <b>:</b> 8
219:1,10	261:11	361:18	Firm 3:14	280:16
FCN@list	313:12,21	<b>final</b> 14:1,3	<b>first</b> 11:13	303:9
305:22	315:18	359:5	14:2,2,2,3	325 <b>:</b> 19
FCN@list	317 <b>:</b> 22	Finally	15:25 20:8	329:11
305:19	320:19	177:9	22:24 23:1	330:17
<b>FDA</b> 220:5,18	322:3	financially	31:15,22	331 <b>:</b> 7
220:19	federal 4:11	360:15	33:19,20	344:11,16
347:1	238:12,14	<b>find</b> 26:17	34:5,8,10	347:16
featured	238:16	50:24 58:3	39:18	356:24
229:8	239:4	62:20	43:18,23	359:14
features	<b>feel</b> 70:7	121:22	45:15,23	first-name
51:11,14	71:22	206:19	47:24	173:17
51:23,24	91:12	230:17,18	53:24 58:8	286:14,19
<b>Feb</b> 73:8	346:1	232:2	58:21 71:2	349:25

LEXITAS LEGAL Phone: 1.800.280.3376

				. 1
350:5,16	floated	following	180:8	301:3,23
350:18,22	92:23	10:22	formulation	302:11
351:4	<b>flood</b> 357:11	22:16	180:16	foundation
Fishers	357 <b>:</b> 17	44:15	<b>forth</b> 27:21	143:11
308:7	358:24	46:21	64:2 77:7	144:1
<b>five</b> 41:3	<b>Flu</b> 13:15	113:5	77:17 78:3	146:11,18
51:24 54:1	<b>fluent</b> 133:9	124:1	119:3	152:24
64:22	357 <b>:</b> 25	181 <b>:</b> 7	123:21	158:5
85 <b>:</b> 25	focus 42:13	183:21	129:4	161:18
89:20	134:7	240:4	173:15	164:14
91:18	245:18	292:17	214:17	184:5
92:14 93:8	250:8	follows 10:5	290:2	186:23
104:25	268:2,5	240:5	356:5	199:10
161:4	focused	316:1	Forty-one	200:13
222:7	266:16	footnote	249:5	208:5,19
253:4	292:13,21	26:16	<b>forum</b> 138:1	210:19
267:14	focusing	27:21	forward 12:1	221:18
343:24	246:10	<b>force</b> 196:25	44:12 59:7	223:4
344:4	<b>FOIA</b> 84:4	197:6,9	61:8 62:5	225:23
five-year	121:5	201:4	65:12 66:7	229:15
36:11,13	122:7,10	204:11	90:16,16	233:8
<b>flag</b> 309:5	122:13	208:1	93:20	234:13,18
flagged	FOIA'd288:4	321:2,12	97:10	235:18
299:14	Folkers 38:1	<b>forced</b> 353:8	101:11	237:23
311:16	38:1,2	354 <b>:</b> 19	104:25	240:24
flagging	39:20 40:7	Ford 244:17	105:3	242:25
309:21,23	40:16 42:8	foregoing	109:9	243:12
311:12	294:9	360:5,7	131:19,24	244:21
329:10,13	<b>folks</b> 39:22	363:6,13	131:25	246:3
Flaherty	182 <b>:</b> 20	forget	156:3,6	249:21
336:13,16	183:11	150:10	237:9,12	250 <b>:</b> 23
336:22	299:14	forgetting	239:8	253:21
<b>flawed</b> 323:9	313:23	108:8	267:15,18	266:12
<b>flea</b> 145:20	follow	forgot	289:20	272 <b>:</b> 9
<b>flip</b> 19:9	230:10	108:12	295:13	273:6,14
25:23	235:22	184 <b>:</b> 15	318:18	273:22
52:21	241:25,25	225:25	forwarded	280:15
64:21	280:5	336:11	62:10,12	281:3,12
84:15	297:9	forgotten	124:15	282:13
85:24	follow-up	226:7	266:14	283:4
89:18	72 <b>:</b> 6	<b>form</b> 193:16	269:10,13	306:6
91:17 93:7	109:14,22	194:4	318:25	314:1,22
101:11	followed	363 <b>:</b> 7	348:7,14	319:5,13
251:2	18:16	<b>former</b> 134:4	forwarding	325 <b>:</b> 5
272:19	53:20	134:4	61 <b>:</b> 17	332:10
309:14	81:24	313:9	348:21	337:1 <b>,</b> 25
Flipping	214:10	formerly	found 244:18	345 <b>:</b> 20
249:17	239:11	265:13	294:14	348:17
252:6	240:16,21	formulating	300:24	<b>four</b> 53:25
			l	

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

84:15	89:21 90:8	272:17	272:14	17:14 25:1
85 <b>:</b> 25	90:20 91:1	281:1	273:10	55:21
86:19 88:6	91:7,10,11	295:13	276:17	57:15
89:20	92:3 93:11	Francisco	front 13:9	116:5,7,7
91:17 93:7	94:2,11,21	133:15	13:17,22	119:14,14
129:6	95:20	174:9,15	29:7 46:19	functions
160:13	108:2	174:17	47:25 84:4	119:9
196:5	109:15,23	175:8	97:8 101:9	fund 39:22
254:6	110:11	231:18	104:24	40:4 57:22
272:21	111:18,23	frankly	112:7	67:18
335:19	114:6	107:19	119:20	71:23
<b>fourth</b> 23:8	115:8	226:7	141:21	149:16,16
23:9 84:16	116:14,18	278:12	178:23	fundamental
226:20	116:24	348:9	185:6	113:8
237:17	118:4	Frederick	188:7	fundamen
271:12,19	120:4	155:10,11	210:21	110:6
284:24	121:20	free 177:11	210:21	114:10
foyered	123:8	177:18	221:23	<b>funded</b> 20:5
21:14	125:9	freedom	222:24	22:23
frame 31:22	126:23	151:16	225:7,19	31:20
102:16	128:13,15	freely	228:2,6	32:21 36:8
121:21	130:17	248:21	242:18	41:2 59:17
129:9	131:8	274:6	248:25	67:15,17
131:4	132:5,12	274:0	249:9,11	67:21
136:14,17	136:12	270.22	253:23	156:13
136:20,22	162:18,20	358:9	263:16	157:5,14
136:20,22	170:14,25	freeze	271:3	157:20
137:2	171:9,9	303:24	335:1	funding
137.2	182:6,12	304:2,7	345:2	19:17,25
169:19	184:1,17	freezer	Frontline	20:5 21:23
180:24	187:16	169:6	227:16	22:6,13
220:4	188:7,9,25	frequently	234:6	26:1 28:4
262:11	189:1,6,11	347:2	234:0	28:17 36:9
279:25	191:15	Friday 48:1	242:15	37:16 45:6
281:10	253:24	51:21 66:6	243:3	58:4,22
315:13	256 <b>:</b> 7	201:23	frustration	59:14
345:18	250.7 257 <b>:</b> 6	344:13	344:12	63:17
framework	257:6	friend	<b>full</b> 159:6	70:11,18
70:20	259:1,8	265:20,22	183:2	70:11,18
70:20	261:5,19	265:20,22	239:9	76:7 79:3
framing	262:11,19	friendship	272:24	156:20
131:8	262:11,19	205:8	272:24	further 52:8
137:3	264:2,10	frightening	325:2	74:18 78:8
Francis	266:9,14	342:21	fully 42:2	80:14
13:14	268:20	343:8	160:8	81:16
66:15 67:6	269:11,16	fringe	298:15	105:17,19
67:9,12,14	269:22	255:11,21	function	105:17,19
67:20 68:1	271 <b>:</b> 25	271:24	6:11 16:3	106:18
75:5 82:23	272:13,16	272:5,13	16:9,12	107:20
70.0 02.25	2/2.13,10	2,2.0,10	10.5,12	107.20
	·	ı	1	ı

LEXITAS LEGAL Phone: 1.800.280.3376

110:5	117:18,21	157 <b>:</b> 25	36 <b>:</b> 25	126 <b>:</b> 12
111:6	174:9,15	158:9	37:19	206:8,19
112:19	174:18	189:4	41:21	244:1
116:14	175:8	191:4	46:12 58:7	245:11
195:1	216:1	<b>German</b> 97:16	67:9 68:16	go 11:11
299:25	228:9	108:8	69:11 73:3	12:1 15:10
303:22	229:17	<b>Gertz</b> 202:19	96:8	17 <b>:</b> 12
359 <b>:</b> 18	230:13	Gertz's	115:15	18:25
360:13	315:21	202:2	122:12	20:19,23
future	316:19	getting 12:6	134:2	21:6 22:24
102:25	general's	26:10	144:14	45 <b>:</b> 17
	9:19 269:3	42:15	146:21	47:14 48:9
G	General's	60 <b>:</b> 25	152 <b>:</b> 17	49:12
<b>G</b> 9:1	2:8	61 <b>:</b> 25	158:19	53:24 54:7
gain 6:11	generally	62:20 91:1	167:14	63 <b>:</b> 15
16:3,9,11	16:1 33:13	104:13	191:14	80:24
17:14	46:16	107:3	232:12	85 <b>:</b> 25
29:15	117:12,14	110:1	271 <b>:</b> 17	89:19
55 <b>:</b> 21	207:24	111:20	284:12	94:20
57 <b>:</b> 15	211:23	114:12	323:18	101:9
116:5,7	241:14	124:9,10	338:20	106:17
gain-of	263:19	126:15	<b>given</b> 11:3	108:21
16:1 25:20	290:16	129:23	14:4 28:24	117:19
25:25 26:4	309:1	149:13	37:8 43:7	122:16,16
27:4 57:2	338:11	151 <b>:</b> 8	43:12 91:5	132:2
61:3 69:25	347 <b>:</b> 19	152 <b>:</b> 4	114:9	134:6
71:7,19	generated	157 <b>:</b> 20	126:8	135:4
118:19,23	36:16 37:2	169:4	133:20	139:9,13
<b>Gannon</b> 135:8	generating	188:2	134:25	140:4
136:2,3	14:6,20,23	215:10	135:12	142:15
GARDNER 3:23	15:22 24:1	233:11	136:9	156:16
garnering	genetic	243:1	153:22	162:12
42:10	24:14	254:3	154:18	165:14
Garry 51:6	genetically	256:13	156:24	166:4
Gates 104:11	34:16	257:8	177:23	173:7
338:22	genetics	258:9	178:1	177:20
<b>gather</b> 87:10	23:14,15	269:1	181:19	178:6
87:12,12 87:18	23:19 24:3	310:8	200:6	189:2
gathering	24:7,10,11 24:22	335:12	216:11	192:7,18
110:18	<b>genome</b> 50:24	342:7	236:24 245:3	198:6 199:5,7,11
111:6	51:12,25	Gingrich 141:17	<b>gives</b> 218:9	201:11
gbdeclar	121:15,25	143:3	331:3	206:8,18
255:1	genomes	Gingrich's	giving 31:1	225:7
general 4:19	36:15 37:4	141:20	145:2	230:4
14:18	49:16 50:3	143:24	glad 173:13	233:12
79:23 95:6	50:10	give 11:23	glance 12:12	236:9
95:9 97:5	genomic 50:6	17:18	global 7:23	247:14,21
108:5	50:7	26:18	15:18	248:23
	•	•	•	

LEXITAS LEGAL Phone: 1.800.280.3376

267:14	78:3 83:18	341:9	327:16,22	207:20,21
271:12	85:25	354:24	330:11	grants 18:24
277 <b>:</b> 15	89:19	359:18,20	Google-o	63:17,18
282:23	91:13 96:8	goings	239:12	63:19 76:6
283:24	104:25	142:12	Google.com	great 7:24
284:24	106:12	gold 244:11	324 <b>:</b> 7	84:18,22
296:10	108:22	244:12,14	Gotcha	84:23
299:21,25	109:25	Gonsalves	294:13	85 <b>:</b> 13
303:22	115:19	265:7,10	gotten 99:8	88:19
320:9	116:25	266:15	Gottlieb	132:6,21
321:8,25	126:18	267:10	346:21	167:24
322:4	127:21,25	268:9	348:3,14	168:2,6
325:19	128:4,23	269:14	349:8	248:13,16
354:21	134:9	296:2,16	351 <b>:</b> 11	249:1,10
359:6 <b>,</b> 7	138:21	<b>good</b> 7:19	352:13 <b>,</b> 18	249:11,14
goes 36:5,9	139:6	10:8 12:24	government	249:18,19
37:13	150:3	39:18	25:25 27:3	250:1
108:25,25	155:9,11	46:12	27:18 28:3	252 <b>:</b> 17
109:6	155:13	52:14	28:17	254:6,12
113:7	156:16	71:22	38:11	254:23
149:14	167:14	77:16	46:14,17	255:3 <b>,</b> 14
152:13	184:15,19	79:17	75:19 <b>,</b> 23	258:10
156:7	192:1	83:16	75 <b>:</b> 25	260:15
164:20	194:16	106:11	177:11,24	264:7
165:12	203:19	139:9,13	178:12	266:9
183:16	219:19	156:9	216:18	267:1
239:9	220:9	173:6	238:12,15	268:6,22
255:10	232:12	226:13	238:17,23	269:3
256:21	241:11	227:8	290:17,20	276:4,17
257:15	242:6,6,8	233:5,15	318:14	277:5
259:17	253:9	234:16	327:9	279:18
268:1	257:4	242:7,9	334:9	280:1,13
273:9	261:18	279:3	342:5	280:17,21
280:5	262:15	323:3	343:4,18	281:8,23
281:18	263:4	329:14	345:4,17	282:11
320:16	268:20	343:14	345:22,25	283:2
342:20	277:12	353:25	grabs 271:9	285:7,10
358:14	279:18 280:19	354:2,5 Google 8:8	<pre>grant19:8   20:7 21:23</pre>	290:10,19 291:12
<b>going</b> 12:4 20:4 25:2	284:12	239:14,23	20:7 21:23	291:12
29:8 38:24	289:15	264:19	36:11 41:5	295:5
39:2 47:7	304:19	280:13,17	41:7,16,19	296:19 <b>,</b> 23
47:8 53:2	313:1	280:20,22	41:23 42:5	297:5,9,16
53:18 54:9	314:18	281:23	42:25	297:27
58:19	320:20	282:11	60:14 72:1	325:22
59:22	326:20	324:9,24	grantee	338:21
60:16	328:25	325:8,12	32:14	Greenberg
63:10,13	329:4	325:20,25	40:10,11	292:18,19
70:9 76:16	340:4	326:8,15	40:21	Greg 38:1,1
	-			
L		=	=	-

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

38:2 39:20	232:1	333:22	187:8,8	harmed
294:9,11	234:6,8,9	guidelines	203:24	225:13
294:11	234:21	16:19	handle	harmful
295:8,9,17	246:21,22	231:11,11	300:14	246:8
Gregg 265:7	246:24	232:9	301:24	288:14
265:10,17	247:2,6	247:24	303:24	harms 217:5
266:15	248:10	332:3,18	304:7,8	<b>Harold</b> 134:3
268:9,12	265:13,14	333:3,11	handled 29:2	135:7
269:14	265:15	<b>Gupta</b> 251:17	handles	Harry 292:18
296:2,16	309:1	256:4	304:3	292:19
gross 314:16	329:3	267:21	handling	Harvard
ground 11:11	332:20	guy 190:2	165:7	132:19
70:17	336:11	261:16	166:7	231:18
grounds	groups 16:5	guys 87:14	happen 86:8	267:19
12:20 13:7	17:8,16	260:7,12	92:19	<b>hasten</b> 271:8
25:11	136:22		107:12,16	<b>Haven</b> 265:12
group 38:4	214:12	Н	155:3	HCQ 245:19
40:8 41:2	246:7,11	<b>H</b> 6:6	156:4	245:22
44:10,19	247:5,15	<b>H5N1</b> 15:1	177 <b>:</b> 25	HCQ/CQ
46:24	growing	<b>half</b> 76:17	315:7	245:11
52:15	188:16	130:16	happened	HCQ/QC 7:23
58:20	344:12	131:23	66:18	head 18:18
59:23	guaranteed	132:22	85 <b>:</b> 22	28:3,17
63:14,24	130:3	298:22	102:24	76:3
81:21	guardrails	358:21	146:9,14	150:23
86:21 87:3	15:4 16:7	halfway	155:4	240:2
87:8,21,25	16:19,21	94:20	156:2	324:11
88:5 89:12	guess 17:19	110:17	157:18,22	327:2
92:13,24	76:13 85:4	144:23	178:4	headline
103:2	97:16	hall 212:6	239:6	209:8
107:17	98:12	241:4	241:4	228:25
109:16	103:11	281:16	happening	271:8
131:3,4,9	105:22	<b>HAMMOND</b> 4:18	102:25	278:2
131:19,20	147:12	<b>hand</b> 25:2	156:7	headlined
131:24,25	177:15,16	136:25	208:25	212:20
132:10,11	202:4	170:9	342:8	health1:19
132:13,18	218:18,18	<b>handed</b> 83:23	happens	4:8,10,17
134:1	224:12,22	111:9	103:21	4:20 10:15
135:20	225:2,6,6	handing 12:9	157:11	28:5,10,13
136:15,18	228 <b>:</b> 2	119:18	174:3	30:2 40:12
136:20,22	266:15	122:24	216:13	40:25
137:2,7,15	279 <b>:</b> 5	130:6	320:14	65:10,11
138:24	349:2	141:15	<b>happy</b> 47:17	79:17 95:7
139:1,6,8	guest141:20	142:18	128:3	95:9 <b>,</b> 17
198:14	guideline	148:4	315:23	96:23
205:12	214:12	158:23	harm 189:10	126:12
225:18,25	247:5	163:7	219:14	165:7
228:1,6	331:22,23	181:23	225:4	169:10
231:7	331:23	185:2	248:4	177:6
		<u> </u>	<u> </u>	<u> </u>

LEXITAS LEGAL Phone: 1.800.280.3376

				1
231:13	hearing	327:7	120:11	243:10
237:3	87:10	328:13	124:17	hotly 358:6
265:11,24	213:1	high 2:9	160:18,21	hour 76:17
267:23	heck 230:23	108:9	161:1	119:12
277:8	held 234:5	195:16	203:12	hours 235:6
288:15,19 288:24	273:2	246:7	Holmstock 9:14	359:12 <b>House</b> 7:11
289:4,8,10	hello 175:4	high-risk 169:21		
· ·	266:2		homes 168:14	197:1
289:15	help 165:15	higher 117:2	honest 68:4	198:23
290:1	178:2	highlighted	103:6	201:3
313:10	188:15	294:14	221:22	207:25
314:5	201:25	highly 44:10	250:25	217:24
333:6	217:4,16	45:11,12	338:8	218:3
334:10	<b>Henry</b> 244:17	80:1 89:13	358:13	271 <b>:</b> 9
342:22	herd 248:21	122:4	honestly	275 <b>:</b> 24
343:15	248:23	135:11	339:1	276:1,3,10
345:24	266:16,20	139:17	<b>Honor</b> 48:6,7	328:11 <b>,</b> 20
346:6,13	266:24	140:3	honorable	329:17 <b>,</b> 21
347:3	267:3	198:14	48:8	330:1
357 <b>:</b> 2 <b>,</b> 6	271:9	216:15	hope 24:9	335:2 <b>,</b> 19
healthcare	275:17	217:12	hoped 189:4	335:23
320:23	276:9	259:9	189:12	336:10,12
321:5	278:3,11	261:2,20	191:3	336:18
<b>hear</b> 41:19	285:2 <b>,</b> 11	281:21	Hopefully	339:22
64:20	292:13,22	<b>Hill</b> 7:14	106:23	359 <b>:</b> 5
173:14	294:25	8:18 209:7	hoping	https://
241:4	295:1,5,12	232:18	324:25	254:19
335:8	295:22	341:1	325:8	https://
<b>heard</b> 45:20	355:11 <b>,</b> 20	342:19	342:6	254 <b>:</b> 19
58:9,21	<b>hero</b> 309:15	Hines 3:1	horrifying	<b>huge</b> 84:9
64:5 71:2	hesitancy	5 <b>:</b> 3	342:11,14	<b>Hugh</b> 30:21
92:8 135:7	338:12	historical	342:16	54:17 <b>,</b> 20
143:18	352 <b>:</b> 5	145:10	hospital	54:24
175:22	hesitant	246:25	169:7	56:13
212:11,25	117:19	history	174:10,16	57:18 61:7
223:8	<b>Hey</b> 208:25	144:12	174:18,20	61:14 62:3
224:8	209:25	<b>hit</b> 169:5	175:8	63:7 66:10
252:14	241:4	<b>HIV</b> 265:18	316:10	68:7 69:2
270:3	260:7	<b>HOFT</b> 5:4	hospital	69:9,23
272:17	303:5	<b>hold</b> 23:6	274 <b>:</b> 4	70:8,8
282:9,21	<b>HHS</b> 139:9	101:23	278:24	71:5,14
282:22,23	299:23	148:24	297:8	72:4,12,16
291:19	303:9	306:9	hospital	<b>Hugh's</b> 58:2
293:9,10	<b>hi</b> 32:19	320:13	343:9	59:1 70:12
296:3	95:1	330:13	hospitals	<b>huh-uh</b> 11:25
334:19,23	254 <b>:</b> 18	<b>Holmes</b> 44:24	169:11	human 4:8,10
334:24	299:13	45:2,3,9	316:3	31:8
335:4,5	311:16	51:4 73:10	<b>hosted</b> 235:6	144:13,18
342:4	325:20	112:15	hosting	146:4
L	-	-	-	-

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

153:25	220:7,12	139:24	275 <b>:</b> 10	218:23
154:20	223:10,15	157:4	277:20	220:25
156:9	223:10,13	266:16	280:9	255:1,2
161:20	224:3,25	272:6	283:13	256:12
198:19	225:21	276:18	284:8	257:2,24
200:10	227:10	289:3	286:5	258:6,21
267:23	229:1,9	identifi	294:7	265:18
313:10	231:2,4,22	12:14	298:19	267:2
humans 43:4	232:8	17:21 25:5	304:25	269:9
Humphrey	235:10	31:4 37:22	307:16	328:18
328:6,7,9	236:22	43:10 84:1	315:8	331:11
329:20,25	239:16	96:11	323:21	immediate
hundred	243:21	111:12	328:1	38:3,16
16:14 32:8	244:2,9,19	114:19	330:7	183:21
33:9 88:2	245:10,23	119:25	334:21	immediately
141:10,11	247:17	123:1	340:23	33:5 50:15
141:23	248:3	130:8	344:1	51:10 73:6
161:11	355 <b>:</b> 7	138:9	346:16	92:1
207:3	356 <b>:</b> 8	141:13	352 <b>:</b> 21	106:17
263:20	358 <b>:</b> 7	142:21	identified	154:14
hundreds	hyperbole	148:13	306:23	240:10
21:7 45:18	188:24	152:19	identify	imminent
112:6	<b>hyphen</b> 39:10	158:21	42:14 43:1	288:21
146:21	39:10,10	163:9	69:8 93:23	immunity
148:1	hypotheses	167:16	287:4	248:22,24
149:15	191:17	170:11	identifying	266:16,20
200:15	hypothesis	172:25	287:15	266:24
244:25,25	208:2	178:19	identities	267:3
293:21,21	hypothet	182:3	167:6	271:9
333:22	156:11	185:18	<b>IG</b> 328:18	275:17
347:11	I	187:11	ignore	276:9
hundredth		196:22	245:14	278:4,11
312:7	<b>I-o-a-n</b> 293:8	201:18	II 288:14	285:2,11
hurt 217:17	i.e316:10	204:1	ill-founded	292:14,22
hurts 237:8	Ian 39:22	209:5	274:2	294:25
hydroxyc 213:22	40:11,19	210:13	277:6 illness	295:1,5,12
	152:21	212:17		295:22
214:2,9,11 214:14	153:7,9,16	213:19	169:25	355:11,21
214:14 215:7,21	153:16,22	221:12 226:11	278:24 imagine 37:6	<pre>impact   353:10</pre>
215:7,21	161:14,21	228:17	46:6 49:18	impeded
216:7,24	161:21,22	232:14	50:5,12	335:12
217:3,11	212:25	242:12	73:24 74:1	imperative
217:12,19	213:1,5	245:6	76:14	169:11
217:12,13	ICU 316:11	249:7	86:16	impersonate
218:6,17	idea 42:20	253 <b>:</b> 16	116:24	303:17
218:19,20	46:12	263:9	179:13	304:4
218:22,24	52:14	266:6	199:1	imperson
219:12	108:20	270:8	216:10	312:19
		-	-	-
L				

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

	_	_		
imperson	importing	326:9	267:8	272 <b>:</b> 12
300:20	321:15	332:17	indirectly	279:2
303:20	impossible	357:3	96:20	291:1
304:12	157:1,10	inclusion	individual	332:21,22
310:16	imposter	135:20	224:24	333:1,24
328:24	301:19,24	inconsis	232:8	influence
329:2	302:1,8,9	50:25 52:5	334:1	297:4
330:2	302:12	71:7,16	individu	312:18
imperson	303:3,8	incorrect	18:24 19:2	influencing
311:19,20	impressed	217:14	individuals	290:8
312:15	165:6	245:17	97:5	influenza
329:4	impression	276:24	169:21	15:9 16:18
imperson	77:21	277:6	231:14	24:8,25
303:12	229:17	339:6	297:9	25:20
implemented	inaccurate	increase	355:24	inform 39:6
28:8	246:23	102:22	INDRANEEL	informal
implemen	inadequate	191:19	3:25	142:23
166:19	323:6	192:12	ineffective	174:5
implicat	inapprop	195:2	319:1	information
15:12	157:13	321:14	infect	14:5,19
107:25	inaugura	increasing	278:23	58:8 73:15
275:5	10:19,21	321:16	infected	104:22
298:15	10:22	increasi	278:11	107:9,15
implying	incident	190:6	314:9,11	111:2,6
147:9	209:12,13	incredibly	317:2	127:11
165:22	include	306:19	infection	139:10
190:25	16:21	independent	167:23	143:4
important	42:17	75 <b>:</b> 20	168:2	151:7
14:5,19	133:1	indicate	247:18	171:19
42:22,24	136:1	215:4	274:3	178:2
46:22	139:1	322:14	285:3,12	194:14,25
52:13 97:3	168:10	361:12	297:8	215:18
97:5	169:21	indicated	314:10,12	217:14
132:18	211:5,11	38:19	infections	219:22
134:19	298 <b>:</b> 7	149:2	170:5	236:24
169:1	330:11	227:11	infectious	237:4,8,19
177:4,5	included	indicates	10:14 46:8	268:21
216:24	55 <b>:</b> 24	48:1 142:4	46:10,14	287:14
238:19	81:19	242:19	46:17	288:20
260:18	includes	245:25	70:16	289:1
319:9,20	170:17	247:16	72:19	300:3
322:18,24	including	283:21	133:24	306:19
322:25	17:5 37:4	284:2	142:13	307:9
323:1	97 <b>:</b> 5	308:4	216:12	312:12
340:1	103:23	324:21	231:15,16	318:17
354:12	111:4	indicating	231:19	323:1,4,4
358:9,14	115:2	121:3	232:10	323:6
Importantly	131:4	indication	248:1	332:7,25
161:25	140:7	194:13	271:24	339:15
	-	-	-	-

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

357:9,12	33:12 36:6	interest	145:1	86:7 131:7
357 <b>:</b> 18	36 <b>:</b> 16	48:4 49:22	170:4	<b>invoke</b> 28:16
358:25	37 <b>:</b> 12	50:11	interrup	28:22
informed	42:17	61:23 98:8	170:3	involve
210:16,23	117:9	100:11	interspe	170:6
357 <b>:</b> 23	132:19	110:18	23:5	involved
infreque	133:8,22	111:6	interven	35:14
246:23	135:1	243:16	151:11	44:25 91:1
initial	142:12	256:20,22	225:13	96:23 99:8
80:13	153:24	335:13	341:24	107:23
81:12	154:19	interested	345:14	110:2
181:7	156:21	87:10	interven	120:18
initially	158:1,11	142:12	345:10	122:6,10
22:23	158:15	257 <b>:</b> 3	346:3,12	125:12
initiated	174:7,8	360:16	357 <b>:</b> 5	126:3,7,10
18:13	175:9	interesting	interview	126:12,15
initiation	205:21	52 <b>:</b> 12	141:8	137:23
19:8	216:6	141:5	146:20	155:1 <b>,</b> 6
inkling	260:19	interfere	interviewed	169:9
137:20	261:1,4	103:20	296:12	203:14
inner 38:2	308:2	interfering	intervie	213:12
38:15	326:19	340:18	359:2	229:20
<b>input</b> 96:22	institutes	357 <b>:</b> 12	interviews	235:22
110:2	1:18 10:15	internat	101:2	239:24
124:12	65:9 <b>,</b> 11	44:10	introduce	241:6
127:10	122:14	45:17	9:16	260:17,19
171:22,24	institution	46:24	289:15	302 <b>:</b> 12
172:12,22	46:9 155:6	89:13	invalid	312:5,8,11
180:8,14	155 <b>:</b> 8	107:24	258 <b>:</b> 7	312:18
180:15,19	292:3	126:12	276:21,21	340:5,8,12
196:8	institut	140:4,6,9	277 <b>:</b> 2	340:17
220:18	133:14	internat	invariably	359:1
ins 357:25	instruct	45 <b>:</b> 22	193:4	involvement
inserted	13:7 25:10	75 <b>:</b> 22	investigate	70:11 71:3
54:5	intent 43:5	internet	80:20,23	81:16 82:4
insights	intention	252:24	138:16	82:9
14:5,19	91:4	349:10	investig	107:20
Instagram	interact	352:5	137:19	110:2
101:2,7	45:19	interpre	investig	122:19,21
211:25	298:3	118:24	357:14	125:18
286:11	346:25	127:11	investig	involves
309:6	interacted	Interrog	213:4	124:13
328:15,18	77:18	287:7	invitation	involving
330:2	175:16,17	interrog	86:17	25:20
Instagrams	264:23	287:3,12	149:2	111:3
101:4	266:2	287:21	invited	170:13
institute	interact	interrupt	172:6	Ioannides
4:17 10:13	126:7	11:14	176:25	293:8,10
19:4 33:8	175:5	127:18,18	inviting	ironic 311:4
		l	<u>I</u>	I

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

				_
irrelevant	<b>JAMES</b> 5:4	88:3,17	86:18 96:4	135:14
207:6,12	Jan 324:24	89:21,25	108:1	361:7
isolation	327:1	90:8,19,20	110:6	362:2
165:8	January	91:6,12	111:3,6	<b>JOSH</b> 3:23
<b>issue</b> 44:11	22:17	92:2,12,19	125:8	journal
67:20 68:1	34:13,18	92:22 93:4	136:12	203:1
82:4,18	35:9 <b>,</b> 14	93:9,15,25	Jeremy-led	Journalist
96:24	40:6 42:6	94:11,22	131:15	212:21
116:19	48:2 51:21	95:1 <b>,</b> 20	<b>Jill</b> 3:1 5:3	journals
136:25	84:17 <b>,</b> 19	97:22 98:4	<b>job</b> 172:21	215:17
145:5	85 <b>:</b> 12	98:20	238:20	<b>Jr</b> 1:8 9:7
169:8	123:23	101:12	260:18	361:7
193:9	351 <b>:</b> 23	102:3,14	326 <b>:</b> 25	362:2
220:11	<b>Jay</b> 251:18	102:18	Joel 272:14	judgment
243:4	267:20	103:5	272 <b>:</b> 15	224:10,12
259:12	291:15	105:7	jog126:2	319:25
292:24	Jayanta 2:24	106:10	127:8,9	Judith
295:21	Jefferson	108:25	130:4	307:20,23
335:6,8	2:10	109:10,15	141:16	308:17,19
339:23	<b>JEFFREY</b> 2:16	109:23,25	147:1	<b>July</b> 225:16
issues	<b>Jen</b> 37:25	110:10,15	341:19,21	226:14
241:24	324:2,23	110:24	jogs 132:8	233:2,15
275:4	325:7,21	111:18,23	John 2:5 3:3	233:18,19
312:9,11	327:1,7	112:16	9:18 296:1	233:20,20
314:24	JENIN 3:2	114:3 115:9	296:6,8,11	328:7,12
353:12 355:13	Jenin.yo 3:9	116:13	John.Sau 2:12	341:1 343:3
356:24	Jennifer	118:3,6,16	John.vec	344:4,5,8
358:7,10	38:5	120:4,10	3:10	jump 154:14
issuing	308:12,14	121:20	John@Bur	198:18
220:6	308:15	123:7	3:18	200:9
item 331:7,8	324:23	124:15	join 86:3,14	264:24
items 284:25	<b>Jeremy</b> 34:19	125:2	86:17	jumped
ivermectin	43:20 44:3	126:23	131:5,8	101:18,20
330:25	44:5,23	128:13	<pre>joined 277:7</pre>	jumping
331:4,5,9	46:11,11	130:17	317:15	173:6
331:16	48:3 50:9	132:5,12	joiners	<b>June</b> 21:23
332:2,8	60:2 66:24	132:17,20	252 <b>:</b> 7	22:1
333:15,19	72:24	132:24	<pre>joint141:2</pre>	220:14
ivermect	73:21,25	133:4,21	<b>Jon</b> 49:6,16	Justice 2:19
331:16	74:1,7	135:20	50:9 61:18	3:21 4:1
	75:1 76:1	136:5	61:24	9:22 361:5
<u>J</u>	76:2 79:7	137:6,14	62:14	justified
<b>J</b> 3:3 352:23	79:12 83:3	160:18	JONATHAN	52:18
352:24	83:6,7	161:1,9	3:13	JUSTIN 2:7
Jack 240:17	84:6,8,16	162:25	Joseph 1:8	juxtaposed
293:2,4	84:23 85:9	170:14,25	9:7 133:10	49:17
Jamal 330:19	85:12,19	171:5,5,16	134:13,23	106:9
331:2	86:2,7,14	Jeremy's	135:6,13	217:9
	l ————————————————————————————————————	<u> </u>	l	l

LEXITAS LEGAL Phone: 1.800.280.3376

	166:8	88:12 89:7	178:6,13	251 <b>:</b> 19
K	206:21,25	90:2,5,10	179:2,8	253:3,20
<b>Katie</b> 202:3	260:14	92:25	181:24	254:8
202:4,15	283:19		182:8	254.6 255 <b>:</b> 24
<b>keep</b> 58:16		93:13,22		
69:19	284:2	95:22	183:3	256:24
86:21	300:21	96:12	184:4	257:20
104:2	310:14	97:11 99:4	185:5,10	259:5,24
108:8	319:9	101:15,18	185 <b>:</b> 15	260:23
155:25	334:9	101:21	186:22	261:13
210:16,23	339:23	108:18	187:18 <b>,</b> 20	262:3
241:10	347 <b>:</b> 23	109:18	187 <b>:</b> 23	266:11
283:9	<b>kinds</b> 17:9	111:25	189:23	268:24
314:16	17:16	112:23	193:18	269:19
keeping 74:8	104:18	113:16	195:4	270:6,17
74:12	Kingdom	114:20	196:13	271:14
128:22	75:17 76:5	115:15	197:2,13	272 <b>:</b> 8
314:13	Kirschner	116:20	199:9	273:5,13
314:13	3:22 9:21	118:13,21	200:12	273 <b>:</b> 21
317:24	9:21 12:15	119:21	201:10	274:12,23
kept 73:21	13:6 14:8	120:25	205:3,25	280:14
157:17	14:12	121:6	206:14	281:2,11
	17:22	125:15	207:18	282:12
232:5	18:20	127:17	208:4,18	283:3
Kheriaty 3:1	19:18	128:2	210:10,18	285:8,19
kicked	20:20 22:7	129:12,15	211:14	286:16
251:23	23:17 24:4	130:9	213:24	287:9,17
335:22	24:17 25:8	134:14	214:19	289:2
<b>kill</b> 170:1	26:6,13	137:12	221:17	291:25
305:25	29:18 30:5	138:10,17	223:3,22	293:14
killed	35:21	143:10,25	224:13	294:1,3,17
194:19	36:18 42:1	144:25	225:22	296:25
killing	43:11 46:4	146:10,17	226 <b>:</b> 22	290.23
344:14,18	47:18 48:6	148:5,10	220.22 227 <b>:</b> 2	298:9
345:5		149:8		
<b>kind</b> 15:25	48:10,17		228:18,21	299:1
35:10	48:22	152:11,23	229:14	301:8,20
38:14 39:9	49:10,12	154:5,22	233:7	302:19
39:13,14	49:24	158:4,24	234:12,17	303:14
42:23	52:24 53:7	159:10,20	235:13,17	304:17
50:16	53:21 54:2	161:17	236:6	305:14,17
53:18	57:3 62:7	162:6	237:11	306:5
59:13 60:9	63:3 65:14	163:25	239:17	308:24
96:24	65:18,22	164:13	240:12,23	310:5,19
103:13	68:15	166:12	242:24	310:25
118:7	69:10 71:9	167:8	243:11	311:5
121:24	73:2 76:16	168:19	244:20	312:16,22
140:14	76:21 <b>,</b> 24	169:23	246:2,14	313:16,25
147:24	78:14 79:9	172 <b>:</b> 15	246:18	314:21
148:6	82:7 83:13	174:21	249:3,20	318:7,22
155:13,19	86:9 <b>,</b> 25	176:6,9,13	250 <b>:</b> 22	319:4,12

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

322:22	35:12 <b>,</b> 25	100:18,24	172 <b>:</b> 2	252 <b>:</b> 21
325:4,14	36:3,3,4	100:10,24	173:19	255:5,20
326:2	36:14,23	103:14,18	174:14,16	255:23,25
327:5,18	36:23 37:1	105:12	175:1,7,15	256:6
329:18,23	37:5 39:7	106:4	177:5,6	257:1,18
331:21	40:2,8,13	107:1,18	179:21	257:22,23
332:9	40:19	108:7,7,22	181:3,16	258:1,12
333:8	44:25 45:7	109:2,4,12	184:17,24	258:16,18
334:11	45:9,10,10	109:24	186:7,11	258:25
336:25	45:13,14	113:1,2,6	186:13,14	259:3,4,22
337:24	45:16 46:2	113:15,19	188:9,24	260:1,21
339:12	46:11,18	113:20,23	189:8	260:24
341:6	49:7,21,21	115:22	194:9,10	263:13
344:7	50:4 51:3	116:1,18	196:4	264:21
345:19	51:5,7	116:22,23	198:23	265:3,7,22
346:17	55:6,15,23	117:3,7	199:11	267:3
347:6	55:25 56:2	118:15	201:4,5,6	268:13,18
348:16	57:8,17,22	119:11	204:24	268:20,25
352 <b>:</b> 7	58:5 <b>,</b> 19	120:13	205:1,2,23	269:16,21
353:17	59:14	127:7,13	206:3,17	269:22
354:22	62:17 63:6	129:8,22	208:21,22	270:18
355:16	64:6,14	133:7	208:22	274 <b>:</b> 25
356:10	67:1,5,23	134:3	209:20,25	275:4 <b>,</b> 16
358:11	70:2,4,9	135:7,8,8	210:4	277:11,14
359:13	74:22	135:22	212:10	279:5,6,23
361:4,8	75:21 <b>,</b> 21	136:16,19	213:3,5,16	281:5,7,8
knee 256:15	76:10,11	137:9,14	217:21	281:14
knew 62:24	76:13,21	138:19,23	221:20,21	282:15
77:17	77:12	139:4,7,10	223:6	283:6,7
136:8	78:11,18	140:1,25	224:14	285:9,10
147:16	81:3 82:19	141:1,4,6	226:15	285:25
181:5	83:4,7,7	143:4,5,17	228:9	286:10,23
195:20	85:15	144:8,10	229:16,19	288:2,2,6
226:6	86:12 <b>,</b> 24	147:17,17	230:5,21	289:20
239:13	87:1,2,6	147:19	230:25	290:20,22
297:5 knockout	88:10 <b>,</b> 15	149:9 151:15	231:25	291:6,22 292:1,18
354:9	89:3,4 91:14,15	151:15	235:19,23 236:7,10	293:2,4,4
know 11:8,8	92:7,7,7,8	153:3,8,10	236:16	293:7,9,10
17:23	92:10,11	154:4,7	238:9,15	295:8,16
18:15 20:3	92:21,22	155:18,19	239:1	296:3,6,6
20:6,12,15	95:5,24	159:9,13	241:16	296:8,9,15
21:1,2	96:22 98:4	159:18	242:1	296:16
23:16 24:6	98:7,12,13	161:12,22	250:24	300:1,3
29:21 30:8	98:13,14	162:20	251:15,21	301:9
31:22 32:6	98:19 99:5	163:6	251:22,22	302:8
32:15,16	99:11,13	167:2,4,6	251:24	304:5,5,6
32:19 33:6	99:20,22	167:12	252:4,13	304:8
33:17	99:24	171:14	252 <b>:</b> 14 <b>,</b> 15	305:7 <b>,</b> 13

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

305:20,22	89:15	279 <b>:</b> 8	200:12	219:1,11
306:13	100:25	<b>KUMAR</b> 4:9	208:4,18	221:14
307:13,23	152:2,12	KYLA 3:24	210:18	222:11
307:13,23	155:11	KILA J. Z4	214:8	<b>LANDRY</b> 2:16
311:7	156:15	L	214.0	lane 110:6
313:6	178:1	<b>L</b> 4:2 361:5	218:14	114:11,15
314:2,3	181:13	lab 33:16	219:18	120:20
322:9	184:14	79:2,21	221:1,17	124:24
323:5	191:21	89:6	223:3	139:1,15
324:18	201:9	116:15	225:22	140:1,5
325:16,24	201.9	155:17	229:14	163:12,18
325:10,24	221:16	156:12	233:7	163:12,16
		157:17		
328:8,19	241:2,20 251:13	182:22	234:12,17 235:17	164:10,20 165:6
329:2,24	269:24	183:14		
332:20	274:14,15	188:19	237:22	166:16,24
335:7,17	•	190:8	240:23	167:19
336:6,13	285:16,23	190:8	242:24	168:4
336:15,15	286:2	208:1,17	243:11	190:20
336:17	290:3,6	209:10,19	244:20	216:5,12
337:10,21	292:12	213:8	246:2,22	253:25
338:1,5,6	307:7	355:9	249:20	254:15
338:13	312:13,17		250:22	259:21
339:16,25	325:15,17	labeled 43:8	253:20	260:21
345:21	326:5	94:24	266:11	261:6,10
346:18,21	334:8	laboratory	272:8	261:17
346:23,25	340:4	14:7,21,24 24:2 34:17	273:5,13	262:11,18
347:10	knowledg	35:11	273:21	262:19
350:4	261:21	77:13	280:14	266:9
351:6,6,7	known 46:11	121:16	281:2,11	308:7
351:13,14	75:24		282:12	312:4
351:19,19	256:7	122:1 145:22	283:3	356:25
352:8,14	260:3	145:22	306:5	358:19
356:11,23	265:16,17		313:25	Lane's 165:2
356:24	291:9	157:12 162:1	314:21	language
357:22	297:17		319:4,12	355:14,18
358:12	351:8	180:5	321:24	355:19,22
knowing	352:24	181:9	325:4	356:2
63:16	knows 22:19	185:23 198:3	332:9	large 46:23
144:17	36:21		336:25	63:14 87:3
156:3	67:17	lack 17:13	337:24	87:21
175:2,4	94:16	143:10,25	345:19	157:25
241:21	155:2	146:10,17	348:16	236:9,23
258:1,19	278:13	152:23	laid 15:3	273:2
259:1,8	Koonin 135:8	158:4	81:25	297:18,21
317:2	Kulldorff	161:17	Lancelet	larger 52:14
knowledge	2:25	164:13	7:18	58:20
33:23	251:17	184:4	Lancet	59:23
36:10 81:7	256:5	186:23	129:11,20	274:4
87:19	267:20	199:9	130:2	Laribee 51:8
	l		l	l

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

<b>Larry</b> 67:6	<b>leak</b> 188:19	296:10	345:10,13	40:11,19
253 <b>:</b> 25	208:2	304:10	346:3,12	152:22
<b>late</b> 34:18	213:8	307 <b>:</b> 12	357:5	161:12,14
246:7	leaked	338:17	likelihood	161:21,21
265:19	157 <b>:</b> 16	letter	64 <b>:</b> 2	Lipkins
latest	<b>leaks</b> 157:12	129:19	limit 210:16	161:22
332:25	learned	letters	210:23	Lipschitz
<b>Lauren</b> 303:5	37 <b>:</b> 11	82:20	line 23:6,8	296:15
303:10,15	164:24	letting	23:9,16	<b>list</b> 46:19
Lavelle	166:9	17:22	26:20	74 <b>:</b> 20
307:20,23	263:5	248:18	38:14	75:12 <b>,</b> 18
308:17,19	<b>leave</b> 357:24	276:22	76 <b>:</b> 18	75 <b>:</b> 24
<b>Law</b> 3:14	358:18	278:3,10	89:24	86:15
Lawrence	<b>led</b> 59:17	278:22	90:12	93:10
65:4,6,8	261:18	<b>level</b> 16:22	91:20	110:14
66:7	321 <b>:</b> 13	16:22 29:2	97 <b>:</b> 25	132:24
<b>lay</b> 295:3	<b>left</b> 132:17	29:11,12	102:2	133:11
lead 104:16	173:7	30:18	113:7	134:7,21
150:11,16	272 <b>:</b> 20	70:21	120:5	136:5 <b>,</b> 7
150:19	283:21	89:11	131:23	211:4
151:3	336:10	117:2,10	148:7	252:7 <b>,</b> 7
193:17	351:1	117:16,17	161:4	263:23
194:5,22	<b>legal</b> 9:14	119:14,14	167:22	284:25
217:15	151:18	140:6,9	194:25	294:14
229:25	356 <b>:</b> 24	195:16	202:11	296:10
274:3	357 <b>:</b> 22	245:16	211:3	305:11,13
297:7	361:1 <b>,</b> 23	248:23	240:10	307:8
306:23	<b>legend</b> 143:6	<b>levels</b> 18:25	264:7	309:11
321:4	Legislative	122:22	324:8	<b>listed</b> 32:10
352:5	38:11	Levitt 252:8	344:11	33:4,5
356:21	legitimate	257:10	362:5,9,13	55 <b>:</b> 17
leader	207:14,16	Lexitas	362:17,21	251:16
301:15	299:15	361:1,23	lines 86:20	listen 47:8
leaders	lessons	Liberties	88:6 115:2	127:21
231:19	164:24	3:4	267:14	134:9
251:16	166:9	life 104:16	link 20:7	listening
leadership	263:4	150:11,17	142:14	77:21,22
171:1,11	let's 60:21	150:20	190:5,5	127:23
171:18,20	69:15 81:1	151:4,9	202:8,10	lists 20:10
196:11	88:24	193:17	255:1,7	252:8
232:10	103:6	194:6	275:13,15	literally
leading	136:24	210:2	275:17,18	61:13
278:23	173:7	349:14	328:15	149:15
338:12 <b>leads</b> 104:13	203:17	356:21 358:16	331:19 links 142:16	263:18 <b>literature</b>
246:23	227:25 233:12	life-saving	202:19,21	102:5
345:13	245:18	151:11	283:23	102:5
346:2,11	253:7	lifesaving	311:8	110:19
358:14	275 <b>:</b> 8	341:23	Lipkin 39:23	158:16
200.14	210.0	J11.4J	LIPATH 39.43	100.10
		l	I	

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

159:7	46:11	197:23	232:5	329:8
181:20	76:23	199:12,13	247:23	342:2
231:21	105:7	201:20	275:14	343:9
232:6	127:25	211:20	298:13	loons 113:12
322:5	128:4	215:1	306:19	loop 75:7
323:10	134:11	221:23	357 <b>:</b> 15	looped 327:2
little 26:24	201:10	222:14	looking 20:2	losing
53:2 60:6	204:22	229:4,5	41:13 50:2	104:13
78:5 127:9	248:8	230:15	62:2 75:23	loss 104:16
127:10	265:16	233:14	80:25	150:11,17
150:9	long-term	237:15	97:15	150:19
170:21	32:13	244:5	112:3	151:3
171:13,21	longer 76:17	247:3,21	114:12	193:17
188:23	76 <b>:</b> 22	248:8,25	156:3,6	194:6
196:8	look 13:9	249:19	197:16	217:7
197:23	14:1 15:6	264:6	202:3	230:1
200:24	17:24	271:2	218:4	356:21
live 169:14	37 <b>:</b> 24	277 <b>:</b> 22	233:23	lost 93:13
176:24	38:13 39:8	279:5	235:3	151:10
177:3	50:14,15	280:11	249:9	170:1
live-str	51:13,15	289:20	295:25	<b>lot</b> 31:16
176:20	52:1,7,15	305:2,9,10	302:24	78 <b>:</b> 21
lives 103:20	52:16,16	306:3,22	303:2,4	88:21
104:14	53:11 54:1	308:19	307:1	103:25
169:17	56:19 78:7	312:1,2	309:24	114:22
217:8	80:11 81:1	320:2 <b>,</b> 9	320 <b>:</b> 15	120:19
230:1	81:2 94:23	322:5	looks 13:18	153:17
256:16	96:16 97:7	328:4	37:10	154:18
342:22	103:1	330:5	38:18	159:14
345:11	106:17	331:13	39:18	160:22
Livestream	108:1	335:14	41:23 42:7	161:22
239:11	112:12	340:25	57:7 86:12	165:5
240:6	113:12	346:14	124:7	170:1
<b>Lloyd</b> 291:17		347:15 <b>,</b> 22	132:16	173:19
291:18	115:4	<b>looked</b> 34:22	149:14	184:18
<b>loaded</b> 169:7	122:11	44:4 46:13	159:5	189:8
located	123:3	70:12	178:7,9	191:22
308:7	124:18	81:10	197:18,19	193:12
location	148:22	95:16	197:20	194:19
314:19	156:18,19	124:16,22	198:25	195:15
lock 168:14	157:5	162:10,14	202:15,20	207:11
lockdown	160:7	170:19	203:7	230:5
261:25	161:3	183:23	269:12	244:25
262:13	163:17	186:3	275:18	256:14
lockdowns	170:21	198:15	284:5	257:8
168:11,12	179:5	204:12	294:22	274:17
168:13	182:16	227:10	295:18	286:19
long 10:23	190:4,23	229:18	305:10,12	298:4,14
11:7 32:1	192:2	230:22	306:13	301:14
L		l	l	I

LEXITAS LEGAL Phone: 1.800.280.3376

321:13	146:22	192:23	111:10,11	327 <b>:</b> 25
338:13	172:13,19	193:10	114:17,18	330:6
349:2	182:20	211:23	114:22	334:20
351:25	183 <b>:</b> 12	212:2	119:24	340:22
355:4,12	228:7,11	manuscript	122:25	343:25
loud 69:14	279:16	81:24	130:7	346:15
Louis 3:16	311:4	114:9	138:8	352:20
361:18	334 <b>:</b> 15	March 170:22	141:12	markets
Louisiana	338:14	176:4	142:18,20	145:20
1:2 2:15	343:5	179:1,4,7	148:12,23	Martin 2:25
2:19,21	man 20:10	180:10,11	152:18	251 <b>:</b> 17
9:10	212:24	180:25,25	158:20	267:20
low 248:23	286:14	182:7,12	163:8	Maryland
314:18	290:22	186:1,20	167:15	1:11,18,20
317:9	management	220:6	170:10	4:24 9:13
lower 86:18	331:24	286:22,24	172:24	155:10,11
86:18 88:6	managers	293:13	178:13 <b>,</b> 18	360:3 <b>,</b> 21
124:16	30:19	298:24	182:2	mask 313:13
137:5	managing	299:22	185:17	313 <b>:</b> 23
lunch 201:11	164:8,11	303:23	187:10	314:12,18
	165:10	318:24	196:21	315:2
M	mandate	319:1	201:17	317:9,23
<b>M</b> 2:16	165:19	mark 12:10	203:25	322:14,15
Machine 7:2	Mandavilli	18:1 99:17	209:4	322:18
magazine	296:13	99:21	210:12	masking
49:6	manipulate	100:21	212:16	317:18
264:14	157 <b>:</b> 2	115:12,13	213:18	318:16,21
Mailman	manipulated	116:10,10	221:11	318:25
40:24	78 <b>:</b> 21	116:15	226:10	319:1
mainstream	121:17	152:1,3	228:16	320 <b>:</b> 19
102:6	162:2	173:4,8,18	232:13	322:2,7
110:19	180:6	173 <b>:</b> 24	242:11	masks 310:13
273:11	181:10	175:11,22	245:5	314:9,24
major 21:13	manipula	175:25	249:6	315:15,18
46:9	16:17	176:4,25	253:15	315:22
248:11	23:20	178:10	263:8	316:3,4,5
273:2	24:14,23	286:14,22	266:5	316:11,20
majority	34:25	287:4,16	270:7	316:23,23
230:18	35:15	288:1,5	275:9	317:5,13
277:7	43:25 44:7	289:7,9,13	277:19	318:3,13
makeup 34:24	64:3 78:1	291:21,23	280:8	319:2,3
50:6,7 80:14	manipula	292:7	283:12	320:20
156:18	122:2	296:15	284:7	321:2,4,7
making 15:7	manmade	marked 12:13 17:20 25:3	286:4	321:9,13
15:14,16	198:2	25:4 31:1	294:6	321:14,15 321:17,17
67:24 91:4	211:23 212:2	31:3 37:21	298:18 304:24	· ·
143:23	mantra 80:3	43:9 83:25	304:24	321:18,20 321:21,25
144:2,4	manufact	96:9,10	323:20,23	321:21,23
	manuract	JU. J, ±U	J2J.ZU,ZJ	J 4 1 • 4 J
	I	ı	I	I

LEXITAS LEGAL Phone: 1.800.280.3376

322:10,15	224:21	measured	235:22	230:14,19
355:7	225:1,6	80:12	236:10	231:17
match 41:23	237:6,12	333:21	238:5,7,10	244:17
41:24	239:2,6	355:19	238:24	284:3,20
material	265:21	measures	239:5,22	293:5
314:15	266:2	164:22	241:7,13	316:6,10
318:1	269:23	165:19	241:15,19	316:24
Matt 264:14	287:12	166:20	241:24	332:23
264:21	292:2,6	168:17	269:17	335:24
matter 1:15	295:16	177:6	270:1,12	353:2
9:6 55:14	296:21	261:25	270:16,23	medication
150:21	300:2	262:14,14	274:10,17	225:3,9
matters	305:20	Med 179:22	274:18,22	medicine
270:12	311:24	media 33:15	275:5	6:12 7:7
333:6	315:3,6	78:11,12	280:2,5	17:7 31:6
347:3	335:5	79:1,14	281:18,25	55:19 56:1
mean 23:19	337:4	98:8,10,15	282:5	56:16,21
24:23 40:3	338:2,7	98:17,22	290:8	56:22 60:3
40:9,22	349:4	99:3,6,12	297:13,15	60:23 61:3
42:19 61:4	351:7,19	99:14,21	301:6,11	62:13 66:9
67:16	355:18	99:24	301:18	71:16
85:21	meaningful	100:6,19	302:18,24	179:11,11
86:12 87:2	120:16	100:25	303:2	179:15
91:9 101:1	124:23	101:3,6	304:15	183:23
101:4	means 40:2,5	102:6,15	307:8	184:2
103:11,25	68:21	102:18	311:23	186:6,20
104:22	70:21	103:10,12	312:3,8,11	186:25
108:15,16	108:23	103:13,16	312:18	189:4,12
113:24,24	116:1,2	104:19,20	333:4	191:3
122:9	127:13	105:17,19	334:7	192:14
145:5	136:20	105:25	335:12	193:8
153:10	155:20	106:13,13	338:12,16	195:3,20
155:8,23	160:5	106:19	340:14	201:6
162:20	169:16	107:6	344:12,18	203:5,8
171:17	236:8,11	110:20,25	345:5	291:3
172:22	259:2	111:4	346:9,10	meet 138:4
174:25	300:11	142:10	355 <b>:</b> 12	173:25
175:7 <b>,</b> 21	304:6	150:15 <b>,</b> 19	356:7 <b>,</b> 12	meeting 21:1
177:7	348:10,13	151:3 <b>,</b> 21	356:16 <b>,</b> 19	21:3,7,11
180:18	meant 58:11	152:8	357 <b>:</b> 19	32:23 39:2
188:22	74:5 88:17	185 <b>:</b> 3	358:1	39:6 113:4
189:25	88:23	186:5,8,9	359:1	113:5
190:23	165:10	186:12,16	medical	114:5
192:9,20	189:18	197:25	10:15,17	147:18,23
192:21	192:15	208:2,11	75:14	148:23,24
195:7	193:11	209:2	175:5	149:5,6,10
200:25	258:17 <b>,</b> 18	210:5,7	217:1	149:11,19
223:14	259:3	213:9,14	229:22	175:3
224:16,19	260:1	213:15	230:7,12	255:14

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

256:5,9	124:11	<b>Meta</b> 7:15	257 <b>:</b> 10	95 <b>:</b> 23
267:22	146:20	8:9 210:15	Miller 202:4	109:19
321:2	149:10	210:22	202:15	137:13
335:19	166:6	211:18,24	million	179:3
336:6,22	180:15	212:7,9,10	170:2	189:24
meetings	184:14,19	286:8,10	235:5	196:14
32:18 34:1	195:14	286:13	236:2,7,8	256 <b>:</b> 25
45:17	216:20	288:12,13	236:10,19	286:17
87:19	240:1	288:25	276:24	302 <b>:</b> 20
148:1	260:25	290:1	millions	310:6
149:15	281:16,17	Meta's 286:7	177:10,18	325:5
292:5	288:5	meta-ana	256:16	mischara
member 38:2	324:24	245:8	mind 103:3	114:24
38:6 197:8	329:3	248:8	104:2	misquided
197:24	332:19	metaanal	151 <b>:</b> 8	297 <b>:</b> 7
205:11	338:5	243:25	156:1	misinfor
265:13,14	340:16	244:5,7	157:17	103:19
308:15,17	351 <b>:</b> 25	methods	184:16	104:4,10
members	352 <b>:</b> 14	168:7,9,10	232:5	104:11,15
31:19	mentioning	mice 115:13	259:8	150:10,14
133:22	302:7	115:24	mine 21:14	150:18
197:6	328:24	116:3,11	93:18	151:2,6,13
memory 29:22	mentions	117:14	206:24	151:22
126:2	19:10	Michael	288:4	188:10
130:4	50:22	252:8	335:13	193:16
132:8	242:9	Michelle	minimal	194:5,7,8
141:16	merely 11:24	296:2	180:16	194:19,23
209:1	138:3	microbes	mining 49:16	210:17,24
338:4	merging	144:12	50:3	217:7,15
341:19,21	114:22	microbio	minister	229 <b>:</b> 25
memory-wise	MERS 25:20	70:15	75 <b>:</b> 17	235:15
138:23	message 49:8	72:19	Minor 291:17	236:4
mention	177:12	133:23	291:18	283:25
50 <b>:</b> 22	337:9	mid 35:9	minute 23:25	284:4,21
78:20	359:6	mid-March	61:13	286:7
104:3,20	met 20:16,18	22 <b>:</b> 17	92:23	288:11,15
113:11	20:25 21:4	<b>middle</b> 105:4	125:1	288:16,18
124:18	32:17 <b>,</b> 17	176:7	245:19	312:12
162:23	32:25	211:9	257 <b>:</b> 13	325:1,9,13
285:13	33:22	283:21	minutes	326:10,11
290:7	147:18,21	311:13	61:13 70:6	326:16
340:20	173:20,21	347:16 <b>,</b> 23	92:14	327 <b>:</b> 17
mentioned	173:23	347:25	253:4	336:24
40:10 42:8	174:1,4	midnight	269:5	338:3,11
57:12 70:8	175:10	60:6,6	mis 339:5	338:14,15
70:25	255 <b>:</b> 11	Mike 50:24	Mischara	338:16,18
77:23	292:4	51:7,8	26:7 36:19	338:22
118:23	296:15	92:3,6	49:25 57:4	339:1
121:22	346:24	93:12	65 <b>:</b> 15	340:16

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

345:5,8,12	molecular	66:16,19	mutual 77:19	131 <b>:</b> 25
345:23	34:23	66:20	muzzled	132:13,14
346:1,5	80:14	68:14	335:10	133:3,19
347:5	81:12,25	226:13		133:21,24
357:17,20	82:24	227:8	N	134:21
358:23	133:9	233:5,15	<b>N</b> 6:1,1 9:1	135:11
359:9	135:25	234:16	361:17	136:8
misleading	156 <b>:</b> 18	261:12	<b>Nabel</b> 15:7	160:25
16:4,10	157 <b>:</b> 7	347 <b>:</b> 2	136:9	251:22
54:4 301:3	160:8	motivated	name 9:14	292:17
301:7	molecularly	321 <b>:</b> 8	10:9,10	296:1
302:17	157:1,21	motivation	13:18	298:13
305:25	moment 68:16	261:18,19	20:11	national
misquote	124:17	mouth 69:19	30:22	1:18 4:16
278:19	149:11	move 60:21	33:19,20	10:13,14
342:18	157 <b>:</b> 21	106:19	54:22 92:8	28:6,13
mission	211:15	107:11	92:10	30:2 65:9
163:13,19	252 <b>:</b> 19	210:2	108:7,9,12	65:11
Missouri 1:5	moments	307 <b>:</b> 12	132:18	142:12
2:4,8,10	269:5	moving 105:3	133:10	188:12
3:16 9:7	momentum	111:20	134:13,24	190:17
9:18 361:7	188:16	125:25	135:2,2,14	191:13
362:2	<b>Monday</b> 234:4	126:15	135:23	natural 78:2
mistaken	271 <b>:</b> 22	MSNBC's	136:5	81:15 82:1
43:6 44:16	money 177:20	229:6	160:24	83:1
202:5	177:23	multi-th	197:21	107:23
228:5	178:1	308:2	205:20	155 <b>:</b> 25
MIT 132:19	monitor	multiawa	231:6,7,10	156:10
Mitchell	106:14	213:4	263:16	189:7
229:7	338:23	multiple	291:19	190:1
233:6,13	Monroe 1:3	18:25 24:8	293:7,10	285:2,11
234:16	9:11	122:22	300:5,22	naturally
mitigate	month 140:15	175:17	301:15	183:18
358:18,20	months 32:5	198:23,23	303:11	nature 6:12
Mm-hmm	32:8	205:6	305:8	7:7 31:6
180:12	225:16	239:21	310:10	35:11
MO 361:18	315:19	280:4	315:8	55:19 56:1
modality	335:3,19	321:1	324:21	56:16,20
315:20	336:12	334:2	328:22	56:22
mode 77:22	moratorium	345:8	362:1,2	59:15 60:3
models 23:12	29:16 71:8	349:14	363:11	60:23 61:3
moderation	Morens	356:15	named 212:24	62:13 64:1
241:15	204:18,20	357:9	290:22	66:9 71:15
modest	204:21	Munster	291:18	77:13
353:21,22	morning 7:19	40:14	names 33:10 33:19	80:17
354:4,16	10:8 58:3	mutations		168:3
modesty 46:7	58:14	162:13	75:23 86:15,15	179:11,11
modulating	65:13,21	198:16	131:19,24	179:14
290:5	65:22 <b>,</b> 25	200:7	101.19,44	183:23
		I	I	I

LEXITAS LEGAL Phone: 1.800.280.3376

184:2	17:17 28:5	268:2	324:16,22	333 <b>:</b> 11
186:6,20	80:19	282:3	327:9	NIH.gov
186:25	95:14	293:6	NIAID's	142:15
189:4,12	123:20	296:14	163:12	305:11,21
191:3	244:13	318:17,17	NIAID.gov	332:4
192:14	316:6	344:3,21	142:15	nine 86:1
193:8	321:6,10	news 7:9	nice 172:21	91:18
195:3,20	needing	185:20	Nicole 305:4	<b>ninth</b> 64:22
201:5	349:8	233:17	305:6	64:23
203:5,7	needs 79:16	234:3	nightmare	235:21
297:15	130:10	277:24	153:25	Nobel 134:4
NBC 277:24	156:17	News's 240:6	154:16,21	252:11
281:1	257:16	Newt 141:17	155:15,19	257 <b>:</b> 9
NbcloUbv	348:23	141:20	156:14	nodding
254:21	negative	143:1,3,19	161:16	11:24
near 34:14	219:24	143:1,3,19	NIH 4:21 7:3	
near 34:14 125:3	219:24	143:24	7:8 16:6	nonhuman 39:24
	230:6	144:23	17:5 18:5	
nearly 332:2			66:16 70:1	<b>nonrespo</b> 134:12
necessarily 39:15	neither 360:10	next-to 191:1	70:14 75:6	145:3
39:15		NIAID 9:12	91:5 121:4	
	neutral			nonsense
162:12	101:13	10:24,25	122:8,13 134:5	277:10,12 277:14
194:9	103:4	18:18	134:5	
237:7	113:8	19:25 20:5		278:4,12
256:19	never 99:8	20:5 21:22	149:17	278:14,24
297:14	108:21	22:6,13	157:5,14	355:21
necessary	122:18	29:14	157:20	nope 101:22
28:13 30:1	173:20	31:20	162:21	normal 353:9
47:20	174:4	32:14,21	163:11	353:9
102:23	225:12	36:8 38:19	164:18	354:6,6
343:22	242:2,3	40:15 41:1	182:6,11	normally
363:9	259:7	67:15,21	184:12	243:16
need 27:24	284:18	72:17,19	186:2	norms 37:8
41:18	290:6	122:7	188:14	North 2:20
60:18	296:3	152:8	206:8,18	32:13,20
68:24	312:4	156:13	231:10	Northwest
69:17 78:4	316:16	186:14	247:5	3:5 4:2
78:6 109:1	327:15	204:22	271:25	361:5
111:20	335:3	205:16,22	291:2,7	notarized
117:22	340:1,7,12	207:20,21	292:20	361:16
125:23	<b>new</b> 3:4 4:13	215:21,25	299:23	<b>notary</b> 1:17
126:14	4:13 8:19	216:2,9,17	300:1,6,10	10:4
150:24	27:18 34:6	238:6	300:18	360:20
207:7	34:9 40:23	265:3	303:7	361:14
316:20	144:12	268:16	305:22	363:23
317:9	169:5	300:11	306:21	<b>note</b> 206:21
326:23	182:20	307:20,25	307:8,25	206:25
349:15	183:12,16	308:1	331:19	noted 199:21
<b>needed</b> 17:9	265:12	309:9	332:6,18	notice1:16

LEXITAS LEGAL Phone: 1.800.280.3376

			_	. 1
noticed	numbers	125:15	236:6	310:25
178:7	41:23	129:12,15	237:22	311:5
notifies	53:18	137:12	239:17	312:16
331:3	273:3	138:17	240:23	313:16,25
<b>notify</b> 95:14	274:5	143:10,25	242:24	314:21
noting 209:1	297:21	146:10,17	243:11	318:7,22
novel 183:18	257.21	149:8	244:20	319:4,12
November	0	152:11,23	246:2,14	322:22
1:12,20	<b>0</b> 6:1 9:1	154:5,22	246:18	325:4,14
9:3 294:10	<b>oath</b> 9:25	158:4	249:20	326:2
294:11,12	<b>object</b> 12:20	159:10,20	250:22	327:5,18
294:13	13:6 49:10	161:17	251:19	329:18,23
359:19	54:4	162:6	253:20	331:21
361:3,10	114:23	163:25	254:8	332:9
362:3	192:6,16	164:13	255:24	333:8
NtP9J7iH	192:21,25	166:12	256:24	334:11
254:20	193:2,12	167:8	257:20	336:25
number 9:8	199:6,7	168:19	259:5,24	337:24
17:4,7	211:14	169:23	260:23	345:19
23:4 30:16	objected	172:15	261:13	347:6
41:5,14,16	97:11	174:21	262:3	348:16
41:19	objection	178:15	266:11	352:7
52:22	12:16	179:2	268:24	353 <b>:</b> 17
64:24	18:20	182:8	269:19	355:16
101:1	19:18 22:7	184:4	270:17	356:10
113:24	23:17 24:4	186:22	272:8	358:11
116:8	24:17 25:8	187:18	273:5,13	observat
130:24	25:12 26:6	189:23	273:21	219:11
136:21	29:18 30:5	193:18	274:12,23	244:19
140:6	35:21	195:4	280:14	observat
144:14	36:18	196:13	281:2,11	113:25
157:25	41:11 46:4	197:2,13	282:12	obtained
178:8	48:6 49:24	199:9	283:3	28:3
185:7	57:3 62:7	200:12	285:8,19	obvious
194:22	63:3 65:14	205:3,25	286:16	88:10,15
207:11	71:9 78:14	206:14	289:2	95:16
216:4	79:9 82:7	207:18	291:25	132:16
219:23	86:9,25	208:4,18	293:14	139:16
223:16	88:12 89:7	210:18	296:25	obviously
228:21	92:25	213:24	297:24	27:9 62:22
231:4	95:22 99:4	214:19	298:9	74:2 85:22
236:17,24	108:18	221:17	301:8,20	88:7,7
248:17	109:18	223:3,22	302:19	91:9
294:3	111:25	224:13	303:14	175:22
297:18	112:23	225:22	304:17	223:19
298:1,2	113:16	229:14	305:14	303:8
304:2	114:21	233:7	306:5	308:1
316:6,8	116:20	234:12,17	308:24	329:6
331:8	118:13,21	235:13,17	310:5,19	occasions
	·	<b> , -</b> -		
L	•		•	

LEXITAS LEGAL
Phone: 1.800.280.3376 Fax: 314.644.1334

				1
46:1	295 <b>:</b> 21	69:21 72:4	205:7,11	333:23
occur 34:1	300:10	76:20,24	242:2	356:18
77:5 149:5	327 <b>:</b> 8	84:15	one-on-one	opinions
220:7	361 <b>:</b> 17	87 <b>:</b> 15	147:23	52:8 320:7
303:12	officer	91:24	one-sent	333:1
316:14	42:16	92:12	98:3	334:3
occurred	75 <b>:</b> 16	93:24 94:7	ones 128:23	355:5,14
77:2 142:5	360 <b>:</b> 4	98:20	151 <b>:</b> 6	356 <b>:</b> 7 <b>,</b> 14
182:14	offices1:18	104:7	207:5,7	356:20
232:2	official	105:3	247:23	opportunity
253:2	66:23	110:17	297:13	14:9 43:12
343:23	148:19	123:25	<b>online</b> 179:1	48:11 53:8
occurrence	239:4	130:10,11	179:7	69:11 73:3
83:1	271 <b>:</b> 21	140:19	180:11	97:13
155:25	303:9,23	147:22	202:24	112:1
156:8,10	328:16	148:10	222:2	115:16
189:8	officially	150 <b>:</b> 2	259 <b>:</b> 18	164:1
October	10:21	163:17	260:4,4,7	176:14
250:20	officials	173:6	283:15	183:4
251:4	108:9	179:8	286:7	187 <b>:</b> 21
253:19	167:3,5,7	185:7	296:23	197:14
254:5,9,11	277 <b>:</b> 8	201:14	297:4,4	271:15
254:13	342:22	210:2	344:15	306:7
263:12	<b>oh</b> 53:17,18	211:2,10	op-ed13:14	353:18
269:13	81:8 100:2	222:3	14:4 24:1	opposed
271:6	101:22	234:1	<b>open</b> 64:7	11:20
275:12,20	155:13	237:14	103:3	75:19
277:25	178:24	240:14	104:2	77:13
282:25	181:25	251:6	126:11,16	191:17
283:24	185:15	252 <b>:</b> 6	137:25	357:12
284:4	206:11	253:8	138:1	opposite
285:17	212:19 231:12	259 <b>:</b> 17	156:1 157:17	53:19
323:25		277:16		oranges
324:2 325:25	242:7 247:14	284:15 286:12	232:5 357:8	157:15 <b>order</b> 16:18
offer 177:17	284:12,17	288:13	openly	54:3
178:2	317:4	301:17	126:17	102:24
offered	343:24	306:16	358:6	170:2
254:7,12	346:19	308:22	opinion	ordinary
offhand	347:25	326:21	77:20	37:14
279:9	okay 12:7	328:7	151:19	organiza
office 2:8	26:22,25	330:8	168:25	76:15 95:7
3:15 4:19	39:19	339:3	223:12,15	95:9,18
9:19 17:5	43:15	354 <b>:</b> 22	225:9	96:23
29:1 38:3	47:13	359:17	236:14	107:23
38:4,10,15	50:19	once 11:6	245:3	organiza
38:16	51:10 68:3	20:16	297:15	17:4
225:7	68:9,18	185:11	312:6	239:22
270:2	69:1,7,19	204:15	318:16	332:17
	, ,			

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

organized	196:18	337:16	70:22	142:16
129:20	213:9	outweigh	<b>page</b> 6:7	144:21
161:8	355:9	221:6	14:2,3	148:18
164:12	<b>OSTP</b> 17:6	overrun	19:9 21:21	161:23
165:11	other's	169:12	22:23,24	163:22
166:2,6	77:19	oversee	23:1 25:24	164:4,18
organizing	outbreak	186:15	47:25 48:1	165:13
129:10	15:12	oversight	48:14 49:1	173:2
origin 43:18	31:25 32:5	16:8 17:9	49:15	176:2,6,8
99:3 111:8	34:5,6,14	17:11,17	50:14	176:11,12
147:6	34:15	overview	52:21 53:5	179:5
156:1,5	42:20	120:22	53:12,14	180:2
159:3	49:17 50:4	121:10	53:25 54:1	182:15,16
171:2	79:16	overwhel	54:15,20	182:25
178:22,25	154:13	227:9	61:10	185:21
179:23	155:2	230:6,12	64:22,23	190:10
201:24	156:5	230:18	68:6 72:20	190:10
201:24	164:21	277:7	72:20,24	197:17,24
original	165:15,20	overwhel	74:18,19	201:20
36:5	166:7,10	145:11	84:4,15,16	210:25
179:13	175:20,24	257:3	86:1 89:18	211:2,8,21
202:24	190:7	298:5	89:20,24	218:9,16
203:9	315:11	343:11	90:3,11	218:25,25
361:10	outcome	Oxford	91:16,19	219:9
originate	360:16	267:22	94:20 97:9	221:23
134:13	Outlook	207.22	97:9,10,20	226:20,21
originated	148:19		101:10,16	226:23
34:16	outrageous	<b>P</b> 9:1	101:21,25	227:8
35:11	182:20	P-I-Z-Z-O	104:24	229:5
77:12 79:2	183:12	290:23	105:1,3,4	232:22
194:1	Outreach	p.m 66:21,24	110:9	233:1,23
origins 89:5	38:12	67:2,3	111:14	234:1
98:23	outs 357:25	148:22	112:12,13	235:3
100:8,9	outside	161:8	115:4,11	237:12
102:15	12:18,21	170:22	120:2,21	239:8,10
103:3,16	16:5 17:5	188:3	123:3	240:11,12
103:23	17:8,15	203:18,21	124:16,25	240:11,12
104:1	25:15	219:4,6	125:1,3,5	242:18
109:17	89:15	253:9,11	125:1,3,3	243:4
110:20	124:24	253:19	125:21	245:8
111:1	177:20	275:12	126:20	249:11,17
129:14	216:17	312:25	127:16	249:22
137:19	290:17,20	313:3	128:9,12	251:2
140:16,21	316:9	354:23	130:13,15	252:6
147:2,10	321:16	355 <b>:</b> 1	130:15,13	264:24
147:14	outward	359:19 <b>,</b> 22	132:3,23	267:9
170:18	99:18	<b>P3</b> 70:20	135:15	271:13,20
184:3	337:22	72:14	136:11	272:19,22
188:20	outwards	<b>P3CO</b> 17:10	142:8,9,14	278:7
				,
L	•	•	. '	

LEXITAS LEGAL Phone: 1.800.280.3376

280:16         panel 231:11         paragraph         parentheses         199:19           283:19,20         231:11         14:1,3         39:21         226:18           283:24         247:24         15:10         332:4         313:21           284:24         333:23         22:25         parody         339:22           288:9,14         paper 15:6         39:18         310:24         39:4 57:           299:25         20:9 22:20         50:19 52:4         311:1         314:18           303:9         29:4,7         98:2,3         22:16 50:8         345:9           306:22,25         60:23 61:8         161:24         51:12,25         parties           307:1,19         61:8 68:18         163:18,23         56:9 72:23         360:12,1           308:4         69:23 71:6         164:5         74:6 80:11         partles           311:13         112:21         177:1,9         135:12         pass 204:1           324:13         114:4,12         180:2         188:24         314:14           325:3,19         119:5,11         183:2,7,8         194:21         317:25           325:19         119:13         188:13         244:13         115:13,2           3
283:19,20       231:11       14:1,3       39:21       226:18         283:24       247:24       15:10       332:4       339:22         288:9,14       panels 232:9       26:21 39:9       310:18,22       339:22         298:21       paper 15:6       39:18       310:24       39:4 57:         299:25       20:9 22:20       50:19 52:4       311:1       314:18         303:9       29:4,7       98:2,3       part 16:24       317:9         305:2       59:7 60:3       125:8       22:16 50:8       345:9         307:1,19       61:8 68:18       163:18,23       56:9 72:23       360:12,1         308:4       69:23 71:6       164:5       74:6 80:11       partly         309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         325:3,19       119:5,11       183:2,7,8       194:21       317:25         325:19       119:13       183:21       212:13       passage         328:5,8       120:11       188:13       244:13       115:13,2         330:18       142:11       191:1       320:18       116:2,3,         337:7 </th
283:24       247:24       15:10       332:4       313:21         284:24       333:23       22:25       parody       339:22         288:9,14       paper 15:6       39:18       310:18,22       39:4 57:31:1         299:25       20:9 22:20       50:19 52:4       311:1       39:4 57:31:1         303:9       29:4,7       98:2,3       part 16:24       317:9         305:2       59:7 60:3       125:8       22:16 50:8       345:9         306:22,25       60:23 61:8       161:24       51:12,25       parties         307:1,19       61:8 68:18       163:18,23       56:9 72:23       360:12,1         309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         324:13       114:4,12       180:2       188:24       314:14         325:3,19       119:13       183:21       212:13       passage         328:5,8       120:11       188:13       244:13       115:13,2         330:18       142:11       191:1       320:18       116:2,3,         330:18       142:11       191:1       320:18       117:13         337:7
284:24       333:23       22:25       parody       339:22         288:9,14       paper 15:6       39:18       310:18,22       particul.         298:21       paper 15:6       39:18       310:24       39:4 57:         299:25       20:9 22:20       50:19 52:4       311:1       314:18         303:9       29:4,7       98:2,3       part 16:24       317:9         305:2       59:7 60:3       125:8       22:16 50:8       345:9         307:1,19       60:23 61:8       161:24       51:12,25       parties         308:4       69:23 71:6       164:5       74:6 80:11       partly         309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         324:13       114:4,12       180:2       188:24       314:14         325:3,19       119:13       183:21       212:13       passage         325:19       119:13       188:13       244:13       115:13,2         329:11       124:2       189:3       299:6       116:2,3,         330:18       142:11       191:1       320:18       117:13         337:7       160:5
288:9,14       panels 232:9       26:21 39:9       310:18,22       particul.         298:21       paper 15:6       39:18       310:24       39:4 57:         299:25       20:9 22:20       50:19 52:4       311:1       314:18         303:9       29:4,7       98:2,3       part 16:24       317:9         305:2       59:7 60:3       125:8       22:16 50:8       345:9         306:22,25       60:23 61:8       161:24       51:12,25       parties         307:1,19       61:8 68:18       163:18,23       56:9 72:23       360:12,1         308:4       69:23 71:6       164:5       74:6 80:11       partly         309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         324:13       114:4,12       180:2       188:24       314:14         325:3,19       119:5,11       183:2,7,8       194:21       317:25         325:19       119:13       183:21       212:13       passage         329:11       124:2       189:3       299:6       116:2,3,         330:18       142:11       191:1       320:18       17:13
298:21       paper 15:6       39:18       310:24       39:4 57:         299:25       20:9 22:20       50:19 52:4       311:1       314:18         303:9       29:4,7       98:2,3       part 16:24       317:9         305:2       59:7 60:3       125:8       22:16 50:8       345:9         306:22,25       60:23 61:8       161:24       51:12,25       parties         307:1,19       61:8 68:18       163:18,23       56:9 72:23       360:12,1         308:4       69:23 71:6       164:5       74:6 80:11       partly         309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         324:13       119:5,11       183:2,7,8       194:21       317:25         325:19       119:13       183:21       212:13       passage         328:5,8       120:11       188:13       244:13       115:13,2         329:11       124:2       189:3       299:6       116:2,3,         330:18       142:11       191:1       320:18       117:13         337:7       160:5,14       218:12,21       321:8       324:21       pasted
299:25       20:9 22:20       50:19 52:4       311:1       314:18         303:9       29:4,7       98:2,3       part16:24       317:9         305:2       59:7 60:3       125:8       22:16 50:8       345:9         306:22,25       60:23 61:8       161:24       51:12,25       parties         307:1,19       61:8 68:18       163:18,23       56:9 72:23       360:12,1         308:4       69:23 71:6       164:5       74:6 80:11       partly         309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         324:13       114:4,12       180:2       188:24       314:14         325:3,19       119:5,11       183:2,7,8       194:21       317:25         328:5,8       120:11       188:13       244:13       115:13,2         329:11       124:2       189:3       299:6       116:2,3,         330:18       142:11       191:1       320:18       117:13         337:7       160:5,14       218:12,21       321:8       324:21       pasted
303:9       29:4,7       98:2,3       part16:24       317:9         305:2       59:7 60:3       125:8       22:16 50:8       345:9         306:22,25       60:23 61:8       161:24       51:12,25       parties         307:1,19       61:8 68:18       163:18,23       56:9 72:23       360:12,1         308:4       69:23 71:6       164:5       74:6 80:11       partly         309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         324:13       114:4,12       180:2       188:24       314:14         325:3,19       119:5,11       183:2,7,8       194:21       317:25         325:19       119:13       183:21       212:13       passage         329:11       124:2       189:3       244:13       115:13,2         330:18       142:11       191:1       320:18       117:13         337:7       160:5,14       218:12,21       321:8       passed 212         341:13       161:2       222:14       324:21       pasted
305:2       59:7 60:3       125:8       22:16 50:8       345:9         306:22,25       60:23 61:8       161:24       51:12,25       parties         307:1,19       61:8 68:18       163:18,23       56:9 72:23       360:12,1         308:4       69:23 71:6       164:5       74:6 80:11       partly         309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         324:13       114:4,12       180:2       188:24       314:14         325:3,19       119:5,11       183:2,7,8       194:21       317:25         325:19       119:13       183:21       212:13       passage         329:11       124:2       189:3       244:13       115:13,2         330:18       142:11       191:1       320:18       117:13         337:7       160:5,14       218:12,21       321:8       passed 212         341:13       161:2       222:14       324:21       pasted
306:22,25       60:23 61:8       161:24       51:12,25       parties         307:1,19       61:8 68:18       163:18,23       56:9 72:23       360:12,1         308:4       69:23 71:6       164:5       74:6 80:11       partly         309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         324:13       114:4,12       180:2       188:24       314:14         325:3,19       119:5,11       183:2,7,8       194:21       317:25         325:19       119:13       183:21       212:13       passage         328:5,8       120:11       188:13       244:13       115:13,2         329:11       124:2       189:3       299:6       116:2,3,         330:18       142:11       191:1       320:18       117:13         337:7       160:5,14       218:12,21       321:8       passed 212         341:13       161:2       222:14       324:21       pasted
307:1,19       61:8 68:18       163:18,23       56:9 72:23       360:12,1         308:4       69:23 71:6       164:5       74:6 80:11       partly         309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         324:13       114:4,12       180:2       188:24       314:14         325:3,19       119:5,11       183:2,7,8       194:21       317:25         325:19       119:13       183:21       212:13       passage         328:5,8       120:11       188:13       244:13       115:13,2         329:11       124:2       189:3       299:6       116:2,3,         330:18       142:11       191:1       320:18       117:13         337:7       160:5,14       218:12,21       321:8       passed 212         341:13       161:2       222:14       324:21       pasted
308:4       69:23 71:6       164:5       74:6 80:11       partly         309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         324:13       114:4,12       180:2       188:24       314:14         325:3,19       119:5,11       183:2,7,8       194:21       317:25         325:19       119:13       183:21       212:13       passage         328:5,8       120:11       188:13       244:13       115:13,2         329:11       124:2       189:3       299:6       116:2,3,         330:18       142:11       191:1       320:18       117:13         337:7       160:5,14       218:12,21       321:8       passed 212         341:13       161:2       222:14       324:21       pasted
309:14,16       71:16       176:19       104:22       156:13         311:13       112:21       177:1,9       135:12       pass 204:1         324:13       114:4,12       180:2       188:24       314:14         325:3,19       119:5,11       183:2,7,8       194:21       317:25         325:19       119:13       183:21       212:13       passage         328:5,8       120:11       188:13       244:13       115:13,2         329:11       124:2       189:3       299:6       116:2,3,         330:18       142:11       191:1       320:18       117:13         337:7       160:5,14       218:12,21       321:8       passed 212         341:13       161:2       222:14       324:21       pasted
311:13     112:21     177:1,9     135:12     pass 204:1       324:13     114:4,12     180:2     188:24     314:14       325:3,19     119:5,11     183:2,7,8     194:21     317:25       325:19     119:13     183:21     212:13     passage       328:5,8     120:11     188:13     244:13     115:13,2       329:11     124:2     189:3     299:6     116:2,3,       330:18     142:11     191:1     320:18     117:13       337:7     160:5,14     218:12,21     321:8     passed 212       341:13     161:2     222:14     324:21     pasted
324:13     114:4,12     180:2     188:24     314:14       325:3,19     119:5,11     183:2,7,8     194:21     317:25       325:19     119:13     183:21     212:13     passage       328:5,8     120:11     188:13     244:13     115:13,2       329:11     124:2     189:3     299:6     116:2,3,       330:18     142:11     191:1     320:18     117:13       337:7     160:5,14     218:12,21     321:8     passed 212       341:13     161:2     222:14     324:21     pasted
325:3,19     119:5,11     183:2,7,8     194:21     317:25       325:19     119:13     183:21     212:13     passage       328:5,8     120:11     188:13     244:13     115:13,2       329:11     124:2     189:3     299:6     116:2,3,       330:18     142:11     191:1     320:18     117:13       337:7     160:5,14     218:12,21     321:8     passed 212       341:13     161:2     222:14     324:21     pasted
325:19     119:13     183:21     212:13     passage       328:5,8     120:11     188:13     244:13     115:13,2       329:11     124:2     189:3     299:6     116:2,3,       330:18     142:11     191:1     320:18     117:13       337:7     160:5,14     218:12,21     321:8     passed 212       341:13     161:2     222:14     324:21     pasted
328:5,8     120:11     188:13     244:13     115:13,2       329:11     124:2     189:3     299:6     116:2,3,       330:18     142:11     191:1     320:18     117:13       337:7     160:5,14     218:12,21     321:8     passed 212       341:13     161:2     222:14     324:21     pasted
329:11     124:2     189:3     299:6     116:2,3,       330:18     142:11     191:1     320:18     117:13       337:7     160:5,14     218:12,21     321:8     passed 212       341:13     161:2     222:14     324:21     pasted
330:18     142:11     191:1     320:18     117:13       337:7     160:5,14     218:12,21     321:8     passed 212       341:13     161:2     222:14     324:21     pasted
337:7 160:5,14 218:12,21 321:8 passed 212 341:13 161:2 222:14 324:21 pasted
341:13   161:2   222:14   324:21   pasted
347:24 170:18 235:4,4 <b>particip</b> 347:23,2
353:6 171:3,12 237:17 74:20,22 347:25
361:11,14   171:22,25   239:9   77:9 79:24   pasting
361:17   172:3,7,12   240:4,8,15   92:24   264:2
362:5,9,13 172:20,22 245:12 93:11 pathogens
362:17,21 179:12 250:6 97:24 17:11
pages 53:25   180:21   267:11   244:18   patient
64:22,23   195:7   271:12,19   participate   163:19
86:1 89:18   197:4   272:24   75:3   224:11,2
90:11,15   200:17,21   273:10   particip   225:12
91:17 93:8 201:1,2,6 278:8 113:22 patients
93:19 94:7   201:7,24   305:23   197:11,21   222:11,1
101:11 202:1,12 325:3 <b>particular</b> 224:6
104:25   202:19,24   335:14   15:6 20:7   237:2,3,
237:9,11 203:2,5,8 342:20 46:3 56:12 Patrick 47
paid         213:16         203:14         347:20         56:14         60:7         75:11,13
241:5 216:23 <b>paragraphs</b> 62:6 75:13
281:22 223:9 41:1 104:19 84:24 85
283:10 299:4 <b>paraphrases</b> 117:17 85:13,19
pandemic         papers 98:5         285:6         119:14         92:3 93:
15:9 17:10   98:7 159:6   Pardis 132:6   139:5   pattern
34:4 160:23 132:7,18 141:25 353:11
182:21 202:8,21 132:21 144:14 <b>pause</b> 16:1
183:13 202:22 135:15,17 153:20 17:2,4
293:19 215:6 135:21 188:13 25:20 26
313:15,19 223:13 136:1 195:23 26:4 27:

LEXITAS LEGAL Phone: 1.800.280.3376

27:20 28:2	352 <b>:</b> 25	174:4	319:20	256:8
28:7,23	352.25 353 <b>:</b> 4	175:7	320:20	250.8 259 <b>:</b> 7
29:14 47:5	<b>people</b> 21:7	173.7 181:12	321:8,9	281:20
69:25	21:9 30:17	189:10	322:19,25	292:23
71:17	30:17	192:22	323:1,7	300:23
83:12	38:13 40:3	193:10	324:6,7	316:14
199:23	40:8,17	194:19	326:24	342:6
200:4,8	40:0,17	194:19	328:11	
200:4,8	45:18 46:8		329:2	perfect
		205:14,16		84:17,21
<b>paused</b> 28:10	46:23,24	207:13	330:10,11	perfectly
92:23	47:1,3	210:16,23	330:21	126:13
pauses	58:10	215:2	332:20,24	207:20
200:14	63:14,25	216:5,11	333:2	perform
pausing 27:3	64:6,7,18	216:25	335:12	69:24
Paxlovid	74:3 75:1	217:3,13	336:23	119:8
354:2	77:17,18	217:16,23	338:23,24	performed
<b>pay</b> 210:8	78:11,25	228:9	339:1	215:16
213:15	81:18 82:6	229:1,10	341:23	performing
235:19	82:17	231:4	342:21	118:19
238:18	87:22,23	236:19,24	343:8,10	period16:14
239:22	88:2,21	238:5,7	343:10,12	26:3 36:13
240:3	89:14	241:11,18	343:13	52:17 79:6
241:8,12	92:10,13	242:5	344:14,19	82:3,15
241:23	95 <b>:</b> 15 <b>,</b> 16	248:18,20	345:6,9,11	129:24
280:7	99:2,19,23	256 <b>:</b> 17	345:13	248:8
281:17,24	101:3,8	258 <b>:</b> 3	346:2,11	251 <b>:</b> 24
301:10	102:20,21	274 <b>:</b> 5	347:11	317:11
335:11	103:15,20	277 <b>:</b> 3	349:9,18	318:13
paying	103:21	278 <b>:</b> 23	351 <b>:</b> 7	336:8
256:14	104:12	286:19	356:1,6,13	peripher
<b>PDF</b> 120:8	105:16	287:1	356:19	255:18
pediatric	106:1,11	292 <b>:</b> 25	357 <b>:</b> 5	Periscope
291:1	106:14	293:12,18	358:15 <b>,</b> 18	240:6,17
<b>peer</b> 18:25	107:8	295 <b>:</b> 25	359 <b>:</b> 2	perjury
246:1,6	133:1,7,8	296:3,3,19	people's	363:12
peer-rev	133:23,24	297:12,15	281:9	permission
159:7	142:11,17	298:1,2,14	302:22,23	326 <b>:</b> 24
179:14,25	151:8,10	300 <b>:</b> 22	357 <b>:</b> 13	perplexed
191:7,9	152:5	301:14	perceived	353 <b>:</b> 6
195:8	154 <b>:</b> 13	302:11	225:20	<b>person</b> 32:24
203:9	155:9,12	303:16	227:21	33:4,11,18
215:17	155:21	310:9,10	percent	33:21,22
penalty	157:2,13	310:16	16:14 32:9	34:20
363:12	160:6	312:10	33:9 44:22	46:14,17
<b>Pence</b> 197:5	161:7	314:9,10	96:2 114:8	76:4 99:25
202:16	165:9	314:11	161:11	136:3
pending 9:9	168:14	315:22	177:22	139:9,13
75:9	170:1,2	316:4,5,23	205:19	139:17
Pennsylv	173:19,25	317:1	220:3,10	140:9

LEXITAS LEGAL Phone: 1.800.280.3376

160:24	130:2	237:2,5	3:12 5:3,4	<b>player</b> 101:6
174:1,5	140:20,25	261:21	plaintiffs	Plaza 4:11
175:23	141:17	334:1	1:6,15	please 9:16
185:7	204:4,24	357 <b>:</b> 1	2:24 6:3	9:25 10:8
189:15,15	205:1	physicians	9:20 10:3	20:20
195:15	206:5	229:20	10:6	26:24
202:6,14	207:16,19	230:14	plan 80:22	47:16 53:6
202:16	Peter's 41:2	231:13	80:24 95:8	54:6 74:16
204:21	petitions	248:1	95:12,19	87:13
205:19	298:14,16	277:8	268:23	94:13
232:9	Pfizer	pick 156:14	269:1	97:12
257 <b>:</b> 12	351:11,14	picking 75:2	planning	100:23
259:9	351:15	picture 21:2	184:17	123:13
261:17	Phil 290:22	21:4	platform	124:6
265:10,23	291:1	<b>piece</b> 20:8	98:18	127:17,18
279:2	phone 34:18	29:4,7	99:12,14	128:1
299:13	34:20	197:4	99:21	132:14
300:1	44:14	216:22	100:19,25	172:1
311:16	45:24	264:3	101:3	183:7
325:20	46:20 47:2	268:9,17	152:8	185:5
335:1	58:17,19	269:9	177:12,14	201:25
342:3	59:1,22	299:4	238:25	209:14
345:15	63:13,15	pieces 22:20	239:12	231:8
350:9,14	63:20	217:6	240:18	237:10
351:8	66:16,18	<b>piped</b> 34:21	241:16	247:13,14
354:5	75:10 79:4	pizzazz	282:6	300:15
356:16	81:17	193:13	285:1	315:25
357 <b>:</b> 2	82:14 83:3	Pizzo 290:23	290:5	339:12
personal	85:8,20	290:23	301:18	359:6
55:9,13	90:9,21	291:1	304:16	361:9,12
178:10	91:8 97:2	<b>place</b> 28:23	335:22	361:16
309:9	97:3 178:8	71:8,8	platforms	pleased
313:18	178:10	164:23	98:11,22	354:3
321:21	287:5	242:4	99:24	<b>plop</b> 281:19
personally	289:17,19	placebo	100:6	podcast 6:24
34:2 45:10	290:14	244:10	151 <b>:</b> 23	141:2,17
297 <b>:</b> 5	photograph	246:12,22	213:9	142:2,5,6
346:23	21:5,10	placebo	238:24	142:10,24
persuadable	phrase 116:1	322:1	274:11	143:24
337:17,23	199:23	placebo	290:1,9	147:10
persuaded	268:5	354:14	301:6	152:4
151:10	physical	placed 42:5	333:5	205:11,12
<b>Peter</b> 20:11	320:12	placeholder	334:7	podcasts
21:16	physically	39:17	344:13	101:2
35:17 36:2	175:14,15	placement	345:5	141:10,11
36:14 37:1	physician	306:2	346:9	141:23
37:6 39:22	104:15,17	<b>places</b> 218:2	357:19 <b>,</b> 21	142:6
40:9 117:8	225:2,9,12	Plaintiff	<b>play</b> 230:3	146:21
129:10,21	228:4	2:3,14	248:11	175:18

LEXITAS LEGAL Phone: 1.800.280.3376

		_		
359:2	27:3,6,19	15:9 29:3	234:4	226:3
podium 201:3	211:25	29:4 44:6	241:19	228:8
point 12:24	283:16	45:24	271:5	252:21
15:7,14,16	284:4,21	71:20	272:5	279:6
34:12	286:8	74:10 83:5	273:20	predate
42:10	288:11	116:6	275 <b>:</b> 14	175:19
67 <b>:</b> 23	333:6	131:16	279:14	prediction
110:18	politicians	147:25	280:25	15:12
114:10	102:4	153 <b>:</b> 16	335:18	predictions
121:1	Politico	157 <b>:</b> 18	337 <b>:</b> 11	23:5,10,11
130:20	7:17 218:5	162:20	347 <b>:</b> 17	23:12
131:2	221:15	176:1	356:6,19	predictive
135:10	222:7,10	177 <b>:</b> 25	<b>posted</b> 43:19	23:12
136:13	222:13	178:4	100:6	predominant
137:6	225:17	209:24	182:12	76:14
144:24	<b>poll</b> 230:13	220:20	225:18	predomin
145:16	230:20	230:2	234:2	74:24,25
189:7	population	238:15	238:24	96:2
198:17	250:17	241:3	270:12,16	preference
200:8	285:3,14	244:24	349:9	12:17
209:1	342:7	262:25	357 <b>:</b> 21	86:20,24
211:22	populations	268:18	posting	premarking
236:17	250:14	277 <b>:</b> 2	348:7	37 <b>:</b> 20
284:25	274 <b>:</b> 7	279:23	potential	premise
299:6	portfolio	281:15	17:10 31:8	257:25
300:15,15	72:2	290:13,21	170:1	258:2,6
300:16	position	291:13,14	221:5	269:6,12
311:4	10:12	292:15 <b>,</b> 25	225:10	273 <b>:</b> 25
316:6,8	37 <b>:</b> 15	293:22	potentially	274:2
334:15	148:3	343:19	14:6,20,24	276:9 <b>,</b> 20
355:20	160:11	345:25	15:2,5,22	276:21 <b>,</b> 25
pointed	331:3	349:12	16:3 17:2	277:1 <b>,</b> 5
21:15	positions	352 <b>:</b> 16	51:15 89:6	278:22
243:14	358:6	possibly	321:4	295:1
283:8	positive	33:24	<b>power</b> 126:9	297:9,16
355:19	166:8	40:14 44:5	137:24	355 <b>:</b> 20
pointing	219:25	44:24 56:1	practice	premises
243:5	246:9	56:2 163:5	37:14	257 <b>:</b> 17
260:3	247:19	198:2	331:23	258:21 <b>,</b> 25
299:7	possession	217:5,17	practiti	259:10
<b>points</b> 38:19	37 <b>:</b> 2	220:15	244:17	preparation
38:23 39:5	possibility	240:1	precautions	12:19,23
43:6	34:25 43:3	251:14	117:22	13:2 25:10
110:14	43:24	301:25	precise	25:15
131:18	67:10 <b>,</b> 15	304:12	42:10	171 <b>:</b> 12
137:5	71:6 80:20	<b>post</b> 3:15	168:3	prepare
policies	80:23	8:3 13:15	234:25	38:23
241:18,20	106:6	13:19	precisely	102:24
policy 17:6	possible	23:13	57 <b>:</b> 20	103:8

LEXITAS LEGAL Phone: 1.800.280.3376

287:14	198:23	102:24	Prize 134:4	353 <b>:</b> 2
prepared	199:15	103:4	252:11	project 6:10
98:5,7	200:3,5	156:6	257:9	18:7,13
114:5	201:8,24	314:9	probably	19:12,17
preparing	202:5,13	preventing	11:9 12:4	20:1 22:6
184:8	202:14,15	317:6	37 <b>:</b> 17	22:13
preponde	204:11	318:5	39:23 51:4	125:14
247:4	217:24	prevention	92:11	projects
319:25	218:3	15:12 35:8	119:12	30:3 79:3
preprint	229:9	prevents	133:8	promote
81:23	230:7	104:12	143:8	195:12
82:15,23	232:18	previous	145:19	promoted
159:2,5,7	234:5,8,9	200:23	159:15	348:22
159:8,19	234:21	204:12	191:5,25	promotes
170:19	240:7	263:24	198:23	285:10
179:18,21	295:3	previously	202:6,17	promoting
180:1,9	359:5	196:6	202:18	268:2
181:4,8,13	pressure	primarily	216:5	321:25
181:14,20	131:20	288:19	240:2	<b>proof</b> 193:9
196:10	137:7,9,15	<b>prime</b> 75:17	248:7	218:1
203:9	137:18	Prince 300:1	261:19	proofs 172:7
prescribe	<pre>pressuring 137:21</pre>	<pre>principal 30:25</pre>	295:9 300:9	<pre>propagate 339:15</pre>
224:6,9 prescribes	137:21	54:25	300:9	
225:9	presume	54:25 57:18	problem	propagated 194:9
prescribing	349:1	principles	329:1	346:8
225:2	presympt	343:14	proceed	propagates
prescrip	316:17	printed 18:4	286:10	217:11
224:24	pretending	Printout	proceedings	propagating
<b>PRESENT</b> 5:1	311:3	6:25 7:15	1:21	346:10
presented	pretenses	8:7,8,9	process 26:1	<b>proper</b> 47:19
273:1	300:23	<b>prior</b> 14:12	139:20	74:4 80:7
president	<b>pretty</b> 60:16	26:15	220:17	134:15,16
10:16,18	206:7	43:13	produced	191:10
197:5,5,12	229:19	48:22 53:9	24:10 84:4	315:8
197:12,25	279:3	68 <b>:</b> 17	121:4	320:12,16
198:5 <b>,</b> 7	355 <b>:</b> 12	97:14	product	320:17
202:16	prevail	128:25	12:20 13:6	323:16
229:8	193:8	160:14	25:11	properly
291:23	prevailing	175:24	production	103:7
313:11	227 <b>:</b> 9	176 <b>:</b> 15	321 <b>:</b> 17	230:4
344:11,17	prevails	234:10,15	professor	proponent
president's	193:5	255:22	291:5	317:12,14
202:5	prevalence	269:1	professors	proposal
press 5:2	293:12	315:19	267:19	255:10
38:24	prevaricate	332:19	program	271:8
172:3	109:7,11	priority	30:17,19	propose
196:25	prevent	195:17	42:16	322:20
197:19	12:23	<b>privy</b> 284:21	324:20	proposed
	l	l	l	l

LEXITAS LEGAL Phone: 1.800.280.3376

248:18	231:13	289:15	265:4	96:1
271:22	320:24	290:13	<b>pull</b> 175:6	104:11
proposing	321:5	300:3	257:4	106:9,13
133:4	provides	333:5,16	pulled	128:5
pros 81:10	134:16	334:6,8,10	135:21	131:19,24
358:4	161:25	337:17,23	136:7	131:25
prospects	providing	341:4	157:25	134:8
198:10	183:17	343:15	216:22	135:22
protect 28:5	provost	345:24	220:13	136:4
28:13	352:25	346:6,13	240:22	139:7
248:19	proximal	357:2	242:22	141:20
258:3	159:3	360:20	274:5	142:13
274:6	170:18	361:14	328:14	164:22
277:3	178:22,25	363:23	pulling	171:20
protecting	184:3	publication	221:9	182:14
314:11	196:18	180:11	239:15	188:15
316:11	203:3	publicly	purchase	190:21
protection	Proximate	158:10	321:3	241:12,13
15:17 30:1	179:23	206:9	purports	245:1
250:8,17	<b>PSA</b> 289:20	244:15	251:6	263:16
266:17	<b>PSAs</b> 177:12	publish	purpose 63:1	308:20
268:2,5	177:25	215:17	89:10	334:25
292:13,22	178:2	published	156:2,4	338:23
307:5	286:21	31:12,14	purposely	339:4,17
protective	287 <b>:</b> 1	82:16	162:2	340:20
321:21	289:14	124:3	180:6	345:1
proved	pseudo	129:20	181:10	putting
354:12	117:11	156 <b>:</b> 25	pursuant	114:25
<b>proven</b> 221:4	<pre>public 1:17</pre>	158:16	1:15 37:3	135:10
225:10	4:20 10:4	159:6	60:14 84:4	145:12
230:17	15:18 28:5	178:21,24	pursue	188:6
276:23	28:10,13	179:1,7,13	102:23	241:11
provide	30:2 40:12	179:17	151:11	277:11
17:23	40:25	182:6	194:23	
47:19	79 <b>:</b> 17	184:23	pursued	Q
122:15	140:16	187 <b>:</b> 2	79:16	qualific
134:15,17	165:7	215:6	153:23	224:22
134:20	169:10	219:2,11	154:19	qualific
171:12	177:6	222:2	pursuing	224:18
250:16	178:9	250:20,25	79:16	279:10
259:2	181:12	251:10	194:24	qualified
314:15	189:15	252 <b>:</b> 3	Pushing	44:10
provided	195 <b>:</b> 2	257 <b>:</b> 16	125:2,10	52:15 80:2
68:19	217:18,23	258:10	<b>put</b> 16:16	89:13
132:22,23	218:2	265:1	17:4 22:16	121:23
332 <b>:</b> 7	265:11,24	290:11	25 <b>:</b> 17	122:4
provider	277 <b>:</b> 8	333:11	27:25 29:7	198:14
243:10	288:19,24	publishing	39:5 42:9	224:11,15
providers	289:4,8,10	184:2	71:8 81:22	224:16,20
	<u> </u>	<u> </u>	<u> </u>	

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

				. 1
qualifies	183:9	43:14 47:8	272 <b>:</b> 25	radiated
339:18	185:12	47:21	quote 7:1	337:16
quantitate	194:21	48:23	41:16 42:9	radiating
236:16	197 <b>:</b> 24	53:10	127:5	337:22
quantitated	198:11	68 <b>:</b> 17	136:14	raise 12:24
297:25	200:25	82:20	144:8	35 <b>:</b> 10
quantita	202:14	94:15,17	145:7	63:19 71:5
298:2	209:22	97:14	146:13	71:14
quantity	215:9	102:3	157 <b>:</b> 16	raised 31:18
235:20	224:16	110:20	163:23	35:2 50:8
question	230:5	127:22	164:4,20	51:20 60:2
11:13,17	236:14	172:3	164:20	96:18
11:18,19	240:20	176:16	192:5	116:18
11:20	247:13	177 <b>:</b> 4	227 <b>:</b> 7	230:22
14:17	260:14	226:25	229:10	252:23
19:22,23	262:5,15	241:10	237:17	raising
20:24	267:19	287:2	260:20	34:13
22:10 25:9	269:11	289:21	271:24,25	52:11
26:25 27:2	270:14	314:5	273:15,19	98:20
35:23	275 <b>:</b> 1	329:25	278:4,4,18	102:14
36:24	281:6	330:25	285:1	<b>Ralph</b> 32:12
41:22,24	282:3	359:14	342:5,5,15	32:15
47:9,11	284:10,10	quick 52:16	344:18	39:22
49:13	288:7	176:18	quoted	40:10
58:25	292:16	257:16,19	271:13	42:17 56:9
60:25 62:1	294:17	258:9,12	281:1	147:15
62:1,19	306:15,16	325:23	290:18	148:24
69:21	310:23	quickly 52:3	<b>quotes</b> 143:3	149:6
83:10,11	312:14	60:16	146:7	ran 45:25
115:12,12	315:10	106:20	218:13	randomiz
116:10,10	330:16	107:10,11	229:6	246:22
116:15	332:19	107:13	275:22,25	randomized
119:17	334:14	239:11	276:3,8	244:10
127:24	335:21	<b>quiet</b> 64:19	342:13	246:21
134:10,10	340:11	quite 23:18		248:10,10
134:17	345:16	30:11 64:7	R	322:1
136:24	350:11,20	81:14	R1:8 9:1,7	354:13
139:3,3	357:8	86:16	361:7	range 118:24
140:17	questioned	107:19	362:2	ranging
147:13	155:9	168:13	R-e-d-d-i-t	175:2
153:8	questioning	174:14	282 <b>:</b> 8	ranking
156:17	76:18	180:18	R-o-w-e	108:9
158:3	148:7	218:14	293:2	rapid 166:19
159:23	questions	219:18,20	<b>radar</b> 42:6,9	rarely 55:11
163:14	12:1,17	226:7	43:19	re-tweeted
174:24	14 <b>:</b> 13	230:9	60:10	229:8
175:6	20:21	278:12	71:25	<b>reach</b> 96:5
176:18	26:11,15	348:8	281:19	reached
181:13	31:18	quotation	340:21	152 <b>:</b> 8
		_		
	-	-	-	·

LEXITAS LEGAL Phone: 1.800.280.3376

				1
245:16	190:25	195:6,14	87 <b>:</b> 24	92:21 93:6
reaching	273:15	207:7	156:22	94:5,5
325:21	294:25	210:8	179:24	95:13
reaction	310:9	218:13		96:15 <b>,</b> 16
166:8	325:10	219:18	reasonably 83:7	96:19,25
				· ·
read 13:12	353:8	230:9,10	297:17	102:17
14:14 19:2	354:5	230:19	reasons 16:5	112:5,7,9
28:1 31:16	real 79:15	232:6	315:23,24	114:7
50:17 59:6	88:20	235:19	316:1	116:8,12
61:7 69:5	167:18	238:19	317:7	120:13
69:14,16	215:19	244:4	320:22,25	124:10,21
69:20	231:19	305:22	reassuring	127:6
103:10	244:4	309:20	183:22	128:25
119:11,12	299:15	312:8	recall 22:21	129:17,22
143:14	323 <b>:</b> 16	314:9,13	26:5 <b>,</b> 9	130:1,4
153:5,19	real-time	316:20	28:24 29:3	131:14,15
176:22	244:16	317:24	29:6 30:8	131:17
181:4	<b>really</b> 23:18	321:5,10	32:3 <b>,</b> 25	132:1,3,3
183:6,8	30:8 32:16	334:14	33:2 34:2	133:6
184:12,13	39:17	335:21	34:12	137:1,3,17
187:19,22	51:12,13	337:10	35:13 40:6	138:19
187:25	51:25 52:1	343:14	42:5 49:7	139:5
190:11,13	57:12 61:5	351:8	49:8,18	140:18,22
245:12	62 <b>:</b> 20	353:10	55:8 <b>,</b> 15	140:23
249:16	78 <b>:</b> 22	358:1	56:12,14	143:23
250:3,4	85:21	<b>reason</b> 17:13	57:10,12	144:2,4,7
253:25	86:21 87:1	43:2 52:13	57:15 <b>,</b> 16	146:16,19
254:1	87:8,21	58:18	57:19,20	146:22
255:3	102:19,23	135:1	59 <b>:</b> 2,5	147:13 <b>,</b> 22
294:23	105:1	166:25	60:4,8,11	147:25
306:9,14	110:4	173:5	61:1,4,5	149:9,12
330:15	111:5,20	182:13	62:10,18	149:21,23
341:8,9	113:5,23	198:24	63:11 64:4	159:17
359:15	114:1,1	247:3	64:17	160:19
361:12	120:16	249:13	66:13,22	162:8,15
362:6,10	125:23	260:11	67:1,3,10	163:2,3
362:14,18	126:14	278:18	68:2 72:8	165:25
362 <b>:</b> 22	128:24	305:24	72:11,16	167:9
363:6	129:22	320:18	73:23 74:9	168:3
reading	134:6	342:17 <b>,</b> 25	74:14	172:13,19
42:12	140:25	344:22	78:17 <b>,</b> 18	173:23
68:20 <b>,</b> 23	151:19	349:17	78:22 79:4	175:23,25
69:1,14	165:4	352 <b>:</b> 1	83:2 <b>,</b> 9	178:1,2,3
102:8,10	168:13	358 <b>:</b> 25	84:14 85:4	178:4
114:14	171 <b>:</b> 18	362:7,11	85:11,14	180:14
130:19	174:13,14	362:15 <b>,</b> 19	85:17 <b>,</b> 21	181:3
180:17	180:13	362 <b>:</b> 23	85:23	184:11,22
184:11	189:20	reasonable	86:11	184:25
188:8	192 <b>:</b> 22	86:16	90:25 91:3	186:7,9,17

LEXITAS LEGAL
Phone: 1.800.280.3376 Fax: 314.644.1334

186:18	284 <b>:</b> 22	263 <b>:</b> 18	36:11	record 7:3
187:5	285:12	received	43:22 44:3	9:3 10:9
188:2,5,8	287:6	19:25	45:20	11:15
189:14	290:13,16	124:2	46:25	18:21
190:24	290:13,16		57:21 58:1	19:19 22:8
		178:12		
191:25	291:13,16	206:21	66:19	30:6 49:25
198:22	292:7,15	256:23	74:13,25	54:6,7,9
202:1,3	292:24	receiving	79:12	54:10,13
208:13	293:1,24	247:17	84:12	65:19
209:21,23	295:9,25	Recess 54:11	111:2	69:17,18
209:23	296:4,21	83:19	120:15	69:20
212:3,9	297:2,3,14	150:4	125:17,19	83:18,21
213:1,10	300:21	203:20	127:8,10	109:20
216:11	301 <b>:</b> 22	219:5	137:22	114:24
217:23	314:2,5,8	253 <b>:</b> 10	147:1	121:8
220:7,8,15	314:20,23	313 <b>:</b> 2	153:14,15	137:13
220:20,21	315:1,4,6	354 <b>:</b> 25	160:24	150:3,6
222:24	318:15	recipient	171:21	163:12
223:7,17	319:6	19:11	172:12	164:18
225:15,24	322:4,5	recipients	216:3	178:9
225:25	326 <b>:</b> 7	263 <b>:</b> 23	220:22,24	179:4
226:3,13	327 <b>:</b> 20	recognize	223:2	203:19,22
226:15,19	328 <b>:</b> 25	12:12,21	234:25	214:20
227:14	329 <b>:</b> 5	13:12 25:7	238:8	215:2
228:1,8,12	335 <b>:</b> 23	25 <b>:</b> 16	283:18	219:3,7
229:13,18	336:1,4	63:12	307:10	232:2
230:2	337 <b>:</b> 4	134:21,24	340:12,19	253:9,12
238:2,3,4	340:4,15	135:6	recombin	313:1,4
238:6,8,10	340:17	153:18,19	23:20	328:2
238:14,16	342:16	159 <b>:</b> 2	recommend	344:8
239:1,4	343:7,17	175:3	139:20	354:21,24
243:13	343:19,21	187 <b>:</b> 17	140:3	355 <b>:</b> 2
244:8,24	343:23	253:18,22	314:17	357 <b>:</b> 9
251:11,14	344:17 <b>,</b> 20	263:11,13	315:18	359:18 <b>,</b> 20
252:17,20	344:23,25	296:1	recommen	recorded 9:5
253:1	345:3,16	299:4	139:12	359:21
255:6,9,16	347:8,10	300:5	317:16,18	redact
256:4	347:12	305:8	321:7	122:18,18
257:5,7	349:11	324:20	recommen	206:18
258:12	351:1	recognized	169:10	redacted
262:1,10	352:2,9,17	46:7	285:7	55:6
263:1	recalled	recognizes	recommended	122:20,22
264:17,20	43:18	12:18	139:15,16	122:22
265:2,6	82:19	25:14	139:18,25	178:9
268:10,11	recalling	recollec	140:11	206:12
268:18,19 269:5	45:25	19:5,7,8	320:18	313:23 348:4
270:13,24	<b>receive</b> 19:17 45:6	27:15,17 28:25 35:4	recommen 250:7	redaction
270:13,24	201:21	35:12	315:1,22	84:9
210.J	∠∪⊥•∠⊥	JJ•14	J + J • + ,	U 1 . J
	I	1	I	I

LEXITAS LEGAL Phone: 1.800.280.3376

redactions	222:10	266:25	regularly	142:24
122:17	257 <b>:</b> 12	267:6	175:9	197:5
<b>Reddit</b> 282:6	349:4	275 <b>:</b> 19	rejects	remdesivir
282:7,10	referring	304:8	276:9	353:7 <b>,</b> 22
282:16	23:19,22	347:21	relate 30:3	remember
Redfield	26:17 40:7	350:7,8,13	related	13:21,22
35:5,6	40:16 41:2	<b>refers</b> 57:14	16:17 43:4	13:23 14:7
<b>redial</b> 92:14	41:21,22	60:13	43:14 82:5	21:1,17
reduce	41:25 50:5	137:7	83:9	32:23 34:5
102:22	50:12	177:14	137:18	44:1 45:16
reduced	51:22 52:3	183:22	262:13	59:3 60:9
360:9	56:18 58:6	255 <b>:</b> 20	283:1	60:15 <b>,</b> 22
refer 15:19	70:2 88:4	349:20,22	289:19	61:22
23:15,24	90:13	350 <b>:</b> 6	301:11	62:25 63:2
24:3,14,20	107:7	reflected	355 <b>:</b> 6	63:7 <b>,</b> 9
33:2 85:22	113:15,20	71:15	360:11	64:10 66:1
155:12	114:2	322:21	relates	72:9 73:20
169:4	115:20,22	reflecting	165:4	74:7 77:14
174:4	115:23	334:3,8	relations	77:15
306:18	116:9	reflects	283:16	78:25
333:2	118:1,16	66:23	327:9	81:21 83:5
349:25	119:1	refusals	relation	85:18 93:1
reference 21:22 49:5	125:7	288:22	33:3 35:17	93:2,4 94:2 95:12
106:18	132:7 133:16	refutation 260:15	36:1 63:16 175:1	95:19
204:18	136:16	266:20	205:8	98:20
211:21	137:9,15	269:13	relation	102:13
254:23	142:8	refuting	174:6,19	114:12
267:5	154:8,9,17	268:22	relative	115:23
299:18	157:12	269:6,12	360:13	116:9
306:12	158:7	regarded	relatively	124:9
348:25	168:5,7	80:1	63:24	126:3
References	174:9	regarding	64:13,19	139:19,21
6:18	193:3,6,14	63:17	336:8	141:7,25
referred	201:2	71:23	release	142:1,3,5
16:1 17:10	214:16,22	110:1	172:3	147:4,5,8
18:7 19:11	218:17,22	111 <b>:</b> 7	released	149:20
26:2 41:8	218:23	226:2	193:11	160:1,2
48:16	219:22	266:9	194:18	174 <b>:</b> 12
57 <b>:</b> 24	220:3	312:11	relevant	175:10,12
90:11	228:6	314:24	42:25	180:17
118:7	234:23,24	regardless	95:15,16	181:17,18
133:13	246:20	353 <b>:</b> 11	<b>relied</b> 122:3	187:1
151:6	248:9	regards	333:5,11	194:7
160:25	250:18	84:10	333:16	198:21
212:24	255 <b>:</b> 21	register	relies	200:1,2,4
214:23	257:18 <b>,</b> 23	282:19	288:25	200:7,10
217:8	258 <b>:</b> 22	regular	rely 290:2,4	200:14
221:14	259 <b>:</b> 14	21:20	remarks	226:5,17
	<u> </u>	<u> </u>	<u> </u>	

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

227:24	213:8	74:15	122:7,13	144:9,11
244:15,23	240:6,16	87:13	287:15	144:13
252:22	300:19	100:23	require 16:8	145:6,9,11
253:23	304:15	145:23	required	residues
254:3	<b>render</b> 363:9	150:22,24	168:17	162:13
256:2	renders	198:8	research	resources
263:14,15	24:15	201:22	6:11 15:15	177:10
263:21	renewed	209:14	15:20 16:1	respect
268:14,15	42:13	213:4	16:2,17,20	77:19
271:1	renowned	360:1	16:23 17:2	224:11
282:20	45:22	reporters	18:11 26:1	241:18
293:17	<b>repeat</b> 19:22	201:8	26:4 27:4	respected
302:4,6,7	35 <b>:</b> 23	271:21	27:18,19	45 <b>:</b> 12
328:23	36:24	290:18	27:24 28:4	103:2
334:25	63:13	296:13	28:8,9	122:4
336:5	241:23	reporting	29:14,25	132:6,21
338:10	280:4	272:15	30:4 33:15	259:9
remembered	281:6	334:3	36:7 37:3	261:3,20
141:9,22	312:7	reports	46:9 57:22	289:8,10
remind 74:16	repeated	75:16	57:23	respects
288:10	198:8	143:15	67:15,17	229:21
reminder	repetitive	229:7	67:18,22	respiratory
309:17	283:9	280:20	70:11 71:6	166:17
removal 240:5	report	336:20 341:3	71:15,19	169:1,25
	164:18,19 190:6		71:23 76:7 117:8	respond 42:2 68:13 72:3
remove 151:22	209:7	represent 9:17	118:7,19	191:24
211:5,11	229:6	represen	133:14	192:4
212:1	232:16,24	46:25	153:14	207:4,8,9
238:1	234:2	230:6	154:12,15	207:10
283:1	242:14,22	represen	154:12,15	responded
288:18	341:1	231:14	155:6,7,13	84:23 90:7
289:1	344:3	represents	156:12	90:19
300:15	reported	232:10	157:4,14	92:17 94:3
301:1	156:25	reputation	215:10,13	116:13
310:4	157:19,24	290 <b>:</b> 7	215:15,16	206:20
removed	233:19	reputations	216:15	257 <b>:</b> 3
156:25	247:11	252:2	261:2,7	276:11
158:10,14	261:24	request	324:22	responding
208:16	309:8	122:10	researcher	143:16
209:19	344:21	132:17	75 <b>:</b> 20	145:5
237:18	reporter	305:24	researchers	204:7
301:1,4,7	9:13,24	329:15,17	174:6,20	226:25
309:22	12:10	requested	175 <b>:</b> 7	341:15,25
311:18,22	17:23	122:15	215:16	responds
329:10,12	26:23	requesting	reserve	134:15
329:13	60:18	295:19	359 <b>:</b> 15	264:10
removing	68:24	requests	reservoir	303:23
211:21	69:16	121:5	143:17	311:16
	<u> </u>	<u> </u>	<u>l                                      </u>	<u> </u>

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

response	247:19	19:13,14	150:12	271:4,7
21:18	280:22,23	19:15,17	158:25	276:13,15
47:20	281:10	22:3 27:8	167:25	277:18
50:16	retracted	32:4,6	170:15,24	278:9
70:12	222:5,21	38:21	171:9	279:13,15
79:22	222:23,24	43:21	172:8	286:18
108:2	222:25	45:11	173:7,12	288:17
118:3	223:1,7,8	47:10	173:16	294:16
121:5	return	48:21 51:2	177:13	295:7
122:6	361:16	51:16	179:6	296:10
132:15,16	returned	55:22 56:6	183:24	298:25
134:18	262:19	56:8,11	187:15	299:9,12
166:10	returning	58:15,18	188:18	299:20,24
198:12	164:10	59:9 61:5	190:18	300:17
206:23	262:12	61:16 62:4	192:6,8,10	307:5
227:15	reverse	62:13	192:13,17	308:7
230:6,12	23:14,15	71:18	192:19	310:3
257:5,7	23:19 24:3	73:14 77:8	193:7	311:14,20
269:3,11	24:6,10,11	77:10	194:3,3	311:20
287:14	24:22	80:21	195:21	317:17
299:22	review 13:1	84:20 85:1	196:1	318:10
314:8	18:25	90:3,22	198:10	320:2
336:18	159:8	91:25	199:25	323:23
342:9	160:4,5	93:25	200:18,20	324:4,17
responses	191:13	94:25 98:1	203:4,13	327:10,13
287:3	214:18	101:25	203:16	327:14
responsi	229:24	105:11,14	204:13	330:14,19
96:1,4	249:14	106:22,25	206:23	330:20
357 <b>:</b> 20	319:1	111:22	207:6	331:18
rest164:25	reviewed	112:17	211:2	333:12 <b>,</b> 14
190:14,22	69:25	116:3,17	212:11	334:5
348:10,13	70:13	118:5,8,10	213:3	339:5,11
restate	159:18	119:17	221:24	342:23
185:12	246:1,6	120:8,9	222:9,19	344:9
restriction	reviewing	123:8,11	227:13,17	348:8
117:17	124:21	123:12	227:20,23	349:6
119:15	revised	124:4,8,20	228:1	350:15,21
restrict	120:5	125:22,24	239:7	351:12 <b>,</b> 22
117:16	128:15	126:1,24	242:18,20	354 <b>:</b> 18
result	revoke	128:19	245:21,24	356:4
112:22	220:19	130:4	250:9,12	359:15
114:5	revoked	131:6,10	250:15	rightly
124:3,5	220:23,25	131:11,12	251:8	46:13
345:11	Reynolds	132:25	253:23	ring 117:4
resulted	264:14,21	133:17	255:12	135:14
355:23	265:1	139:4	257:11	184:16,20
results	rid 309:25	140:25	261:2	209:12
42:18	right 15:21	146:9	264:1,14	239:5,7
246:9,24	15:24	148:21	266:21	264:22

LEXITAS LEGAL Phone: 1.800.280.3376

				=
285:23	324:2,23	SARS-CoV-2	50:13 53:4	138:25
291:19	327:1	43:5 50:7	53:11,13	141:14
293:15	Rowe 293:2	144:16	53:23 54:6	142:22
337:5	rules 11:11	156:19	54:14 57:5	143:12
338:7	rumor 145:21	157:1,3,3	60:20	144:6
349:16	146:1	157:9	62:11 63:5	145:2,13
352:15	run 21:7,9	159:3	65:16,20	145:25
ringing	33:1,25	162:1	65:24 69:4	146:15,25
98:24	110:1	171 <b>:</b> 2	69:22	148:8,15
292:16	175 <b>:</b> 23	178:22,25	71:13 73:5	148:17
rings 270:25	264:22	179:23	74:17	149:18,24
343:20	308:2,9	180:5	76:19,23	150:7
Rio 296:16	316:4	203:3	76:25	151:1
rip 278:22	321:3	SARS-like	78:16	152:16,20
rise 29:1	running 34:2	31:7	79:19	153:2
70:21	175:25	Saturday	82:11	154:6
risen 256:19	260:18	46:21 55:2	83:11,22	155:14
risk 13:15		61:14	84:2 86:10	158:8,22
15:8,15,17	s	66:25 77:4	87:4,17	158:25
18:5,8	<b>s</b> 2:6 6:1,6	82:14 85:5	88:14	159:1,12
22:14 41:4	9:1 10:10	89:25	89:17 90:6	159:24
41:9,15	<b>Sabeti</b> 132:7	91:22	90:14 93:3	161:19
221:6	132:18	93:16	93:17 94:1	162:17
314:18	135:15,17	124:1	94:16,19	163:10
317:10	136:1	341:17	96:7 <b>,</b> 14	164:3,6,15
<b>Rob</b> 336:13	<b>safer</b> 285:3	<b>Sauer</b> 2:5	97:18	166:14
336:16,22	285:13	6:4 9:18	99:10	167:13,17
Robert 35:5	safety	9:18 10:7	102:1	168:23
35 <b>:</b> 6	117:10	12:24,25	108:24	170:8,12
Rochelle	118:11	13:8 14:16	109:21	172:17
296:17	313:19	18:3,22	110:8	173:1
Rockefeller	314:24	19:20	111:13	174:13,23
292:3	358 <b>:</b> 17	20:22	112:11,25	176:10,17
<b>role</b> 75:2	359:6 <b>,</b> 7	22:11	113:18	178:11,15
76:1	<b>San</b> 133:15	23:23	115:3,21	178:16,20
100:12	174:9,15	24:13,19	117:6	179:5,16
248:11	174:17	25:6 <b>,</b> 22	118:17	181:25
rolling	175:8	26:8,19	119:2,23	182:4,9
283:20	231:18	27:1 29:20	120:1	183:10
Roman 288:14	Sandra	30:13 31:5	121:4,9	184:6
room 4:12	324:15	35:24	123:2	185:9,10
149:14	325:7,20	36:20,22	125:20	185:19
Rouge 2:21	Santa 293:12	37:23	127:20	187:7,14
rough 123:14	293:18	41:11,17	128:6	188:1
124:2,7	<b>SARS</b> 25:21	42:4 43:16	129:13,18	190:3
<b>Routh</b> 37:25	55:21,25	47:4,22,23	130:12	193:21
38:5	57:1 61:3	48:13,15	134:22	195:18
308:12,14	SARS-CoV-1	48:20,24	137:16	196:15,23
308:15	144:15	49:20	138:12,20	197:7,22

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

199:17	254 <b>:</b> 2,10	319:8,16	71:21 74:7	342:16,16
200:16	256:1	322:23	84:17 86:2	344:13,17
201:10,12	257 <b>:</b> 21	323:18,22	86:14	344:20,21
201:10,12	259:16	325:10,22	90:20	344:24
203:17,23	260:8	326:3	91:11 92:1	348:19,22
204:2	261:9,15	327:6,23	99:2 103:6	356:3
205:13	262:9	328:3	103:16	357:10
206:2,15	263:10	329:19	116:24	<b>says</b> 15:16
207:23	266:7,18	330:4,9	121:7,7	22:1 23:4
208:6,8,20	269:15 <b>,</b> 25	331:25	132:5	25 <b>:</b> 24
209:6,15	270:9,20	332:11	136:23	26:16 27:8
209:20	271 <b>:</b> 18	333:9	139:4	39:20 41:1
210:11,14	272:18	334:16,22	143:3	42:13 49:2
210:20	273:8,17	337:2	144:10	50:23
211:19	274:8,13	338:9	145:6	51:24 52:6
212:18	275:6,11	339:20	146:8,16	54 <b>:</b> 17
213:20	277:21	340:24	161:15	55:18,25
214:3,23	280:10,18	341:11	163:15	63:10
215:8	281:4,13	344:2,10	164:21	65:19 67:2
219:8	282:14	346:4,19	179:4	68:19
221:13,19	283:5,14	346:20	180:13	69:24
223:5,11	284:11	347 <b>:</b> 7	189:6,11	70:19 73:8
224:4,17	285:15,21	348:24	191:6	73:15 84:8
226:4,12	286:6,20	352:11 <b>,</b> 22	192:5,11	85:11
226:23,24	287:13 <b>,</b> 17	354 <b>:</b> 17	197 <b>:</b> 25	86:20 88:6
227:6	287 <b>:</b> 23	355:3 <b>,</b> 25	198:21	89:24
228:18,23	289:5	356:17	199:4	93:24 95:1
229:23	292:9	<b>save</b> 103:20	200:7	97:16
232:15	293:16	144:15	206:21	102:3,19
233:9	294:5,8,19	169:17	218:13	103:2,12
234:14	297:11	342:22	226:3,7,8	106:13
235:2,14	298:6,11	saved 151:10	228:11,12	108:2
235:25	298:20	345:12	228:14	110:18
236:12	299:5	saving	229:7,13	112:4
237:13,16	301:12	256:16	234:9	113:10,11
237:22,24	302:3	<b>saw</b> 81:13	244:8	115:12
239:19	303:1,18	130:3	245:13	116:14
240:15,19	304:22	165:13	272:11	118:2,16
240:25	305:1,15	184:21	274:16	120:7,22
242:13	305:18	196:6	283:9	121:14
243:6,19 244:22	306:11 307:17	<b>saying</b> 11:24 25:12	288:16 289:10,20	123:13 124:6,17
244:22	309:3	27:25	304:19	125:2,9
246:4,15	310:17,21	32:19	310:8,11	127:1,1
240:4,13	311:2,10	34:22	315:15	128:15
249:5,8,24	312:24	40:16 48:3	316:20	131:2,18
251:1,20	313:5,20	58:2 61:22	324:24	131:27
253:4,7,13	314:7,25	64:10	328:13	132:12
253:17	318:11,23	69:23	342:4,13	137:6,15
	310.11,20		5 12 • 1 <b>,</b> 10	10,10,10
				•

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

139:22	245:19	scan 197:17	scientif	303 <b>:</b> 2
142:25	246:5	scenario	37:7	scours 260:4
143:13	247:20	156:14,15	scientist	screen 9:4
144:23	249:11,18	SCHMITT 2:6	32:13,20	42:6,10
145:19	250:1	scholar	33:8,11	43:19
146:8,12	251:4	258:19	40:11,14	60:10
146:13	254:1,8,18	259:9	40:23 44:6	71:25
148:24	255:1	scholarly	45:22 47:2	281:19
149:13	260:9,10	258 <b>:</b> 20	104:15	340:21
153:22	264:5,12	259:13	147:20	screened
161:24	267:18	333:21	191:16	263:19
164:16,17	268:4	scholars	193:3	scrutini
164:19	271 <b>:</b> 20	334:4	204:22	322:11
170:25	272 <b>:</b> 25	School 40:12	207:14,17	search
171:15	273 <b>:</b> 7	40:24,24	261:3,22	280:22,22
172:1	275:22,25	265:11	292:19	281:10
177:13	278:2,2	291:3	293 <b>:</b> 7	searching
179:6,11	280:16	science 17:5	334:1	302:13
180:7	288:18	17:7 49:6	357 <b>:</b> 1	<b>sec</b> 204:16
182:19	299:13	50:9 62:14	scientists	271 <b>:</b> 17
183:11	300:2,17	110:19	32:18 33:2	<b>second</b> 17:18
188:8,14	303:5,10	111:7	44:19	19:9,11
190:16	303:15 <b>,</b> 23	113:8	46:20	25:24
191:11	304:1,6	193:4,4	58:25	26:18,21
197:3,4,18	305:21,24	273:11	59:23	39:9,12,14
197:18	307 <b>:</b> 25	319:17	63:21	47:5 50:19
198:4,5,20	308:19	323:10	75:22 80:1	52:4 62:3
202:20	309:8,16	scientific	148:2	101:24
203:7	309:19	21:7 34:1	149:16	102:10
209:11	311:24	37:8 75:14	251 <b>:</b> 15	105:1,3,10
210:21,22	324:19	75:16 76:7	271:10	111:14
211:3	325:20	77:7 79:3	297:18,21	115:4
212:23	327 <b>:</b> 7	102:5	298:4	120:2
213:3	328:17	175:5	scope 58:4	125:8,21
218:8,25	329:9	183:17	58:23	127:4,7
219:10,15	330:24	189:7,12	59:12	132:11,23
219:16	331:9,22	191:7,9,16	62:21	144:24
222:1,13	332:2	195:8	63:16 70:7	145:16
222:16,23	335:2,17	201:23	71:22	161:23,24
222:25	335:18	202:12,21	Scott 267:23	171:23
224:20	337:9,10	215:4	300:1	180:2
226:25	337:14	216:1	346:21	182:16,25
229:3,12	341:15,24	218:13	348:3,21	194:21
232:17	342:24	219:17	349:8	197:24
233:18	344:8,11	259:11,12	350:6,6	218:9,12
234:2	344:16	273:3	351:11	224:12,22
235:5 237:21	353:5 <b>scale</b> 153:22	292:4 295:3	352:1,3,9	225:2,5,6 229:4
243:2	244:1	295:3 318:17	352:13,18 scour 302:24	252 <b>:</b> 8
243.4	८44 • ⊥	210:11	300ur 302:24	2J2:0
		I	I	

LEXITAS LEGAL
Phone: 1.800.280.3376 Fax: 314.644.1334

0.67 0 10	F1 14	176 00	204 1	104 7
267:9,10	51:14	176:22	324:1	124:7
283:19,20	52:17	179:7,8	325:2,7	127:4
298:21	53:14	182:19	328:5	132:14
311:11	54:15	183:11,15	329:11	138:24
324:13	55:17 <b>,</b> 18	185:20,24	330:18	153:18
325:2	65:12 68:6	185:25	331:22	159:9
328:4,8	72:4,23	190:13	332:1	202:10,19
329:10	73:6 <b>,</b> 18	197:17	335:17	261:6
332:14	74:19,21	202:17	337:11 <b>,</b> 18	275:13
335:14	75:23 78:7	204:3	341:12	295:9
341:12	84:10 86:6	207:7,14	344:3,5	sending
353:6	86:22	207:15	347:17,17	37:25 49:8
359:15	89:23	209:7	350:7	61:22 67:8
second-t	93:10	222:1,5	352 <b>:</b> 1	266:19
97:10,19	94:25 98:6	225:12	353:13	268:21
98:2	101:14	232:16,20	354:15	330:21
101:10	102:2,7,9	232:23,25	seeing170:6	350 <b>:</b> 3
126:19	103:11	234:6,7	188:8	senior
307:19	105:4,15	235:3	263:20	108:14
secondary	106:21	242:16	284:22	271:20
145:21	110:14,22	244:24	<b>seen</b> 19:2	<b>sense</b> 143:8
146:1	111:4,14	248:7	20:8 21:10	146:3
seconds	113:13	254:1,18	25:17 48:4	205:7
51:24	115:14	259:18,19	125:22	229:22
secret	116:16	259 <b>:</b> 20	175:16	230:19
349:13	119:18	260 <b>:</b> 7	205:7,10	sensitive
secretary	120:22	263 <b>:</b> 4	205:20	357 <b>:</b> 2
5:2 255:12	121:10	267:4,7,12	279:20	sensitivity
255 <b>:</b> 15	123:9	267:16	283:16	74:3
256:5 <b>,</b> 10	125:4	270 <b>:</b> 4	284:18	<b>sent</b> 49:18
267:24	130:18	271:19	322:6	50:5 54:20
313:9	137:5	272:2,24	337 <b>:</b> 15	54:24
security	139:10	274:15	<b>sees</b> 164:3	61:14,18
28:6,14	142:1,25	275:16	selected	66:9 68:11
30:2	143:1,21	277:23,24	74:23	68:14,18
348:23	144:23	283:20	selection	69:9 <b>,</b> 24
349:8,13	145:17	284:10	75:1	75:8 89:25
349:15,18	146:5	285:4,5	selectively	91:22 92:2
see 12:12	148:18,25	294:23	258:3	120:15
13:22	152:21	295:19	277:3	127:7
14:15	153:6	298:22	self-cor	128:17
21:25	154:2	299:16,21	323:10,11	129:1,4
22:25 23:4	156:6	305:5	selling	132:4
26:20 31:6	163:11,15	306:12,17	310:12	135:19
39:11,16	163:16,24	306:24	send 55:2	139:21
39:25 41:6	166:23	308:6,12	61:20	159:14,15
43:2 44:12	167:18	309:6	82:22	160:4,17
48:1,16,25	170:23	311:13	120:10	160:21,24
50:15,19	176:5 <b>,</b> 21	317:3	123:15	161:15
			l	l

LEXITAS LEGAL Phone: 1.800.280.3376

173:22	sequenti	239:12	287:18,19	319:15,18
179:18	116:2	<b>SHEET</b> 362:1	287:21	319:22
189:18	serial	sheets	315:7	322:19
196:5,10	115:13,23	361:11,13	341:4	358:5,9
202:8	116:2,10	361:16	342:2,3	sign 29:9
208:24	117:13	Sheryl	343:21	298:14
254:5,11	293:11	296:13	showed 21:2	359:16
254:15	series	Shi 33:5,14	21:15	361:13
		35:17 36:1	35:18	
263:22	176:19	36:6,16		signature
269:8	217:18	•	60:12	308:5
294:13,21	serious 88:1	37:2,7,13	160:22,22	324:21
295:8,12	seriously	55:19,25	180:1	361:11,13
305:11	88:24	56:9,16,23	214:10	361:17
307:21	358:3	60:23 61:2	219:24	362:25
311:11	service	62:13	221:1	signed
sentence	241:15,17	71:15	237:1	248:17
14:3 42:24	282:25	117:8	269:2	251:5
52:4,6	285 <b>:</b> 17	119:4	316:9	297 <b>:</b> 22
105:10	Services 4:8	<b>shiny</b> 192:6	337 <b>:</b> 15	298:7 <b>,</b> 14
121:11,14	4:10	192:16,21	342:3	significant
153:22	267 <b>:</b> 23	192:25	347:12 <b>,</b> 13	76:12
161:24	313:10	193:2,11	352 <b>:</b> 17	187:5
164:17	session	199:4,6,7	353 <b>:</b> 21	267:3
165:5,12	359 <b>:</b> 21	<b>short</b> 2:17	showing	323:14
166:1	<b>set</b> 27:21	83:15 <b>,</b> 15	215:7	signoff29:5
180:4	119:3	152 <b>:</b> 21	217:10	silent63:24
191:11	setting	316:3	318:25	64:13
199:22	238:21	shortage	323:17	silently
211:10	<b>settle</b> 189:5	316:22	<b>shown</b> 12:22	69 <b>:</b> 20
245:18	189:13	321:2,5,13	22:23 25:9	similar
267:15	191:4	321:20,23	189:12	102:25
284:2	<b>seven</b> 54:1	Shortlander	<b>shows</b> 31:8	144:15,19
344:16	85 <b>:</b> 25	110:12,13	246:9	315:13
sentences	91 <b>:</b> 18	245:22	247:18	Sincerely
23:3 70:24	228:3	shortly	347:2	361:20
162:11	359 <b>:</b> 12	10:19	348:2	<b>sir</b> 47:1
September	severe	277 <b>:</b> 13	<b>shut</b> 69:20	69 <b>:</b> 21
123:19,22	262 <b>:</b> 22	<b>show</b> 12:16	92:13 <b>,</b> 19	75 <b>:</b> 13
158:1,11	shaking	25:13 78:2	242:16	135:5
sequence	150:23	180:4	<b>shuts</b> 243:3	163:14
189:5	<b>share</b> 89:5	192:1	shutting	226:18
191:4	164:24	206:24	93:2 94:3	<b>sit</b> 14:19
sequences	201:23	209:22	94:6	132:13
51:14 78:9	297:12	219:25	262:23	<b>Sitar</b> 324:15
121:15	<b>shared</b> 73:16	221:7	<b>sick</b> 42:15	<b>site</b> 153:24
157 <b>:</b> 25	73:17	242:8,9	sickness	283:15
158:9,14	297:17	248:6	274:4	sitting
158:16	sharing	257 <b>:</b> 4	<b>side</b> 78:1	253 <b>:</b> 23
198:15,16	237:19	277:13	<b>sides</b> 319:11	308:9

LEXITAS LEGAL Phone: 1.800.280.3376

	-	-		
situation	smaller	238:23	somebody	199:7
28:11	92:12	239:5,22	21:3,12	211:7
42:20	235:4	241:7,13	34 <b>:</b> 12	212:19
106:10	smiling	241:15,19	99:13,22	227:7
117:21	173:5	241:23	209:24	230:10
151:5	<b>SMITH</b> 2:7	262:6,14	212:12	240:9
154:11	sneezes	262 <b>:</b> 22	213:2	243:1
167:1	314:17	269:17	241:3	254:11
169:12	sniffling	270:1,12	242:5	270:14
220:5	138:5	270:16,23	266:1	284:9,17
317:10	<b>SNOW</b> 3:24	274:10,17	302 <b>:</b> 7	286:24
322:17	<b>social</b> 78:12	274:18,22	332:14	295:15
situations	79:1,14	275:5	349:24	305:17
155:8	98:10,15	280:2,5	someone's	306:16
322:14	98:17,22	281:18,25	259:8	327:1
six 54:1	99:3,6,11	282:5	somewhat	334:19
64:23	99:13,21	290:8	80:16	343:24
85:25	99:24	301:6,11	169:16	347:20
91:18	100:6,19	301:18	soon 148:6	350:12
161:14	100:25	302:18,24	251:12	sort 14:2
228:2	101:3	303:2	317:14	51:19
300:4	102:5,14	304:15	<b>sorry</b> 19:22	79:18
<b>sixth</b> 89:20	102:18	307 <b>:</b> 8	20:18 22:9	80:25
skewed 247:2	103:9,12	311:23	26:10	87 <b>:</b> 19
<b>Slack</b> 337:9	103:13,16	312:3,8,11	39:17	119:5
Slavitt	104:19,20	312:18	53:17,19	141:7
336:6,7,8	105:17,19	333:4	53:22	143:5
336:15,22	105:25	334:7	60:16,17	155:19
337:10,14	106:13,13	335:11	60:24	213:12
<b>slide</b> 284:16	106:18	338:12,16	61:25	244:16
slight	107:6	340:14	65:21	284:18,19
314:15	110:20,25	344:12,18	71:11	338:18
<b>slow</b> 26:24	111:4	345:5	101:22,23	342:6
60:19	150:15,19	346:9,10	102:11	347:13
74:16	151:3,21	356:7,12	105:7	<b>sound</b> 78:8
87:13,15	152:8	356:16,19	119:9	208:13
100:23	165:14,20	357:19	123:23	258:13
145:24	166:19	358:1	125:5	323 <b>:</b> 7
150:25	168:25	socially	135:3	sources
209:14	169:10,15	346:24	145:23	190:6
<b>slowly</b> 12:4	169:18,20	society	149:3	207:11
12:6	208:2,11	169:22	163:14	Southeast
<b>small</b> 51:12	209:2	194:18	178:24	140:8
51:25	210:4,7	258:4	181:25	<b>space</b> 226:24
92:24	213:9,13	278:23	182:23	<b>spare</b> 204:15
236:9	213:15	software	185:21	<b>speak</b> 12:4,5
314:14	235:22	100:1,13	187:15	54:18 58:3
317:25	236:10	<b>solid</b> 191:15	188:4	58:14
336:8	238:5,7,10	265:23	190:9	68:25

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

69:17	186:9	138:18	213:8	104:5
192:14	187:4	155:7	270:16	169:2
speaking	188:6,22	206:1	352:4	194:17
63:11	216:11	268:24	spend 80:24	314:10
107:5	223:17	269:20	303:4	317:2
260:2	228:12	speculat	Spiked 8:6	spreads
Spec-305:14	238:16	80:5 106:3	280:12	237:4
special 28:1	244:3	speculative	spillover	spring
species	258:16,18	86:9,25	43:3	217:22
198:18	260:2	88:13 89:7	spirit 97:1	spurious
200:10	263:1,21	92:25	153:11	329:13
specific	268:11	95:23	<b>spoke</b> 45:25	squarely
42:13 61:6	270:24	108:19	72:15	340:20
71:5,14	285:13	129:15	136:7	<b>ss</b> 360:2
82:10	293:24	146:11	216:23	<b>St</b> 3:16
130:1	302:6	149:8	272:13	361:18
181:3	304:14	152:11	273:24	<b>staff</b> 29:2
187:1	314:3,5	154:5	318:15	29:11 38:3
219:21	315:1	167:8	341:16	38:7,23
258:15	325:1,9	182:8	342:1	39:5 42:22
267:4,7	326:10	210:19	351:24	58:10
281:6	328:25	234:13,18	<b>spoken</b> 45:14	136:10
327:21	329:1	246:18	45:23	139:2
329:5	340:17	255:24	91:10	152:7
344:24	344:23	257 <b>:</b> 20	sponsor	186:14,15
352:9	347:12	259:5,24	138:15	205:16
specific	352:2	259:25	spot 48:14	260:5
20:7 29:6	354:9	260:23	48:16,25	268:16
34:2 49:19	specifics	274 <b>:</b> 12	spouting	270 <b>:</b> 22
67:19	58:9 77:24	285:8	229:1,10	300:18
72:15	speculate	289:2	<b>spread</b> 79:22	301:2,5,13
78:23	87:2,6	301:8	103:22	302:14,17
79:20 83:5	speculating	303:14	151:13	302:21
83:9 91:3	40:5 89:16	304:17	166:3,19	304:21
95:19	102:20	310:19,25	168:17	308:16,18
96:25	speculation	311:6	177 <b>:</b> 8	308:21
103:24	24:5,18	312:16	194:11	309:21
118:25	29:19	313:16	258:4	310:3,11
124:10	35:22 40:7	318:7	262:1,8,23	310:15
139:18	41:12 46:5	325:14	274:16,18	312:10
142:4	62:8 73:25	326:2	278:3	<b>stage</b> 173:2
147:8	74:6 79:25	327 <b>:</b> 5	302:22	316 <b>:</b> 17
159 <b>:</b> 17	88:16	329:18 <b>,</b> 23	316 <b>:</b> 25	stages
162:16	89:11	331:21	317:4	313:14
163:3	108:19	333 <b>:</b> 8	318:5	stamping
169:4	112:24	334:11	339:23	54:3
175:12,25	113:17	speech	340:2,8,13	<b>Stand</b> 150:2
181:18	116:21	151:16	344:15	standard
184:25	118:14	208:1,10	spreading	7:22 9:4
			]	

LEXITAS LEGAL Phone: 1.800.280.3376

19:1	145:7	stating	193:3	214:10,16
179:21	146:22,24	193:10	sticking	214:17,21
242:15	162:10	214:13	80:3,4,10	214:24
243:2	173 <b>:</b> 14	237:18	80:10	215:11
244:11,12	200:4	statistical	<b>STILES</b> 2:18	219:23,24
244:14	219:17	320:12,16	Stolberg	219:25
standing	224:20	322:11	296:13	223:17,18
12:16	225:17	323 <b>:</b> 16	<b>stop</b> 100:16	244:1,25
25:11	232:21	statisti	304:13,15	244:25
114:21	233:19,20	247:7	339:23	245:9,11
236:20	248:19	323:6,14	stopped	245:20
standpoint	263:18	statisti	110:3	246:1
165:7	279:11,12	244:5	stopping	247:4,6,8
Stanford	304:6	247:22	340:2,5,8	247:10
252:9	322:10	<b>status</b> 126:9	340:13,16	293:22
257:10	323:13	<b>stay</b> 52:20	strains	316:9,13
267:21	333:25	72:4,6	23:13	317:21
290:12	334:6,8	84:24	strategy	318:2
291:4,5,15	343:12	85:15	268:2	320:3,9,11
291:23	345:2	125:1	271:23	322:2,6,8
292:20	statements	staying	stream	322:11,14
<b>start</b> 12:9	64:5 70:25	50:14	176:24	323:15
22:1 89:16	140:16	234:1	177:3	<b>study</b> 35:18
91:16 97:8	214:12	<b>Stemmy</b> 42:16	Street 2:9	82 <b>:</b> 16
136:23	217:18,23	205:14,17	2:20 3:5	109:16
started	218:2	205:22	4:2 361:5	183:16
111:21	228:7	Stenotype	361:18	185:22
190:7	234:11,15	1:21	strict 15:3	198:13
starting	237:1	<b>step</b> 354:10	strictly	219:12,22
26:3 53:24	272:15,17	<b>Steph</b> 101:5	16:7	220:2
97:9 102:4	273:19	101:5	strike	221:14
<b>state</b> 1:5,17	278:16	Stephanie	275:21	222:11,21
2:3,14 9:6	279:17 <b>,</b> 18	1:16,22	<b>strong</b> 353:7	244:10,16
9:17 10:8	312:3	9:13 360:4	355 <b>:</b> 12 <b>,</b> 13	244:16
341:5	315 <b>:</b> 12	<b>steps</b> 73:17	355:18,22	245:3
342:10	317:10	109:15	356:2	246:12
343:2	333:5 <b>,</b> 16	151 <b>:</b> 12	strongly	247:21,23
360:3,21	343:5	191:19	28:8 169:9	248:6,7,12
361:7	355 <b>:</b> 12	192:12	189:7	293:12 <b>,</b> 17
362:2	359:18	195:1	346:1	293:23
363:1	states 1:1	227:18	354:8	298:2
stated	9:9 14:4	229:21	structured	318:25
218:20	166:10	230:8	164:12	320 <b>:</b> 15
297:19	168:22	234:22	165:11	323:9
statement	177 <b>:</b> 24	236:20	studied	354 <b>:</b> 3
81:23	182:11	296:22	156:20	studying
106:9	276 <b>:</b> 6	297:3	198:9	15:1
129:10,23	321 <b>:</b> 16	358:20	studies 7:23	<b>stuff</b> 100:6
144:4,5	360:2	<b>stick</b> 191:16	116:25	210:7
			l	

LEXITAS LEGAL Phone: 1.800.280.3376

213:13	160:10	<b>Sunday</b> 105:5	72:13 74:1	259:1,3,6
235:22	171:21,24	341:4	76:4,13	259:7,8
289:22	172:12,19	342:2	79:11	270:19
328:24	172 <b>:</b> 22	347 <b>:</b> 2	88:20 91:4	272 <b>:</b> 10
<b>style</b> 154:25	succeeded	Sunetra	91:15	273 <b>:</b> 23
258:22	329:8	251 <b>:</b> 17	107:18	274:18 <b>,</b> 19
279:22	<b>sucker</b> 342:6	267:21	113:23	276:19
<b>sub</b> 90:12	<b>sudden</b> 88:21	<b>supply</b> 316:3	114:1,8	282:4,16
subaward	suffering	321:14	115:18,20	283:7
36:5,10	169:3	353:11	117:24	285:9
37 <b>:</b> 12	sufficient	supported	124:12	286:25
156:21	52 <b>:</b> 25	133:14	126:10	287:11,20
subawards	suggest	supports	138:5	289:14,16
37:16	92:13	174:15	140:2	292:6
<pre>subject 39:3</pre>	suggested	supposed	147:18	293:6
83:10	44:18	109:3,4	150:1	300:23,24
91:23	208:16	suppress	153:10	301:2
120:5	337 <b>:</b> 14	354 <b>:</b> 15	156:3,8	303:16
215:22	suggesting	suppressing	160:3,20	304:3,18
216:24	313:23	209:2	161:11	306:20
264:7	suggestion	suppression	163:6	310:7
320:12	107:21	208:10,14	167:4	311:8
322:11	132:9	Supreme	174:1,14	317:20
328:17	suggestions	225:19	174:25	320:8
330:24	172:2	227:19	175:8,15	334:14,24
351:21	198:1	228:2,7	178:8	348:19
subscribe	suggestive	230:9	180:13,18	350:12
363:11	81:14	234:23	181:6	355:17
subsequent	suggests	236:21	190:24,25	Surely
29:23 322:13	245:15	<b>SUR</b> 3:25	191:23 193:20	116:14
	<b>suit</b> 240:6 240:16,21	<b>sure</b> 11:12 11:19	193:20	surfing 252:24
subseque	Suite 3:6	16:14,16	200:6,25	
81:24	summary	16:25	200:0,23	surgeon 315:21
215:6	111:19	20:13	205:17,10	316:19
220:13	112:4,5,8	23:18,21	208:22	surmise
subset	112:10,18	30:11	216:4,20	154:9
335:18	112:21	36:25 37:5	220:10	surmising
347:17	113:2,3,4	41:20	223:25	191:8
Substack	120:7,15	44:17 47:6	224:21	surprised
8:17,20	222:15	48:18 50:4	227:25	83:8
substance	245:13	51:6,9	234:20,25	162:22
363:8	Summary	56:3 57:10	242:3	163:2
substantial	123:11	62:23	245:2,13	181:7,11
180:19	Summary.PDF	66:14,21	246:19 <b>,</b> 25	181:15,21
substant	126:24	67 <b>:</b> 23	249:12	184:18
289:23	summer	68:21 70:8	255 <b>:</b> 19	187 <b>:</b> 2
substantive	217:20 <b>,</b> 22	70:10,19	256:9,12	216:22
114:13	347:9	71:22	257 <b>:</b> 4	347:14
]				

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

surprising	12:11	253 <b>:</b> 10	27:16	349:3
187:6	13:11	307:9	38:19,23	353:15,16
261:8	14:22 21:3	328:22	39:5,15,19	355:20
	41:7 51:23	358:20	40:17 43:6	talks 35:13
332:14,16				
332:24	77:2 80:23	360:5,8,13	50:7 52:4	50:10
333:4,10	81:1,6	361:10	58:5 59:3	131:23
333:16	83:12	362:3	63:2,7	136:13
334:7	104:24	takes 237:2	72:9 77:24	250:7
surveill	109:9,16	talk 64:7	81:18	257:19
57:23,25	109:25	81:18	84:13	259:10
156:9	117:22	101:7	88:22	tangent
157:5	119:12	133:4	90:25 93:4	47:14
surveyed	123:20	135:19	106:4	tangents
222:11	131:7	136:4	107:1,3	127:25
susceptible	148:6	157 <b>:</b> 7	109:12	128:4
258:3	149:24	248:7	116:24	tap 122:14
suspended	152:9	258:9	117:4	<b>tape</b> 230:3
209:25	165:9	287:10	129:24	230:15
335:20	191:19	292:21	130:21	target 258:3
suspending	192:11	303:25	138:14	targeted
209:16	193:25	318:13	139:6	250:16
suspends	194:24	326:8	140:15	274:7
209:8	195:1	327:11	150:14	<b>task</b> 79:15
suspicion	203:17	329:3	154:4	87 <b>:</b> 21
50:8 52:18	217:13,16	338:2	163:18	196:25
88:18	230:13,20	341:4	168:21	197:6,9
suspicious	247:21	349:18	169:19	201:3
77 <b>:</b> 25	248:7	351:19	171:14	204:11
swift259:22	253:4,5,5	<b>talked</b> 23:25	187:13	208:1
<b>sworn</b> 1:16	257 <b>:</b> 24	56:10,24	188:4	321:1,12
10:4 360:7	284:18	85:6 91:14	195:21	<b>tasks</b> 58:7
<b>Sylvia</b> 313:6	296:22	130:25	202:9	59:10
313:9,17	301:24	136:13	206:17	team 39:21
314:3	302:2	147:15	212:5	40:3
symptoms	312:1,2,23	157:11	224:15	123:14
316:15,16	313:23	163:19	226:1	139:22
system	322 <b>:</b> 5	203:6	228:8	299:13
122:13	334 <b>:</b> 7	225:17	230:24	308:23
357:11,18	338:17	233:6	234:21	311:17
358:24	357 <b>:</b> 20	261:12	240:15	324:4,11
	takedown	286:8	241:21	324:24
T	257:17,19	297:13	258:20	325:8,11
T6:1,1,6	258:10,13	351:18	269:6	325:12,24
<b>Tabak</b> 65:4,6	259:23	355:6,7,8	287:8,8,21	326:15,19
65:7,8	taken 1:18	355:10,11	295:15	327:3,13
66:7 67:4	1:21 9:6	talking	307:13	336:9,18
253:25	151:13	11:15 15:8	314:23	teams 131:20
<b>TAG</b> 265:14	219:5	22:2 23:7	341:22	137:8
take 12:11	243:10	23:24	347:18	technical
		<del>-</del>		
	•		ı	•

LEXITAS LEGAL
Phone: 1.800.280.3376 Fax: 314.644.1334

177:10	282:9	329:10,12	248:9	241:11
289:21	terminol	354:20	281:22	243:18
308:5,20	258:14	thanks 84:23	282:23	256:15
308:25	terminology	206:21	303:20	269:7,10
Technology	16:4,9,11	303:10,15	304:13	274:16,17
17:6	17:14	that'd	306:14	276:12
<b>Tedros</b> 95:3	24:23	338:21	328:23	279:23
95:5,6,21	108:21	theme 97:1	329:14	301:10
95:25 96:5	terms 154:25	126:5,17	341:10	302:17,25
96:17,21	241:14,17	136:23	353:25	310:1,12
108:2,4,5	282:25	283:9	things 16:21	310:13
108:14	285:17	358:22	19:1,3	311:21,22
110:11	terrain	theories	23:20,21	315:6,7
139:23	58:23	78:12	39:7 42:23	316:21,21
teleconf	Tessier	143:18,19	56:19	335:12
90:18,18	291:21	143:20	64:12,16	340:6
91:23	Test 23:4,9	theorists	80:1,7	349:9
93:25	23:11,12	185:22	89:16	352:16
television	tested 23:13	theory 51:1	102:25	355:6
226:16	testified	52:6 79:20	113:25	358:15,16
tell 61:7	10:5 43:17	188:20	115:19	359:13
87:7,9	77:1,6	193:16	116:8	think 11:20
118:25	123:18	194:1,4	117:12	16:15
156:23	140:24	199:4	122:18	20:13,14
158:6	243:20	213:8	128:5	21:13,15
177:6	339:10	264:4	129:25	21:18
233:21	testimony	therapeu	142:17	34:24
278:13	26:2,7	245 <b>:</b> 16	143:17	38:14 40:5
287:22	50:1 60:21	therapy	144:9,11	42:19,24
298:3	256:25	265:14	145:7,8,10	43:17
301:17	302:20	thereabouts	150:15	44:16
315:23	310:6	325:25	151:19	46:22
347:22	340:7	thereon	155:20	52:10,12
telling	360:6,8	363:10	156:4	57:14,23
69:14 70:5	text 22:25	thereto	157:12	60:5,12,13
301:25	39:14	360:15	159:14	62:18 63:9
temporary	74:19	they'd	160:5	63:10 70:5
170:4	<b>thank</b> 18:1	108:21	162:10,12	74:5 79:13
ten 92:14	84:18,21	<b>thing</b> 38:22	174:2	79:23 80:9
tend 96:4	132:5,20	39:1 77:15	177 <b>:</b> 8	80:18 87:2
192:22	145:14	131:15	185:14	87:24 88:3
tens 25:18	148:16	137:21	189:17	88:3 <b>,</b> 23
tensions	171:1,15	142:10	191:22	90:10 96:3
102:22	171:19	155 <b>:</b> 20	194:8,22	97:19 <b>,</b> 21
tenth 91:19	179:8	174:13	195:15	101:1,3,5
235:21	196:10	190:2	210:2	101:15,18
<b>tenure</b> 78:3	206:24	192:23	212:8	101:22
term 24:7	277 <b>:</b> 18	225:5	226:2	102:18
118:22	325:21	233:13	238:19	103:1,5,25

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

				1
107.00	250.21	126.11 12	200.24	E0.0E E4.0
107:22	259:21	136:11,13	208:24	52:25 54:8
108:13	260:1,2,6	176:2,11	242:4,5	54:12
109:8,24	260:11	176:12	263:18	57:13
110:3	261:24	189:3	288:3	59:16
114:7	262:16,16	210:25	290:14,14	60:22,24
119:4,16	265:23	218:25	315:7	65:8,15,17
128:4	269:1	219:9	<b>thread</b> 337:9	66:15 68:9
132:2	270:2	222:14	threat	69:8 71:2
138:2	274:9	232:22	105:17	74:8 76:2
141:5	277:4,10	233:1	threatened	78:4,6
143:16	282:17	234:1	349:14	79:6 80:19
150:13	286:8	249:17	<b>three</b> 53:25	80:23 <b>,</b> 24
151:5,12	289:22	272:24	60:14	81:6,20
154:10,16	303:4,20	278 <b>:</b> 7	85 <b>:</b> 25	82:3,15
154:25	303:21	283:24	89:20	83:17 <b>,</b> 20
155:1	304:11	305:2,23	91:17 93:7	93:23 95:2
156:17	306:22	337:7	94:7 99:18	95:10
159:22	309:16	thirdly	177:2,3,3	99:15
164:23	310:14	316:13	249:22	102:15
169:18,20	311:24,25	Thirteen	251:15	106:7
171:16	312:19	66:2	255:11,13	109:25
173:24	322:25	Thirty-two	255:21	110:3
175:15,21	326:23	210:10,11	294:14	121:20
176:9	329:14	thoroughly	315:22,23	123:20
177:2	333:18,20	107:8	316:1,18	125:13
181:24	335:10,20		316:21	126:18
184:9	338:24	thought 42:22	317:3,4,7	129:9,24
188:23,25	339:5,18	46:12	331:4	138:13
190:1,23	341:5	261:21	three-way	139:5
191:15,21	343:13	336:19	34:21	144:15
192:13	351:7	358:3	threw 192:24	147:12
	354:16			
193:7,16	355:19	thoughtful	throw 80:5 thrown 112:7	150:3,5
195:13,16			tidied 127:1	169:19
195:19 201:6	356:6,20	112:4,8		172:9,14
	357:7,14	thousand	127:5,13	173:23
202:6	357:19	153:13	ties 70:23	175:10
205:10	358:5,8,13	207:3,3	tight 86:21	180:9,24
207:14	thinking	244:18	87:8 88:4	192:18
214:23	60:7	300:4	time 9:3,5	194:13
220:9	108:11	thousands	11:8 16:13	197:8
223:24	144:7	21:14	16:15 19:6	199:5,8
226:6	223:14	22:20	20:8 22:6	203:18,21
227:18	257:24	25:18	22:12,22	204:23
228:5,5	third 121:10	32:18 33:1	27:11,14	219:4,6
229:17	128:17,20	45:18	27:23 28:7	220:4
237:3	130:13,15	112:6	31:22 35:6	223:2,8
249:3	130:20	129:24	36:4 43:18	226:6
252:16	131:2	148:1	45:15,23	227:3
256:6	133:10	173:25	46:11,18	230:16,20
		l		

LEXITAS LEGAL Phone: 1.800.280.3376

				1
235:21	175 <b>:</b> 17	today's	142:7,25	tough 335:21
239:14	201:22	359 <b>:</b> 20	173:11	touted
240:20	205:6,10	told 57:21	179:6	236:21
242:8	226:16	147:5	185:21	touting
248:8	239:21	210:5	197:4	225:19
249:16	280:4	212:13	204:3	227:21
250:4	282:1	260:17	209:8	229:9
251:24	296:14	271 <b>:</b> 21	211:3,8,21	235:10
252:2	321:1	272:5	216:12	toxicity
253:8,11	334:2	289:7	222:1,2	225:11
255:4,18	344:3,21	312:6	226:22	toy 199:4
256:11,17	345:8	317:23	233:2	tracing
256:22	349:14	321:1	247:25	165:8
258:9	353:9	357:24	249:18	TRACY 2:17
262:11	354 <b>:</b> 6	tomorrow	251:3	traditional
276:16	354:0 356:15	109:8	256:19	103:9
278:17	357:10,15	tone 52:2	264:6	transcribed
279:25	timestamp	tonight	271:10	1:22 12:6
281:10	143:1	109:8	305:10	transcript
282:18	timing 84:17	Tony 84:10	324:1	6:24 8:22
288:3	84:21	84:17,21	327:3	143:15
291:6	title 30:24	128:15	333:1	144:3
293:20	41:9,14	130:18	341:12	146:7,23
294:1	50:2 56:16	170:25	top-perf	196:24
303:4	57:9 76:4	171:7	234:4	190.24
312:8,25	179:22	173:13,19	topic 195:11	198:25
312:0,23	210:22	174:4	215:24	361:12
315:10,13	210:22	204:14,15	216:21	transcri
316:9,12	212:23	254:18	218:18	142:23
316:14	titled 18:8	348:23,25	262:18	transgenic
317:11	305:25	349:20,22	286:1	115:13,24
318:13,21	titles 41:24	350:6,7,13	295:24	116:11
319:19	294:22	Tonys 349:2	topics	117:13
321:19	today 9:3,13	_	_	
322:13	11:21 13:2	top 25:24 32:11	238:21 total 73:16	transition 146:5
325:22	14:19	37:24	73:21	transmis
336:9	35:13 48:3	39:13 46:7	77:22 88:8	24:16
341:22	49:2,14	46:14,17	88:11	transmis
341:22	50:23 58:7	54:19 84:5	231:12	15:11 23:5
345:17	59:11	86:3 89:24		146:5
			totality 59:21	
351:11,15	109:1 112:9	91:20,21 93:9,14,15		315:21 316:12,14
351:20,22 353:1	123:15	101:11	totally 91:9 198:18	316:12,14
354:23	123:15	111:17	198:18	
	234:3	120:23	200:9	transparent 103:4
355:1,18 359:19	243:22	120:23		126:11
359:19 times 8:19	243:22 282:1	125:3,3,5	206:11 312:20	traveling
11:5 45:15	334:2	130:16	touch 84:25	313:14,22
71:1	355 <b>:</b> 5	130:16	85:16	315:14,22
/	333.3	134.44	00.10	210.4
	!	I	I	I

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

				1
treat 88:7	262:12,20	153 <b>:</b> 12	240:13	298:23
123:13	trouble	156:5	267:9	299:8,13
124:6	235:11	166:2	278:7	299:19
224:25	troubles	236:18	288:8	300:13,19
treated	104:17,18	250:16	298:21	300:20
88:11	troublesome	256:15	303:9	303:23
treating	237:5,6	269:9	307:19	304:16
331:5,9	troubling	303:16	324:14	335:2,20
treatment	310:12	304:11,13	337:7	336:3,3,23
15:13	trucks 169:6	304:14	341:3	337:8,21
213:22	true 160:3	309:25	turned	347:19
229:10	204:19	312:18	155:15	348:5,15
231:10,11	229:2,11	321:14,20	Turning	348:22,22
232:9	273:4	329:6	219:9	349:24
237:19,20	302:25	334:25	tweet 103:14	350:5,7,14
245:14	339:16,17	339:23	139:23	350:37,19
246:6,7,8	346:8	351 <b>:</b> 7	210:6	350:27,24
246:10,21	363:9,13	Tuesday	213:15,16	351:5,8,9
247:15,16	<b>Trump</b> 197:5	115:7	241:8	two 17:1
247:24	229:8	124:1	348:20,21	32:10
265:15	Trust 76:5,6	126:22	tweeted	35:18 41:1
331:23	<b>truth</b> 79:25	233:17	269:14	53:25
332:3,18	80:10	tuned 72:4,6	tweets 270:2	56:23
333:3,22	106:11	turn 53:5	270:3,4	62:12 85:5
353:23	107:9,10	61:10 68:5	Twenty	85 <b>:</b> 25
treatments	107:13	72:20	158 <b>:</b> 24	89:19
236:5	177 <b>:</b> 6	74:18	Twenty-five	90:11,16
355:5	228:10	90:15	182:1	90:16
triage	323:17	93:19 94:7	Twenty-s	91:17 93:7
169:13	<b>try</b> 44:12	97:9	187 <b>:</b> 15	93:19,20
trial 353:21	70:22	104:25	Twenty-six	101:11
353:25	107:8	110:9	185:9	128:20
354:14	125:13	120:2,21	<b>twice</b> 20:16	131:18
trials	156 <b>:</b> 3	124:25	205 <b>:</b> 7	137:5
214:12	160:2	126:19	Twitter 98:9	185 <b>:</b> 13
221:1	190:21	127:15 <b>,</b> 16	98:10 <b>,</b> 13	202:23
227:9	259:13	128:7,9	98:21 99:6	203:11
231:9	307 <b>:</b> 8	130:13	100:1,2,5	207:3
247:5	323:16	136:11	100:12,14	228:19
324:20	357 <b>:</b> 10	157 <b>:</b> 10	208:15	233:14
<b>tried</b> 46:23	<b>trying</b> 18:11	161:23	209:1,8,16	234:10,15
157:2	41:20 90:9	163:22	209:25	237:9,11
274:6	90:21 91:7	176 <b>:</b> 2	210:5,5	240:10
<b>trip</b> 138:15	91:8 103:5	210:25	239:23	279:11
140:1,5,12	103:20	226:20	240:5,16	296:13
164:11	106:11	232:22	240:21	311:18
165:3,3,24	114:7	233:1	242:22	316:8,24
167:3,5	126:3	237:9	266:15	330:21
261:11	128:4	239:8	270:3	358:21
	<u> </u>			

LEXITAS LEGAL Phone: 1.800.280.3376

359 <b>:</b> 13	114:1	321:16	update 39:6	343:13
Tying 193:15	121:6	360:2	210:16,22	vaccine 24:8
type 17:12	122:9	universal	285:16	104:12
21:18	160:8	317:16,18	updated	106:14
163:5	162:11	university	233:18	173:14
typed 331:12	189:18	32:20	284:3	211:13
types 168:12	212:12	133:15	344:8	256:16
238:19	323:9	174:17	359:8	288:22
typewriting	348:19	265:12	ups 81:11	324:22,25
360:10	understa	267:21,22	<b>urban</b> 143:6	325:8,12
typical	74:10	313:11	urgently	325:23
191:15	understa	352:25	28:5,12	326:1,9,16
206:23	147:9	353:3,3,4	use 108:21	327:11,16
314:12	understa	unknown	155:18	336:2,23
317:23	15:11 18:5	158:17	177:11	338:12,23
typically	18:8,14	unleashed	199:23	339:18
245:14	19:16,23	344:12	220:11	344:15
210,14	19:24	unnecessary	221:3	351:24,24
U	22:13	274:3	258:14	351:24,24
U.S 4:1 9:22	24:21	297:8	332:17	352:3,5
25:25 27:3	27:22 28:2	345:11	useful	vaccines
27:18 28:3	29:13	355:23	294:15	288:16,19
28:17	35:20 41:4	unorthodox	uses 101:6	337:23
177:11	41:9,14	230:9	304:3	347:5
238:23	70:17	unpreced	usually	351:17,20
361:5	118:6	169:8	14:25 29:1	351:21,22
<b>uh-huh</b> 11:25	246:16	unrelated	127:14	355:10,10
UK 76:15	315:20	14:17	136:23	<b>vague</b> 22:7
ultimate	316:2	unreport	179:22	29:22
29:5	329:22	208:12	332:22	35:22 71:9
ultimately	underway	untrue 194:8	349:18	78:14 79:9
143:16	259:19,23	194:10	347.10	79:12 82:7
248:22	260:10	237:1		89:8
unavailable	unfortunate	unusual 21:6	<b>v</b> 1:7 9:7	120:14
108:17	306:1	37:17 39:1	361:7	129:14
unbiased	UnHerd 7:16	44:8 51:11	362:2	154:22
107:8	unidenti	51:23,24	vaccinated	155:19
157:7	350:8,14	113:25	24:9 99:19	166:12
uncensored	uninfected	135:25	101:8	168:19
228:25	314:11	174:3	104:13	169:23
uncertai	Union 341:5	261:5	151:8	174:21
14:4	342:10	263:2	152:5	186:22
understand	343:2	unvaccin	287:1	193:18
11:18 15:9	United 1:1	343:10,11	338:24	207:18
18:12	9:9 75:17	unwarranted	342 <b>:</b> 7	208:5
29:23	76:5	80:16,17	343:10	213:24
42:23	166:10	81:13	359:3	251:19
70:10	168:22	unwitting	vaccinating	291:25
71:25	177:24	358:15	285:3,14	293:14
	·	·	1	•

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

297:24	verify	294:2	77:23 80:2	116:3,5,25
318:22	299:23	312:25	89:14	121:12,15
319:13	<b>versed</b> 40:18	313:3	122:4	121:16,17
345:20	63:14	354 <b>:</b> 23	198:15	129:14
352:7	version	355:1	virology	137:19
355:16	123:15	359:11,17	33:8 36:6	138:16
vaguely	159:3	Videotaped	36:17 64:9	140:16,21
13:23	170:19	1:13	89:16	147:3
18:10	178:21,24	<b>view</b> 101:13	114:11,15	155:16
142:5	179:17,19	101:24	117:9	156:13
225:25	180:1,10	109:1	120:19	162:2
254:4	203:9	150:18	124:13	168:18,22
300:21	228:19	151 <b>:</b> 2	133:9	169:2
302:7	284:20	154:20	135:25	177:7
314:23	versions	194:4	156:23	180:6
valence	228:19	217:8	158:12	181:10
75:12	versus	243:22	160:8	189:10
valid 247:7	160:25	273:2	Virology's	194:1
validated	246:21	276:16	158:2	198:2,9
80:15	320:15	278:10	virulent	208:16
validity	<b>vice</b> 197:5	297:12,22	24:16	247:18
248:12	197:12	319:10	<b>virus</b> 13:15	248:18,20
Vallance	202:5,16	334:8	14:6,21,24	248:22
47:1 75:11	352:25	346:9	15:5,11	258:4
75:13,13	<b>video</b> 9:4,5	356:21	16:18	262:1,8,23
85:9 92:3	199:18,21	viewpoints	23:20 24:1	274:6
93:12	225:19	322:20	24:8,15,24	276:22
97 <b>:</b> 22	227:15	views 223:20	24:25 25:1	277 <b>:</b> 1
variables	229:1,7,18	235:6,23	34:15,22	278 <b>:</b> 22
247:1	232:18	236:2,8,10	34:24 35:1	287 <b>:</b> 2
variations	234:2	236:17	35:11,15	293:19
303:11,25	235:5,10	243:21	43:19,25	314:14
304:7	236:1,20	Vincent	44:8 50:6	315:17 <b>,</b> 20
various	237:18	39:21	50:10	317:1,2,25
95:14	238:1	40:13,14	51:12 <b>,</b> 25	354:15
122:7	239:12 <b>,</b> 15	<b>viral</b> 232:17	52:17	358 <b>:</b> 8
142:16	240:5,22	virologist	62 <b>:</b> 23	virus's
189:19	242:22	45:4,12	77:12 79:2	79 <b>:</b> 22
283:23	305:25	121:24	79:21	98:22 99:3
332:23	306:3,18	135:18	80:12	109:17
<b>Varmus</b> 134:3	359:20	157 <b>:</b> 7	82:18,25	viruses
135:7	videogra	160:9,12	89:5 100:9	15 <b>:</b> 23
136:8	9:2,15,24	209:9,17	100:10	25:21 27:4
varying	54:8,12	virologi	102:15	30:4 36:15
175:1	83:17 <b>,</b> 20	210:1	103:17,23	43:3
VECCHIONE	150:2,5	virologists	104:1,4	117:11
3:3	203:18,21	44:11	110:21	118:19
<b>venue</b> 39:15	219:4,6	52 <b>:</b> 15	111:1	156:19 <b>,</b> 21
<b>verbal</b> 11:23	253:8,11	58:20 64:1	113:21,25	156 <b>:</b> 24

LEXITAS LEGAL Phone: 1.800.280.3376

157:6,9	110:7	137:22,24	86:12	90:10
158:10	115:1	137:22,24	103:4	101:10
visibility	117:1	164:24	104:22	104:25
191:5,10	132:9	188:10	104.22	104.25
191:12,14	134:7,8	197:25	116:4	136:24
191:12,14	148:9	263:3	139:22	150:24
192:12	149:25	309:5	151:9	172:7
195:12	150:8	337:10	152:10	173:6
visit 149:17	156:8	wanting 43:2	157:5	181:24
vitro 117:12	176:18	92:22	164:12	187:8
245:15	178:18	106:10	165:11	202:8
	192:11	137:2		
<b>vivo</b> 116:25	198:5	191:16	166:2,7,18	203:19,22
117:22			170:21	219:7
viz 337:15	201:11 205:8	321:8 wants 94:17	184:23 194:15	233:23 253:9,12
vocal 317:12	205:8			,
317:14	230:3	warfare	195:14	262:15
Volume		143:6	212:6 232:4	263:6
179:11	231:9	warranted		307:1
von 97:16,21 VRC 324:20	237:14	169:17	236:14	313:4
	246:25	Washington	239:10	354:24
vulnerable	253:5,5	3:7 4:3	241:6	355:2
248:20	282:20	7:22 8:3	259:11	<b>we've</b> 25:3
250:17	300:25	13:15,19	268:17	31:1 40:10
277:3	301:4	201:22	284:5	76:16
W	306:20	242:14	305:12	104:1
	330:15,15	243:2	311:3	107:7
wait 39:12	330:17	271:5	312:19	114:17
185:5	332:24	272:5	320:5,9,10	125:22
waiting	342:22	273:19	326:18	138:14
=	348:18	275:14	328:13	140:15
Walensky	355:22	279:14	343:6	170:1
296:17	357:13	280:25	347:9	171:2
walked	359:15	361:6	357:8,16	175:17
295:20	wanted 42:25	wasn't 59:19	358:23	195:9
walking	58:10,16	66:21	Wayback 7:2	203:5
241:3	58:22	123:22	ways 15:1	274:25
281:16	59:12,14	166:23	156:7	276:24
317:1	59:23	223:9	we'll 85:15	355:4
want 12:11	62:19,23	329:24	278:11	weak 353:8
18:1 28:12	64:8,19	watched	302:1	354 <b>:</b> 6
36:24	66:13 70:6	199:18	359:18	weapons
53:11 58:3	71:2,21	watching	we're 11:15	145:21
62:20	74:1 79:24	199:21	27:16 29:8	146:2
63:15 70:8	87:7 89:4	228:10	37:19	wear 313:13
70:9 74:3	114:20	236:19	39:19	314:17
83:12	121:1	way 19:1,3	54:13 58:5	315:2,18
87:20,25	126:9,10	24:15	83:18,21	316:20
88:1,2,4	126:16	44:12 60:3	85:24	317:9
88:20	136:17	80:12	89:19	321 <b>:</b> 25
	l	l	l	

LEXITAS LEGAL Phone: 1.800.280.3376

Fax: 314.644.1334

wearing	went107:18	<b>widely</b> 88:25	100:24	214:1,21
317:12	144:18	169:2	101:17,20	214:25
322:15,15	168:8	181:22	101:23	223:23
322:18	195:13	widespread	108:20	224:14
web 243:10	200:17	166:17	112:3	225:24
website 18:5	208:12	235:9	115:18	227:5
158:2	210:1	293:19	116:22	228:20
206:18	240:2	WILBUR 2:18	118:15,22	229:16
242:16	261:10	wild 79:25	125:17	234:19
243:3,9	263:3	103:4,9	127:18	235:19
280:12	291:3	106:3,3	128:3	236:7
WeChat 98:9	321:24	118:2,11	129:17	237:14
98:10,13	336:11	118:16	130:9,11	240:14
98:14,21	342:19	wildly 89:16	134:19	243:1,13
Wednesday	weren't	wind 263:20	137:14	246:19
1:12,20	157:24	winner 134:4	137:14	249:22
week 131:3	West 2:9	252:11	144:2	250:24
131:21	118:2,12	257:9	145:1,4	253:22
137:8	118:16	Wire 264:3	146:12,19	255 <b>:</b> 25
161:14	Western 1:2	Wired 264:14	148:14,16	257 <b>:</b> 1
267:16,18	9:10	witness1:16	149:9	259:6,25
325:22	What'd104:9	6:2 10:3	150:1,21	260:24
weeks 11:1	what-hav	13:7 14:11	150:1,21	262:5
351:23	39:3	14:14	152:12,25	266:13
weigh 188:12	whatsoever	20:21 22:9	154:24	268:25
190:17	214:8,14	23:18 24:6	158:6	269:21
191:13	white 7:11	25:10,16	159:22	270:18
weighs	197:1	26:16,25	162:8	271:17
155:24	198:23	30:7 35:23	164:5	272:10
weight	201:3	41:13 42:2	167:9	273:7,15
333:21,23	207:25	43:15 46:6	168:21	273:7713
333:21,23	217:24	47:19 48:8	169:24	274:25
weighted	217:24	48:11,18	176:7	280:16
343:11	226:24	49:11,13	179:10	284:9
well-est	271:9	50:2 53:22	183:6	285:9
40:23	275:23	62:9 68:18	185:13,16	286:18
147:20	276:1,2,10	68:20,21	186:24	287:11,20
well-known	328:11,20	68:23 69:1	187:12,19	289:3
135:17,24	329:17,21	69:11,13	187:22,25	292:1
136:3	329:25	69:19	189:25	293:15
139:17	335:2,18	71:11	193:20	297:2,25
well-pow	335:23	79:11 82:9	195:6	298:10
354:13	336:10,12	83:15 87:1	197:3,16	299:3
well-rec	336:18	87:15 89:9	199:11	301:9,22
45:4	339:22	90:4 93:1	200:14	302:21
well-reg	359:5	93:15,24	201:14	303:15
166:7	WHO-spon	95:13,24	205:5	304:18
Wellcome	261:11	97:12,15	207:19	306:9
76:5,6	262:12	99:5	211:17	308:25
' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '	202.12		<b>∠</b> ⊥ ⊥ • ⊥ /	500.25
	I	I		I

LEXITAS LEGAL Phone: 1.800.280.3376

310:7,20	116:4	36:1 87:25	wouldn't	153 <b>:</b> 16
311:1,7	145:8	100:4	22:18 32:7	268:9,12
312:17	188:25	120:11	42:8 96:3	Wuhan 33:8
313:17	189:14,15	132:10	108:22	33:11,16
314:2,23	189:16	134:1	116:15	33:21 36:6
318:8	190:22	136:21	124:11	36:16
319:6,14	277 <b>:</b> 11	164:23	147:17	37 <b>:</b> 12
323:18	wore 316:23	171 <b>:</b> 2	153:17	42:17
325 <b>:</b> 15	work 12:20	260:12	157 <b>:</b> 3	117:9
327:20	13:6 19:1	310:4	181:11	143:7
329:24	19:3 25:11	works 45:4	184:18	145:22
330:8	35:19 36:7	72 <b>:</b> 17	187:2	146:2
331:22	42:15,18	83:14	213:3,5,16	153:24
334:13	58:12	99:11,13	235:23	154:19 <b>,</b> 20
338:1	59:13 <b>,</b> 15	99:20,22	257 <b>:</b> 2	155 <b>:</b> 17
339:12,14	59:17 <b>,</b> 21	100:18,25	321:10	156 <b>:</b> 21
341:7,8	70:20,24	101:5	wound 256:16	158:1,11
344:9	72:14	204:21	write 184:15	166:3,4
345:21	99:24,25	214:14	184:17	190:8
348:18	100:14	217:3	258:24	x
352:8	101:3	218:2	259:13	
353:20	131:4,9	248:3	354:7	<b>x</b> 1:4,10 6:6
355:17	133:1	300:6,9	writer 308:5	Y
356:11	136:14,17	308:1	308:20	<b>ya</b> 354:7
358:12	136:20,22	319:2	writers	yada 354:7
359:14	137:2,18	350:4,17 350:19	309:1 writes	Yale 265:11
360:6,8 361:12	140:7 205:16,22	350:19	132:20	265:12
362:1,25	210:16,23	world 46:10	173:13	yeah 13:4,11
woman 33:15	210:10,23	95:7,9,17	184:18	14:11,14
228:4	219:24	96:23	258:23	14:22 22:3
wondering	220:1	103:21	325:7	22:4 23:2
188:14	238:20	164:25	writing 14:7	23:14 24:6
225:6	269:17	192:24	258:20	27 <b>:</b> 23
269:2	300:4,11	193:2	314:8,20	28:19,21
299:14	302:23	215:19	359:1	30:7 33:17
wont 171:17	317 <b>:</b> 6	223:24	written	36:9 42:19
word 45:11	326:18 <b>,</b> 18	234:4	13:24	43:22
113:24	350 <b>:</b> 24	world's	113:9	47:22 49:3
155 <b>:</b> 18	work-rel	39 <b>:</b> 23	130:2	50:18,21
156:14	55 <b>:</b> 14	worried	153:1	54:17 <b>,</b> 18
165:19	<b>worked</b> 100:2	273:1	160:18,20	54:19
207:6	156:24	worries	224:19	55:20
222:4	217 <b>:</b> 25	302:14 <b>,</b> 17	287 <b>:</b> 15	58:18
225:1	316:11	302:21	wrong 101:22	61:11,21
261:3	319:3	worry 276:12	194:11	62:9,16
words 56:20	350:22	302:23	240:11	65:2 66:5
57:11	351:4	worth 13:15	wrote 48:2	66:8,11
109:11	working 17:8	15:17	57:8 114:2	68:8 <b>,</b> 12
		<u> </u>	<u> </u>	

LEXITAS LEGAL Phone: 1.800.280.3376

72:22 73:1	212:12	34:9 36:13	YouTube's	50:14
83:13,15	221:25	72:1 76:9	240:5	91:22
84:19,21	222:6,17	100:17	283:15	162:12
85:7 86:12	226:19	years 11:1	285:17	300:10
86:18	231:7	11:10	200.17	331:8
90:17,19	240:11,18	13:24,25	Z	<b>1:13</b> 65:13
91:23	242:17	16:5 27:16	Zachary	<b>1:19</b> 65:21
92:18	247:20	28:23	218:21	203:21
93:21 94:9	254:4,4	29:10,15	<b>Zeke</b> 352:24	<b>1:37</b> 219:4
101:24	265:25	29:23 32:5	354:4,8	1:38 219:6
102:8	272:10	32:6,7	zero 213:14	<b>10</b> 6:4,18
105:9,17	275:17	41:3 43:23	Zhengli 33:5	114:17,18
105:18	282:23	44:22	33:14	115:2,5
108:20	283:22	45:19	35:17 36:1	<b>10,000</b> 212:8
113:14	284:1	141:24	36:6,16	10/3/2025
115:6	286:18	148:2	37:3,7	360:22
118:10	287:11,20	167:10	56:9 117:9	<b>100</b> 44:22
119:7,23	292:1,6	175:4	Zoom 175:13	96:2 114:8
120:6	295:2,16	188:5	Zoom-type	177:22
125:6	300:7,9	212:5	175:18	205:19
130:19	306:9,20	219:20	Zooms 174:2	220:3,10
131:1	307:4,22	275:4	175:19	256:8
133:19	310:7	295:11	Zuckerberg	259:7
134:19	315:5,14	313:18	99:17,21	281:20
144:22	315:16,19	314:4	100:21	292:23
145:18	318:4	358:21	133:11,12	300:23
148:8,15	319:6,21	<b>Yep</b> 90:5	133:14	<b>10278</b> 4:13
159:5	319:24	yesterday	152:1,3	<b>11</b> 6:19
161:10	320:4,6,11	359:3	173:4,8,18	13:23
164:7	323:5	York 4:13,13	173:24	119:18,24
168:12	324:3,9,9	8:19 40:23	174:7,8,15	<b>11:09</b> 150:3
170:16,20	325:10	169:5	174:16	<b>11:21</b> 150:5
171:8	326:23	293:6	175:11,22	<b>11:47</b> 68:14
172:11	331:13,14	296:14	175:25	69:2
173:5	332:5	344:3,21	176:4,25	<b>1100</b> 4:2
174:12,12	334:13,18	you-all	177 <b>:</b> 24	361:5
176:22,23	337:19	85:18	178:10	<b>111</b> 6:17
183:6	338:21	YOUNES 3:2	286:14,22	<b>114</b> 6:18
189:21	339:7,7,9	<b>YouTube</b> 8:7	287:4,16	<b>119</b> 6:19
190:12	339:11,14	239:12,15	288:1	<b>11th</b> 148:19
192:3	342:12	239:23	289:7	149:7,22
195:22	344:5	240:21		152:22
196:8	346:7	242:23	0	341:1
199:16,20	348:6,18	282:21,22		361:18
202:12	348:25	282:24	1	<b>12</b> 6:8,20
205:5	350:2,12	285:1	<b>1</b> 6:8 12:11	16:15
206:6	350:12	286:1	12:13	122:24,25
207:2	353:14	305:25	13:10	288:9,14
209:18	<b>year</b> 24:9	325 <b>:</b> 12	26:16,17	<b>12:27</b> 203 <b>:</b> 18
	<del>-</del>			
L				

LEXITAS LEGAL Phone: 1.800.280.3376

<b>12:29</b> 55:2	<b>163</b> 7:3	<b>1st</b> 21:23	27:3,16	222:2
61:14	<b>167</b> 7 <b>:</b> 4	22:1 43:15	71:8	225:16
62:14	<b>16th</b> 344:4,5	44:16 55:3	<b>2015</b> 31:12	226:14
<b>120</b> 36:13	<b>17</b> 6:9,25	61:15 66:6	31:14 56:5	233:2
120,00072:1	148:4,12	66:17 69:3	60:2,7	242:19
<b>122</b> 6:20	148:14	72:25 73:8	71:6 119:4	243:7
<b>1225</b> 3:5	179:7	77:5 82:14	286:22	250:21
<b>127</b> 233:23	180:11	86:2,13	<b>2019</b> 21:24	253:19
<b>13</b> 6:21	192:4	89:25	34:10	261:11
130:6,7	199:2	93:16	158:1,11	263:12
249:23	235:5	113:22	2023:8 4:4	271:6
251:2	236:1,7,8	120:12	2020 22:17	275:17
252:6	236:10,19	123:19	34:9,11,13	277:25
287:4,16	<b>17:51</b> 68:10	161:8	34:19 35:9	282:25
287:24	<b>170</b> 7 : 5	242:19	35:14 40:6	283:21,25
<b>13:19</b> 65:19	<b>172</b> 7 : 6	243:7	42:6 48:2	284:4
<b>13:13</b> 03:13 <b>13:27</b> 90:1	<b>178</b> 7 : 7	294:12,13	61:15 69:3	285:17
<b>130</b> 6:21	17th 159:4	201.12,10	72:25	286:24
130,000	179:1,4	2	91:22 93:9	287:16
36:13	180:25	<b>2</b> 6:9 17:19	93:16	288:1
<b>1300</b> 13:24	197:1	17:20 18:4	105:5	293:13
<b>138</b> 6:22	199:14	22:23 41:8	120:4	294:10
13th 275:12	201:4	41:14	129:20	298:24
275:20	207:25	119:4	139:14	307:18
<b>14</b> 6:22	<b>18</b> 7 <b>:</b> 1	<b>2,000</b> 207:1	140:14	313:12,21
16:15	152:17,18	<b>2:00</b> 66:21	141:18	315:12,21
138:7,8	<b>18:47</b> 48:2	66:24 67:2	144:8	317:15,22
<b>141</b> 6:23	<b>18:48</b> 143:1	67:3 161:8	147:3	318:2,24
<b>142</b> 6:24	<b>182</b> 7 : 8	<b>2:17</b> 253:8	148:20	319:1
<b>148</b> 6:25	<b>185</b> 7:9	<b>2:28</b> 253 <b>:</b> 11	149:7,22	322:3
14th 188:3	<b>187</b> 7:10	<b>2:30</b> 148:22	152:22	324:1,2
271:6	<b>1885</b> 2:20	149:22	159:4	325:25
298:24	<b>18th</b> 204:8	<b>2:31</b> 253:19	167:19	<b>2021</b> 31:21
299:22		<b>20</b> 7:3	169:20	328:7,13
303:23	158:20,24	158:23	170:22	335:19,24
<b>15</b> 6:23 11:9	158:25	163:7,8	173:11	336:23
141:12,15	237:12	363:15	176:4	341:1
277:25	<b>19:06</b> 143:16	<b>20-plus</b> 11:9	179:1,7,12	343:3
<b>15,000</b> 298:7	<b>19:09</b> 93:9	<b>20:30</b> 91:22	182:7,12	344:4,6,8
298:14	93:16	<b>20036</b> 3 : 7	186:2	347:4,9
<b>15:30</b> 105:6	<b>191250</b> 3:15	<b>201</b> 7:12	188:3	350:25
<b>15:48</b> 91:6	<b>196</b> 7:11	<b>2011</b> 6:8	197:1	<b>2022</b> 1:12,20
<b>152</b> 7:1	<b>1980s</b> 265:19	13:13,20	201:21	9:3 192:4
<b>1524</b> 72:25	<b>1990</b> 265:19	16:15 24:1	203:8	359:19
<b>158</b> 7 : 2	<b>19th</b> 3:5	<b>2013</b> 93:18	204:5,8	361:3,10
<b>15th</b> 176:4	201:21	93:25	213:21	362:3
<b>16</b> 6:24	204:4	<b>2014</b> 16:15	217:20	<b>203</b> 7:13
142:19,20	344:8	18:13	218:10	<b>2050</b> 94:24
240:13	<b>1R01</b> 41:16	21:23 26:3	220:6,14	<b>20530</b> 4:3
		•	•	

LEXITAS LEGAL www.lexitaslegal.com Phone: 1.800.280.3376 Fax: 314.644.1334

361:6	182 <b>:</b> 2	211:2,21	<b>340</b> 8:18	<b>43</b> 6:14 8:1
208924:24	<b>253</b> 7 <b>:</b> 25	3:22-CV	<b>343</b> 8:19	263:7,8
2097:14	<b>26</b> 4:11 7:9	9:8	<b>346</b> 8:20	<b>44</b> 8 <b>:</b> 2
217:4	181:23	3:22-cv	<b>35</b> 7 : 18	197:17
167:14,15	185:2,17	1:7	221:10,11	266:4,5
<b>210</b> 7:15	187:9,12	<b>3:36</b> 275:12	<b>351</b> 245:25	<b>449</b> 245:19
<b>212</b> 4:14	<b>263</b> 8:1	<b>3:39</b> 312:25	246:6	246:1
7:16	264-6373	<b>3:55</b> 313:3	<b>352</b> 8:21	<b>45</b> 8:3 270:5
<b>213</b> 7:17	4:14	<b>30</b> 6:8 7:13	<b>36</b> 7:19	270 <b>:</b> 7
<b>22</b> 7:5 170:9	<b>266</b> 8:2	203:24,25	226:9,10	271 <b>:</b> 3
170:10	<b>26th</b> 182:7	247:25	<b>37</b> 6:13 7:20	45,000
22-06-26	182:12	333:23	228:15,16	206:24
94:8	186:20	361 <b>:</b> 17	<b>371</b> 246:6	<b>450</b> 3:6
<b>221</b> 2:9 7:18	<b>27</b> 7:10	<b>304</b> 8:12	247:10,15	<b>46</b> 8:4 275:8
<b>225</b> 2:22	173:11,18	<b>307</b> 8:13	<b>38</b> 7 <b>:</b> 21	275:9
<b>226</b> 7:19	179:12	<b>30th</b> 13:20	10:25	<b>47</b> 8 <b>:</b> 5
<b>228</b> 7:20	187:10,13	84:17,19	232:12,13	277:17,19
<b>22nd</b> 167:19	199:14	85 <b>:</b> 12	<b>39</b> 7 <b>:</b> 22	<b>48</b> 8:6
218:10	233:2	324 <b>:</b> 2	242:10,11	197 <b>:</b> 17
222:2	<b>270</b> 8:3	325 <b>:</b> 25	<b>3908</b> 4:12	280:8,11
<b>23</b> 1:12,20	<b>275</b> 8 : 4	<b>31</b> 1:19,19	<b>3rd</b> 2:20	<b>49</b> 8:7
7:6 172:24	<b>277</b> 8:5	4:22,23	317:15	283:11,12
173:2	<b>27th</b> 40:6	6:12 7:14	318:1	<b>4th</b> 115:8
361:10	42:6 186:1	9:12 209:3		123:7,25
362:3	222:8	209:4	4	126:23
<b>232</b> 7:21	226:14	<b>314</b> 3:17	<b>4</b> 6:12 31:2	127:5
<b>23rd</b> 9:3	233:16,20	<b>31st</b> 21:23	31:3 35:19	128:20
359:19	<b>28</b> 7 : 11	34:8,10	56:4,20,22	160:14
<b>24</b> 7:7 178:5	196:20,21	48:2 51:21	272:19,20	250:20
178:7,17	197:4	318:24	272:22	251:4
178:18	361:3	319:1	284:24	254:5,13
179:25	<b>280</b> 8 : 6	<b>32</b> 7 <b>:</b> 15	288:9,14 <b>4:23</b> 170:22	5
<b>24/7</b> 95:2	<b>283</b> 8 : 7	210:12	<b>4:23</b> 170:22 <b>4:46</b> 354:23	<b>5</b> 6:13 37:19
<b>2402</b> 54:5 <b>242</b> 7:22	<b>284</b> 8:8 <b>286</b> 8:9	<b>323</b> 8:14	<b>4:46</b> 354:23 <b>4:55</b> 355:1	37:21
<b>242</b> /:22 <b>2421</b> 53:15	<b>286</b> 8:9 <b>28th</b> 226:14	<b>326-6766</b> 2:22	<b>4:55</b> 555:1 <b>40</b> 7:23	60:13
53:20	233:15,18	<b>327</b> 8:15	245:4,5	164:4,18
64:25 65:1	233:15,18	329-5040	247:25	227:8
<b>2426</b> 54:5	<b>29</b> 7:12	3:17	247.25	237:12
<b>2430</b> 53:19	201:16,17	<b>33</b> 7:16	249:4	257:12 251:2
<b>2431</b> 53:20	<b>294</b> 8:10	210:9	332:20	272:21,22
<b>2431</b> 53.20 <b>2432</b> 52:22	<b>298</b> 8:11	210.9	333:23	284:24
53:16,17	2nd 73:8	212:13,10	334:4	<b>5:01</b> 359:19
54:4	105:5	<b>330</b> 8:16	40-plus	359:22
<b>245</b> 7:23	294:10,11	<b>334</b> 8:17	231:14	<b>5:02</b> 188:3
<b>249</b> 7:24		<b>34</b> 7:17	<b>41</b> 7 <b>:</b> 24	<b>5:41</b> 294:2
<b>24th</b> 350:24	3	213:17,18	249:4,6,9	<b>5:51</b> 68:10
<b>25</b> 6:11 7:8	<b>3</b> 6:11 23:4	<b>34:30</b> 144:23	<b>42</b> 7 <b>:</b> 25	<b>50</b> 8:8 87:23
181:24	25:3,4	145:16	253:14,15	282:1
	,		, -	
		•	•	

LEXITAS LEGAL
Phone: 1.800.280.3376 Fax: 314.644.1334

284:6,7,14	347 <b>:</b> 15	<b>918-6905</b> 3 <b>:</b> 8	
284:19	<b>63</b> 8:21	<b>96</b> 6:16	
316:14	352:19,20	96,000	
500,000	<b>63101</b> 361:18	222:11	
36:12	<b>63119</b> 3:16	96,000-p	
<b>51</b> 8:9 286:3	<b>65101</b> 2:10	219:11	
286:4	6th 170:22	96,032	
<b>52</b> 8:10	0011170.22	222:16	
293:25	7	9th 97:2	
294:5,6	<b>7</b> 6:15 83:24		
<b>53</b> 8:11	83:25	144:7	
298:17,18	120:7	T 4 4 • /	
<b>54</b> 8:12	240:12		
304:23,24	<b>7:13</b> 84:19		
<b>55</b> 8:13	<b>70804</b> 2:21		
307:15	<b>711</b> 361:17		
<b>56</b> 8:14	751-8870		
323:19,20	2:11		
<b>57</b> 8:15	<b>7A-18</b> 149:13		
327:24,25	149:15		
<b>573</b> 2:11	<b>7th</b> 120:3		
<b>58</b> 8:16	129:2		
330:5,6	160:15		
<b>59</b> 8:17			
334:17,20	8		
335:15	<b>8</b> 6:16 96:9		
<b>598-3846</b> 4:4	96:10 97:7		
<b>5th</b> 128:13	101:10		
128:18,21	180:10		
160:14	252 <b>:</b> 6		
	254 <b>:</b> 11		
6	<b>8:08</b> 1:20		
<b>6</b> 6:14 43:8	9:4		
43:9 47:25	<b>83</b> 6:15		
49:15	8th 180:25		
52:21	253:19		
272:20	254:9		
<b>6.3</b> 72:1	263:12		
<b>6.4</b> 260:18	269:13		
<b>60</b> 8:18	9		
316:14			
340:22,25	96:17		
341:24	111:10,11		
600,000	<b>9:04</b> 54:8		
36:12	<b>9:05</b> 54:12 <b>9:37</b> 83:14		
<b>61</b> 8:19	<b>9:37</b> 83:14 <b>9:38</b> 83:17		
343:24,25			
<b>62</b> 8:20	<b>9:50</b> 83:20 <b>90</b> 342:6		
346:14,15	<b>90</b> 342 <b>.</b> 0		
	<u> </u>	<u> </u>	

**LEXITAS LEGAL** www.lexitaslegal.com Phone: 1.800.280.3376